570150006432800000000000us-gaap:OperatingLeaseRightOfUseAssetus-gaap:OperatingLeaseRightOfUseAssetus-gaap:OtherAccruedLiabilitiesCurrentus-gaap:OtherAccruedLiabilitiesCurrentus-gaap:OperatingLeaseLiabilityNoncurrentus-gaap:OperatingLeaseLiabilityNoncurrent0001583107--12-312020FYfalsetrue0001583107us-gaap:StateAndLocalJurisdictionMembertbph:ResearchAndDevelopmentMember2020-12-310001583107us-gaap:DomesticCountryMembertbph:ResearchAndDevelopmentMember2020-12-310001583107country:IEus-gaap:CapitalLossCarryforwardMember2020-12-3100015831072020-02-142020-02-140001583107us-gaap:RetainedEarningsMember2020-12-310001583107us-gaap:AdditionalPaidInCapitalMember2020-12-310001583107us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001583107us-gaap:RetainedEarningsMember2019-12-310001583107us-gaap:AdditionalPaidInCapitalMember2019-12-310001583107us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001583107us-gaap:RetainedEarningsMember2018-12-310001583107us-gaap:AdditionalPaidInCapitalMember2018-12-310001583107us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001583107us-gaap:RetainedEarningsMember2017-12-310001583107us-gaap:AdditionalPaidInCapitalMember2017-12-310001583107us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310001583107us-gaap:CommonStockMember2020-01-012020-12-310001583107us-gaap:CommonStockMember2019-01-012019-12-310001583107us-gaap:CommonStockMember2018-01-012018-12-3100015831072020-02-140001583107tbph:EquityIncentivePlan2013AndNewEmployeeEquityIncentivePlan2014Member2019-12-310001583107tbph:EquityIncentivePlan2013AndNewEmployeeEquityIncentivePlan2014Member2020-01-012020-12-310001583107tbph:EquityIncentivePlan2013AndNewEmployeeEquityIncentivePlan2014Member2020-12-310001583107srt:ManagementMembertbph:EmployeePerformanceRestrictedStockUnitsRSUMember2016-12-310001583107tbph:EmployeePerformanceRestrictedStockMember2016-12-310001583107tbph:NewEmployeeEquityIncentivePlan2014Member2014-12-310001583107tbph:EquityIncentivePlan2013Member2013-12-310001583107tbph:EmployeeSharePurchasePlan2013Member2013-12-310001583107tbph:EmployeeSharePurchasePlan2013Member2020-01-012020-12-310001583107tbph:EmployeeSharePurchasePlan2013Member2019-01-012019-12-310001583107tbph:EmployeeSharePurchasePlan2013Member2018-01-012018-12-310001583107srt:MinimumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310001583107srt:MinimumMembertbph:EmployeeSharePurchasePlan2013Member2020-01-012020-12-310001583107srt:MaximumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310001583107srt:MaximumMembertbph:EmployeeSharePurchasePlan2013Member2020-01-012020-12-310001583107srt:MinimumMembertbph:EmployeeSharePurchasePlan2013Member2019-01-012019-12-310001583107srt:MaximumMembertbph:EmployeeSharePurchasePlan2013Member2019-01-012019-12-310001583107srt:MinimumMembertbph:EmployeeSharePurchasePlan2013Member2018-01-012018-12-310001583107srt:MaximumMembertbph:EmployeeSharePurchasePlan2013Member2018-01-012018-12-310001583107tbph:EmployeePerformanceRestrictedStockUnitsRSUMember2020-12-310001583107us-gaap:RestrictedStockUnitsRSUMember2019-12-310001583107tbph:EmployeePerformanceRestrictedStockUnitsRSUMember2019-12-310001583107tbph:EmployeePerformanceRestrictedStockMember2019-12-310001583107tbph:EmployeePerformanceRestrictedStockUnitsRSUMember2020-01-012020-12-310001583107tbph:EmployeePerformanceRestrictedStockMember2020-01-012020-12-310001583107tbph:EmployeePerformanceRestrictedStockMember2020-12-310001583107us-gaap:EmployeeStockOptionMembertbph:EquityIncentivePlan2012Membertbph:ShareBasedCompensationAwardMonthlyVestingInRemainingThreeYearsMember2014-06-022014-06-020001583107us-gaap:EmployeeStockOptionMembertbph:EquityIncentivePlan2012Membertbph:ShareBasedCompensationAwardFirstYearTrancheMember2014-06-022014-06-020001583107us-gaap:EmployeeStockOptionMembertbph:NewEmployeeEquityIncentivePlan2014Membertbph:ShareBasedCompensationAwardMonthlyVestingInRemainingThreeYearsMember2014-01-012014-12-310001583107us-gaap:EmployeeStockOptionMembertbph:NewEmployeeEquityIncentivePlan2014Membertbph:ShareBasedCompensationAwardFirstYearTrancheMember2014-01-012014-12-310001583107tbph:EmployeePerformanceRestrictedStockMember2016-01-012016-12-310001583107us-gaap:EmployeeStockOptionMembertbph:EquityIncentivePlan2013Membertbph:ShareBasedCompensationAwardMonthlyVestingInRemainingThreeYearsMember2013-01-012013-12-310001583107us-gaap:EmployeeStockOptionMembertbph:EquityIncentivePlan2013Membertbph:ShareBasedCompensationAwardFirstYearTrancheMember2013-01-012013-12-310001583107us-gaap:EmployeeStockOptionMembertbph:EquityIncentivePlan2013Member2013-01-012013-12-310001583107tbph:YupelriMonotherapyMember2020-10-012020-12-310001583107tbph:YupelriMonotherapyMember2020-07-012020-09-300001583107tbph:YupelriMonotherapyMember2020-04-012020-06-300001583107us-gaap:RoyaltyMembertbph:TheravanceRespiratoryCompanyLlcMember2020-01-012020-12-310001583107tbph:TheravanceRespiratoryCompanyLlcMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementAndThirdPartyMember2020-01-012020-12-310001583107us-gaap:LicenseMember2020-01-012020-12-310001583107tbph:CoPromoteAgreementMember2020-01-012020-12-310001583107srt:EuropeMember2020-01-012020-12-310001583107tbph:YupelriMonotherapyMember2020-01-012020-03-310001583107tbph:YupelriMonotherapyMember2019-10-012019-12-310001583107tbph:YupelriMonotherapyMember2019-07-012019-09-300001583107tbph:YupelriMonotherapyMember2019-04-012019-06-300001583107us-gaap:RoyaltyMembertbph:TheravanceRespiratoryCompanyLlcMember2019-01-012019-12-310001583107tbph:PfizerInc.Membertbph:SalesMilestonesMember2019-01-012019-12-310001583107tbph:AlfasigmaMembertbph:DevelopmentAndCommercializationAgreementMember2019-01-012019-12-310001583107us-gaap:LicenseMember2019-01-012019-12-310001583107tbph:CoPromoteAgreementMember2019-01-012019-12-310001583107srt:EuropeMember2019-01-012019-12-310001583107tbph:YupelriMonotherapyMember2019-01-012019-03-310001583107us-gaap:RoyaltyMembertbph:TheravanceRespiratoryCompanyLlcMember2018-01-012018-12-310001583107tbph:AlfasigmaMembertbph:DevelopmentAndCommercializationAgreementMember2018-01-012018-12-310001583107us-gaap:ProductMember2018-01-012018-12-310001583107tbph:CoPromoteAgreementMember2018-01-012018-12-310001583107srt:EuropeMember2018-01-012018-12-310001583107srt:AsiaMember2018-01-012018-12-310001583107tbph:MylanMembertbph:Milestone50PercentEnrollmentInPhase3Membertbph:DevelopmentAndCommercializationAgreementMember2016-01-012016-12-310001583107srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2018-12-310001583107srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-3100015831072019-01-012019-01-310001583107srt:DirectorMember2020-01-012020-12-310001583107srt:DirectorMember2019-01-012019-12-310001583107srt:DirectorMember2018-01-012018-12-310001583107srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2020-01-012020-12-310001583107srt:MinimumMembertbph:SoftwareAndComputerEquipmentMember2020-01-012020-12-310001583107srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2020-01-012020-12-310001583107srt:MaximumMembertbph:SoftwareAndComputerEquipmentMember2020-01-012020-12-310001583107us-gaap:SoftwareDevelopmentMember2020-01-012020-12-310001583107us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-12-310001583107us-gaap:OtherMachineryAndEquipmentMember2020-12-310001583107us-gaap:LeaseholdImprovementsMember2020-12-310001583107us-gaap:FurnitureAndFixturesMember2020-12-310001583107us-gaap:ComputerEquipmentMember2020-12-310001583107us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2019-12-310001583107us-gaap:OtherMachineryAndEquipmentMember2019-12-310001583107us-gaap:LeaseholdImprovementsMember2019-12-310001583107us-gaap:FurnitureAndFixturesMember2019-12-310001583107us-gaap:ComputerEquipmentMember2019-12-310001583107us-gaap:DiscontinuedOperationsDisposedOfBySaleMembertbph:VIBATIVProductMember2018-11-122018-11-120001583107us-gaap:SeniorNotesMember2016-11-012016-11-300001583107tbph:TheravanceRespiratoryCompanyLlcMember2021-10-012021-10-310001583107us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001583107us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001583107us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310001583107us-gaap:StateAndLocalJurisdictionMember2020-12-310001583107us-gaap:RetainedEarningsMember2020-01-012020-12-310001583107us-gaap:RetainedEarningsMember2019-01-012019-12-310001583107tbph:TheravanceRespiratoryCompanyLlcMember2019-01-012019-12-310001583107us-gaap:RetainedEarningsMember2018-01-012018-12-310001583107tbph:TheravanceRespiratoryCompanyLlcMember2018-01-012018-12-310001583107country:KY2020-01-012020-12-310001583107country:KY2019-01-012019-12-310001583107country:KY2018-01-012018-12-310001583107tbph:NonRecourseDebt2033Member2020-01-012020-12-310001583107us-gaap:DiscontinuedOperationsDisposedOfBySaleMembertbph:VIBATIVProductMembertbph:InterestAndOtherIncomeExpenseNetMember2018-01-012018-12-3100015831072020-10-310001583107tbph:NationalDemocraticAllianceGroupMember2020-12-310001583107tbph:GlaxoGroupLimitedAndAffiliatesMember2020-12-310001583107tbph:IssuerTwoClassCUnitsMember2020-02-210001583107tbph:TheravanceIncMember2021-01-012021-01-310001583107tbph:TheravanceIncMember2020-10-012020-12-310001583107us-gaap:RestrictedStockUnitsRSUMember2020-12-310001583107us-gaap:EmployeeStockOptionMember2020-12-310001583107us-gaap:EmployeeStockMember2020-12-310001583107tbph:EmployeePerformanceRestrictedStockAwardsAndRestrictedStockUnitsMember2020-12-3100015831072020-10-012020-12-3100015831072020-07-012020-09-3000015831072020-04-012020-06-3000015831072020-01-012020-03-3100015831072019-10-012019-12-3100015831072019-07-012019-09-3000015831072019-04-012019-06-3000015831072019-01-012019-03-310001583107us-gaap:DiscontinuedOperationsDisposedOfBySaleMembertbph:VIBATIVProductMember2019-04-300001583107us-gaap:DiscontinuedOperationsDisposedOfBySaleMembertbph:VIBATIVProductMember2018-11-012018-11-010001583107tbph:NonRecourseDebt2033Member2020-02-280001583107us-gaap:DeferredBonusMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-01-012020-12-310001583107us-gaap:DeferredBonusMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2019-01-012019-12-310001583107us-gaap:DeferredBonusMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2019-01-012019-12-310001583107us-gaap:DeferredBonusMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2018-01-012018-12-310001583107us-gaap:DeferredBonusMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2018-01-012018-12-310001583107us-gaap:CorporateNoteSecuritiesMember2020-12-310001583107us-gaap:CommercialPaperMember2020-12-310001583107us-gaap:CorporateNoteSecuritiesMember2019-12-310001583107us-gaap:CommercialPaperMember2019-12-310001583107tbph:TheravanceBiopharmaRAndDIncMembertbph:NonRecourseDebt2033Member2020-02-012020-02-290001583107tbph:TheravanceBiopharmaRAndDIncMembertbph:TermNotesDue2035Member2020-12-310001583107tbph:NonRecourseDebt2035Member2020-12-310001583107tbph:NonRecourseDebt2033Member2020-12-310001583107tbph:TheravanceBiopharmaRAndDIncMembertbph:NonRecourseDebt2033Member2018-11-300001583107tbph:NonRecourseDebt2033Member2018-11-300001583107us-gaap:SeniorNotesMember2016-11-300001583107us-gaap:SeniorNotesMember2019-12-310001583107tbph:NonRecourseDebt2033Member2019-12-310001583107us-gaap:SeniorNotesMember2020-12-310001583107tbph:TermNotesDue2035Member2020-12-310001583107country:US2020-01-012020-12-310001583107country:GB2020-01-012020-12-310001583107country:US2019-01-012019-12-310001583107country:GB2019-01-012019-12-310001583107country:US2018-01-012018-12-310001583107country:GB2018-01-012018-12-310001583107us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2020-12-310001583107us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2019-12-310001583107us-gaap:SeniorNotesMember2020-01-012020-12-310001583107tbph:MylanMember2019-06-012019-06-300001583107tbph:MylanMember2020-12-310001583107tbph:JanssenBiotechIncMember2020-12-310001583107tbph:AlfasigmaMember2020-12-310001583107tbph:PfizerInc.Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001583107tbph:MylanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001583107tbph:JanssenBiotechIncMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001583107tbph:AlfasigmaMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001583107tbph:PfizerInc.Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001583107tbph:MylanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001583107tbph:JanssenBiotechIncMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001583107tbph:AlfasigmaMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001583107tbph:PfizerInc.Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001583107tbph:MylanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001583107tbph:JanssenBiotechIncMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001583107tbph:AlfasigmaMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001583107us-gaap:CommonStockMember2020-12-310001583107us-gaap:CommonStockMember2019-12-310001583107us-gaap:CommonStockMember2018-12-310001583107us-gaap:CommonStockMember2017-12-3100015831072017-12-3100015831072018-12-310001583107us-gaap:SoftwareDevelopmentMember2020-12-310001583107us-gaap:SoftwareDevelopmentMember2019-12-310001583107tbph:MylanMembertbph:YupelriMonotherapyMembertbph:SalesMilestonesMember2020-12-310001583107tbph:MylanMembertbph:YupelriMonotherapyMembertbph:RegulatoryActionsMember2020-12-310001583107tbph:MylanMembertbph:YupelriMonotherapyMembertbph:DevelopmentAndCommercializationAgreementMember2020-12-310001583107tbph:MylanMembertbph:SalesMilestonesMember2020-12-310001583107tbph:MylanMembertbph:NebulizedTD4208Member2020-12-310001583107tbph:MylanMembertbph:FuturePotentialCombinationProductsMember2020-12-310001583107tbph:MylanMember2020-03-310001583107tbph:MylanMembertbph:FuturePotentialCombinationProductsMembertbph:DevelopmentAndSalesMilestonesMember2019-06-300001583107tbph:MylanMembertbph:YupelriMonotherapyMember2019-06-300001583107tbph:MylanMembertbph:SalesMilestonesMember2019-06-300001583107tbph:MylanMembertbph:FuturePotentialCombinationProductsMember2019-06-300001583107us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2019-12-310001583107us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateNoteSecuritiesMember2020-12-310001583107us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310001583107us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2020-12-310001583107us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMember2020-12-310001583107tbph:MarketableSecuritiesMember2020-12-310001583107us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateNoteSecuritiesMember2019-12-310001583107us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2019-12-310001583107us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMember2019-12-310001583107tbph:MarketableSecuritiesMember2019-12-310001583107tbph:TheravanceRespiratoryCompanyLlcMember2020-12-310001583107tbph:TheravanceRespiratoryCompanyLlcMember2019-12-310001583107us-gaap:StockCompensationPlanMember2020-01-012020-12-310001583107us-gaap:PerformanceSharesMember2020-01-012020-12-310001583107us-gaap:ConvertibleSubordinatedDebtMember2020-01-012020-12-310001583107us-gaap:StockCompensationPlanMember2019-01-012019-12-310001583107us-gaap:PerformanceSharesMember2019-01-012019-12-310001583107us-gaap:ConvertibleSubordinatedDebtMember2019-01-012019-12-310001583107us-gaap:StockCompensationPlanMember2018-01-012018-12-310001583107us-gaap:RestrictedStockMember2018-01-012018-12-310001583107us-gaap:PerformanceSharesMember2018-01-012018-12-310001583107us-gaap:ConvertibleSubordinatedDebtMember2018-01-012018-12-310001583107us-gaap:ScenarioPlanMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2021-01-012021-03-310001583107us-gaap:ScenarioPlanMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-01-012020-12-310001583107us-gaap:ScenarioPlanMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-01-012020-12-310001583107us-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-01-012020-12-310001583107us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310001583107us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001583107us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001583107us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001583107us-gaap:EmployeeStockMember2020-01-012020-12-310001583107tbph:EmployeePerformanceRestrictedStockUnitsRsuAndCashBonusMilestonesMember2020-01-012020-12-310001583107tbph:EmployeePerformanceRestrictedStockAwardsAndRestrictedStockUnitsMember2020-01-012020-12-310001583107us-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-01-012020-03-310001583107tbph:TheravanceIncMemberus-gaap:RestrictedStockMember2019-01-012019-12-310001583107us-gaap:ShareBasedCompensationAwardTrancheTwoMember2019-01-012019-12-310001583107us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-310001583107us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310001583107us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-12-310001583107us-gaap:EmployeeStockOptionMember2019-01-012019-12-310001583107us-gaap:EmployeeStockMember2019-01-012019-12-310001583107tbph:EmployeePerformanceRestrictedStockUnitsRsuAndCashBonusMilestonesMember2019-01-012019-12-310001583107tbph:EmployeePerformanceRestrictedStockAwardsAndRestrictedStockUnitsMember2019-01-012019-12-310001583107tbph:TheravanceIncMemberus-gaap:RestrictedStockMember2018-01-012018-12-310001583107tbph:TheravanceIncMemberus-gaap:EmployeeStockOptionMember2018-01-012018-12-310001583107us-gaap:ShareBasedCompensationAwardTrancheTwoMember2018-01-012018-12-310001583107us-gaap:ShareBasedCompensationAwardTrancheOneMember2018-01-012018-12-310001583107us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-01-012018-12-310001583107us-gaap:RestrictedStockUnitsRSUMember2018-01-012018-12-310001583107us-gaap:ResearchAndDevelopmentExpenseMember2018-01-012018-12-310001583107us-gaap:EmployeeStockOptionMember2018-01-012018-12-310001583107us-gaap:EmployeeStockMember2018-01-012018-12-310001583107tbph:EmployeePerformanceRestrictedStockAwardsAndRestrictedStockUnitsMember2018-01-012018-12-310001583107us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001583107us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001583107us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-310001583107us-gaap:DiscontinuedOperationsDisposedOfBySaleMembertbph:VIBATIVProductMember2018-11-010001583107us-gaap:DomesticCountryMember2020-12-310001583107tbph:EmployeePerformanceRestrictedStockUnitsMember2020-01-012020-12-310001583107tbph:EquityIncentivePlan2012Member2014-06-022014-06-0200015831072014-06-022014-06-020001583107tbph:EmployeeSharePurchasePlan2013Member2013-01-012013-12-310001583107tbph:MylanMembertbph:OrdinarySharePurchaseAgreementMember2015-01-012015-12-310001583107tbph:PfizerInc.Member2020-01-012020-12-310001583107tbph:AlfasigmaMember2018-04-012018-04-300001583107tbph:MylanMember2015-01-012015-01-3100015831072018-02-012018-02-280001583107us-gaap:OperatingExpenseMember2018-01-012018-09-300001583107us-gaap:EmployeeStockOptionMembertbph:EquityIncentivePlan2012Member2014-06-022014-06-020001583107us-gaap:EmployeeStockOptionMembertbph:NewEmployeeEquityIncentivePlan2014Member2014-01-012014-12-310001583107us-gaap:EmployeeStockOptionMembertbph:EquityIncentivePlan2013Member2014-01-012014-12-310001583107srt:MinimumMembertbph:TheravanceRespiratoryCompanyLlcMember2020-02-212020-02-210001583107srt:MaximumMembertbph:TheravanceRespiratoryCompanyLlcMember2020-02-212020-02-210001583107srt:MaximumMembertbph:EquityIncentivePlan2013Member2013-01-012013-12-310001583107srt:MaximumMembertbph:EmployeeSharePurchasePlan2013Member2013-01-012013-12-310001583107tbph:GlaxoSmithKlinePlcSeniorNotesMember2020-06-222020-06-220001583107tbph:TermNotesDue2035Member2020-02-210001583107tbph:YupelriMonotherapyMember2020-01-012020-12-310001583107us-gaap:DeferredBonusMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-01-012020-12-310001583107us-gaap:DeferredBonusMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-01-012020-12-310001583107us-gaap:DeferredBonusMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-01-012020-12-310001583107tbph:MylanMembertbph:DevelopmentAndCommercializationAgreementMember2020-01-012020-12-310001583107tbph:PfizerInc.Member2019-01-012019-12-310001583107tbph:MylanMembertbph:DevelopmentAndCommercializationAgreementMember2015-01-012015-12-310001583107country:IE2020-01-012020-12-310001583107country:IE2019-01-012019-12-310001583107country:IE2018-01-012018-12-310001583107tbph:TheravanceRespiratoryCompanyLlcMembertbph:IssuerTwoClassCUnitsMember2020-02-212020-02-210001583107tbph:TheravanceRespiratoryCompanyLlcMember2020-02-212020-02-210001583107tbph:IssuerTwoClassCUnitsMember2020-02-212020-02-210001583107tbph:ArbitrationAgainstInnovivaAndTrcMembertbph:TheravanceRespiratoryCompanyLlcMember2020-01-012020-12-310001583107us-gaap:DiscontinuedOperationsDisposedOfBySaleMembertbph:VIBATIVProductMembertbph:InterestAndOtherIncomeExpenseNetMember2018-11-122018-11-120001583107tbph:EmployeeMemberus-gaap:DeferredBonusMember2016-01-012016-12-310001583107tbph:GlaxoSmithKlinePlcSeniorNotesMember2020-06-220001583107tbph:NonRecourseDebt2033Member2020-02-282020-02-280001583107tbph:NonRecourseDebt2033Member2018-11-012018-11-300001583107tbph:YupelriMonotherapyMembertbph:CoPromoteAgreementMember2020-01-012020-12-310001583107tbph:OthersMember2020-01-012020-12-310001583107tbph:CoPromoteAgreementMember2020-01-012020-12-310001583107tbph:CollaborativeArrangementRevenueMember2020-01-012020-12-310001583107tbph:AlfasigmaMember2020-01-012020-12-310001583107tbph:YupelriMonotherapyMembertbph:CoPromoteAgreementMember2019-01-012019-12-310001583107tbph:OthersMember2019-01-012019-12-310001583107tbph:CollaborativeArrangementRevenueMember2019-01-012019-12-310001583107tbph:AlfasigmaMember2019-01-012019-12-310001583107tbph:YupelriMonotherapyMembertbph:CoPromoteAgreementMember2018-01-012018-12-310001583107tbph:OthersMember2018-01-012018-12-310001583107tbph:CollaborativeArrangementRevenueMember2018-01-012018-12-310001583107tbph:AlfasigmaMember2018-01-012018-12-310001583107tbph:MylanMember2020-01-012020-12-310001583107tbph:MylanMember2019-01-012019-12-310001583107tbph:JanssenBiotechIncMember2019-01-012019-12-310001583107tbph:MylanMember2018-01-012018-12-310001583107tbph:JanssenBiotechIncMember2018-01-012018-12-310001583107tbph:JanssenBiotechIncMembertbph:Td1473Memberus-gaap:CollaborativeArrangementMember2018-02-012018-02-280001583107tbph:CoPromoteAgreementMember2019-01-012019-12-310001583107tbph:CoPromoteAgreementMember2018-01-012018-12-310001583107tbph:JanssenBiotechIncMember2020-01-012020-12-310001583107tbph:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2018-02-012018-02-280001583107tbph:AlfasigmaMembertbph:DevelopmentAndCollaborationAgreementMember2018-04-012018-04-300001583107tbph:JanssenBiotechIncMember2018-02-012018-02-280001583107tbph:AlfasigmaMembertbph:DevelopmentAndCollaborationAgreementMember2018-01-012018-12-310001583107tbph:TheravanceRespiratoryCompanyLlcMember2020-01-012020-12-310001583107country:IE2020-12-3100015831072019-01-012019-12-3100015831072018-01-012018-12-3100015831072020-12-3100015831072019-12-3100015831072020-06-3000015831072021-02-1900015831072020-01-012020-12-31tbph:segmenttbph:individualxbrli:sharesiso4217:USDutr:sqftxbrli:puretbph:buildingtbph:Optiontbph:plantbph:itemiso4217:USDxbrli:shares

[Table of Contents](#TOC)

​

​

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-K**

**(Mark One)**

​

|  |  |  |
| --- | --- | --- |
|  | **☒** | **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

​

**For the fiscal year ended December 31, 2020**

​

**OR**

​

|  |  |  |
| --- | --- | --- |
|  | **☐** | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

​

**For the transition period from                  to**

​

**Commission File No. 001-36033**

**THERAVANCE BIOPHARMA, INC.**

(Exact name of registrant as specified in its charter)

|  |  |  |
| --- | --- | --- |
| ​ | ​ | ​ |
| **Cayman Islands** |  | **98-1226628** |
| (State or Other Jurisdiction of | ​ | (I.R.S. Employer |
| Incorporation or Organization) | ​ | Identification No.) |
| ​ | ​ | ​ |
| **P.O. Box 309** | ​ | ​ |
| **Ugland House, South Church Street** | **​** | **​** |
| **George Town, Grand Cayman, Cayman Islands** | **​** | **KY1-1104** |
| (Address of Principal Executive Offices) | ​ | (Zip Code) |

​

​

Registrant’s telephone number, including area code: **650-808-6000**

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

​

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | ​ | ​ | ​ |  |
| **Title of Each Class** |  | **Trading Symbol** |  | **Name of Each Exchange On Which Registered** |
| Ordinary Share $0.00001 Par Value | ​ | TBPH | ​ | The Nasdaq Global Market |

​

SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT: **NONE**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒  No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

|  |  |
| --- | --- |
|  |  |
| Large Accelerated Filer ☒ | Accelerated Filer ☐ |
| Non-accelerated Filer ☐ | Smaller reporting company ☐ |
| ​ | Emerging growth company ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $1.28 billion, based upon the closing price of $20.99 on the Nasdaq Global Market on June 30, 2020.

On February 19, 2021, there were 64,327,830 of the registrant’s ordinary shares outstanding.

**DOCUMENTS INCORPORATED BY REFERENCE**

Specified portions of the registrant’s definitive Proxy Statement to be issued in conjunction with the registrant’s 2021 Annual Meeting of Shareholders, which is expected to be filed not later than 120 days after the registrant’s fiscal year ended December 31, 2020, are incorporated by reference into Part III of this Annual Report. Except as expressly incorporated by reference, the registrant’s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10-K.

​

​

​

[Table of Contents](#TOC)

**THERAVANCE BIOPHARMA, INC.**

**2020 Form 10-K Annual Report**

**Table of Contents**

|  |  |  |  |
| --- | --- | --- | --- |
| ​ |  | ​ | ​ |
| ​ | **PART I** |  | ​ |
| [Item 1.](#ITEM1BUSINESS_825817) | [Business](#ITEM1BUSINESS_825817) | ​ | 4 |
| [Item 1A.](#ITEM1ARISKFACTORS_683066) | [Risk Factors](#ITEM1ARISKFACTORS_683066) | ​ | 21 |
| [Item 1B.](#ITEM1BUNRESOLVEDSTAFFCOMMENTS_630681) | [Unresolved Staff Comments](#ITEM1BUNRESOLVEDSTAFFCOMMENTS_630681) | ​ | 58 |
| [Item 2.](#ITEM2PROPERTIES_614986) | [Properties](#ITEM2PROPERTIES_614986) | ​ | 58 |
| [Item 3.](#ITEM3LEGALPROCEEDINGS_900504) | [Legal Proceedings](#ITEM3LEGALPROCEEDINGS_900504) | ​ | 58 |
| [Item 4.](#ITEM4MINESAFETYDISCLOSURES_772024) | [Mine Safety Disclosures](#ITEM4MINESAFETYDISCLOSURES_772024) | ​ | 58 |
| ​ | ​  [**PART II**](#PARTII_207346) | ​ | ​ |
| [Item 5.](#ITEM5MARKETFORTHEREGISTRANTSCOMMONEQUIT) | [Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](#ITEM5MARKETFORTHEREGISTRANTSCOMMONEQUIT) | ​ | 59 |
| [Item 6.](#ITEM6SELECTEDFINANCIALDATA_588522) | [Selected Financial Data](#ITEM6SELECTEDFINANCIALDATA_588522) | ​ | 61 |
| [Item 7.](#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOF) | [Management’s Discussion and Analysis of Financial Condition and Results of Operations](#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOF) | ​ | 61 |
| [Item 7A.](#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOS) | [Quantitative and Qualitative Disclosures About Market Risk](#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOS) | ​ | 75 |
| [Item 8.](#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTAR) | [Financial Statements and Supplementary Data](#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTAR) | ​ | 76 |
| [Item 9.](#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOU) | [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOU) | ​ | 118 |
| [Item 9A.](#ITEM9ACONTROLSANDPROCEDURES_271679) | [Controls and Procedures](#ITEM9ACONTROLSANDPROCEDURES_271679) | ​ | 118 |
| [Item 9B.](#ITEM9BOTHERINFORMATION_197725) | [Other Information](#ITEM9BOTHERINFORMATION_197725) | ​ | 120 |
| ​ | **​**  [**PART III**](#PARTIII_84846) | ​ | ​ |
| [Item 10.](#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORP) | [Directors, Executive Officers and Corporate Governance](#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORP) | ​ | 120 |
| [Item 11.](#ITEM11EXECUTIVECOMPENSATION_845193) | [Executive Compensation](#ITEM11EXECUTIVECOMPENSATION_845193) | ​ | 120 |
| [Item 12.](#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFIC) | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFIC) | ​ | 120 |
| [Item 13.](#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRA) | [Certain Relationships and Related Transactions, and Director Independence](#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRA) | ​ | 120 |
| [Item 14.](#ITEM14PRINCIPALACCOUNTANTFEESANDSERVICE) | [Principal Accountant Fees and Services](#ITEM14PRINCIPALACCOUNTANTFEESANDSERVICE) | ​ | 120 |
| ​ | **​**  [**PART IV**](#PARTIV_28179) | ​ | ​ |
| [Item 15.](#ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHE) | [Exhibits and Financial Statement Schedules](#ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHE) | ​ | 121 |
| [Exhibit Index](#ExhibitIndex) | | ​ | 122 |
| Signatures | | ​ | 126 |

​

​

​

2

[Table of Contents](#TOC)

**Special Note regarding Forward-Looking Statements**

*This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements involve risks, uncertainties and assumptions. All statements in this Annual Report on Form 10-K, other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, intentions, designs, expectations and objectives are forward-looking statements. The words “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “designed,” “developed,” “drive,” “estimate,” “expect,” “forecast,” “goal,” “indicate,” “intend,” “may,” “mission,” “opportunities,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “represent,” “seek,” “suggest,” “should,” “target,” “will,” “would,” and similar expressions (including the negatives thereof) are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. These statements reflect our current views with respect to future events or our future financial performance, are based on assumptions, and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We may not actually achieve the plans, intentions, expectations or objectives disclosed in our forward-looking statements and the assumptions underlying our forward-looking statements may prove incorrect. Therefore, you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and objectives disclosed in the forward-looking statements that we make. Factors that we believe could cause actual results or events to differ materially from our forward-looking statements include, but are not limited to, those discussed in “Risk Factors,” in Item 1A, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 and elsewhere in this Annual Report on Form 10-K. Our forward-looking statements in this Annual Report on Form 10-K are based on current expectations and we do not assume any obligation to update any forward-looking statements for any reason, even if new information becomes available in the future. In addition, while we expect the effects of COVID-19 to continue to adversely impact our business operations and financial results, the extent of the impact on our ability to generate revenue from YUPELRI® (revefenacin), our clinical development programs (including but not limited to our later stage clinical programs for izencitinib and ampreloxetine), and the value of and market for our ordinary shares, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time. These potential future developments include, but are not limited to, the ultimate duration of the COVID-19 pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, other measures taken by us and those we work with to help protect individuals from contracting COVID-19, and the effectiveness of actions taken globally to contain and treat the disease, including vaccine availability, distribution, acceptance and effectiveness. When used in this report, all references to “Theravance Biopharma”, the “Company”, or “we” and other similar pronouns refer to Theravance Biopharma, Inc. collectively with its subsidiaries.*

*​*

**​**

3

[Table of Contents](#TOC)

**PART I**

**ITEM 1. BUSINESS**

**Overview**

Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Our research is focused in the areas of inflammation and immunology.

​

In pursuit of our purpose, we apply insights and innovation at each stage of our business and utilize our internal capabilities and those of partners around the world. We apply organ-selective expertise to biologically compelling targets to discover and develop medicines designed to treat underserved localized diseases and to limit systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including the United States (“US”) Food and Drug Administration (the “FDA”) approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (“COPD”). Our pipeline of internally discovered programs is targeted to address significant patient needs.

​

We have an economic interest in potential future payments from Glaxo Group or one of its affiliates (“GSK”) pursuant to its agreements with Innoviva, Inc. (“Innoviva”) relating to certain programs, including TRELEGY.

​

**2020 Highlights**

Despite the delays and disruption caused by the COVID-19 pandemic, 2020 was a successful year in terms of progress as our key programs advanced towards important milestones.

​

*YUPELRI Sales Growth*

In the second full year since its commercial launch in the first quarter of 2019, YUPELRI continued to experience solid net sales growth in 2020. Through the combined commercialization efforts with our partner Viatris Inc. (formerly, Mylan N.V.), our collaboration revenue related to YUPELRI increased by 221% in 2020 compared to 2019. YUPELRI is the first and only once-daily, nebulized maintenance medicine for COPD. Theravance Biopharma and Viatris copromote in the US, with our combined sales infrastructures targeting health care professionals that treat the universe of COPD patients suitable for YUPELRI. Theravance Biopharma focuses on the hospital segment whereas Viatris focuses on the outpatient segment. While the COVID-19 pandemic impacted YUPELRI’s sales growth trajectory in 2020, we saw sales growth recover in the second half of the year, and we continue to be encouraged by market feedback and performance indicators, including hospital formulary success, patient uptake, and market access, over the past 12 months.

​

*Progression of Late-Stage Studies of Ampreloxetine and Izencitinib*

Ampreloxetine, our norepinephrine reuptake inhibitor, continued to progress in two Phase 3 studies, one designed to assess treatment benefit over four weeks and the other to assess durability of response. Given limitations of existing neurogenic orthostatic hypotension (“nOH”) treatments, ampreloxetine may represent an important treatment option for patients and a meaningful commercial opportunity in the US. To address the challenges presented by COVID-19, we modified our Phase 3 program to allow for a decentralized approach for treating patients in the trial. We anticipate reporting results on our Phase 3 clinical study of ampreloxetine in symptomatic nOH in the third quarter of 2021.

​

Izencitinib (formerly known as TD-1473), our oral gut-selective pan-JAK inhibitor for inflammatory intestinal diseases, partnered with Janssen Biotech, Inc. (“Janssen”), continued to progress in a Phase 2b/3 study in ulcerative colitis and a Phase 2 study in Crohn’s disease. Izencitinib is intended to treat inflammatory intestinal disease directly at the site of inflammation in an organ-selective manner, with minimal systemic exposure or corresponding immunosuppressive effects. We anticipate reporting results from both studies in the third quarter of 2021.

4

[Table of Contents](#TOC)

​

*Positive Phase 1 Data and Clinical Progression of TD-0903*

TD-0903 is a lung-selective, nebulized Janus kinase inhibitor (“JAKi”) in development for the potential treatment of hospitalized patients with Acute Lung Injury caused by COVID-19. We dosed our first patient in a Phase 1 study in April 2020 and results from that study in healthy volunteers showed a favorable safety and tolerability profile across the full range of nebulized doses and low systemic levels of TD-0903 in the systemic circulation, consistent with the lung-selective design. Data from Phase 1 provided confidence to continue dosing patients in a Phase 2 study, with results expected in the second quarter of 2021.

​

*Advancement of TD-5202 into the Clinic*

TD-5202, our oral gut-selective irreversible JAK3 inhibitor for inflammatory intestinal diseases, partnered with Janssen, continued to progress in the clinic. In the third quarter of 2019, we initiated a Phase 1 single ascending dose and multiple ascending dose study primarily designed to evaluate the safety and tolerability of TD-5202 in healthy subjects. In February 2020, we announced that data from the Phase 1 study indicated that TD-5202 was generally well tolerated as a single oral dose up to 2000 milligrams and as a twice-daily oral dose up 2000 milligrams total per day given for ten consecutive days in healthy subjects. We and our partner Janssen believe TD-5202 represents a promising additional therapeutic approach for addressing a range of inflammatory intestinal diseases.

​

*Financing*

We successfully closed on two financing transactions during the first quarter of 2020. In February 2020, we closed on an offering of 5,500,000 ordinary shares at a price to the public of $27.00 per share raising $148.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. Also, in February 2020, we closed on a private placement of $400.0 million of non-recourse Triple II 9.5% fixed rate term notes. The notes are secured by a portion of the future payments we expect to receive related to royalties due on net sales of TRELEGY. We used a portion of the net proceeds from this transaction to repay in full the remaining outstanding balance of the $250.0 million Triple PhaRMASM 9.0% fixed rate term notes due 2033. We are using the remainder of the net proceeds from both transactions to support continued execution of our key development programs.

​

**Impact of COVID-19 Pandemic**

The effects of the COVID-19 pandemic and the related actions by governments, companies, and individuals around the world to attempt to contain the spread of the virus (including new variants of COVID-19) continues to present a substantial public health and economic challenge and is affecting our employees, patients, communities, clinical trial sites, suppliers, business partners and business operations. The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact our business, results of operations and financial condition, including revenue, expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain and may be impacted by the emergence of new information concerning the COVID-19 pandemic, ongoing spread of the disease across the US and the globe, and the actions taken to contain or treat the disease, including vaccine availability, distribution, acceptance and effectiveness.

​

*YUPELRI (revefenacin) Inhalation Solution*

​

We and our collaboration partner, Viatris, continue to supply YUPELRI to our patients and currently do not anticipate any interruptions in supply. The manufacture of YUPELRI continues at or near normal levels.

​

In mid-March 2020, we suspended in-person sales calls to accounts in response to the COVID-19 pandemic. Our promotional focus and efforts quickly pivoted to increased digital promotional investments and, in early August 2020, leveraging an optimized hybrid selling model with virtual and in-person selling interactions. While overall market challenges remain due to the ongoing COVID-19 pandemic, YUPELRI increased its market share and it was profitable on a stand-alone brand basis for the first time in the second half of 2020.

​

5

[Table of Contents](#TOC)

We continue to monitor the impact of the ongoing COVID-19 pandemic on demand for YUPELRI, including the duration and degree to which we may see declines in customer orders or delays in starting new patients on YUPELRI.

​

At this time, we are unable to predict with certainty the ultimate disruptive impact of the ongoing COVID-19 pandemic on both YUPELRI and the rest of our business, but we believe the pandemic may continue to put downward pressure on our sales to the extent that it continues to depress in-person customer interactions.

​

*Clinical Trial Activity*

​

While we are currently continuing the clinical trials that we had underway in sites across the globe prior to the onset of the pandemic, the timelines have been adversely impacted. We frequently evaluate each of our clinical trial programs to determine any additional necessary modifications and have worked closely with regulators, sites, clinical research organizations and data safety monitoring boards. Given the significant strains on the healthcare system across the globe, we made the decision in mid-March 2020 to temporarily suspend the screening of new patients for our clinical trials of izencitinib, a gut-selective oral JAKi in development for inflammatory intestinal disease in Crohn’s and ulcerative colitis, and ampreloxetine, a norepinephrine reuptake inhibitor (“NRI”) under evaluation for the treatment of symptomatic nOH, which are further discussed below. The screening of new patients into these trials was temporarily suspended for 4 weeks in order to prioritize ongoing support for patients who were already in screening and those who were already randomized. We implemented mitigation plans to help ensure patients in the clinical trials continued to have access to drug supply and regular visits with their physicians for study visits per trial protocols.

​

Screening of new patients resumed in mid-April 2020 in a controlled and measured fashion as individual sites confirmed their ability to support the study requirements, and new patients were able to be assessed for their eligibility to participate in the izencitinib and ampreloxetine studies. Study sites and necessary supporting medical infrastructure for our studies, such as endoscopy suites for our study of izencitinib in ulcerative colitis, have been gradually available for participation in and support of our trial through the year, increasing as cases dip and deceasing as cases surge. In recognition of the increasing range of barriers presented by the ongoing pandemic on the ability of nOH patients to travel to sites and access medicines, we worked with the FDA to decentralize the Phase 3 studies in the ampreloxetine program. We are working to offer the decentralized approach across the ampreloxetine Phase 3 program in the US and globally in an effort to overcome the challenges patients face regarding travel, healthcare access and participation in clinical trials. We currently expect Phase 3 results for ampreloxetine for symptomatic nOH and for izencitinib Phase 2b results in ulcerative colitis and Phase 2 results in Crohn's disease in the third quarter of 2021.

​

During the second quarter of 2020, we progressed our preclinical candidate TD-0903 into the clinic at an accelerated pace in response to the COVID-19 pandemic. We designed TD-0903 to be a lung-selective nebulized JAKi with the intent of addressing lung hyperinflammation in both the acute and chronic setting. In June 2020, we completed Phase 1 and entered a two-part Phase 2 study in the United Kingdom (“UK”) to explore the potential of TD-0903 to treat hospitalized patients with Acute Lung Injury caused by COVID-19 and prevent progression to Acute Respiratory Distress Syndrome and the need for assisted ventilation. To expedite enrollment, we opened additional sites in other regions including Europe, US, South Africa and South America. We have completed Phase 2, Part 1 dose escalation and moved into Part 2. Phase 2, Part 2 is a randomized, double-blind, parallel-group study evaluating efficacy and safety of one dose (3 mg) of TD-0903 (selected based on the data from Part 1) as compared with placebo in 198 hospitalized patients with confirmed symptomatic COVID-19 who require supplemental oxygen. We expect to report results from the Phase 2, Part 2 study in the second quarter of 2021.

*​*

*Business Operations*

​

We continue to monitor the ongoing COVID-19 pandemic and plan to continue taking steps to identify and attempt to mitigate the adverse impacts on, and risks to, our business posed by its spread and actions taken by governmental and health authorities to address the COVID-19 pandemic. The threat of COVID-19 has caused us to modify our business practices, including implementing a work from home policy for all employees, with the exception of key operations and lab personnel, since early March 2020. We have restricted all non-essential business travel, and we expect to continue to implement measures as may be required or recommended by government authorities or as we

6

[Table of Contents](#TOC)

determine are in the best interests of our employees, clinical trial sites and participants, the patients we serve and other stakeholders in light of COVID-19.

​

**Our Programs**

The table below summarizes the status of our approved product and our other product candidates in development. The table also includes the status of the respiratory programs in which we have an economic interest and for which GSK is responsible pursuant to agreements between Innoviva and GSK (“GSK-Partnered Respiratory Programs”). These programs consist primarily of the Trelegy program. We have an economic interest in these programs through our interest in Theravance Respiratory Company, LLC (“TRC”), a limited liability company managed by Innoviva. The status of all GSK-Partnered Respiratory Programs referenced in this Annual Report on Form 10-K are based solely upon publicly available information and may not reflect the most recent developments under the programs.

​

​

​

|  |  |  |
| --- | --- | --- |
|  | (1) | We hold an 85% economic interest in upward-tiering royalty stream of 6.5% – 10% payable by GSK (net of TRC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC Agreement over the next four fiscal quarters). 75% of TRC royalties received is pledged to service outstanding notes, and 25% of royalties received are retained by us. All statements concerning TRELEGY are based on publicly available information. |

​

**Glossary of Defined Terms used in Table Above:**

**COPD:** Chronic Obstructive Pulmonary Disease;

**CD:** Crohn’s Disease;

**FF:** Fluticasone Furoate;

**JAKi**: Janus Kinase Inhibitor;

**LAMA:** Long-Acting Muscarinic Antagonist;

**nOH:** Neurogenic Orthostatic Hypotension;

**NRI:** Norepinephrine Reuptake Inhibitor;

**UC:** Ulcerative Colitis;

**UMEC:** Umeclidinium; and

**VI:** Vilanterol

​

7

[Table of Contents](#TOC)

**Program Highlights**

***YUPELRI(revefenacin) Inhalation Solution***

​

YUPELRI (revefenacin) inhalation solution is a once-daily, nebulized long-acting muscarinic antagonist (“LAMA”) approved for the maintenance treatment of COPD in the US. LAMAs are recognized by international COPD treatment guidelines as a cornerstone of maintenance therapy for COPD, regardless of severity of disease. Our market research indicates there is an enduring population of COPD patients in the US that either need or prefer nebulized delivery for maintenance therapy. The stability of revefenacin in both metered dose inhaler and dry powder inhaler (“MDI/DPI”) formulations suggests that revefenacin could also serve as a foundation for novel handheld combination products.

​

In November 2018, YUPELRI was approved by the FDA for the maintenance treatment of patients with COPD. Following shipments into commercial channel in late 2018, we and Viatris formally launched our sales and marketing efforts in early 2019. As described above and in *Item 1A.* *Risk Factor* *entitled* *“We face risks related to health epidemics, including the recent COVID-19 pandemic, which could have a material adverse effect on our business and results of operations,”* although YUPELRI net sales growth continued for the year ended December 31, 2020 compared to 2019, the trajectory was impacted by COVID-19, and we have observed increased volatility in YUPELRI sales. However, our YUPELRI operations were profitable on a brand basis for the first time in the second half of 2020. In addition, we are tracking several key performance metrics to gauge success in building market acceptance, including formulary success and market access.

​

*Viatris Collaboration*

​

In January 2015, Viatris and we established a strategic collaboration for the development and commercialization of revefenacin. Partnering with a leader in nebulized respiratory therapies enables us to expand the breadth of our revefenacin development program and extend our commercial reach beyond the acute care setting. Viatris funded the Phase 3 development program of YUPELRI, enabling us to advance other high value pipeline assets alongside YUPELRI.

​

Under the terms of the Viatris Development and Commercialization Agreement (the “Viatris Agreement”), Viatris and we co-develop revefenacin for COPD and other respiratory diseases. We led the US Phase 3 development program for YUPELRI in COPD, and Viatris was responsible for reimbursement of our costs related to the registrational program up until the approval of the first new drug application (“NDA”), after which costs are shared. With YUPELRI approved in the US, Viatris is leading commercialization, and we co-promote the product in the US under a profit and loss sharing arrangement (65% to Viatris; 35% to Theravance Biopharma). Outside the US, Viatris is responsible for development and commercialization and will pay us a tiered royalty on net sales at percentage royalty rates ranging from low double-digits to mid-teens.

​

In June 2019, we announced the expansion of the Viatris Agreement to grant Viatris exclusive development and commercialization rights to nebulized revefenacin in China and adjacent territories, which include Hong Kong SAR, the Macau SAR, and Taiwan. In exchange, we received an upfront payment of $18.5 million (before a required tax withholding) and will be eligible to receive additional potential development and sales milestones totaling $54.0 million and low double-digit tiered royalties on net sales of nebulized revefenacin, if approved. In March 2020, we earned a $1.5 million development milestone for the acceptance of a clinical trial application associated with the use of revefenacin monotherapy in China and adjacent territories. Viatris is responsible for all aspects of development and commercialization in the partnered regions, including pre- and post-launch activities and product registration and all associated costs. We retain worldwide rights to revefenacin delivered through other dosage forms, such as a MDI/DPI.

​

Under the Viatris Agreement, as of December 31, 2020, we are eligible to receive from Viatris potential global development, regulatory and sales milestone payments totaling up to $257.5 million in the aggregate with $205.0 million associated with YUPELRI monotherapy and $52.5 million associated with future potential combination products. Of the $205.0 million associated with monotherapy, $187.5 million relates to sales milestones based on achieving certain levels of net sales and $17.5 million relates to global development and regulatory actions. The $52.5 million associated with future potential combination products relates solely to global development and regulatory actions.

8

[Table of Contents](#TOC)

​

***Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (TD-0903)***

​

TD-0903 is a lung-selective, nebulized Janus kinase inhibitor (“JAKi”), in clinical development for the potential treatment of hospitalized patients with Acute Lung Injury (“ALI”) caused by COVID-19. We discovered TD-0903, and it has been shown in experimental murine models to have potent, broad inhibition of JAK-STAT signaling in the airways following challenges with multiple cytokines. Preclinical studies suggest that TD-0903 has a very high lung to plasma ratio and rapid metabolic clearance resulting in low systemic exposure, compatible with its lung selectivity. TD-0903 is administered via nebulized inhalation solution, which further enhances its lung selectivity. Preclinical pharmacodynamic studies indicate that TD-0903 has an extended duration of action that should enable once daily dosing in humans.

​

We believe TD-0903 has the potential to inhibit the cytokine storm associated with ALI and prevent progression to Acute Respiratory Distress Syndrome (“ARDS”). The first healthy volunteer was dosed in a Phase 1 study of TD-0903 in April 2020, and in June 2020, we completed Phase 1 and entered a two-part Phase 2 study. Phase 2 is designed to evaluate the efficacy, safety, and tolerability of TD-0903 in subjects with confirmed symptomatic COVID-19 hospitalized for symptomatic respiratory insufficiency. This study will also evaluate the PK of TD-0903 in these subjects. To expedite enrollment, we opened additional sites in other regions including Europe, the US, South Africa and South America.

​

We completed Phase 2, Part 1 a small sub-study of 25 patients intended to assess safety, PK and exploratory clinical measures of three doses of TD-0903 versus placebo. Data showed that inhaled administration of nebulized TD-0903, once daily over seven days, was generally well-tolerated and showed a numerical trend towards improved clinical status, reduced hospital stay and fewer deaths compared to placebo during a 28-day observation period. TD-0903 also demonstrated evidence of improvements in several relevant inflammatory biomarkers and low systemic exposure at all doses. This demonstrates the lung-selective design features of the molecule.

​

We have moved into Phase 2 Part 2, which is a randomized, double-blind, parallel-group study evaluating efficacy and safety of one dose (3 mg) of TD-0903 (selected based on the data from Part 1) as compared with placebo in 198 patients. We expect to report results from the Phase 2 Part 2 study in the second quarter of 2021.

​

***Ampreloxetine (TD-9855)***

**​**

Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor (“NRI”) being developed for the treatment of patients with symptomatic neurogenic orthostatic hypotension (“nOH”). nOH is caused by primary autonomic failure conditions, including multiple system atrophy, Parkinson’s disease and pure autonomic failure. The compound has high affinity for binding to norepinephrine transporters. By blocking the action of these transporters, ampreloxetine causes an increase in extracellular concentrations of norepinephrine. Ampreloxetine is wholly owned by us.

​

Based on positive top-line four-week results from a small exploratory Phase 2 study in nOH and discussions with the FDA, we advanced ampreloxetine into a Phase 3 program. The Phase 3 program includes two studies. The first study (SEQUOIA) is a four-week, randomized double-blind, placebo-controlled study designed to evaluate the efficacy and safety of ampreloxetine in patients with symptomatic nOH. The second study (REDWOOD) is a four-month open label study followed by a six-week randomized withdrawal phase to evaluate the durability of patient response of ampreloxetine. We announced the initiation of patient dosing in each Phase 3 study in early 2019. Phase 3 also includes a 26-week open-label study (OAK), which is a long-term extension study that will be ongoing at the time of registration, to allow participants completing REDWOOD to have continued access to ampreloxetine for up to 3.5 years and to collect safety and tolerability data over the course of treatment. As described above and in *Item 1A. Risk Factors*, the COVID-19 pandemic has impacted the timeline for our clinical trials. In recognition of the increasing range of barriers presented by the ongoing pandemic on the ability of patients to travel to sites and access medicines, we worked with the FDA to decentralize the Phase 3 studies in the ampreloxetine program. We are working to offer the decentralized approach across the ampreloxetine Phase 3 program in the US and globally in an effort to overcome the challenges patients face regarding travel, healthcare access and participation in clinical trials. We expect the SEQUOIA study to report data in the third quarter of 2021.

9

[Table of Contents](#TOC)

​

***Gut-selective Pan-JAK Inhibitor Program (Izencitinib)***

**​**

JAK inhibitors function by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2) that play a key role in cytokine signaling. Inhibiting these JAK enzymes interferes with the JAK/STAT signaling pathway and, in turn, modulates the activity of a wide range of pro-inflammatory cytokines. JAK inhibitors are currently approved for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis and have demonstrated therapeutic benefit for patients with Crohn’s disease. However, these products are known to have side effects based on their systemic exposure. In izencitinib, our program goal is to develop an orally administered, gut-selective pan-JAK inhibitor specifically designed to distribute adequately and predominantly to the tissues of the intestinal tract, treating inflammation in those tissues while minimizing systemic exposure. We believe izencitinib could be a potential treatment for a range of inflammatory intestinal diseases, and it is in development for the treatment of ulcerative colitis and Crohn’s disease.

​

Based on positive results from a Phase 1b exploratory study in ulcerative colitis and following dialogues with the FDA and European Medicines Agency (“EMA”) regarding study design, we advanced izencitinib into two clinical studies in inflammatory intestinal diseases. The Phase 2 (DIONE) study is a twelve-week randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of patients with Crohn’s disease, which began dosing patients in late 2018. The Phase 2b/3 (RHEA) study is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eight weeks induction and 44 weeks maintenance therapy in patients with ulcerative colitis, which began dosing patients in early 2019. As described above and in *Item 1A. Risk Factors,* the COVID-19 pandemic has impacted the timeline for our clinical trials. Data from the Phase 2b portion of the ulcerative colitis study and the Phase 2 Crohn’s disease studies is expected in the third quarter of 2021.

​

***Irreversible JAK3 Inhibitor (TD-5202)***

***​***

TD-5202 is an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that has demonstrated a high affinity for the JAK3 enzyme. Through the selective inhibition of JAK3, TD-5202 interferes with the JAK/STAT signaling pathway and, in turn, modulates the activity of select pro-inflammatory cytokines, including IL-2, IL-15, and IL-21 which play a central role in the pathogenesis of T-cell mediated disease, including inflammatory intestinal disease, such as celiac disease. Importantly, TD-5202 is specifically designed to act locally within the intestinal wall thereby limiting systemic exposure.

​

In September 2019, we announced the initiation of a Phase 1 single ascending dose and multiple ascending dose trial designed to evaluate the safety and tolerability of TD-5202 in healthy participants, plus assess plasma pharmacokinetics of TD-5202 to confirm circulating levels are low, consistent with a gut-selective approach. In February 2020, we announced that data from the Phase 1 study indicated that TD-5202 was generally well tolerated as a single oral dose up to 2000 milligrams and as a twice-daily oral dose up 2000 milligrams total per day given for ten consecutive days in healthy participants.

​

We are developing izencitinib and TD-5202 in collaboration with Janssen as part of the companies’ global co-development and commercialization agreement for novel, gut-selective JAK inhibitors.

​

*Janssen Biotech Collaboration*

*​*

In February 2018, we announced a global co-development and commercialization agreement with Janssen for izencitinib and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. Under the terms of the agreement, we received an upfront payment of $100.0 million and will be eligible to receive up to an additional $900.0 million in potential payments, inclusive of a potential opt-in payment following completion of the Phase 2 Crohn’s study and the Phase 2b induction portion of the ulcerative colitis study. At that time, Janssen can elect to obtain an exclusive license to develop and commercialize izencitinib and certain related compounds by paying us a fee of $200.0 million. Upon such election, we and Janssen will jointly develop and commercialize izencitinib in inflammatory intestinal diseases, and we and Janssen will share profits and losses in the US and expenses related to a potential Phase 3 program (67% to Janssen; 33% to Theravance Biopharma). In addition, we would receive royalties on ex-US sales at double-digit tiered percentage royalty rates.

​

10

[Table of Contents](#TOC)

The closing of the opt-in portion of the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act (“HSR Act”). After Phase 2, Janssen would lead subsequent development of izencitinib in Crohn’s disease if it makes such an election. We will lead development of izencitinib in ulcerative colitis through completion of the Phase 2b/3 study. If izencitinib is commercialized, we have the option to co-commercialize in the US, and Janssen would have sole commercialization responsibilities outside the US.

​

***Lung-selective Pan-JAK Inhibitor Program (TD-8236)***

***​***

TD-8236 is an investigational, inhaled lung-selective pan-JAK inhibitor that has demonstrated a high affinity for each of the JAK family of enzymes (JAK1, JAK2, JAK3 and TYK2) that play a key role in cytokine signaling. Inhibiting these JAK enzymes interferes with the JAK/STAT signaling pathway and, in turn, modulates the activity of a wide range of pro-inflammatory cytokines. While orally-administered JAK inhibitors are currently approved for the treatment of a range of inflammatory diseases, no inhaled JAK inhibitor is approved for the treatment of airway disease, including asthma. The pan-JAK activity of TD-8236 suggests that it may impact a broad range of cytokines that have been associated both T2-high and T2-low asthma. Many moderate to severe asthma patients comprising both T2 phenotypes remain symptomatic despite being compliant on high doses of inhaled steroids. Importantly, TD-8236 is designed to distribute and exert its anti-inflammatory effect within the lungs following dry powder inhalation, with the potential to treat inflammation within that organ while minimizing systemic exposure. In preclinical assessments, TD-8236 has shown to potently inhibit targeted mediators of T2-high and T2-low asthma in human cells.

​

In September 2019, we announced positive results from a Phase 1 single-ascending dose and multiple-ascending dose clinical trial of TD-8236. The Part C extension portion of the Phase 1 trial, assessing additional biomarkers in patients with moderate to severe asthma, demonstrated that biomarkers of JAK target engagement (including exhaled nitric oxide and pSTAT1 and pSTAT6 in cellular fractions of bronchoalveolar lavage fluid) were reduced after 7 days of once-daily dosing at a dose level of 1500 µg. In December 2019, we announced the initiation of a Phase 2 allergen challenge study of TD-8236 in mild allergic asthma patients, and we reported results of the Phase 1C study in the third quarter of 2020. TD-8236 is the first JAK inhibitor to be studied in a Phase 2a Lung Allergen Challenge (“LAC”) study, but inconsistent with our expectations, it had no impact on decrease in lung function (FEV1) following allergen inhalation after 14 days of once-daily dosing at dose levels of 150 µg and 1500 µg compared to placebo and did not meet the primary study objective. The collective data set (preclinical, Phase 1, Phase 2a) demonstrates TD-8236 engages the JAK mechanism at a dose of 1500 µg as evidenced by the reduction in FeNO and reductions in pSTAT, but does not protect against the lung function decline seen after allergen inhalation.

​

After completing additional analysis on TD-8236 gene signature and biomarker data from the Phase 1C study, we found that the data are consistent with target engagement in the lung. However, based on our current understanding of TD-8236, we have decided to pause the clinical program for this specific compound in its current form and apply our learnings to refining and expanding molecules in our portfolio of inhaled JAK inhibitors. The robust body of scientific evidence from TD-8236 and TD-0903 programs provide confidence for us to continue the lung-selective inhaled JAK inhibitor program for asthma. The full data set for TD-8236 will be presented at future scientific meetings.

​

**Economic Interest in GSK-Partnered Respiratory Programs**

We hold an 85% economic interest in any future payments that may be made by GSK to Theravance Respiratory Company, LLC (“TRC”) pursuant to its agreements with Innoviva (net of TRC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters) relating to the GSK-Partnered Respiratory Programs, which Innoviva partnered with GSK and assigned to TRC in connection with Innoviva’s separation of its biopharmaceutical operations into its then wholly-owned subsidiary Theravance Biopharma in June 2014. The GSK-Partnered Respiratory Programs consists primarily of the TRELEGY program, which is described in more detail below. We are entitled to this economic interest through our equity ownership in TRC. Our economic interest does not include any payments associated with RELVAR ELLIPTA/BREO ELLIPTA, ANORO ELLIPTA or vilanterol monotherapy.

​

The following information regarding the TRELEGY program is based solely upon publicly available information and may not reflect the most recent developments under the programs.

​

11

[Table of Contents](#TOC)

***TRELEGY (the combination of fluticasone furoate/umeclidinium bromide/vilanterol)***

TRELEGY provides the activity of an inhaled corticosteroid (FF) plus two bronchodilators (UMEC, a LAMA, and VI, a long-acting beta2 agonist, or LABA) in a single delivery device administered once-daily. TRELEGY is approved for use in the US and European Union (“EU”) for the long-term, once-daily, maintenance treatment of patients with COPD. We hold an 85% economic interest in the royalties payable by GSK to TRC on worldwide net sales (net of TRC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters) through our interest in TRC. Those royalties are upward-tiering from 6.5% to 10%, resulting in cash flows to us of approximately 5.5% to 8.5% of worldwide net sales of TRELEGY (net of TRC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters). Theravance Biopharma is not responsible for any of GSK’s costs related to the development or commercialization of TRELEGY.

​

GSK and Innoviva conducted two global pivotal Phase 3 studies of TRELEGY in COPD, the IMPACT study and the FULFIL study. In September 2017, GSK and Innoviva announced that the FDA approved TRELEGY for the long-term, once-daily, maintenance treatment of appropriate patients with COPD. In August 2019, GSK announced that it had filed a supplemental new drug application (“sNDA”) to the FDA supporting revised labelling for TRELEGY on reduction in risk of all-cause mortality compared with ANORO ELLIPTA in patients with COPD. The FDA postponed an Advisory Committee meeting that was previously scheduled for April 21, 2020 related to this sNDA which was subsequently rescheduled for August 31, 2020. During the FDA’s Advisory Committee, the panel voted against the proposed all-cause mortality labeling claim. GSK announced during their third-quarter conference call on October 28, 2020 that the company received a Complete Response Letter from the FDA for the label update.

​

Additionally, GSK and Innoviva conducted a Phase 3 (CAPTAIN) study of TRELEGY in patients with asthma. In May 2019, GSK and Innoviva announced that the study had met its primary endpoint, and in October 2019, GSK announced it had filed a sNDA with the FDA seeking an additional indication for the use of once-daily, single-inhaler triple therapy, TRELEGY, for the treatment of asthma in adults. The FDA approved the asthma sNDA in September 2020 making TRELEGY the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US.

*​*

***Theravance Respiratory Company, LLC***

Prior to the June 2014 spin-off from Innoviva, our former parent company, Innoviva assigned to Theravance Respiratory Company, LLC (“TRC”), a Delaware limited liability company formed by Innoviva, its strategic alliance agreement with GSK and all of its rights and obligations under its collaboration agreement with GSK, other than with respect to RELVAR ELLIPTA/BREO ELLIPTA, ANORO ELLIPTA and vilanterol monotherapy.

​

Our equity interest in TRC is the mechanism by which we are entitled to the 85% economic interest in any future payments made by GSK under the strategic alliance agreement and under the portion of the collaboration agreement assigned to TRC by Innoviva (net of TRC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters). TRELEGY is currently the only commercial product arising out of the GSK agreements assigned by Innoviva to TRC. Royalty payments from GSK to TRC arising from the net sales of Trelegy are presented in our consolidated statements of operations within “Income from investment in TRC, LLC” and is classified as non-operating income. During the three months ended June 30, 2020, we also recorded $8.5 million within “Income from investment in TRC, LLC” representing our share of a $10.0 million fee that GSK agreed to pay TRC upon termination of the inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist (“MABA”) program in June 2020. Seventy-five percent of the “Income from investment in TRC, LLC,” as evidenced by the Issuer II Class C Units (defined below), is available only for payment of the $400.0 million aggregate amount of 9.5% fixed rate non-recourse term notes due 2035 (the “Non-Recourse 2035 Notes”) and is not available to pay our other obligations or the claims of our other creditors.

​

Our special purpose subsidiary Triple Royalty Sub II LLC (the “Issuer II”) issued the Non-Recourse 2035 Notes in February 2020, the proceeds of which were used in part to repay the outstanding balance of our 9.0% non-recourse notes, due on or before 2033 (the “Non-Recourse 2033 Notes”) that were issued in November 2018. The Non-Recourse 2035 Notes are secured by all of the Issuer II’s rights, title and interest as a holder of certain membership

12

[Table of Contents](#TOC)

interests (the “Issuer II Class C Units”) in TRC. The Issuer II Class C Units entitle the Issuer II to receive 63.75% of the economic interest that TRC receives in any future payments made by GSK under the agreements described above, or 75% of the income from our 85% ownership interest in TRC.

**​**

On June 10, 2020, we disclosed in a Form 8-K that we had formally objected to TRC and Innoviva, as the manager of TRC, regarding their proposed plan to use TRELEGY royalties to invest in certain privately-held companies, funds that would otherwise be available for distribution to us under the terms of the TRC LLC Agreement. We intend to continue to seek to protect our interests in this matter consistent with the dispute resolution procedures of the TRC LLC Agreement. In this regard, we initiated an arbitration proceeding against Innoviva and TRC in October 2020 challenging the authority of Innoviva and TRC to pursue such a business plan rather than distribute such funds to us in a manner consistent with the TRC LLC Agreement and our 85% economic interest in TRC. The arbitration hearing was held during the week of February 16, 2021, with post-hearing briefing and arguments to take place over the next few weeks. We currently anticipate a decision in those proceedings near the end of the first quarter or early in the second quarter of 2021.

​

**Other Economic Interests**

***Selective 5-HT4 Agonist (TD-8954)***

​

TD-8954 is a selective 5-HT4 receptor agonist being developed for potential use in the treatment of gastrointestinal motility disorders.

​

*Takeda Collaborative Arrangement*

​

In June 2016, we entered into a License and Collaboration Agreement (the “Takeda Agreement”) with Millennium Pharmaceuticals, Inc. (“Millennium”), in order to establish a collaboration for the development and commercialization of TD-8954 (TAK-954). Millennium is an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”). TD-8954 is currently in a Phase 2 study as a potential treatment for post-operative gastrointestinal dysfunction. Under the terms of the Takeda Agreement, Takeda is responsible for worldwide development and commercialization of TD-8954. We received an upfront cash payment of $15.0 million and will be eligible to receive success-based development, regulatory and sales milestone payments from Takeda. We will also be eligible to receive a tiered royalty on worldwide net sales by Takeda at percentage royalty rates ranging from low double-digits to mid-teens.

**​**

***Skin-selective Pan-JAK inhibitor program***

In December 2019, we entered into a global license agreement with Pfizer Inc. (“Pfizer”) for our preclinical skin-selective, locally-acting pan-JAK inhibitor program (the “Pfizer Agreement”). The compounds in this program are designed to target validated pro-inflammatory pathways and are specifically designed to possess skin-selective activity with minimal systemic exposure.

​

Under the Pfizer Agreement, Pfizer has an exclusive license to develop, manufacture and commercialize certain compounds for all uses other than gastrointestinal, ophthalmic and respiratory applications. We received an upfront cash payment of $10.0 million and are eligible to receive up to an additional $240.0 million in development and sales milestone payments from Pfizer. In addition, we are eligible to receive a tiered royalty on worldwide net sales of any potential products under the license at percentage royalty rates ranging from middle single-digits to low double-digits.

​

**Research Projects**

Our research goal is to design organ-selective medicines that target diseased tissues, without systemic exposure, in order to maximize patient benefit and minimize risk. The intention is to expand the therapeutic index of our potential medicines compared to conventional systemic therapies. Our efforts leverage years of experience in developing lung-selective medicines, such as YUPELRI, to treat respiratory diseases, and have led to the discovery of the gut-selective pan-JAK inhibitor izencitinib and irreversible JAK3 inhibitor TD-5202 for inflammatory intestinal diseases and the lung-selective inhaled JAK inhibitor TD-8236 and nebulized pan JAK inhibitor TD-0903 in serious respiratory disease. We plan to advance towards the clinic other research projects with various mechanisms of action, each specifically tailored for the organ of interest, as we identify and validate potentially appropriate compounds. Our research is focused

13

[Table of Contents](#TOC)

in the areas of inflammation and immunology, and our pipeline of internally discovered programs is targeted to address significant patient needs.

​

**Our Strategy**

Our core purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. We strive to apply insight and innovation at each stage of our business, including research, development and commercialization. Our principle strategic objective is to transform the treatment of serious diseases through the discovery, development, and commercialization of organ-selective medicines designed to maximize patient benefit while minimizing patient risk.

​

We follow these core guiding principles in our mission to drive value creation:

​

|  |  |  |
| --- | --- | --- |
|  | • | Focus on insight and innovation; |

|  |  |  |
| --- | --- | --- |
|  | • | Outsource non-core activities; |

|  |  |  |
| --- | --- | --- |
|  | • | Create and foster an integrated environment; and |

|  |  |  |
| --- | --- | --- |
|  | • | Aggressively manage uncertainty. |

We manage our pipeline with the goal of optimizing program value and allocation of resources. We employ multiple strategies for commercialization of our products. Our approach may involve retaining product rights and marketing a product independently in the US or we may partner a product to extend our commercial reach, to expand our geographic reach, and/or to manage the financial risk associated with the program. Alternatively, we may monetize or divest an asset that we designate as outside our core business, where we believe the program is optimized by leveraging partner capabilities and removing or limiting our research and development costs.

​

**Manufacturing**

We rely primarily on a network of third-party manufacturers, including contract manufacturing organizations, to produce the active pharmaceutical ingredients (“API”) and drug products required for our clinical trials and drug product. We believe that we and our partners have in-house expertise to manage this network of third-party manufacturers, and we believe that we will be able to continue to negotiate third-party manufacturing arrangements on commercially reasonable terms and that it will not be necessary for us to rely on internal manufacturing capacity in order to develop or, potentially, commercialize our products. However, if we are unable to obtain contract manufacturing or obtain such manufacturing on commercially reasonable terms, or if manufacturing is interrupted at one of our suppliers, whether due to regulatory or other reasons, we may not be able to develop our products or commercialize product as planned.

​

Any inability to acquire sufficient quantities of API or drug product in a timely manner from current or future sources could disrupt our research and development programs, the conduct of future clinical trials or our commercialization efforts. For more information, see the risk factor under the heading “*There is a single source of supply for a number of our product candidates and for YUPELRI, and our business will be harmed if any of these single-source manufacturers are not able to satisfy demand and alternative sources are not available*” of this Annual Report on Form 10-K.

​

**Government Regulation**

The development and commercialization of pharmaceutical products and our product candidates by us, our collaboration partners and licensees, GSK, and Cumberland Pharmaceuticals Inc. (“Cumberland”) and our ongoing research are subject to extensive regulation by governmental authorities in the US and other countries. Before marketing in the US, any medicine must undergo rigorous preclinical studies and clinical studies and an extensive regulatory approval process implemented by the FDA under the Federal Food, Drug, and Cosmetic Act. Outside the US, the ability to market a product depends upon receiving a marketing authorization from the appropriate regulatory authorities which are subject to equally rigorous regulatory obligations. The requirements governing the conduct of clinical studies,

14

[Table of Contents](#TOC)

marketing authorization, pricing and reimbursement vary widely from country to country. In any country, however, the commercialization of pharmaceutical products is permitted only if the appropriate regulatory authority is satisfied that we have presented adequate evidence of the safety, quality and efficacy of the product.

​

Before commencing clinical studies in humans in the US, we must submit to the FDA an investigational new drug application (“IND”) that includes, among other things, the general investigational plan and protocols for specific human studies and the results of preclinical studies. An IND will go into effect 30 days following its receipt by the FDA unless the FDA issues a clinical hold. Once clinical studies have begun under the IND, they are usually conducted in three phases and under FDA oversight. These phases generally include the following:

***​***

***Phase 1.*** The product candidate is introduced into patients or healthy human volunteers and is tested for safety, dose tolerance and pharmacokinetics.

***​***

***Phase 2.*** The product candidate is introduced into a limited patient population to assess the efficacy of the drug in specific, targeted indications, assess dosage tolerance and optimal dosage, and identify possible adverse effects and safety risks.

***​***

***Phase 3.*** If a compound is found to be potentially effective and to have an acceptable safety profile in Phase 2 evaluations, the clinical study will be expanded to further demonstrate clinical efficacy, optimal dosage and safety within an expanded patient population.

​

The results of product development, preclinical studies and clinical studies must be submitted to the FDA as part of an NDA. The NDA also must contain extensive manufacturing information. The Prescription Drug User Fee Act (“PDUFA”) establishes timeframes for FDA review of NDAs, with a performance goal of reviewing and acting on 90 percent of priority new molecular entity (“NME”) NDA submissions within 6 months of the 60-day filing date, and to review and act on 90 percent of standard NME NDA submissions within 10 months of the 60-day filing date. The 2007 Food and Drug Administration Amendments Act gave the FDA authority to require implementation of a formal Risk Evaluation and Management Strategy to ensure that the benefits of a product outweigh its risks. At the end of the review period, the FDA communicates either approval of the NDA or a complete response listing the application’s deficiencies.

​

Once approved, the FDA may withdraw the product approval if compliance with post-marketing regulatory standards is not maintained or if safety or quality issues are identified after the product reaches the marketplace. In addition, the FDA may require post-marketing studies, sometimes referred to as Phase 4 studies, to monitor the safety and effectiveness of approved products, and may limit further marketing of the product based on the results of these post-marketing studies. The FDA has broad post-market regulatory and enforcement powers, including the ability to suspend or delay issuance of approvals, seize products, withdraw approvals, enjoin violations, and initiate criminal prosecution.

​

If regulatory approval for a medicine is obtained, the clearance to market the product will be limited to those diseases and conditions approved by FDA and for which the medicine was shown to be effective, as demonstrated through clinical studies and specified in the medicine’s labeling. Even if this regulatory approval is obtained, a marketed medicine, its manufacturer and its manufacturing facilities are subject to continual review and periodic inspections by the FDA. The FDA ensures the quality of approved medicines by carefully monitoring manufacturers’ compliance with its current Good Manufacturing Practice (“cGMP”) regulations. The cGMP regulations for drugs contain minimum requirements for the methods, facilities, and controls used in manufacturing, processing, and packaging of a medicine. The regulations are intended to make sure that a medicine is safe for use, and that it has the ingredients and strength it claims to have. Discovery of previously unknown problems with a medicine, manufacturer or facility may result in restrictions on the medicine or manufacturer, including costly recalls or withdrawal of the medicine from the market.

​

We, our collaboration partners and licensees are also subject to various laws and regulations regarding laboratory practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances in connection with our research. In each of these areas, as above, the FDA and other regulatory authorities have broad regulatory and enforcement powers, including the ability to suspend or delay issuance of approvals, seize

15

[Table of Contents](#TOC)

products, withdraw approvals, enjoin violations, and initiate criminal prosecution, any one or more of which could have a material adverse effect upon our business, financial condition and results of operations.

​

Outside the US our, our collaboration partners’, licensees’, GSK’s and Cumberland’s ability to market products will also depend on receiving marketing authorizations from the appropriate regulatory authorities. Risks similar to those associated with FDA approval described above exist with the regulatory approval processes in other countries.

​

**United States Healthcare Reform**

The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (together the “Healthcare Reform Act”), substantially changed the way healthcare is financed by both governmental and private insurers, and impacts pricing and reimbursement of YUPELRI and the marketed drugs with respect to which we are entitled to royalty or similar payments, and related commercial operations. Certain provisions of the Healthcare Reform Act have been subject to judicial challenges as well as efforts to repeal or replace them or to alter their interpretation or implementation. We expect that the Healthcare Reform Act, its implementation, efforts to repeal or replace, or invalidate, the Healthcare Reform Act or portions thereof, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on the ability of us, our collaboration partners, or those commercializing products with respect to which we have an economic interest or right to receive royalties to maintain or increase sales of our existing products or to successfully commercialize our product candidates, if approved. For more information, see the risk factor under the heading *“Changes in healthcare law and implementing regulations, including government restrictions on pricing and reimbursement, as well as healthcare policy and other healthcare payor cost-containment initiatives, may negatively impact us, our collaboration partners, or those commercializing products with respect to which we have an economic interest or right to receive royalties”* of this Annual Report on Form 10-K.

​

**Pharmaceutical Pricing and Reimbursement**

We participated in and had certain price reporting obligations under the Medicaid Drug Rebate program for VIBATIV for which we remain responsible, as described in greater detail under the risk factor “*If we failed to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects”* of this Annual Report on Form 10-K.

​

Our ability, and the ability of our collaboration partners, licensees, or those commercializing products with respect to which we have an economic interest or right to receive royalties to commercialize our products successfully, and our ability to attract commercialization partners for our products, depends in significant part on the availability of adequate financial coverage and reimbursement from third-party payors, including, in the US, governmental payors such as the Medicare and Medicaid programs, managed care organizations, and private health insurers. The reimbursement environment is described in greater detail under the risk factor *“Changes in healthcare law and implementing regulations, including government restrictions on pricing and reimbursement, as well as healthcare policy and other healthcare payor cost-containment initiatives, may negatively impact us, our collaboration partners, or those commercializing products with respect to which we have an economic interest or right to receive royalties”* of this Annual Report on Form 10-K.

​

**Fraud and Abuse Laws**

Our interactions and arrangements with customers and third-party payors are subject to applicable US federal and state fraud and abuse laws and equivalent third country laws. These laws and the related risks are described in greater detail under the risk factor “*Our relationships with customers and third-party payors are subject to applicable anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion, contractual damages, reputational harm and diminished profits and future earnings*” of this Annual Report on Form 10-K.

​

16

[Table of Contents](#TOC)

**Data Privacy and Protection**

We are subject to laws and regulations that address privacy and data security. In the US, numerous federal and state laws and regulations, including state data breach notification laws, state health information and/or genetic privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act (“FTC Act”)), govern the collection, use, disclosure, and protection of health-related and other personal information. Similar obligations apply outside of the US. For example, the General Data Protection Regulation (“GDPR”) which entered into force on May 25, 2018 amplified existing data protection obligations in the EU. These laws and related risks are described in greater detail under the risk factor *“If we fail to comply with data protection laws and regulations, we could be subject to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity, which could negatively affect our operating results and busines*s” of this Annual Report on Form 10-K.

​

**Patents and Proprietary Rights**

We will be able to protect our technology from unauthorized use by third parties only to the extent that our technology is covered by valid and enforceable patents or is effectively maintained as trade secrets. Our success in the future will depend in part on obtaining patent protection for our product candidates. Accordingly, patents and other proprietary rights are essential elements of our business. Our policy is to seek in the US and selected foreign countries patent protection for novel technologies and compositions of matter that are commercially important to the development of our business. For proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug discovery process that involve proprietary know-how and technology that is not covered by patent applications, we rely on trade secret protection and confidentiality agreements to protect our interests. We require all of our employees, consultants and advisors to enter into confidentiality agreements. Where it is necessary to share our proprietary information or data with outside parties, our policy is to make available only that information and data required to accomplish the desired purpose and only pursuant to a duty of confidentiality on the part of those parties.

​

As of December 31, 2020, we owned 507 issued US patents and 2,253 granted foreign patents, as well as additional pending US patent applications and foreign patent applications. The claims in these various patents and patent applications are typically directed to compositions of matter, including claims covering product candidates, crystalline forms, lead compounds and key intermediates, pharmaceutical compositions, methods of use and/or processes for making our compounds. In particular, our wholly-owned subsidiary Theravance Biopharma R&D IP, LLC owns the following US patents which are listed in the FDA *Approved Drug Products with Therapeutic Equivalence Evaluations* (Orange Book) for YUPELRI (revefenacin) inhalation solution: US Patent No. 7,288,657, expiring on December 23, 2025; US Patent No. 7,491,736, expiring March 10, 2025; US Patent No. 7,521,041, expiring March 10, 2025; US Patent No. 7,550,595, expiring March 10, 2025; US Patent No. 7,585,879, expiring March 10, 2025; US Patent No. 7,910,608, expiring March 10, 2025; US Patent No. 8,034,946, expiring March 10, 2025; US Patent No. 8,053,448, expiring March 10, 2025; US Patent No. 8,273,894, expiring March 10, 2025; US Patent No. 8,541,451, expiring August 25, 2031; US Patent No. 9,765,028, expiring July 14, 2030; US Patent No. 10,106,503, expiring March 10, 2025; US Patent No. 10,343,995, expiring March 10, 2025; and US Patent No. 10,550,081, expiring July 14, 2030 (each of the aforementioned expiration dates not including any patent term extensions that may be available under the Drug Price Competition and Patent Term Restoration Act of 1984). Thus, the last to expire patent currently listed in the Orange Book for YUPELRI (revefenacin) inhalation solution expires on August 25, 2031. On December 19, 2018, we filed patent term extension (“PTE”) applications in the US Patent and Trademark Office (“USPTO”) for US Patent Nos. 7,288,657 and 7,585,879. These PTE applications are currently pending and if granted, we will be permitted to extend the term of one of these patents for the period determined by the USPTO.

​

Issued US and foreign patents generally expire 20 years after their filing date. The patent rights relating to YUPELRI (revefenacin) inhalation solution currently consist of issued US patents, pending US patent applications and counterpart patents and patent applications in a number of jurisdictions, including Europe. Additionally, our patent rights relating to ampreloxetine and izencitinib currently include issued US composition of matter patents that expire in 2030 and 2036, respectively (not including any patent term extensions that may be available under the Drug Price Competition and Patent Term Restoration Act of 1984), as well as additional issued US patents, pending US patent applications and/or counterpart patents and patent applications in a number of jurisdictions. Nevertheless, issued patents can be

17

[Table of Contents](#TOC)

challenged, narrowed, invalidated or circumvented, which could limit our ability to stop competitors from marketing similar products and threaten our ability to commercialize our product candidates. Our patent position, similar to other companies in our industry, is generally uncertain and involves complex legal and factual questions. To maintain our proprietary position, we will need to obtain effective claims and enforce these claims once granted. It is possible that, before any of our products can be commercialized, any related patent may expire or remain in force only for a short period following commercialization, thereby reducing any advantage of the patent. Also, we do not know whether any of our patent applications will result in any issued patents or, if issued, whether the scope of the issued claims will be sufficient to protect our proprietary position.

​

**Competition**

Our late-stage development programs, and the marketed products to which we are entitled to profit share revenue, royalty or similar payments, primarily target three therapeutic areas— respiratory, gastrointestinal, and neurological. In research, we apply organ-selective expertise to biologically compelling targets to discover and develop medicines designed to treat underserved localized diseases and to limit systemic exposure, in order to maximize patient benefit and minimize risk. Our commercial infrastructure is focused primarily on the acute care setting. We expect that any medicines that we commercialize with our collaborative partners or on our own will compete with existing and future market-leading medicines.

​

Many of our competitors have substantially greater financial, technical and personnel resources than we have. In addition, many of these competitors have significantly greater commercial infrastructures than we have. Our ability to compete successfully will depend largely on our ability to leverage our experience in drug discovery, development and commercialization to:

​

|  |  |  |
| --- | --- | --- |
|  | • | discover and develop medicines that are superior to other products in the market; |

|  |  |  |
| --- | --- | --- |
|  | • | attract and retain qualified scientific, clinical development and commercial personnel; |

|  |  |  |
| --- | --- | --- |
|  | • | obtain patent and/or other proprietary protection for our medicines and technologies; |

|  |  |  |
| --- | --- | --- |
|  | • | obtain required regulatory approvals; |

|  |  |  |
| --- | --- | --- |
|  | • | commercialize approved products; and |

|  |  |  |
| --- | --- | --- |
|  | • | successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new medicines. |

***YUPELRI (revefenacin) inhalation solution, a long-acting muscarinic antagonist (LAMA)***

YUPELRI competes predominately with the nebulized LAMA Lonhala® Magnair® (glycopyrrolate) dosed two times per day and with short acting nebulized bronchodilators that are dosed three to four times per day.

*​*

***Trelegy or FF/UMEC/VI (fluticasone furoate/umeclidinium bromide/vilanterol)***

For treatment of COPD, Trelegy competes in the US with AstraZeneca’s Breztri® Aerosphere® (budesonide/glycopyrronium/formoterol fumarate, dosed twice per day). Breztri was approved for COPD by EMA in December 2020 and is expected to launch in 2021. Trimbow (beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide, dosed twice per day) from Chiesi Farmaceutici is an additional COPD competitor in Europe. TRELEGY also competes with Breztri in Japan and China for COPD.

​

For treatment of asthma, TRELEGY is the only triple therapy approved in the US and competes in Japan with Novartis’s Enerzair® Breezhaler® (indacaterol acetate, glycopyrronium bromide and mometasone furoate, dosed once daily). Enerzair and Trimbow are currently under review by EMA, and, if approved in Europe they will compete with TRELEGY.

​

18

[Table of Contents](#TOC)

In both COPD and asthma, TRELEGY also competes with “open triple” therapy which can be accomplished by the concurrent use of two or three products. An example of such use includes a LABA/ICS combination such as AstraZeneca’s Symbicort and a LAMA such as Boehringer Ingelheim’s Spiriva.

​

***Gut-selective Pan-JAK Inhibitor Program (Izencitinib)***

If successfully developed and approved, izencitinib would be expected to compete with biologics, which have become the mainstay of treatment in moderate-to-severe IBD patients, steroids, immunosuppressants, and other JAK inhibitors (all of which provide systemic exposure and are, thus, not gut-selective). Biologics for treatment of IBD (all of which require intravenous or sub-cutaneous administration) include the anti-TNF monoclonal antibodies Humira® (adalimumab), marketed by AbbVie Inc., and Remicade® (infliximab), marketed by Janssen Pharmaceuticals, Inc., and the anti-integrin antibody Entyvio® (vedolizumab), marketed by Takeda Pharmaceuticals America, Inc. Pfizer Inc.’s Xeljanz® (tofacitinib) was the first systemic JAK inhibitor approved by the FDA for the treatment of ulcerative colitis, although other systemic JAK inhibitors are currently in clinical development for IBD including filgotinib (Gilead Sciences, Inc.) and upadacitinib (AbbVie Inc.).

​

***Ampreloxetine norepinephrine reuptake inhibitor (“NRI”)***

If successfully developed and approved, ampreloxetine would be expected to compete predominantly with Northera*®* (droxidopa) marketed by Lundbeck NA Ltd., and to a lesser extent, midodrine and fludrocortisone which are available as generics. In addition, generic droxidopa is expected to enter the US market in February 2021 following expiration of the orphan drug exclusivity for Northera*®*.

​

**Human Capital**

As of December 31, 2020, we had 359 employees. Of these employees, 331 were in the US and 28 were non-US.

​

Our ability to sustain and grow our business requires us to hire, retain and develop a highly skilled and diverse workforce. We emphasize the importance of character and integrity as much as professional qualifications, and we seek to foster a culture of empowerment where employees have ownership in business outcomes. We strive to keep our people engaged and working collaboratively with an understanding that behaviors that matter are reflected in our Core Values - *thinking it through, finding a way, getting it done, and winning together.* Our employees are encouraged through many forms of corporate communication such as an open-door policy, all employee meetings, an anonymous online suggestion box, and an Employee Pulse Survey, to ask questions, make suggestions, and provide input.

*​*

*Diversity and Inclusion*

*​*

We strive to build a culture of diversity and inclusion through our business and human resources practices and policies, and we work to eliminate discrimination and harassment in all of its forms, including related to color, race, sex or gender, sexual orientation, gender identity, age, pregnancy, caste, disability, ethnicity, national origin or ancestry, religious beliefs, veteran status, uniformed servicemember status, or physical or mental disability. We have both a Diversity & Inclusion Council and a Women’s Leadership Network, which are each Company-sponsored, employee-led groups that aim to improve attraction, retention, development, inclusion, and engagement of a diverse and global workforce.

*​*

*Talent Acquisition and Retention*

​

We believe that our philosophy of providing competitive compensation and benefits and our focus on providing opportunities for career growth and development fosters interest from external candidates in Company openings, increases Company employee tenure, and reduces voluntary employee turnover. The global acceptance rate of our employment offers is consistently high. We believe we are successful in our retention efforts because we provide challenging work assignments, cross functional teamwork experiences and career progression supported by new skill building. We invest in employee learning and development by identifying and providing training and development programs, speakers, and other materials and have personnel specifically focused on employee learning and development. Based upon informal and formal feedback, including our Employee Pulse Surveys, management’s relationship with

19

[Table of Contents](#TOC)

employees is very good. Because retention of the employee base is key to our business strategy, executive management provides quarterly updates on turnover metrics to our board of directors.

*​*

*Total Rewards*

​

We reward our employees beyond a competitive base salary. Our employees also receive cash bonus opportunities, equity incentives, health and wellness benefits and programs, and educational benefits. We strive to offer a competitive total rewards package that is responsive to market needs based upon the specific requirements of the job. Some examples of benefits offered include:

​

|  |  |  |
| --- | --- | --- |
|  | ● | quality, affordable health insurance coverage available to both full-time and part-time employees and their eligible dependents; |

|  |  |  |
| --- | --- | --- |
|  | ● | matching contributions to a tax-qualified defined contribution savings (“401k”) plan, on a dollar-for-dollar basis up to a set dollar amount of an employee’s cash compensation; |

|  |  |  |
| --- | --- | --- |
|  | ● | an employee stock purchase plan (“ESPP”); and |

|  |  |  |
| --- | --- | --- |
|  | ● | training and development programs designed to support and improve workplace performance. |

*Culture*

​

We expect all employees to observe the highest levels of business ethics, while also delivering the highest levels of performance. These expectations are set forth in various documents and forms of communication within and across our Company. The Company encourages employees to speak up and raise questions and concerns promptly about any situation that may violate our Code of Business Conduct, our core values or our policies. We believe that it benefits the entire Company for employees to raise concerns so the Company may consider them carefully and address them properly. We seek to promote an environment that fosters honest communications about matters of conduct related to our business activities, whether that conduct occurs within the Company, involves one of the Company’s contractors, suppliers, consultants, or clients, or involves any other party with a business relationship with the Company. We work to make clear that management is prepared to address any reported violations and to ensure that it is known that any form of retaliation is strictly prohibited. In addition, we have an easily-accessible hotline available to employees wishing to report complaints anonymously.

​

**Financial Information About Geographic Areas**

Information on our total revenues attributed to geographic areas and customers who represented at least 10% of our total revenues is included in *“Item 8, Note 4. Segment Information,”* to our consolidated financial statements in this Annual Report on Form 10-K.

​

**Corporation Information**

Theravance Biopharma was incorporated in the Cayman Islands in July 2013 under the name Theravance Biopharma, Inc. Theravance Biopharma began operating as an independent, publicly-traded company on June 2, 2014 following a spin-off from Innoviva, Inc. Our corporate address in the Cayman Islands and principal executive office is P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands and the address of our wholly-owned US operating subsidiary Theravance Biopharma US, Inc. is 901 Gateway Boulevard, South San Francisco, California 94080. While Theravance Biopharma is incorporated under Cayman Island law, the Company became an Irish tax resident effective July 1, 2015. The address of our wholly-owned Irish operating subsidiary, Theravance Biopharma Ireland Limited, is Connaught House, Burlington Road, Dublin 4, Ireland.

​

**Available Information**

Our Internet address is *www.theravance.com*. Our investor relations website is located at *http://investor.theravance.com*. We make available free of charge on our investor relations website under “SEC Filings” our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, our directors’ and officers’ Section 16 Reports and any amendments to those reports as soon as reasonably practicable after filing or

20

[Table of Contents](#TOC)

furnishing such materials to the US Securities and Exchange Commission (“SEC”). Our current Code of Business Conduct, Corporate Governance Guidelines, Articles of Association, Board of Director Committee Charters, and other materials, including amendments thereto, may also be found on our investor relations website under “Corporate Governance.” The information found on our website is not part of this or any other report that we file with or furnish to the SEC. Theravance Biopharma and the Theravance Biopharma logo are registered trademarks of the Theravance Biopharma group of companies. Trademarks, tradenames or service marks of other companies appearing in this report are the property of their respective owners.

​

**ITEM 1A. RISK FACTORS**

The risks described below and elsewhere in this Annual Report on Form 10-K and in our other public filings with the SEC are not the only risks facing the Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

​

**Summary of Principal Risks Associated with Theravance Biopharma’s Business**

​

|  |  |  |
| --- | --- | --- |
|  | ● | We anticipate that we will incur losses for the foreseeable future. We may never achieve or sustain profitability; |

|  |  |  |
| --- | --- | --- |
|  | ● | We face risks related to health epidemics, including the recent COVID-19 pandemic, which could have a material adverse effect on our business and results of operations; |

|  |  |  |
| --- | --- | --- |
|  | ● | Any delay in commencing or completing clinical studies for product candidates and any adverse results from clinical or non-clinical studies or regulatory obstacles product candidates may face, would harm our business and the price of our securities could fall; |

|  |  |  |
| --- | --- | --- |
|  | ● | If our product candidates are not approved by regulatory authorities, including the FDA, we will be unable to commercialize them; |

|  |  |  |
| --- | --- | --- |
|  | ● | If additional capital is not available, we may have to curtail operations or we could be forced to share our rights to commercialize our product candidates with third parties on terms that may not be favorable to us; |

|  |  |  |
| --- | --- | --- |
|  | ● | If our partners do not satisfy their obligations under our agreements with them, or if they terminate our partnerships with them, we may not be able to develop or commercialize our partnered product candidates as planned; |

|  |  |  |
| --- | --- | --- |
|  | ● | We do not control TRC and, in particular, have no control over the GSK Partnered Respiratory Programs, including TRELEGY, or access to non-public information regarding the development of the GSK Partnered Respiratory Programs; |

|  |  |  |
| --- | --- | --- |
|  | ● | If there are any adverse developments or perceived adverse developments with respect to the GSK-Partnered Respiratory Programs in which we have a substantial economic interest, including TRELEGY, our business will be harmed, and the price of our securities could fall; and |

|  |  |  |
| --- | --- | --- |
|  | ● | Our ongoing drug discovery and development efforts might not generate additional successful product candidates or approvable drugs. |

**RISKS RELATING TO THE COMPANY**

​

***We anticipate that we will incur losses for the foreseeable future. We may never achieve or sustain profitability.***

First as part of Innoviva, Inc., and since June 2, 2014 as Theravance Biopharma, we have been engaged in discovery and development of compounds and product candidates since mid-1997. We may never generate sufficient

21

[Table of Contents](#TOC)

revenue from the sale of medicines, royalties on sales by our partners or from our interest in Theravance Respiratory Company, LLC (“TRC”) to achieve profitability. During the year ended December 31, 2020, 2019, and 2018, we recognized net losses of $278.0 million, $236.5 million and $215.5 million, respectively, which are reflected in the shareholders’ deficit on our consolidated balance sheets. We reflect cumulative net loss incurred after June 2, 2014, the effective date of our spin-off from Innoviva, Inc. (the “Spin-Off”), as accumulated deficit on our consolidated balance sheets, which was $1.5 billion as of December 31, 2020. We expect to continue to incur net losses at least over the next several years as we continue our drug discovery and development efforts and incur significant preclinical and clinical development costs related to our current product candidates and commercialization and development costs relating to YUPELRI. In particular, to the extent we continue to advance our product candidates into and through additional clinical studies, we will incur substantial expenses. For example, we initiated a Phase 2b/3 induction and maintenance study of izencitinib in ulcerative colitis, we initiated a Phase 2 induction study of izencitinib in Crohn’s disease, and we have progressed ampreloxetine (TD-9855) into a Phase 3 registrational program. The expenses associated with these clinical studies are substantial. While our YUPELRI operations were profitable on a brand basis for the second half of 2020, we will continue to incur costs and expenses associated with the commercialization of YUPELRI in the United States (“US”), including the maintenance of an independent sales and marketing organization with appropriate technical expertise, a medical affairs presence and consultant support, and post-marketing studies. Our commitment of resources to the continued development of our existing product candidates, our discovery programs, and YUPELRI will require significant additional funding. Our operating expenses also will increase if, among other things:

|  |  |  |
| --- | --- | --- |
|  | • | our earlier stage potential products move into later-stage clinical development, which is generally more expensive than early stage development; |

|  |  |  |
| --- | --- | --- |
|  | • | additional preclinical product candidates are selected for clinical development; |

|  |  |  |
| --- | --- | --- |
|  | • | we pursue clinical development of our potential or current products in new indications; |

|  |  |  |
| --- | --- | --- |
|  | • | our clinical trials become more complicated due to the COVID-19 pandemic or other similar external factors; |

|  |  |  |
| --- | --- | --- |
|  | • | we increase the number of patents we are prosecuting or otherwise expend additional resources on patent prosecution or defense; or |

|  |  |  |
| --- | --- | --- |
|  | • | we acquire or in-license additional technologies, product candidates, products or businesses. |

While we are generating revenues from (i) sales of YUPELRI, (ii) our economic interest in royalties from net sales of TRELEGY paid to TRC (63.75% of which amounts are used to make payments on the Non-Recourse 2035 Notes), (iii) payments under collaboration agreements, and (iv) minor royalties from the net sales of VIBATIV, we do not expect to generate significant revenues or become profitable in the near future. As a result of the COVID-19 pandemic (defined below), we could experience declines in revenues from these sources. Since we or our collaborators or licensees may not successfully develop additional products, obtain required regulatory approvals, manufacture products at an acceptable cost or with appropriate quality, or successfully market and sell such products with desired margins, our expenses will continue to exceed any revenues we may receive for the foreseeable future.

22

[Table of Contents](#TOC)

In the absence of substantial licensing payments, contingent payments or other revenues from third-party collaborators, royalties on sales of products licensed under our intellectual property rights, future revenues from those product candidates in development that receive regulatory approval or other sources of revenues, we will continue to incur operating losses and will require additional capital to execute our business strategy. The likelihood of reaching, and the time required to reach, and then to sustain, profitability are highly uncertain. As a result, we expect to continue to incur substantial losses for the foreseeable future. We are uncertain when or if we will ever be able to achieve or sustain profitability. Failure to become and remain profitable would adversely affect the price of our securities and our ability to raise capital and continue operations.

***We face risks related to health epidemics, including the recent COVID-19 pandemic, which could have a material adverse effect on our business and results of operations.***

Our business has been and will continue to be adversely affected by the recent widespread and contagious outbreak of respiratory illness caused by a novel strain of coronavirus, SARS-CoV-2, causing the Coronavirus Disease 2019, also known as COVID-19 (the “COVID-19 pandemic”). Global health concerns relating to the COVID-19 pandemic have been weighing on the macroeconomic environment, and the pandemic has significantly increased economic volatility and uncertainty.

The pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. These measures have adversely impacted and may further impact our employees and operations and the operations of our customers, suppliers and business partners, and may negatively impact spending patterns, payment cycles and insurance coverage levels. In addition, certain aspects of our business, such as laboratory-based research, cannot be conducted remotely and other aspects of our business, like our hospital-based sales team, our field-based medical affairs team, and our support of sites in our clinical trials, cannot be accomplished as effectively or efficiently remotely. These measures by government authorities, as well as the precautions we will take in order to operate our business responsibly in light of the COVID-19 pandemic, may continue to remain in place for a significant period of time, and they are likely to continue to adversely affect our business and results of operations.

In addition, we expect sales cycles, particularly for new customers, to continue to be impacted as a result of the COVID-19 pandemic, and we have observed continued volatility in YUPELRI sales. Sales momentum has been affected by COVID-19 and may continue to be in the future. We market YUPELRI in the hospital setting, where healthcare workers are prioritizing the treatment of patients with or suspected of COVID-19 disease. In mid-March 2020, we suspended in-person sales calls to accounts in response to the COVID-19 pandemic. We are currently re-engaging with these customers in-person when certain criteria are met and remotely via telephone calls, electronic mail, digital outreach or video conferencing as we seek to continue to support healthcare professionals and patient care. Customer orders or new patient use of YUPELRI may decline as a result of, among other things, a shift in our marketing efforts to remote communication methods, increased workload of healthcare providers, and the impact of the Center for Disease Control interim guidelines for limiting the exposure of health care workers to the virus that causes COVID-19, in which drug nebulization in COVID-19 positive patients is listed as a high-risk procedure while present in the room for procedures when the healthcare providers’ eyes, nose, or mouth are not protected. We are preparing for continued volatility during 2021 as disruptions of day-to-day operations of hospitals and clinics may continue. In addition, while we do not currently anticipate any supply issues, the COVID-19 pandemic could impact our supply of YUPELRI in the future. At this stage, we are unable to predict with certainty the ultimate disruptive impact of the COVID-19 pandemic on both YUPELRI and the rest of our business.

23

[Table of Contents](#TOC)

In addition, the COVID-19 pandemic makes the conduct of clinical trials more challenging given the paramount importance of adequate safety monitoring, collection of data and distribution of study drug, all of which are traditionally achieved by in-person visits to our study sites. We expect challenges to continue to arise from quarantines, shelter-in-place or stay-at-home orders, site closures, travel limitations, potential interruptions to the supply chain for investigational products, other measure to help prevent the spread of COVID-19 or other considerations if site personnel or trial participants become infected with COVID-19. These challenges may lead to difficulties in meeting protocol-specified procedures. In light of the COVID-19 pandemic, the Company is implementing mitigation plans to help ensure patients in the clinical trials have continued access to drug supply and regular visits with their physicians for study visits per trial protocols, but there is a risk that our trial data could be impacted if our efforts are insufficient. It is also possible that demand for products that we may pursue could be materially and adversely affected as a result of COVID-19 and any related economic impact. Furthermore, we cannot assure you that our publicly-announced initiatives addressing COVID-19 will result in commercially-viable products.

The spread of COVID-19 has caused us to modify our business practices (including employee travel, mandating that all personnel other than key operations and lab personnel work from home, temporary closures of offices, and reduction of physical participation in commercial activities, meetings, events and conferences), and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, customers and business partners. There is no certainty that such actions will be sufficient to mitigate the risks posed by the virus or otherwise be satisfactory to government authorities. If significant portions of our workforce, and particularly our field-based teams and laboratory staff, are unable to work effectively, including due to illness, quarantines, social distancing, government actions or other restrictions in connection with the COVID-19 pandemic, our operations will be impacted. The COVID-19 pandemic could limit the ability of our customers, suppliers and business partners to perform under their contracts with us, including third-party payers’ ability to make timely payments to us during and following the pandemic. We may also experience a shortage of supplies and materials or a suspension of services from third parties. Additionally, while the potential economic impact brought by, and the duration of, the coronavirus pandemic is difficult to assess or predict, the impact of the coronavirus on the global financial markets may reduce our ability to access capital, which could negatively impact our long-term liquidity. Even after the COVID-19 pandemic subsides, we may continue to experience an adverse impact to our business as a result of its global economic impact, including any recession that has occurred or may occur in the future.

The extent to which the COVID-19 pandemic impacts our business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict, including, but not limited to, the duration and spread of the pandemic, its severity, the actions to contain the virus or address its impact, vaccine rollout and how quickly and to what extent normal economic and operating activities can resume. There are no comparable recent events which may provide guidance as to the effect of the spread of the COVID-19 pandemic, and, as a result, the ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of COVID-19’s impact on our business, our operations, or the global economy as a whole. However, the effects are likely to continue to have a material adverse impact on our future results of operations.

***Any delay in commencing or completing clinical studies for product candidates and any adverse results from clinical or non-clinical studies or regulatory obstacles product candidates may face, would harm our business and the price of our securities could fall.***

Each of our product candidates must undergo extensive non-clinical and clinical studies as a condition to regulatory approval. Non-clinical and clinical studies are expensive, take many years to complete and study results may lead to delays in further studies, new requirements for conducting future studies or decisions to terminate programs. The commencement and completion of clinical studies for our product candidates may be delayed and programs may be terminated due to many factors, including, but not limited to:

|  |  |  |
| --- | --- | --- |
|  | • | lack of effectiveness of product candidates during clinical studies; |

|  |  |  |
| --- | --- | --- |
|  | • | adverse events, safety issues or side effects (or perceived adverse developments or results) relating to the product candidates or their formulation into medicines; |

24

[Table of Contents](#TOC)

|  |  |  |
| --- | --- | --- |
|  | • | inability to raise additional capital in sufficient amounts to continue our development programs, which are very expensive; |

|  |  |  |
| --- | --- | --- |
|  | • | inability to enter into partnering arrangements relating to the development and commercialization of our programs and product candidates or partner decisions not to maintain a partnership with us; |

|  |  |  |
| --- | --- | --- |
|  | • | delays in patient enrollment and variability in the number and types of patients available for clinical studies; |

|  |  |  |
| --- | --- | --- |
|  | • | the need to sequence clinical studies as opposed to conducting them concomitantly in order to conserve resources; |

|  |  |  |
| --- | --- | --- |
|  | • | our inability or the inability of our collaborators or licensees to manufacture or obtain from third parties materials sufficient for use in non-clinical and clinical studies; |

|  |  |  |
| --- | --- | --- |
|  | • | governmental or regulatory delays or suspensions of the conduct of the clinical trials and changes in regulatory requirements, policy and guidelines, including as a result of any class-based risks that emerge as an area of FDA or other regulatory agency focus; |

|  |  |  |
| --- | --- | --- |
|  | ● | challenges related to the COVID-19 pandemic, including with recruitment and/or progressing patients through studies; |

|  |  |  |
| --- | --- | --- |
|  | • | failure of our partners to advance our product candidates through clinical development; |

|  |  |  |
| --- | --- | --- |
|  | • | difficulty in maintaining contact with patients after treatment, resulting in incomplete data; |

|  |  |  |
| --- | --- | --- |
|  | • | varying regulatory requirements or interpretations of data among the FDA and foreign regulatory authorities; and |

|  |  |  |
| --- | --- | --- |
|  | • | a disturbance where we or our collaborative partners are enrolling patients in clinical trials, such as a pandemic, terrorist activities or war, political unrest or a natural disaster. |

Any adverse developments or results or perceived adverse developments or results with respect to our clinical programs including, without limitation, any delays in development in our programs as we are currently experiencing due to the COVID-19 pandemic, any halting of development in our programs, any difficulties or delays encountered with regard to the FDA or other third country regulatory authorities with respect to our programs, or any indication from clinical or non-clinical studies that the compounds in our programs are not safe or efficacious, could have a material adverse effect on our business and cause the price of our securities to fall.

In July 2019, the FDA issued a Boxed Warning for a systemically active pan-JAK inhibitor, calling out an increased risk of pulmonary embolism and death following the results of a safety study in patients with rheumatoid arthritis. We are focused on developing pan-JAK inhibitors that are designed to remain organ-selective so that they do not become systemically active in order to minimize the risk of side effects. It is unknown at this time what, if any, additional requirements the FDA may put in place with respect to the development of JAK inhibitors generally or what other future FDA actions may have on the prospects for JAK inhibitors. Delays or adverse developments or results or perceived adverse developments or results relating to JAK inhibitors could harm our business and could cause the price of our securities to fall. Examples of such adverse developments include, but are not limited to:

|  |  |  |
| --- | --- | --- |
|  | • | the FDA and/or other regulatory authorities determining that additional non-clinical or clinical studies are required with respect to our JAK inhibitor programs; |

|  |  |  |
| --- | --- | --- |
|  | • | safety, efficacy or other concerns relating to our JAK inhibitor programs or JAK inhibitors under development or commercialized by other companies; |

|  |  |  |
| --- | --- | --- |
|  | • | the FDA determining that class-based warnings are required for JAK inhibitors generally; or |

25

[Table of Contents](#TOC)

|  |  |  |
| --- | --- | --- |
|  | • | any change in FDA policy or guidance regarding JAK inhibitors. |

***If our product candidates are not approved by regulatory authorities, including the FDA, we will be unable to commercialize them.***

The FDA must approve any new medicine before it can be marketed and sold in the US. We will not obtain this approval for a product candidate unless and until the FDA approves an NDA. We, or our collaborative partners, must provide the FDA and similar foreign regulatory authorities with data from preclinical and clinical studies that demonstrate that our product candidates comply with the regulatory requirements for the quality of medicinal products and are safe and effective for a defined indication before they can be approved for commercial distribution. FDA or foreign regulatory authorities may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. The processes by which regulatory approvals are obtained from the FDA and foreign regulatory authorities to market and sell a new product are complex, require a number of years, depend upon the type, complexity and novelty of the product candidate and involve the expenditure of substantial resources for research, development and testing. The FDA has substantial discretion in the drug approval process and may require us to conduct additional non-clinical and clinical testing or to perform post-marketing studies. Further, the implementation of new laws and regulations, and revisions to FDA clinical trial design guidance may lead to increased uncertainty regarding the approvability of new drugs. See the risk factor entitled “*Any delay in commencing or completing clinical studies for product candidates and any adverse results from clinical or non-clinical studies or regulatory obstacles product candidates may face, would harm our business and the price of our securities could fall*” above for additional information. The rapidly shifting environment surrounding the collective response to the COVID-19 pandemic has led to additional guidance from US and foreign regulatory agencies with respect to numerous matters regarding the conduct of clinical trials in general and the development of COVID-19 related therapies, which is subject to the risk of further change, misinterpretation or non-compliance due to the rapidly changing regulatory landscape. In addition, the FDA has additional standards for approval of new drugs, including recommended advisory committee meetings for certain new molecular entities, and formal risk evaluation and mitigation requirements at the FDA’s discretion. Even if we receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed or impose significant restrictions or limitations on the use and/or distribution of such product.

In addition, in order to market our medicines in foreign jurisdictions, we or our collaborative partners must obtain separate regulatory approvals in each country. The approval procedure varies among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Conversely, failure to obtain approval in one or more jurisdictions may make approval in other jurisdictions more difficult. These laws, regulations, additional requirements and changes in interpretation could cause non-approval or further delays in the FDA’s or other regulatory authorities’ review and approval of our and our collaborative partner’s product candidates, which would materially harm our business and financial condition and could cause the price of our securities to fall.

***If additional capital is not available, we may have to curtail operations or we could be forced to share our rights to commercialize our product candidates with third parties on terms that may not be favorable to us.***

Based on our current operating plans and financial forecasts, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to meet our anticipated operating needs for at least the next twelve months. However, our current operating plans or financial forecasts occasionally change. For example, in August 2017, we announced an increase in our anticipated operating loss for 2017, primarily driven by our decision to accelerate funding associated with the next phase of development of izencitinib in our JAK inhibitor program. If our current operating plans or financial forecasts change, we may require or seek additional funding sooner in the form of public or private equity or equity-linked offerings, debt financings or additional collaborations and licensing arrangements.

We may need to raise additional capital in the future to, among other things:

|  |  |  |
| --- | --- | --- |
|  | • | fund our discovery efforts and research and development programs; |

26

[Table of Contents](#TOC)

|  |  |  |
| --- | --- | --- |
|  | • | fund our commercialization strategies for any approved products and to prepare for potential product approvals; |

|  |  |  |
| --- | --- | --- |
|  | • | support our independent sales and marketing organization and medical affairs team; |

|  |  |  |
| --- | --- | --- |
|  | • | support our additional investments in YUPELRI, including potential post-marketing clinical studies; |

|  |  |  |
| --- | --- | --- |
|  | • | progress any additional product candidates into later-stage development without funding from a collaboration partner; |

|  |  |  |
| --- | --- | --- |
|  | • | progress mid-to-late stage product candidates into later-stage development, if warranted; |

|  |  |  |
| --- | --- | --- |
|  | • | respond to competitive pressures; and |

|  |  |  |
| --- | --- | --- |
|  | • | acquire complementary businesses or technologies. |

Our future capital needs depend on many factors, including:

|  |  |  |
| --- | --- | --- |
|  | • | the scope, duration and expenditures associated with our discovery efforts and research and development programs; |

|  |  |  |
| --- | --- | --- |
|  | • | continued scientific progress in these programs; |

|  |  |  |
| --- | --- | --- |
|  | • | the extent to which we encounter technical obstacles in our research and development programs; |

|  |  |  |
| --- | --- | --- |
|  | • | the outcome of potential licensing or partnering transactions, if any; |

|  |  |  |
| --- | --- | --- |
|  | • | competing technological developments; |

|  |  |  |
| --- | --- | --- |
|  | • | the extent of our proprietary patent position in any approved products and our product candidates; |

|  |  |  |
| --- | --- | --- |
|  | • | our facilities expenses, which will vary depending on the time and terms of any facility lease or sublease we may enter into, and other operating expenses; |

|  |  |  |
| --- | --- | --- |
|  | • | the scope and extent of the expansion of our sales and marketing efforts; |

|  |  |  |
| --- | --- | --- |
|  | • | potential litigation and other contingencies; and |

|  |  |  |
| --- | --- | --- |
|  | • | the regulatory approval process for our product candidates. |

We may seek to raise additional capital or obtain future funding through public or private equity offerings, debt financings or additional collaborations and licensing arrangements to meet our capital needs or to take advantage of opportunistic market conditions. We may not be able to obtain additional financing on terms favorable to us, if at all. General market conditions may make it difficult for us to seek financing from the capital markets. We may be required to relinquish rights to our technologies, product candidates or territories, or grant licenses on terms that are not favorable to us, in order to raise additional funds through collaborations or licensing arrangements. We may sequence preclinical and clinical studies as opposed to conducting them concomitantly in order to conserve resources, or delay, reduce or eliminate one or more of our research or development programs and reduce overall overhead expenses. If we are unable to raise additional capital or obtain future funding in sufficient amounts or on terms acceptable to us, we may have to make reductions in our workforce and may be prevented from continuing our discovery, development and commercialization efforts and exploiting other corporate opportunities. This would likely harm our business, prospects and financial condition and cause the price of our securities to fall.

27

[Table of Contents](#TOC)

***We may seek to obtain future financing through the issuance of debt or equity, which may have an adverse effect on our shareholders or may otherwise adversely affect our business.***

If we raise funds through the issuance of additional debt, including convertible debt or debt secured by some or all of our assets, or equity, any debt securities or preferred shares issued will have rights, preferences and privileges senior to those of holders of our ordinary shares in the event of liquidation. Neither the terms of our $230.0 million of 3.25% convertible senior notes, due 2023 (the “Convertible Senior 2023 Notes”) nor the terms of the Issuer II’s 9.5% Fixed Rate Term Notes due on or before 2035 (the “Non-Recourse 2035 Notes”) restrict our ability to issue additional debt. If additional debt is issued or we otherwise borrow additional funds, there is a possibility that once all senior claims are settled, there may be no assets remaining to pay out to the holders of ordinary shares. Moreover, 75% of the income from our investment in TRC, as evidenced by the Issuer II Class C Units, is currently available only for payment of the Non-Recourse 2035 Notes and is not available to pay our other obligations or the claims of our other creditors. In addition, if we raise funds through the issuance of additional equity, whether through private placements or public offerings, such an issuance would dilute ownership of our current shareholders that do not participate in the issuance. If we are unable to obtain any needed additional funding, we may be required to reduce the scope of, delay, or eliminate some or all of, our planned research, development and commercialization activities or to license to third parties the rights to develop and/or commercialize products or technologies that we would otherwise seek to develop and/or commercialize ourselves or on terms that are less attractive than they might otherwise be, any of which could materially harm our business.

Furthermore, the terms of any additional debt securities we may issue in the future may impose restrictions on our operations, which may include limiting our ability to incur additional indebtedness, pay dividends on or repurchase our share capital, or make certain acquisitions or investments. In addition, we may be subject to covenants requiring us to satisfy certain financial tests and ratios, and our ability to satisfy such covenants may be affected by events outside of our control.

***If our partners do not satisfy their obligations under our agreements with them, or if they terminate our partnerships with them, we may not be able to develop or commercialize our partnered product candidates as planned.***

In January 2015, we entered into a collaboration agreement with Viatris for the development and commercialization of a nebulized formulation of our LAMA revefenacin, including YUPELRI. Under the terms of the agreement, we and Viatris will co-develop nebulized revefenacin, including YUPELRI, for COPD and other respiratory diseases. In June 2016, we entered into a License and Collaboration Agreement with Millennium Pharmaceuticals, Inc., an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (collectively with Millennium, “Takeda”) in order to establish a collaboration for the development and commercialization of TD-8954, a selective 5-HT4 receptor agonist in development for gastrointestinal motility disorders. Under the terms of the agreement, Takeda is responsible for worldwide development and commercialization of TD-8954. In February 2018, we announced a global co-development and commercialization agreement with Janssen for izencitinib and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn’s disease. In December 2019, we entered into a License Agreement with Pfizer Inc. (“Pfizer”). Under the license agreement, we provide Pfizer with an exclusive global license to develop, manufacture and commercialize compounds from our preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized. We also have an exclusive development and commercialization agreement with Alfasigma for velusetrag, our internally discovered 5-HT4 agonist for the treatment of gastromotility disorders, under which we have transferred to Alfasigma global rights for velusetrag. In connection with these agreements, these parties have certain rights regarding the use of patents and technology with respect to the compounds in our development programs, including development and marketing rights.

Our partners have in the past and may in the future not fulfill all of their obligations under these agreements, and, in certain circumstances, they or we may terminate our partnership with them. In addition, our partners may also be facing significant business interruptions as a result of the COVID-19 pandemic. In either event, we may be unable to assume the development and commercialization responsibilities covered by the agreements or enter into alternative arrangements with a third-party to develop and commercialize such product candidates. If a partner elected to promote alternative products and product candidates such as its own products and product candidates in preference to those licensed from us, does not devote an adequate amount of time and resources to our product candidates or is otherwise unsuccessful in its efforts with respect to our products or product candidates, the development and commercialization of

28

[Table of Contents](#TOC)

product candidates covered by the agreements could be delayed or terminated, and future payments to us could be delayed, reduced or eliminated and our business and financial condition could be materially and adversely affected. Accordingly, our ability to receive any revenue from the product candidates covered by these agreements is dependent on the efforts of our partners. If a partner terminates or breaches its agreements with us, otherwise fails to complete its obligations in a timely manner or alleges that we have breached our contractual obligations under these agreements, the chances of successfully developing or commercializing product candidates under the collaboration could be materially and adversely affected. In addition, effective collaboration with a partner requires coordination to achieve complex and detail-intensive goals between entities that potentially have different priorities, capabilities and processes and successful navigation of the challenges such coordination entails. We could also become involved in disputes with a partner, which could lead to delays in or termination of our development and commercialization programs and time-consuming and expensive litigation or arbitration. Furthermore, termination of an agreement by a partner could have an adverse effect on the price of our ordinary shares or other securities even if not material to our business.

***We do not control TRC and, in particular, have no control over the GSK-Partnered Respiratory Programs or access to non-public information regarding the development of the GSK-Partnered Respiratory Programs.***

Innoviva assigned to TRC its strategic alliance agreement with GSK and all of its rights and obligations under its LABA collaboration agreement other than with respect to RELVAR ELLIPTA/BREO ELLIPTA, ANORO ELLIPTA and vilanterol monotherapy. Our equity interest in TRC entitles us to an 85% economic interest in any future payments made by GSK under the strategic alliance agreement and under the portion of the collaboration agreement assigned to TRC (the “GSK Agreements”) (net of TRC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters), which agreements govern Innoviva’s and GSK’s respective interests in the GSK-Partnered Respiratory Programs. Our equity interest primarily covers TRELEGY (the combination of fluticasone furoate, umeclidinium, and vilanterol in a single ELLIPTA inhaler) products. Our economic interest does not include any payments by GSK associated with RELVAR ELLIPTA/BREO ELLIPTA, ANORO ELLIPTA or vilanterol monotherapy. Innoviva controls TRC and, except for certain consent rights, we have no right to participate in the business and affairs of TRC. Innoviva has the exclusive right to appoint TRC’s manager who, among other things, is responsible for the day-to-day management of the GSK-Partnered Respiratory Programs and exercises the rights relating to the GSK-Partnered Respiratory Programs. As a result, we have no rights to participate in, or access to non-public information about, the development and commercialization work GSK and Innoviva are undertaking with respect to the GSK-Partnered Respiratory Programs and no right to enforce rights under the GSK Agreements assigned to TRC. We have had, currently have and may in the future have disagreements with Innoviva and TRC regarding Innoviva’s decisions regarding the management of TRC that could require invoking the dispute resolution procedures set forth in the TRC LLC Agreement and that, if resolved in a manner adverse to our interests, could have a material impact on our operations. See *Part II, Item 1 “Legal Proceedings.”* Moreover, we have many of the same risks with respect to our and TRC’s dependence on GSK as we have with respect to our dependence on our own partners, including any adverse impacts on GSK’s operations as a result of the COVID-19 pandemic.

***If there are any adverse developments or perceived adverse developments with respect to the GSK-Partnered Respiratory Programs in which we have a substantial economic interest, including TRELEGY, our business will be harmed, and the price of our securities could fall.***

We have no access to non-public information regarding the development progress of, or plans for, the GSK-Partnered Respiratory Programs, including TRELEGY, and we have little, if any, ability to influence the progress of those programs because our interest in these programs is only through our ownership interest in TRC, which is controlled by Innoviva. However, if any of the GSK-Partnered Respiratory Programs in which we have a substantial economic interest encounter delays, do not demonstrate required quality, safety and efficacy, are terminated, or if there are any adverse developments or perceived adverse developments with respect to such programs, our business will be harmed, and the price of our securities could fall. Examples of such adverse developments include, but are not limited to:

|  |  |  |
| --- | --- | --- |
|  | • | disappointing or lower than expected sales of TRELEGY; |

|  |  |  |
| --- | --- | --- |
|  | • | the emergence of new closed triple or other alternative therapies or any developments regarding competitive therapies, including comparative price or efficacy of competitive therapies; |

29

[Table of Contents](#TOC)

|  |  |  |
| --- | --- | --- |
|  | • | disputes between GSK and Innoviva or between us and Innoviva, such as our 2019 arbitration and our current dispute with Innoviva (See *Part II, Item 1 “Legal Proceedings”*), each of which concern the withholding of royalty payments we believe are due to us under the TRC LLC Agreement; |

|  |  |  |
| --- | --- | --- |
|  | • | GSK deciding to modify, delay or halt the TRELEGY program; |

|  |  |  |
| --- | --- | --- |
|  | • | the FDA and/or other national or foreign regulatory authorities determining that any of the studies under the TRELEGY program does not demonstrate the required quality, safety or efficacy, or that additional non-clinical or clinical studies are required with respect to the program; |

|  |  |  |
| --- | --- | --- |
|  | ● | any adverse effects resulting from the COVID-19 pandemic; |

|  |  |  |
| --- | --- | --- |
|  | • | any safety, efficacy or other concerns regarding the TRELEGY program or any GSK-Partnered Respiratory Program in which we have a substantial economic interest; or |

|  |  |  |
| --- | --- | --- |
|  | • | any particular FDA requirements or changes in FDA policy or guidance regarding the TRELEGY program or any other GSK-Partnered Respiratory Program or any particular regulatory requirements in other jurisdictions or changes in the policies or guidance adopted by foreign regulatory authorities. |

***Because GSK is a strategic partner of Innoviva, a strategic partner of TRC and a significant shareholder of us, it may take actions that in certain cases are materially harmful to our business and to our other shareholders.***

Based on our review of publicly available filings, as of December 31, 2020, GSK beneficially owned 15.0% of our outstanding ordinary shares (although GSK, through a subsidiary, has issued $280,336,000 of exchangeable senior notes due 2023 (the “GSK Notes”), initially exchangeable into 9,644,792 of our ordinary shares which, as of December 31, 2020, represented 15.0% of our outstanding ordinary shares). GSK is also a strategic partner to Innoviva with rights and obligations under the GSK Agreements, which include the strategic alliance agreement and the collaboration agreement assigned to TRC, that may cause GSK’s interests to differ from our interests and those of our other shareholders. For example, GSK’s commercialization efforts are guided by a portfolio approach across products in which we have an indirect interest through TRC and products in which we have no interest. Accordingly, GSK’s commercialization efforts may have the effect of reducing the value of our interest in TRC. Furthermore, GSK has a substantial respiratory product portfolio in addition to the products covered by the GSK Agreements. GSK may make respiratory product portfolio decisions or statements about its portfolio which may be, or may be perceived to be, harmful to the respiratory products partnered with Innoviva and TRC. For example, GSK could promote its own respiratory products and/or delay or terminate the development or commercialization of the respiratory programs covered by the GSK Agreements, which include TRELEGY. Also, given the potential future royalty payments GSK may be obligated to pay under the GSK Agreements, GSK may seek to acquire us or acquire our interests in TRC in order to effectively reduce those payment obligations and the price at which GSK might seek to acquire us may not reflect our true value. As a result of these differing interests, GSK may take actions that it believes are in its best interest but which might not be in the best interests of either us or our other shareholders. In addition, GSK could also seek to challenge our or Innoviva’s post-Spin-Off operations as violating or allowing it to terminate the GSK Agreements, including by violating the confidentiality provisions of those agreements or the master agreement between GSK, Innoviva and us entered into in connection with the Spin-Off (the “Master Agreement”), or otherwise violating its legal rights. While we believe our operations fully comply with the GSK Agreements, the Master Agreement and applicable law, there can be no assurance that we or Innoviva will prevail against any such claims by GSK. Moreover, regardless of the merit of any claims by GSK, we may incur significant cost and diversion of resources in defending them. In addition, any other action or inaction by either GSK or Innoviva that results in a material dispute, allegation of breach, litigation, arbitration, or significant disagreement between those parties or between us and either of those parties may be interpreted negatively by the market or by our investors, could harm our business and cause the price of our securities to fall. Other examples of these kinds of issues include but are not limited to non-performance of other contractual obligations and allegations of non-performance, disagreements over the relative marketing and sales efforts for Innoviva’s partnered products and other GSK respiratory products, disputes over public statements, and similar matters. In general, any uncertainty about respiratory programs partnered with GSK, the enforceability of the GSK Agreements or the relationship/partnership between Innoviva and GSK or between us and Innoviva could result in significant reduction in the market price of our securities and other material harm to our business.

30

[Table of Contents](#TOC)

***We do not control the commercialization of TRELEGY and we do not control TRC; accordingly the amount of royalties we receive will depend on, among other factors, GSK’s ability to further commercialize TRELEGY and TRC’s decisions concerning use of cash in accordance with the TRC LLC Agreement.***

We only receive revenues from TRELEGY based on the amount of sales of this product by GSK in the form of our economic interest in the royalties paid by GSK to TRC, which is managed by Innoviva. There are no required minimum future payments associated with the product and any royalties we receive will depend on GSK’s ability to commercialize the product, the future payments, if any, made by GSK to TRC, TRC’s expenses, and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement. Following our 2019 arbitration with Innoviva concerning its withholding of certain royalty distributions to the TRC members, the arbitrator ruled, among other things, that in the future if Innoviva desires to invest TRC funds in any initiatives that require the consent of GSK under the collaboration agreement, Innoviva must first obtain the consent of GSK. The timeframe for seeking GSK’s consent for these initiatives and the associated dates by which GSK’s consent must be received means that royalty distributions could be delayed for several quarters (if GSK ultimately does not consent) or perhaps not made at all until the completion of the initiatives (to the extent that GSK does consent and agrees with TRC that TRC funding will be used for such initiatives). This involves a number of risks and uncertainties, including:

|  |  |  |
| --- | --- | --- |
|  | • | any future withholding by Innoviva or TRC of royalty distributions; |

|  |  |  |
| --- | --- | --- |
|  | • | GSK’s ability to have an adequate supply of TRELEGY product; |

|  |  |  |
| --- | --- | --- |
|  | • | ongoing compliance by GSK or its suppliers with the FDA’s current Good Manufacturing Practice; |

|  |  |  |
| --- | --- | --- |
|  | • | compliance with other applicable FDA and other regulatory requirements in the US or other foreign jurisdictions, including those described elsewhere in this report; |

|  |  |  |
| --- | --- | --- |
|  | • | competition, whether from current competitors or new products developed by others in the future; |

|  |  |  |
| --- | --- | --- |
|  | • | claims relating to intellectual property; |

|  |  |  |
| --- | --- | --- |
|  | • | any future disruptions in GSK’s business which would affect its ability to commercialize TRELEGY, including, disruptions due to the COVID-19 pandemic; |

|  |  |  |
| --- | --- | --- |
|  | • | the ability of TRELEGY to achieve wider acceptance among physicians, patients, third-party payors, or the medical community in general; |

|  |  |  |
| --- | --- | --- |
|  | • | the amount of cash associated with any additional future TRELEGY commercialization initiatives that Innoviva proposes to GSK for TRC to pursue, the time it may take to present those initiatives to GSK for approval and the time it takes for GSK to consent or not consent; |

|  |  |  |
| --- | --- | --- |
|  | • | global economic conditions; |

|  |  |  |
| --- | --- | --- |
|  | • | decisions made by Innoviva, as TRC’s manager, regarding the timing and amount of distributions; |

|  |  |  |
| --- | --- | --- |
|  | • | the resolution of any disputes between Innoviva and TRC, on the one hand, and us, on the other, regarding the timing of distributions, the amount of distributions, and the proper business activities of TRC, including the current dispute with Innoviva and TRC described below; and |

|  |  |  |
| --- | --- | --- |
|  | • | any of the other risks relating to commercialization of TRELEGY. |

These risks and uncertainties could materially impact the amount and timing of future royalties or other revenues we may receive from sales of TRELEGY, which could have a material adverse effect on our future revenues, other financial results and our financial position and cause the price of our securities to fall.

On June 10, 2020, we disclosed in a Form 8-K that we had formally objected to TRC and Innoviva, as the manager of TRC, regarding their proposed plan to use TRELEGY royalties to invest in certain privately-held companies, funds that would otherwise be available for distribution to us under the terms of the TRC LLC Agreement. We intend to

31

[Table of Contents](#TOC)

continue to seek to protect our interests in this matter consistent with the dispute resolution procedures of the TRC LLC Agreement. In this regard, we initiated an arbitration proceeding against Innoviva and TRC in October 2020 challenging the authority of Innoviva and TRC to pursue such a business plan rather than distribute such funds to us in a manner consistent with the TRC LLC Agreement and our 85% economic interest in TRC. The arbitration hearing was held during the week of February 16, 2021, with post-hearing briefing and arguments to take place over the next few weeks. We currently anticipate a decision in those proceedings near the end of the first quarter or early in the second quarter of 2021. There can be no assurance that we will prevail in the arbitration or that it will result in us receiving additional distributions from TRC. An adverse result could materially and adversely affect the funds that we and our affiliates would otherwise expect to receive from TRC in the future.

In the future, Innoviva may cause TRC to withhold funds from distribution to its members, including our affiliates, for additional TRELEGY development or commercialization initiatives that may be proposed, which would need to be approved by GSK in order to be implemented, or for other purposes. To the extent any TRELEGY development or commercialization initiatives are timely approved by GSK and implemented, such initiatives may require funding beyond the amount withheld by TRC, and TRC may withhold additional amounts in subsequent quarters with respect to these initiatives. Accordingly, we cannot predict the amount of the funds that our affiliates would otherwise expect to receive from TRC that TRC may withhold in the future, or the timing of any such withholding.

We may object to the withholding of funds for additional proposed TRELEGY initiatives or other purposes on the basis that such withholding is in violation of the terms of the TRC LLC Agreement or otherwise, and such objection could result in additional legal proceedings between us, TRC and Innoviva. Any such legal proceedings could divert the attention of management and cause us to incur significant costs, regardless of the outcome, which we cannot predict. An adverse result could materially and adversely affect the funds that our affiliates would otherwise expect to receive from TRC in the future and thus have a material adverse effect on our business, financial condition, and results of operations.

***Our ongoing drug discovery and development efforts might not generate additional successful product candidates or approvable drugs.***

Our compounds in clinical trials and our future leads for potential drug compounds are subject to the risks and failures inherent in the development of pharmaceutical products. These risks include, but are not limited to, the inherent difficulty in selecting the right drug and drug target and avoiding unwanted side effects, as well as unanticipated problems relating to product development, testing, enrollment, obtaining regulatory approvals, maintaining regulatory compliance, manufacturing, competition and costs and expenses that may exceed current estimates.

Clinical studies involving our product candidates may reveal that those candidates are ineffective, inferior to existing approved medicines, unacceptably toxic, or that they have other unacceptable side effects. In addition, the results of preclinical studies do not necessarily predict clinical success, and larger and later-stage clinical studies may not produce the same results as earlier-stage clinical studies.

Frequently, product candidates that have shown promising results in early preclinical or clinical studies have subsequently suffered significant setbacks or failed in later non-clinical or clinical studies. In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, varying levels of adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Clinical and non-clinical studies of product candidates often reveal that it is not possible or practical to continue development efforts for these product candidates. In addition, the design of a clinical trial can determine whether its results will support regulatory approval and flaws in the design of a clinical trial may not become apparent until the clinical trial is well underway or completed. If our clinical studies for our current product candidates, such as the clinical studies for our JAK inhibitor programs or ampreloxetine in patients with nOH, are substantially delayed or suggest that any of our product candidates may not be efficacious or well tolerated, we could choose to cease development of these product candidates. In addition, our product candidates may have undesirable side effects or other unexpected characteristics that could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities.

32

[Table of Contents](#TOC)

***We face substantial competition from companies with more resources and experience than we have, which may result in others discovering, developing, receiving approval for or commercializing products before or more successfully than we do.***

Our ability to succeed in the future depends on our ability to demonstrate and maintain a competitive advantage with respect to our approach to the discovery, development and commercialization of medicines. Our objective is to discover, develop and commercialize new small molecule medicines with superior efficacy, convenience, tolerability and/or safety using our proprietary insight in chemistry, biology and multivalency, where applicable. We expect that any medicines that we commercialize with or without our collaborative partners will compete with existing or future market-leading medicines.

Many of our current and potential competitors have substantially greater financial, technical and personnel resources than we have. In addition, many of these competitors have significantly greater commercial infrastructures than we have. Our ability to compete successfully will depend largely on our ability to leverage our experience in drug discovery and development, and, more recently, commercialization, to:

|  |  |  |
| --- | --- | --- |
|  | • | discover and develop medicines that are superior to other products in the market; |

|  |  |  |
| --- | --- | --- |
|  | • | attract and retain qualified personnel; |

|  |  |  |
| --- | --- | --- |
|  | • | obtain and enforce patent and/or other proprietary protection for our medicines and technologies; |

|  |  |  |
| --- | --- | --- |
|  | • | conduct effective clinical trials and obtain required regulatory approvals; |

|  |  |  |
| --- | --- | --- |
|  | • | develop and effectively implement commercialization strategies, with or without collaborative partners; and |

|  |  |  |
| --- | --- | --- |
|  | • | successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new medicines. |

Pharmaceutical companies, including companies with which we collaborate, may invest heavily to quickly discover and develop or in-license novel compounds that could make our product candidates obsolete. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA or equivalent regulatory approval outside the US or discovering, developing and commercializing medicines before we do. Other companies are engaged in the discovery of medicines that would compete with the product candidates that we are developing.

Any new medicine that competes with a generic or proprietary market leading medicine must demonstrate compelling advantages in efficacy, convenience, tolerability and/or safety in order to overcome severe price competition and be commercially successful. For example, YUPELRI competes predominantly with the nebulized LAMA Lonhala® Magnair® (glycopyrrolate) dosed two times per day and with short acting nebulized bronchodilators that are dosed three to four times per day. If we are not able to compete effectively against our current and future competitors, our business will not grow, our financial condition and operations will suffer and the price of our securities could fall.

***If we are unable to enter into future collaboration arrangements or if any such collaborations with third parties are unsuccessful, we will be unable to fully develop and commercialize all of our product candidates and our business will be adversely affected.***

We have collaborations with a number of third parties including Janssen for izencitinib and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn’s disease and Viatris for the development and commercialization of a nebulized formulation of revefenacin, our LAMA compound (including YUPELRI). Also, through our interest in TRC we may participate economically in Innoviva’s collaborations with GSK with respect to the GSK-Partnered Respiratory Programs. Additional collaborations will likely be needed to fund later-stage development of certain programs that have not been licensed to a collaborator and to commercialize the product candidates in our programs if approved by the necessary regulatory authorities. We evaluate commercial strategy on a product by product basis either to engage pharmaceutical or other healthcare companies with an existing sales and marketing organization and distribution system to market, sell and distribute our products or to commercialize a product ourselves. However, we may not be able to establish these sales and distribution relationships on acceptable

33

[Table of Contents](#TOC)

terms, or at all, or may encounter difficulties in commercializing a product ourselves. For any of our product candidates that receive regulatory approval in the future and are not covered by our current collaboration agreements, we will need a partner in order to commercialize such products unless we establish independent sales, marketing and distribution capabilities with appropriate technical expertise and supporting infrastructure.

Collaborations with third parties regarding our programs may require us to relinquish material rights, including revenue from commercialization of our medicines, or to assume material ongoing development obligations that we would have to fund. These collaboration arrangements are complex and time-consuming to negotiate, and if we are unable to reach agreements with third-party collaborators, we may fail to meet our business objectives and our financial condition may be adversely affected. We face significant competition in seeking third-party collaborators. We may be unable to find third parties to pursue product collaborations on a timely basis or on acceptable terms. Furthermore, for any collaboration, we may not be able to control the amount of time and resources that our partners devote to our product candidates and our partners may choose to prioritize alternative programs or otherwise be unsuccessful in their efforts with respect to our products or product candidates. In addition, effective collaboration with a partner requires coordination to achieve complex and detail-intensive goals between entities that potentially have different priorities, capabilities and processes and successful navigation of the challenges such coordination entails. For example, Viatris has a substantial existing product portfolio and other considerations that influence its resource allocation, and other priorities and internal organizational processes that differ from our own. As a result of these differing interests and processes, Viatris may take actions that it believes are in its best interest but which might not be in the best interests of either us or our other shareholders. Our inability to successfully collaborate with third parties would increase our development costs and may cause us to choose not to continue development of certain product candidates, would limit the likelihood of successful commercialization of some of our product candidates, may cause us not to continue commercialization of our authorized products and could cause the price of our securities to fall.

***We depend on third parties in the conduct of our non-clinical and clinical studies for our product candidates.***

We depend on independent clinical investigators, contract research and manufacturing organizations and other third-party service providers in the conduct of our non-clinical and clinical studies for our product candidates. We rely heavily on these parties for execution of our non-clinical and clinical studies, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that our clinical studies are conducted in accordance with good clinical, laboratory and manufacturing practices (“GXPs”) and other regulations as required by the FDA and foreign regulatory authorities, and the applicable protocol. Failure by these parties to comply with applicable regulations and practices in conducting studies of our product candidates can result in a delay in our development programs or non-approval of our product candidates by regulatory authorities. Furthermore, to the extent the operations of these third parties are disrupted as result of the COVID-19 pandemic or otherwise, our development programs could be delayed.

The FDA, and equivalent authorities in third countries, enforces GXPs and other regulations through periodic inspections of trial sponsors, clinical research organizations (“CROs”), principal investigators and trial sites. If we or any of the third parties on which we have relied to conduct our clinical studies are determined to have failed to comply with GXPs (or other equivalent regulations outside the US), the study protocol or applicable regulations, the clinical data generated in our studies may be deemed unreliable. This could result in non-approval of our product candidates by the FDA, or equivalent authorities in other countries, or we, the FDA, or equivalent authorities in other countries may decide to conduct additional audits or require additional clinical studies, which would delay our development programs, could result in significant additional costs and cause the price of our securities to fall.

34

[Table of Contents](#TOC)

***There is a single source of supply for a number of our product candidates and for YUPELRI, and our business will be harmed if any of these single-source manufacturers are not able to satisfy demand and alternative sources are not available.***

We have limited in-house production capabilities for preclinical and clinical study purposes and depend primarily on a number of third-party Active Pharmaceutical Ingredient (“API”) and drug product manufacturers. We may not have long-term agreements with these third parties and our agreements with these parties may be terminable at will by either party at any time. In addition, there is a single supplier of YUPELRI API and a single supplier of YUPELRI drug product. If, for any reason, any of these third-party manufacturers are unable or unwilling to perform, or if their performance does not meet regulatory requirements, alternative manufacturers may not be available or may not be available on acceptable terms. Any inability to acquire sufficient quantities of API and drug product in a timely manner from these third parties could delay preclinical and clinical studies, prevent us from developing our product candidates in a cost-effective manner or on a timely basis or adversely impact the commercialization of YUPELRI. In addition, manufacturers of our API and drug product are subject to the FDA’s current Good Manufacturing Practice (“cGMP”) regulations and similar foreign standards and we do not have control over compliance with these regulations by our manufacturers.

Our manufacturing strategy presents the following additional risks:

|  |  |  |
| --- | --- | --- |
|  | • | because of the complex nature of many of our compounds, our manufacturers may not be able to successfully manufacture our APIs and/or drug products in a cost-effective and/or timely manner and changing manufacturers for our APIs or drug products could involve lengthy technology transfer, validation and regulatory qualification activities for the new manufacturer; |

|  |  |  |
| --- | --- | --- |
|  | • | the processes required to manufacture certain of our APIs and drug products are specialized and available only from a limited number of third-party manufacturers; |

|  |  |  |
| --- | --- | --- |
|  | • | some of the manufacturing processes for our APIs and drug products have not been scaled to quantities needed for continued clinical studies or commercial sales, and delays in scale-up to higher quantities could delay clinical studies, regulatory submissions and commercialization of our product candidates; and |

|  |  |  |
| --- | --- | --- |
|  | • | because some of the third-party manufacturers are located outside of the US, there may be difficulties in importing our APIs and drug products or their components into the US as a result of, among other things, FDA import inspections, incomplete or inaccurate import documentation or defective packaging. |

***We have a significant amount of debt, including our Non-Recourse 2035 Notes and Convertible Senior 2023 Notes, that are senior in capital structure and cash flow, respectively, to holders of our ordinary shares. Satisfying the obligations relating to our debt could adversely affect the amount or timing of distributions to our shareholders.***

As of December 31, 2020, we had $649.2 million in total long-term liabilities outstanding, comprised primarily of $378.3 million in net principal that remains outstanding under the Issuer II’s (defined below) Non-Recourse 2035 Notes and $230.0 million in principal that remains outstanding under our Convertible Senior 2023 Notes (together with the Non-Recourse 2035 Notes, the “Notes”).

The Convertible Senior 2023 Notes are unsecured debt and are not redeemable by us prior to the maturity date except for certain changes in tax law. Holders of the Convertible Senior 2023 Notes may require us to purchase all or any portion of their notes at 100% of their principal amount, plus any unpaid interest, upon a fundamental change such as a change of control of us or the termination of trading of our ordinary shares in accordance with the indenture governing the Convertible Senior 2023 Notes.

Until the Non-Recourse 2035 Notes are paid in full, holders of the Non-Recourse 2035 Notes have a perfected security interest in the Issuer II Class C Units that represent a 63.75% economic interest in any future payments that may be made by GSK to TRC under the strategic alliance agreement and under the portion of the collaboration agreement assigned to TRC by Innoviva (net of TRC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters) relating to the GSK-Partnered Respiratory Programs, including the TRELEGY program.

35

[Table of Contents](#TOC)

Prior to and including the December 5, 2024 payment date, the terms of the Non-Recourse 2035 Notes provide that in the event that the distributions received by the Issuer II from TRC in a quarter is less than the interest accrued for that quarter, the principal amount of the Non-Recourse 2035 Notes will increase by the interest shortfall amount for that quarter. The terms of the Non-Recourse 2035 Notes also provide that Theravance Biopharma, at its option, may satisfy the quarterly interest payment obligations by making a capital contribution to the Issuer II.

Satisfying the obligations of these Notes could adversely affect the amount or timing of any distributions to our shareholders. In addition, the Non-Recourse 2035 Notes may be redeemed by Issuer II on and after February 28, 2022, in whole or in part, at specified redemption premiums. We may further choose to satisfy, repurchase, or refinance any Non-Recourse 2035 Notes, to the extent allowable, through public or private equity or debt financings if we deem such financings are available on favorable terms. If any or all of the Convertible Senior 2023 Notes are not converted into our ordinary shares before the maturity date, we will have to pay the holders the full aggregate principal amount of the Convertible Senior 2023 Notes then outstanding. If the Non-Recourse 2035 Notes are not refinanced or paid in full the holders of the Non-Recourse 2035 Notes will have the right to foreclose on the Issuer II Class C Units that represent a 63.75% economic interest in future royalties due on net sales of TRELEGY and related assets. If the Issuer II Class C Units are foreclosed upon, we will lose any right to receive 75% of the future royalty payments made by GSK in connection with the net sales of TRELEGY and related assets. Any of the above payments could have a material adverse effect on our cash position. Our failure to satisfy these obligations may result in a default under the applicable indenture governing these Notes, which could result in a default under certain of our other debt instruments, if any. Any such default would harm our business and the price of our securities could fall. For more information, see Part II—Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources**.**

***Servicing our Convertible Senior 2023 Notes requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our debt. Additionally, holders may require us to repurchase our Convertible Senior 2023 Notes under certain circumstances, and we may not have sufficient cash to do so.***

Our ability to make interest or principal payments when due or to refinance the Convertible Senior 2023 Notes depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations sufficient to satisfy our obligations under the Convertible Senior 2023 Notes and any future indebtedness we may incur and to make necessary capital expenditures. In addition, the issuance of the Non-Recourse 2035 Notes reduced the cash available for us to make interest or principal payments on, or to refinance, the Convertible Senior 2023 Notes. We may be required to adopt one or more alternatives, such as reducing or delaying investments or capital expenditures, selling assets, refinancing or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance the Convertible Senior 2023 Notes or future indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities on desirable terms or at all, which could result in a default on the Convertible Senior 2023 Notes or future indebtedness.

The holders of the Convertible Senior 2023 Notes may have the right to require us to repurchase the Convertible Senior 2023 Notes upon the occurrence of a “fundamental change” such as a change of control of our Company or the termination of trading of our ordinary shares, as defined in the indenture governing the Convertible Senior 2023 Notes. We may not have sufficient funds to repurchase the Convertible Senior 2023 Notes in cash or have the ability to arrange necessary financing on acceptable terms. Our failure to repurchase the Convertible Senior 2023 Notes when required would result in an event of default with respect to the Convertible Senior 2023 Notes. In addition, any acceleration of the repayment of the Convertible Senior 2023 Notes or future indebtedness after any applicable notice or grace periods could have a material adverse effect on our business, results of operations and financial condition.

***Our business and operations would suffer in the event of significant disruptions of information technology systems or security breaches.***

We rely extensively on computer systems to maintain information and manage our finances and business. In the ordinary course of business, we collect, store and transmit large amounts of confidential information (including but not limited to trade secrets or other intellectual property, proprietary business information and personal information) and it is critical that we maintain the confidentiality and integrity of such confidential information. Although we have security

36

[Table of Contents](#TOC)

measures in place, our internal information technology systems and those of our CROs and other service providers, including cloud-based and hosted applications, data and services, are vulnerable to service interruptions and security breaches from inadvertent or intentional actions by our employees, service providers and/or business partners, from cyber-attacks by malicious third parties, and/or from, natural disasters, terrorism, war and telecommunication and electrical failures. Cyber-attacks are increasing in their frequency, sophistication, and intensity, and have become increasingly difficult to detect. Significant disruptions of information technology systems or security breaches could adversely affect our business operations and result in financial, legal, business and reputational harm to us, including significant liability and/or significant disruption to our business. If a disruption of information technology systems or security breach results in a loss of or damage to our data or regulatory applications, unauthorized access, use, or disclosure of, or the prevention of access to, confidential information, or other harm to our business, we could incur liability and reputational harm, we could be required to comply with federal and/or state breach notification laws and foreign law equivalents, we may incur legal expenses to protect our confidential information, the further development of our product candidates could be delayed and the price of our securities could fall. For example, the loss of clinical trial data from completed or ongoing clinical trials of our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. As another example, we may incur penalties imposed by the competent authorities in the EU Member States in case of breach of the EU rules governing the collection and processing of personal data, including unauthorized access to or disclosure of personal data. Although we have security and fraud prevention measures in place, we have been subject to immaterial payment fraud activity. In 2017, we filed a lawsuit (which has since been resolved) against a former employee for misappropriation of our confidential, proprietary and trade secret information. Moreover, there can be no assurance that such security measures will prevent service interruptions or security breaches that could adversely affect our business. These same risks also apply to our partners and vendors, who similarly hold sensitive and critical information related to our business in computer systems and are similarly potentially vulnerable to attack.

***If we lose key management or scientific personnel, or if we fail to attract and retain key employees, our ability to discover and develop our product candidates and commercialize our products, if any, will be impaired.***

We are highly dependent on principal members of our management team and scientific staff, and in particular, our Chief Executive Officer, Rick E Winningham, to operate our business. Mr. Winningham has significant pharmaceutical industry experience. The loss of Mr. Winningham’s services could impair our ability to discover, develop and commercialize new medicines.

If we fail to retain our qualified personnel or replace them when they leave, we may be unable to continue our discovery, development and commercialization activities, which may cause the price of our securities to fall.

In addition, our US operating subsidiary’s facility and most of its employees are located in northern California, headquarters to many other biotechnology and biopharmaceutical companies and many academic and research institutions. As a result, competition for certain skilled personnel in our market is intense. None of our employees have employment commitments for any fixed period of time and they all may leave our employment at will. If we fail to retain our qualified personnel or replace them when they leave, we may be unable to continue our development and commercialization activities and the price of our securities could fall.

***Global economic, political and social conditions may harm our ability to do business, increase our costs and negatively affect our stock price.***

Worldwide economic conditions remain uncertain due to the United Kingdom (“UK”) recent withdrawal from the EU (often referred to as “Brexit”), current global economic challenges, the COVID-19 pandemic, and other disruptions to global and regional economies and markets.

Brexit has created significant uncertainty about the future relationship between the UK and the EU, including with respect to the laws and regulations that will apply as the UK determines which EU laws to replace or replicate in the event of a withdrawal. From a regulatory perspective, the UK’s withdrawal bears significant complexity and risks.

In light of the fact that a significant portion of the regulatory framework in the UK is derived from EU laws, Brexit could materially impact the EU regulatory regime governing development, manufacture, importation, approval and commercialization of our product candidates in the UK or the EU. For example, a marketing authorization for a

37

[Table of Contents](#TOC)

medicinal product granted by the European Commission or by the competent authorities of EU member states will no longer encompass the UK. A separate authorization granted by the UK competent authorities will be required to place medicinal products on the UK market. In addition, the UK’s withdrawal from the EU affects manufacturing sites that hold an EU manufacturing authorization issued by the UK competent authorities which could impact our ability to rely on UK manufacturing sites to supply medicinal products intended for the EU market will depend on. All of these changes could increase our costs and otherwise adversely affect our business. In addition, currency exchange rates for the British Pound and the Euro with respect to each other and to the US dollar have already been, and may continue to be, negatively affected by Brexit, which could cause volatility in our quarterly financial results.

Further, development of our product candidates and/or regulatory approval may be delayed for other political events beyond our control. For example, a US federal government shutdown or budget sequestration, such as ones that occurred during 2013, 2018, and 2019, may result in significant reductions to the FDA’s budget, employees and operations, which may lead to slower response times and longer review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

Our operations also depend upon favorable trade relations between the US and those foreign countries in which our materials suppliers have operations. A protectionist trade environment in either the US or those foreign countries in which we do business, such as a change in the current tariff structures, export compliance or other trade policies, may materially and adversely affect our operations.

External factors, such as potential terrorist attacks, acts of war, geopolitical and social turmoil or similar events in many parts of the world, could also prevent or hinder our ability to do business, increase our costs and negatively affect our stock price. These geopolitical, social and economic conditions could harm our business.

***Our US operating subsidiary’s facility is located near known earthquake fault zones, and the occurrence of an earthquake, extremist attack or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations.***

Our US operating subsidiary’s facility is located in the San Francisco Bay Area near known earthquake fault zones and therefore will be vulnerable to damage from earthquakes. In October 1989, a major earthquake struck this area and caused significant property damage and a number of fatalities. We are also vulnerable to damage from other types of disasters, including power loss, attacks from extremist organizations, fire, floods, communications failures and similar events. If any disaster were to occur, our ability to operate our business could be seriously impaired. In addition, the unique nature of our research activities and of much of our equipment could make it difficult and costly for us to recover from this type of disaster. We may not have adequate insurance to cover our losses resulting from disasters or other similar significant business interruptions and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business and financial condition, which could cause the price of our securities to fall.

***If YUPELRI does not continue to be accepted by physicians, patients, third-party payors, or the medical community in general, we may not receive significant additional revenues from sales of this product.***

The commercial success of YUPELRI depends upon its acceptance by physicians, patients, third-party payors and the medical community in general. YUPELRI may not continue to be accepted by these parties. YUPELRI competes predominantly with the nebulized LAMA Lonhala® Magnair® (glycopyrrolate) dosed two times per day and with short acting nebulized bronchodilators that are dosed three to four times per day. We have seen increased volatility in sales of YUPELRI coinciding with the suspension of in-person sales calls, having less access to physicians and other healthcare providers and the progression of the COVID-19 pandemic and, if physicians, patients, third-party payors, or the medical community in general believe that nebulized therapy presents a risk of further spreading COVID-19 or that YUPELRI is otherwise not a preferred treatment option for those with COPD, we may see long-term declines. Shifts to novel marketing tactics are being deployed in an effort to keep awareness levels and business generation positive, but these untested and unvalidated tactics may not be effective at maintaining YUPELRI brand growth. If YUPELRI’s acceptance does not continue to grow, or declines from previous levels, our business and financial results could be materially harmed.

38

[Table of Contents](#TOC)

***In collaboration with Viatris, we are responsible for marketing and sales of YUPELRI in the US, which subjects us to certain risks.***

We currently maintain a sales force in the US and plan to continue to augment our sales and marketing personnel to support our co-promotion obligations for YUPELRI under our agreement with Viatris. The risks of fulfilling our US co-promotion obligations to Viatris include:

|  |  |  |
| --- | --- | --- |
|  | • | costs and expenses associated with maintaining an independent sales and marketing organization with appropriate technical expertise and supporting infrastructure, including third-party vendor logistics and consultant support, which costs and expenses could, depending on the scope and method of the marketing effort, exceed any product revenue for several years; |

|  |  |  |
| --- | --- | --- |
|  | • | our ability to retain effective sales and marketing personnel and medical science liaisons in the US; |

|  |  |  |
| --- | --- | --- |
|  | • | the ability of our sales and marketing personnel to obtain access to and educate adequate numbers of physicians about prescribing YUPELRI, in appropriate clinical situations; and |

|  |  |  |
| --- | --- | --- |
|  | • | the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines. |

If we are not successful in maintaining a sales and marketing organization with appropriate experience, technical expertise, supporting infrastructure and the ability to obtain access to and educate adequate numbers of physicians about prescribing YUPELRI in appropriate clinical situations, we will have difficulty maintaining effective commercialization of YUPELRI in the hospital setting, which would adversely affect our business and financial results and the condition and the price of our securities could fall.

***We are subject to extensive and ongoing regulation, oversight and other requirements by the FDA and failure to comply with these regulations and requirements may subject us to penalties that may adversely affect our financial condition or our ability to commercialize any approved products.***

Prescription drug advertising and promotion are closely scrutinized by the FDA, including substantiation of promotional claims, disclosure of risks and safety information, and the use of themes and imagery in advertising and promotional materials. As with all companies selling and marketing products regulated by the FDA in the US, we are prohibited from promoting any uses of an approved product, such as YUPELRI, that are outside the scope of those uses that have been expressly approved by the FDA as safe and effective on the product’s label.

The manufacturing, labeling, packaging, adverse event reporting, advertising, promotion and recordkeeping for an approved product remain subject to extensive and ongoing regulatory requirements. If we become aware of previously unknown problems with an approved product in the US or overseas or at a contract manufacturer’s facilities, a regulatory authority may impose restrictions on the product, the contract manufacturers or on us, including requiring us to reformulate the product, conduct additional clinical studies, change the labeling of the product, withdraw the product from the market or require the contract manufacturer to implement changes to its facilities.

We are also subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the US Department of Health and Human Services (“OIG”) and other regulatory bodies with respect to any approved product, such as YUPELRI, as well as governmental authorities in those foreign countries in which any product is approved for commercialization. The Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal and state statutes and regulations govern to varying degrees the research, development, manufacturing and commercial activities relating to prescription pharmaceutical products, including non-clinical and clinical testing, approval, production, labeling, sale, distribution, import, export, post-market surveillance, advertising, dissemination of information and promotion. If we or any third parties that provide these services for us are unable to comply, we may be subject to regulatory or civil actions or penalties that could significantly and adversely affect our business.

39

[Table of Contents](#TOC)

Regulatory approval for our product candidates, if any, may include similar or other limitations on the indicated uses for which we can market our medicines or the patient population that may utilize our medicines, which may limit the market for our medicines or put us at a competitive disadvantage relative to alternative therapies.

Failure to satisfy required post-approval requirements and/or commitments may have implications for a product’s approval and may carry civil monetary penalties. Any failure to maintain regulatory approval will materially limit the ability to commercialize a product or any future product candidates and if we fail to comply with FDA regulations and requirements, the FDA could potentially take a number of enforcement actions against us, including the issuance of untitled letters, warning letters, preventing the introduction or delivery of the product into interstate commerce in the US, misbranding charges, product seizures, injunctions, and civil monetary penalties, which would materially and adversely affect our business and financial condition and may cause the price of our securities to fall.

The risks identified in this risk factor relating to regulatory actions and oversight by agencies in the US and throughout the world also apply to the commercialization of any partnered products by our collaboration partners and those commercializing products with respect to which we have an economic interest or right to receive royalties, including GSK and Cumberland Pharmaceuticals Inc. (“Cumberland”), and such regulatory actions and oversight may limit those parties’ ability to commercialize such products, which could materially and adversely affect our business and financial condition, and which may cause the price of our securities to fall.

***We and/or our collaboration partners and those commercializing products with respect to which we have an economic interest or right to receive royalties may face competition from companies seeking to market generic versions of any approved products in which we have an interest, such as TRELEGY or YUPELRI.***

Under the Drug Price Competition and Patent Term Restoration Act of 1984, a company may submit an abbreviated new drug application (“ANDA”) under section 505(j) of the Federal Food, Drug, and Cosmetic Act to market a generic version of an approved drug. Because a generic applicant does not conduct its own clinical studies, but instead relies on the FDA’s finding of safety and effectiveness for the approved drug, it is able to introduce a competing product into the market at a cost significantly below that of the original drug. Although we have multiple patents protecting YUPELRI until at least 2025 that are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, and those commercializing products with respect to which we have an economic interest or right to receive royalties similarly have patents protecting their products, such as TRELEGY and VIBATIV, generic applicants could potentially submit “paragraph IV certifications” to FDA stating that such patents are invalid or will not be infringed by the applicant’s product. We have not received any such paragraph IV notifications nor are we aware of any with respect to products in which we have an economic interest or right to receive royalties, but if any competitors successfully challenge the patents related to these products, we and/or our collaboration partners and those commercializing products with respect to which we have an economic interest or right to receive royalties would face substantial competition. If we are not able to compete effectively against such future competition, our business will not grow, our financial condition and operations will suffer and the price of our securities could fall.

For additional discussion of the risk of generic competition to YUPELRI, please see the following risk factor below “*If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our current or future markets*.”

***We may be treated as a US corporation for US federal income tax purposes.***

For US federal income tax purposes, a corporation generally is considered tax resident in the place of its incorporation. Theravance Biopharma is incorporated under Cayman Islands law and established tax residency in Ireland effective July 1, 2015. Therefore, it should be a non-US corporation under this general rule. However, Section 7874 of the Internal Revenue Code of 1986, as amended (the “Code”), contains rules that may result in a foreign corporation being treated as a US corporation for US federal income tax purposes. The application of these rules is complex and there is little guidance regarding certain aspects of their application.

Under Section 7874 of the Code, a corporation created or organized outside the US will be treated as a US corporation for US federal tax purposes if (i) the foreign corporation directly or indirectly acquires substantially all of the properties held directly or indirectly by a US corporation, (ii) the former shareholders of the acquired US corporation hold at least 80% of the vote or value of the shares of the foreign acquiring corporation by reason of holding stock in the

40

[Table of Contents](#TOC)

US acquired corporation, and (iii) the foreign corporation’s “expanded affiliated group” does not have “substantial business activities” in the foreign corporation’s country of incorporation relative to its expanded affiliated group’s worldwide activities. For this purpose, “expanded affiliated group” generally means the foreign corporation and all subsidiaries in which the foreign corporation, directly or indirectly, owns more than 50% of the stock by vote and value, and “substantial business activities” generally means at least 25% of employees (by number and compensation), assets and gross income of our expanded affiliated group are based, located and derived, respectively, in the country of incorporation.

We do not expect to be treated as a US corporation under Section 7874 of the Code, because we do not believe that the assets contributed to us by Innoviva constituted “substantially all” of the properties of Innoviva (as determined on both a gross and net fair market value basis). However, the Internal Revenue Service may disagree with our conclusion on this point and assert that, in its view, the assets contributed to us by Innoviva did constitute “substantially all” of the properties of Innoviva. In addition, there could be legislative proposals to expand the scope of US corporate tax residence and there could be changes to Section 7874 of the Code or the Treasury Regulations promulgated thereunder that could apply retroactively and could result in Theravance Biopharma being treated as a US corporation.

If it were determined that we should be treated as a US corporation for US federal income tax purposes, we could be liable for substantial additional US federal income tax on our post-Spin-Off taxable income. In addition, though we have no current plans to pay any dividends, payments of any dividends to non-US holders may be subject to US withholding tax.

***Taxing authorities may challenge our structure and transfer pricing arrangements.***

We are incorporated in the Cayman Islands, maintain subsidiaries in the Cayman Islands, the US, the UK and Ireland, and effective July 1, 2015, we migrated our tax residency from the Cayman Islands to Ireland. Due to economic and political conditions, various countries are actively considering changes to existing tax laws. We cannot predict the form or timing of potential legislative changes that could have a material adverse impact on our results of operations. We are aware that Ireland has implemented certain tax law changes and is expected to implement additional tax law changes to comply with the European Union Anti-Tax Avoidance Directives. These changes include the first ever Irish controlled foreign company (“CFC”) rules which came into effect on January 1, 2019. Due to provisions in *Finance Bill 2019*, Ireland will also implement certain transfer pricing rule changes, with effect from 2020. We are continuing to evaluate and monitor the applicability of the CFC rules published in *Finance Act 2018*, but our current assessment, based on the rules and guidance published to date, is that the rules are unlikely to have a material impact on our operations. Statutory language has been provided for the transfer pricing rule changes, and we believe that the transfer pricing rules are unlikely to have a material impact on our operations. New UK tax legislation was introduced by the *Finance Act 2019* (“FA 2019”) that imposes a tax related to offshore receipts in respect of intangible property held in low tax jurisdictions (“ORIP”) and became effective in April 2019. FA 2019 also included a power for amendments to the ORIP legislation to be made by regulation by December 31, 2019. On October 15, 2019, the UK published further guidance intended to facilitate the administration of the ORIP regime. However, a number of issues and areas of uncertainty remain. We have reviewed the original legislation in conjunction with the guidance and believe that the ORIP regime may apply to certain cash receipts. Based on this analysis, we believe that the ORIP charge on UK-derived cash receipts through 2020 is not material.

In April 2020, we became aware of a withholding tax regulation that could be interpreted to apply to certain of our previous intra-group transactions. Additional draft guidance on this withholding tax regime was released in late 2020 and early 2021, and based on our analysis of this guidance, we do not believe the exposure to be material. We continue to monitor the evolving legislation relating to this matter and will consider its impact on our consolidated financial statements.

In addition, significant judgment is required in determining our worldwide provision for income taxes. Various factors may have favorable or unfavorable effects on our income tax rate including, but not limited to the performance of certain functions and ownership of certain assets in tax-efficient jurisdictions such as the Cayman Islands and Ireland, together with intra-group transfer pricing agreements. Taxing authorities may challenge our structure and transfer pricing arrangements through an audit or lawsuit. Responding to or defending such a challenge could be expensive and consume time and other resources, and divert management’s time and focus from operating our business. We cannot predict

41

[Table of Contents](#TOC)

whether taxing authorities will conduct an audit or file a lawsuit challenging this structure, the cost involved in responding to any such audit or lawsuit, or the outcome. We may be required to pay taxes for prior periods, interest, fines or penalties, and may be obligated to pay increased taxes in the future which could result in reduced cash flows and have a material adverse effect on our business, financial condition and growth prospects.

***We were a passive foreign investment company, or “PFIC,” for 2014, but we were not a PFIC from 2015 through 2020, and we do not expect to be a PFIC for the foreseeable future.***

For US federal income tax purposes, we generally would be classified as a PFIC for any taxable year if either (i) 75% or more of our gross income (including gross income of certain 25% or more owned corporate subsidiaries) is “passive income” (as defined for such purposes) or (ii) the average percentage of our assets (including the assets of certain 25% or more owned corporate subsidiaries) that produce passive income or that are held for the production of passive income is at least 50%. In addition, whether our Company will be a PFIC for any taxable year depends on our assets and income over the course of each such taxable year and, as a result, cannot be predicted with certainty until after the end of the year.

Based upon our assets and income during the course of 2014, we believe that our Company and one of our Company’s wholly-owned subsidiaries, Theravance Biopharma R&D, Inc. was a PFIC for 2014. Based upon our assets and income from 2015 through 2020, we do not believe that our Company is a PFIC since 2015. Based on existing tax law, we do not expect to be a PFIC for the foreseeable future based on our current business plans and current business model. For any taxable year (or portion thereof) in which our Company is a PFIC that is included in the holding period of a US holder, the US holder is generally subject to additional US federal income taxes plus an interest charge with respect to certain distributions from Theravance Biopharma or gain recognized on a sale of Theravance Biopharma shares. Similar rules would apply with respect to distributions from or gain recognized on an indirect sale of Theravance Biopharma Ireland Limited. US holders of our ordinary shares may have filed an election with respect to Company shares held at any time during 2014 to be treated as owning an interest in a “qualified electing fund” (“QEF”) or to “mark to market” their ordinary shares to avoid the otherwise applicable interest charge consequences of PFIC treatment with respect to our ordinary shares. A foreign corporation will not be treated as a QEF for any taxable year in which such foreign corporation is not treated as a PFIC. QEF and mark to market elections generally apply to the taxable year for which the election is made and all subsequent taxable years unless the election is revoked with consent of the Secretary of Treasury. US holders of our ordinary shares should consult their tax advisers regarding the tax reporting implications with respect to any QEF and mark to market elections made with respect to our Company and with respect to their indirect interests in Theravance Biopharma R&D, Inc.

***If we are unable to maintain effective internal controls, our business, financial position and results of operations could be adversely affected.***

If we are unable to maintain effective internal controls, our business, financial position and results of operations could be adversely affected. We are subject to the reporting and other obligations under the Exchange Act, including the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, which require annual management assessments of the effectiveness of our internal control over financial reporting. Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the US. Any failure to achieve and maintain effective internal controls could have an adverse effect on our business, financial position and results of operations. In addition, our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting annually. If our independent registered public accounting firm is unable to attest to the effectiveness of our internal control over financial reporting, investor confidence in our reported results will be harmed and the price of our securities may fall. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources.

42

[Table of Contents](#TOC)

***Agreements entered into with or for the benefit of GSK in connection with the Spin-Off may significantly restrict our business and affairs.***

On March 3, 2014, in connection with the Spin-Off, we, Innoviva and GSK entered into a number of agreements that may significantly restrict our business and affairs. In particular, we, Innoviva and GSK entered into the Master Agreement which, among other things, requires GSK’s consent to make any changes to (i) a Separation and Distribution Agreement and ancillary agreements that would, individually or in the aggregate, reasonably be expected to adversely affect GSK in any material respect or (ii) the TRC LLC Agreement, which consent is not to be unreasonably withheld, conditioned or delayed, provided that GSK may withhold, condition or delay such consent in its sole discretion with respect to certain sections of the TRC LLC Agreement and any changes to the governance structure of TRC, the confidentiality restrictions, the consent rights, and the transfer restrictions in the TRC LLC Agreement. We and GSK also entered into (i) the Governance Agreement that expired on December 31, 2017, (ii) a registration rights agreement that gives GSK certain registration rights with respect to our ordinary shares held by GSK and (iii) an extension agreement that extends to us certain restrictive covenants similar to those applicable to Innoviva under the GSK Agreements. There can be no assurance that these restrictions will not materially harm our business, particularly given that GSK’s interests may not be aligned with the interests of our business or our other shareholders.

***Certain of our directors and officers may have actual or potential conflicts of interest because of their equity ownership in Innoviva, which actual or potential conflicts may harm our business, prospects and financial condition and result in the diversion of corporate opportunities to Innoviva.***

Certain of our directors and officers hold shares of Innoviva’s common stock or rights to acquire such shares, and these holdings may be significant for some of these individuals compared to their total assets. This ownership of Innoviva common stock by certain of our directors and officers may create, or may create the appearance of, conflicts of interest when these directors and officers are faced with decisions that could have different implications for Innoviva and for us. For example, potential or actual conflicts could arise relating to: our relationship with Innoviva, including Innoviva’s and our respective rights and obligations under agreements entered into in connection with the Spin-Off; Innoviva’s management of TRC, particularly given that we and Innoviva have different economic interests in TRC; and corporate opportunities that may be available to both companies in the future. Although we and Innoviva have implemented policies and procedures to identify and properly address such potential and actual conflicts of interest, there can be no assurance that, when such conflicts are resolved in accordance with applicable laws, such conflicts of interest will not harm our business, prospects and financial condition and result in the diversion of corporate opportunities to Innoviva.

***If we are required to indemnify Innoviva or Cumberland, or if we are not able to enforce our indemnification rights against Innoviva or Cumberland, our business prospects and financial condition may be harmed.***

We agreed to indemnify Innoviva from and after the Spin-Off with respect to (i) all debts, liabilities and obligations transferred to us in connection with the Spin-Off (including our failure to pay, perform or otherwise promptly discharge any such debts, liabilities or obligations after the Spin-Off), (ii) any misstatement or omission of a material fact resulting in a misleading statement in our Information Statement distributed to Innoviva stockholders in connection with the Spin-Off and (iii) any breach by us of certain agreements entered into with Innoviva in connection with the Spin-Off (namely, the Separation and Distribution Agreement, a Transition Services Agreement, an Employee Matters Agreement, a Tax Matters Agreement, and a Facility Sublease Agreement). We are not aware of any existing indemnification obligations at this time, but any such indemnification obligations that may arise could be significant. Under the terms of the Separation and Distribution Agreement, Innoviva agreed to indemnify us from and after the Spin-Off with respect to (i) all debts, liabilities and obligations retained by Innoviva after the Spin-Off (including its failure to pay, perform or otherwise promptly discharge any such debts, liabilities or obligations after the Spin-Off) and (ii) any breach by Innoviva of the Separation and Distribution Agreement, the Transition Services Agreement, the Employee Matters Agreement, the Tax Matters Agreement, and the Facility Sublease Agreement. Our and Innoviva’s ability to satisfy these indemnities, if called upon to do so, will depend upon our and Innoviva’s future financial strength. If we are required to indemnify Innoviva, or if we are not able to enforce our indemnification rights against Innoviva, our business prospects and financial condition may be harmed.

43

[Table of Contents](#TOC)

In addition, the agreement relating to the sale of VIBATIV to Cumberland contains indemnification obligations of both us and Cumberland. If we are required to indemnify Cumberland or if we are unable to enforce our indemnification rights against Cumberland for any reason, our business and financial condition may be harmed.

**RISKS RELATED TO LEGAL AND REGULATORY UNCERTAINTY**

***If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our current or future markets.***

We rely upon a combination of patents, patent applications, trade secret protection and confidentiality agreements to protect the intellectual property related to our technologies. Any involuntary disclosure to or misappropriation by third parties of this proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. The status of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and is very uncertain. As of December 31, 2020, we owned 507 issued US patents and 2,253 granted foreign patents, as well as additional pending US and foreign patent applications. Our patent applications may be challenged or fail to result in issued patents and our existing or future patents may be invalidated or be too narrow to prevent third parties from developing or designing around these patents. If the sufficiency of the breadth or strength of protection provided by our patents with respect to a product candidate is threatened, it could dissuade companies from collaborating with us to develop product candidates and threaten our ability to commercialize products. Further, if we encounter delays in our clinical trials or in obtaining regulatory approval of our product candidates, the patent lives of the related product candidates would be reduced.

In addition, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, for processes for which patents are difficult to enforce and for any other elements of our drug discovery and development processes that involve proprietary know-how, information and technology that is not covered by patent applications. Although we require our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information and technology to enter into confidentiality agreements, we cannot be certain that this know-how, information and technology will not be misappropriated, disclosed or used for unauthorized purposes or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the US. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the US and abroad. If we are unable to prevent material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish or, if established, maintain a competitive advantage in our market, which could materially adversely affect our business, financial condition and results of operations, which could cause the price of our securities to fall.

***Litigation to protect or defend our intellectual property or third-party claims of intellectual property infringement would require us to divert resources and may prevent or delay our drug discovery and development efforts.***

Our commercial success depends in part on us and our partners not infringing the patents and proprietary rights of third parties. Third parties may assert that we or our partners are using their proprietary rights without authorization. There are third-party patents that may cover materials or methods for treatment related to our product candidates. At present, we are not aware of any patent infringement claims with merit that would adversely and materially affect our ability to develop our product candidates, but nevertheless the possibility of third-party allegations cannot be ruled out. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Furthermore, parties making claims against us or our partners may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense against these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.

In the event of a successful claim of infringement against us, we may have to pay substantial damages, obtain one or more licenses from third parties or pay royalties. In addition, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly.

44

[Table of Contents](#TOC)

In addition, in the future we could be required to initiate litigation to enforce our proprietary rights against infringement by third parties, prevent the unauthorized use or disclosure of our trade secrets and confidential information, or defend the validity of our patents. For example, in 2017, we filed a lawsuit against a former employee for misappropriation of certain of our confidential, proprietary and trade secret information. While this litigation has since been resolved, prosecution of claims to enforce or defend our rights against others involve substantial litigation expenses and divert substantial employee resources from our business but may not result in adequate remedy to us or sufficiently mitigate the harm to our business caused by any intellectual property infringement, unauthorized access, use or disclosure of trade secrets. If we fail to effectively enforce our proprietary rights against others, our business will be harmed and the price of our securities could fall.

***If the efforts of our partners or future partners to protect the proprietary nature of the intellectual property related to collaboration assets are not adequate, the future commercialization of any medicines resulting from collaborations could be delayed or prevented, which would materially harm our business and could cause the price of our securities to fall.***

The risks identified in the two preceding risk factors may also apply to the intellectual property protection efforts of our partners or future partners and to GSK with respect to the GSK-Partnered Respiratory Programs in which we hold an economic interest. To the extent the intellectual property protection of any partnered assets is successfully challenged or encounters problems with the US Patent and Trademark Office or other comparable agencies throughout the world, the future commercialization of these potential medicines could be delayed or prevented. Any challenge to the intellectual property protection of a late-stage development asset, particularly those of the GSK-Partnered Respiratory Programs in which we hold an economic interest, could harm our business and cause the price of our securities to fall.

***Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our medicines.***

The risk that we may be sued on product liability claims is inherent in the development and commercialization of pharmaceutical products. Side effects of, or manufacturing defects in, products that we or our partners develop or commercialize could result in the deterioration of a patient’s condition, injury or even death. Once a product is approved for sale and commercialized, the likelihood of product liability lawsuits tends to increase. Claims may be brought by individuals seeking relief for themselves or by individuals or groups seeking to represent a class, asserting injuries based both on potential adverse effects described in the label as well as adverse events not yet observed. We also face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials. In addition, changes in laws outside the US are expanding our potential liability for injuries that occur during clinical trials. Product liability claims could harm our reputation, regardless of the merit or ultimate success of the claim, which may adversely affect our and our partners’ ability to commercialize our products and cause the price of our securities to fall. These lawsuits may divert our management from pursuing our business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities and may be forced to limit or forgo further commercialization of the applicable products.

Although we maintain general liability and product liability insurance, this insurance may not fully cover potential liabilities and we cannot be sure that our insurer will not disclaim coverage as to a future claim. In addition, inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims could prevent or inhibit the commercial production and sale of our products, which could adversely affect our business.

We may also be required to prosecute or defend general commercial, intellectual property, securities and other lawsuits. Litigation typically involves substantial expenses and diverts substantial employee resources from our business. The cost of defending any product liability litigation or engaging in any other legal proceeding, even if resolved in our favor, could be substantial and uncertainties resulting from the initiation and continuation of the litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace and achieve our business goals.

45

[Table of Contents](#TOC)

***If we fail to comply with data protection laws and regulations, we could be subject to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity, which could negatively affect our operating results and business.***

We are subject to data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the US, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the FTC Act), govern the collection, use, disclosure, and protection of health related and other personal information. In California, the California Consumer Privacy Act (“CCPA”) took effect on January 1, 2020. The CCPA establishes certain requirements for data use and sharing transparency, and provides California residents certain rights concerning the use, disclosure, and retention of their personal data. Similarly, there are a number of legislative proposals in the United States, at both the federal and state level, that could impose new obligations or limitations in areas affecting our business. These laws and regulations are evolving and subject to interpretation, and may impose limitations on our activities or otherwise adversely affect our business. The obligations to comply with the CCPA and evolving legislation require us, among other things, to update our notices and develop new processes internally and with our partners. We may be subject to fines, penalties, or private actions in the event of non-compliance with the such laws. Failure to comply with data protection laws and regulations could result in unfavorable outcomes, including increased compliance costs, delays or impediments in the development of new products, increased operating costs, diversion of management time and attention, government enforcement actions and create liability for us (which could include civil and/or criminal penalties), private litigation and/or adverse publicity that could negatively affect our operating results and business.

In addition, we may obtain health information from third parties (e.g., healthcare providers who prescribe our products) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, and its implementing regulations, (collectively, “HIPAA”). Although we are not directly subject to HIPAA—other than with respect to providing certain employee benefits—we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA. HIPAA generally requires that healthcare providers and other covered entities obtain written authorizations from patients prior to disclosing protected health information of the patient (unless an exception to the authorization requirement applies). If authorization is required and the patient fails to execute an authorization or the authorization fails to contain all required provisions, then we may not be allowed access to and use of the patient’s information and our research efforts could be impaired or delayed. Furthermore, use of protected health information that is provided to us pursuant to a valid patient authorization is subject to the limits set forth in the authorization (e.g., for use in research and in submissions to regulatory authorities for product approvals). In addition, HIPAA does not replace federal, state, international or other laws that may grant individuals even greater privacy protections.

EU Member States and other jurisdictions where we operate have adopted data protection laws and regulations, which impose significant compliance obligations. For example, the General Data Protection Regulation (“GDPR”) which became applicable on May 25, 2018, replacing the EU Data Protection Directive, imposes strict obligations and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting.

Switzerland has adopted laws that impose restrictions and obligations similar to the GDPR. These obligations and restrictions concern, in particular, the consent of the individuals to whom the personal data relate, the information provided to the individuals, the transfer of personal data out of the European Economic Area (“EEA”) or Switzerland, security breach notifications, security and confidentiality of the personal data, as well as substantial potential fines for breaches of the data protection obligations. Data protection authorities from the different EU Member States may interpret the GDPR and applicable related national laws differently and impose requirements additional to those provided in the GDPR. In addition, guidance on implementation and compliance practices may be updated or otherwise revised, which adds to the complexity of processing personal data in the EU. When processing personal data of subjects in the EU, we have to comply with the applicable data protection laws. In particular, as we rely on service providers processing personal data of subjects in the EU, we have to enter into suitable contract terms with such providers and receive sufficient guarantees that such providers meet the requirements of the applicable data protection laws, particularly the GDPR which imposes specific and relevant obligations.

46

[Table of Contents](#TOC)

Legal mechanisms to allow for the transfer of personal data from the EEA to the US have been challenged in the European Court of Justice, which generally increases uncertainty around compliance with EU privacy law requirements as these relate to transfer of data from the EU to the US. In 2016, the European Commission and the US Department of Commerce (“DOC”) put in place the EU US “Privacy Shield,” which has been relied on by some US companies since that time to transfer data to the US, and, in its third annual review of the Privacy Shield in October 2019, the European Commission concluded that the US continues to ensure an adequate level of protection for personal data transferred under the Privacy Shield. However, on July 16, 2020, the European Court of Justice ruled that the Privacy Shield is invalid. As a result, from July 16, 2020 companies may no longer rely on the Privacy Shield as a basis on which to transfer personal data from the EU to the US. US-based companies are permitted to rely on other authorized means and procedures to transfer personal data provided by the GDPR. However, the most common authorized procedure to transfer personal data out of the EU, the European Commission’s Standard Contractual Clauses, may, as a result of the Court judgement of July 16, 2020, also come under increased scrutiny. Following the Court’s ruling, the European Data Protection Board issued a statement providing among other things that it is a primary responsibility of the exporter and the importer, when considering whether to rely on Standard Contractual Clauses to export data from the EU to third countries, to ensure that these third countries maintain a level of protection that is essentially equivalent to that guaranteed by the GDPR in light of the EU Charter of Human Rights. Companies may need to revise their Standard Contractual Clauses in light of the July 16, 2020 judgement. Companies that have not taken steps to demonstrate that their Standard Contractual Clauses and personal data recipients in the US are suitable to transfer to receive the personal data may be subject to enforcement actions by competent authorities in the EU for failure to comply with related data privacy rules.

In addition, the privacy and data security landscape in the EU continues to remain in flux. The agreement that has been concluded between the EU and the UK following the UK’s withdrawal from the EU on January 31, 2020 may require organizations to revisit the way they transfer personal data from and to the UK from the EU. The Trade and Cooperation Agreement concluded between the EU and the UK provides for a transition period of six months starting January 1, 2021. During this period personal data may, in accordance with the requirements of the GDPR, flow from the EEA to the UK and from the UK to the EEA. If the European Commission does not adopt an Adequacy Decision concerning the level of data protection in the UK within this six month period, any potential flows of personal data between the EEA and the UK will subsequently be subject to the same restrictions as those imposed on other third countries.

If we or our vendors fail to comply with applicable data privacy laws, or if the legal mechanisms we or our vendors rely upon to allow for the transfer of personal data from the EEA or Switzerland to the US (or other countries not considered by the European Commission to provide an adequate level of data protection) are not considered adequate, we could be subject to government enforcement actions, including an order to stop transferring the personal data outside of the EEA and significant penalties against us. Moreover, our business could be adversely impacted if our ability to transfer personal data out of the EEA or Switzerland to the US is restricted, which could adversely impact our operating results.

***Changes in healthcare law and implementing regulations, including government restrictions on pricing and reimbursement, as well as healthcare policy and other healthcare payor cost-containment initiatives, may negatively impact us, our collaboration partners, or those commercializing products with respect to which we have an economic interest or right to receive royalties.***

The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care may adversely affect us, our collaboration partners, or those commercializing products with respect to which we have an economic interest or right to receive royalties in regard to one or more of the following:

|  |  |  |
| --- | --- | --- |
|  | • | the ability to set and collect a price believed to be reasonable for products; |

|  |  |  |
| --- | --- | --- |
|  | • | the ability to generate revenues and achieve profitability; and |

|  |  |  |
| --- | --- | --- |
|  | • | the availability of capital. |

47

[Table of Contents](#TOC)

The pricing and reimbursement environment for products may change in the future and become more challenging due to, among other reasons, policies advanced by the current or new presidential administrations, federal agencies, new healthcare legislation passed by Congress or fiscal challenges faced by all levels of government health administration authorities. Among policy makers and payors in the US and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access to healthcare. In the US, the pharmaceutical industry has been a particular focus of these efforts and has been and may in the future be significantly affected by major regulatory or legislative initiatives. For instance, while Medicare Part B payment for most drugs has been established at the average sales price of the drug plus 6% (reduced to 4.3% as a result of sequestration), a regulatory change may alter the level of payment for some drugs. In a November 20, 2020 interim final rule, Center for Medicare and Medical Services (“CMS”) established a “Most Favored Nation” demonstration model that would lower Medicare Part B reimbursement of certain drugs based on international reference prices. The rule has become subject to judicial challenges, and federal courts have enjoined the rule at this time. There is also proposed legislation pending that would establish an international reference price-based payment methodology. We expect we, our collaboration partners or those commercializing products with respect to which we have an economic interest or right to receive royalties may experience pricing pressures in connection with the sale of drug products, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative enactments.

The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (together the “Healthcare Reform Act”), is a sweeping measure intended to expand healthcare coverage within the US, primarily through the imposition of health insurance mandates on employers and individuals, the provision of subsidies to eligible individuals enrolled in plans offered on the health insurance exchanges, and expansion of the Medicaid program. This law has substantially changed the way healthcare is financed by both governmental and private insurers and has significantly impacted the pharmaceutical industry. The Healthcare Reform Act contains a number of provisions that impact our business and operations, including those governing enrollment in federal healthcare programs, reimbursement changes, benefits for patients within a coverage gap in the Medicare Part D prescription drug program (commonly known as the “donut hole”), rules regarding prescription drug benefits under the health insurance exchanges, changes to the Medicare Drug Rebate program, expansion of the Public Health Service Act’s 340B drug pricing program, fraud and abuse and enforcement. These changes have impacted previously existing government healthcare programs and have resulted in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program.

In particular, CMS issued final regulations to implement the changes to the Medicaid Drug Rebate program under the Healthcare Reform Act. These regulations became effective on April 1, 2016. Congress could enact additional legislation that further increases Medicaid drug rebates or other costs and charges associated with participating in the Medicaid Drug Rebate program. On December 21, 2020, CMS issued a final regulation that modified prior Medicaid Drug Rebate program regulations to permit reporting multiple best price figures with regard to value-based purchasing arrangements (beginning in 2022); provide definitions for “line extension,” “new formulation,” and related terms, with the practical effect of expanding the scope of drugs considered to be line extensions that are subject to an alternative rebate formula (beginning in 2022); and revise best price and average manufacturer price exclusions of manufacturer-sponsored patient benefit programs, specifically regarding applicability of such exclusions in the context of pharmacy benefit manager “accumulator” programs (beginning in 2023). It is currently unclear whether the Biden administration will delay or suspend implementation of this final rule. The issuance of regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate program has increased and will continue to increase the costs and the complexity of compliance, has been and will be time-consuming to implement, and could have a material adverse effect on results of operations for us, our collaboration partners, or those commercializing products with respect to which we have an economic interest or right to receive royalties, particularly if CMS challenges the approach we take in our implementation of the final regulation.

Some states have elected not to expand their Medicaid programs by raising the income limit to 133% of the federal poverty level, as is permitted under the Healthcare Reform Act. For each state that does not choose to expand its Medicaid program, there may be fewer insured patients overall, which could impact the sales, business and financial condition of us, our collaboration partners, or those commercializing products with respect to which we have an economic interest or right to receive royalties. Where Medicaid patients receive insurance coverage under any of the new

48

[Table of Contents](#TOC)

options made available through the Healthcare Reform Act, manufacturers may be required to pay Medicaid rebates on drugs used under these circumstances, which could impact manufacturer revenues.

Certain provisions of the Healthcare Reform Act have been subject to judicial challenges as well as efforts to repeal or replace them or to alter their interpretation or implementation. For example, the Tax Cuts and Jobs Act enacted on December 22, 2017 (the “Tax Act”), eliminated the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, commonly referred to as the individual mandate, effective January 1, 2019. Currently, the Supreme Court is considering whether the Healthcare Reform Act’s individual mandate, post-repeal of its associated tax penalty, is unconstitutional, and, if so, whether the remaining provisions of the Healthcare Reform Act are inseverable from the mandate. A ruling is expected by mid-2021 and could produce any of a number of results, including invalidation of the Healthcare Reform Act in its entirety if there is a finding of inseverability. It is unclear how the ultimate decision in this case, or other efforts to repeal, replace, or invalidate the Healthcare Reform Act or its implementing regulations, or portions thereof, will affect the Healthcare Reform Act or our business. Additional legislative changes to and regulatory changes under the Healthcare Reform Act remain possible, but the nature and extent of such potential additional changes are uncertain at this time. We expect that the Healthcare Reform Act, its implementation, efforts to repeal or replace, or invalidate the Healthcare Reform Act, or portions thereof, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on the ability of us, our collaboration partners, or those commercializing products with respect to which we have an economic interest or right to receive royalties to maintain or increase sales of existing products or to successfully commercialize product candidates, if approved.

The Bipartisan Budget Act of 2018, among other things, amended the Healthcare Reform Act to increase the point-of-sale discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D. Additionally, in November 2020, the U.S. Department of Health and Human Services finalized a previously abandoned proposal to amend the discount safe harbor regulation of the federal anti-kickback statute in a purported effort to create incentives to manufacturers to lower their list prices, and to lower federal program beneficiary out-of-pocket costs. The rule, which takes full effect January 1, 2022, revises the discount safe harbor to exclude manufacturer rebates to Medicare Part D plans, either directly or through pharmacy benefit managers (PBMs), creates a new safe harbor for point-of-sale price reductions that are set in advance and are available to the beneficiary at the point-of-sale, and creates a new safe harbor for service fees paid by manufacturers to PBMs for services rendered to the manufacturer. It is too early to know what the effect of the rule will be on negotiations of coverage for our products with Medicare Part D plans, or whether the rule will affect our coverage arrangements with commercial insurers. It is also unclear whether the rule will have the intended effect of reducing net prices and beneficiary out-of-pocket costs without also increasing Medicare Part D premiums, which may impact the willingness of Part D plans to cover our products and the price concessions or other terms the plans or their PBMs may seek from us. There have been other proposals to modify the Medicare Part D benefit, including by imposing federally mandated rebates on all drugs dispensed to Medicare Part D enrollees or on only those drugs dispensed to certain groups of lower income beneficiaries. If any of these proposals are adopted including any that result in additional rebates, this could have a negative impact on revenues for our collaboration partners, or those commercializing products with respect to which we have an economic interest or right to receive royalties, which could impact our revenues.

On August 2, 2011, the Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals for spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction, which triggered the legislation’s automatic reductions. In concert with subsequent legislation, this has resulted in aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year through 2030 (with the exception of a temporary suspension from May 1, 2020 through March 31, 2021) unless Congress takes additional action. As long as these cuts remain in effect, they could adversely impact payment for any products that are reimbursed under Medicare.

Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement limitations, marketing cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. For example, California has enacted a prescription drug price transparency

49

[Table of Contents](#TOC)

law requiring prescription drug manufacturers to provide advance notice and explanation for price increases of certain drugs with prices that exceed a specified threshold, and to report new prescription drugs introduced to the market at a wholesale acquisition cost exceeding the Medicare Part D specialty drug threshold.

We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for product or additional pricing pressures for our collaboration partners, or those commercializing products with respect to which we have an economic interest or right to receive royalties, which could impact our revenues.

***If we failed to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.***

Prior to the sale of VIBATIV to Cumberland, we had certain price reporting obligations to the Medicaid Drug Rebate program and other governmental pricing programs, and we had obligations to report average sales price under the Medicare program. Following the consummation of the transaction with Cumberland, our price reporting obligations related to VIBATIV have been transitioned to Cumberland, and price reporting obligations for YUPELRI reside with Viatris. However, we retain liability related to price reporting for VIBATIV for historic periods.

Under the Medicaid Drug Rebate program, a manufacturer is required to pay a rebate to each state Medicaid program for its covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds being made available to the states for our drugs under Medicaid and Medicare Part B. Those rebates are based on pricing data reported by the manufacturer on a monthly and quarterly basis to CMS, the federal agency that administers the Medicaid Drug Rebate program. These data include the average manufacturer price and, in the case of innovator products, the best price for each drug which, in general, represents the lowest price available from the manufacturer to any entity in the US in any pricing structure, calculated to include all sales and associated rebates, discounts and other price concessions.

Federal law requires that any company that participates in the Medicaid Drug Rebate program also participate in the Public Health Service’s 340B drug pricing program in order for federal funds to be available for the manufacturer’s drugs under Medicaid and Medicare Part B. The 340B program requires participating manufacturers to agree to charge no more than the 340B “ceiling price” for the manufacturer’s covered outpatient drugs to a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. Manufacturers also are required to report their 340B ceiling prices to HRSA on a quarterly basis, and HRSA then publishes them to 340B covered entities. A final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities became effective on January 1, 2019. Moreover, under a final regulation effective January 13, 2021, HRSA newly established an administrative dispute resolution (“ADR”) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could subject us to onerous procedural requirements and could result in additional liability.

Federal law also requires that a company that participates in the Medicaid Drug Rebate program report average sales price information each quarter to CMS for certain categories of drugs that are paid under the Medicare Part B program. Manufacturers calculate the average sales price based on a statutorily defined formula as well as regulations and interpretations of the statute by CMS. CMS uses these submissions to determine payment rates for drugs under Medicare Part B.

Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by the manufacturer, governmental or regulatory agencies and the courts. A manufacturer that becomes aware that its Medicaid reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, is obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase the costs for complying with the laws and regulations governing the Medicaid

50

[Table of Contents](#TOC)

Drug Rebate program and could result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the 340B ceiling price.

We are liable for errors associated with our submission of pricing data. In addition to retroactive rebates and the potential for 340B program refunds, if we are found to have knowingly submitted any false price information to the government, we may be liable for significant civil monetary penalties per item of false information. If we are found to have made a misrepresentation in the reporting of our average sales price, the Medicare statute provides for significant civil monetary penalties for each misrepresentation for each day in which the misrepresentation was applied. If we are found to have charged 340B covered entities more than the statutorily mandated ceiling price, we could be subject to significant civil monetary penalties. Our failure to submit the required price data on a timely basis could result in a significant civil monetary penalty per day for each day the information is late beyond the due date. Such failure also could be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we participate in the Medicaid program. In the event that CMS terminates our rebate agreement, federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs.

In order to be eligible to have its products paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by the Department of Veterans Affairs (“VA”), Department of Defense (“DoD”), Public Health Service, and Coast Guard (the “Big Four agencies”) and certain federal grantees, a manufacturer is required to participate in the VA Federal Supply Schedule (“FSS”) pricing program, established under Section 603 of the Veterans Health Care Act of 1992. Under this program, the manufacturer is obligated to make its covered drugs available for procurement on an FSS contract and charge a price to the Big Four agencies that is no higher than the Federal Ceiling Price (“FCP”), which is a price calculated pursuant to a statutory formula. The FCP is derived from a calculated price point called the “non-federal average manufacturer price” (“Non-FAMP”), which the manufacturer calculates and reports to the VA on a quarterly and annual basis. Pursuant to applicable law, knowing provision of false information in connection with a Non-FAMP filing can subject a manufacturer to significant penalties for each item of false information. The FSS contract also contains extensive disclosure and certification requirements.

Under Section 703 of the National Defense Authorization Act for FY 2008, the manufacturer is required to pay quarterly rebates to DoD on utilization of its innovator products that are dispensed through DoD’s Tricare network pharmacies to Tricare beneficiaries. The rebates are calculated as the difference between the annual Non-FAMP and FCP for the calendar year that the product was dispensed. A manufacturer that overcharges the government in connection with the FSS contract or Tricare Retail Pharmacy Rebate Program, whether due to a misstated FCP or otherwise, is required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations.

Individual states in the United States, as noted, have also passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including marketing cost disclosure and transparency measures. Some states require the submission of reports related to pricing information, including based on the introduction of new prescription drugs, certain increases in wholesale acquisition cost of prescription drugs, marketing of prescription drugs within the state, and sales of prescription drugs in or into the state. Some states may pursue available enforcement measures, including imposition of civil monetary penalties, for a manufacturer’s failure to report such information.

***Our relationships with customers and third-party payors are subject to applicable anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion, contractual damages, reputational harm and diminished profits and future earnings.***

Healthcare providers, physicians, distributors and third-party payors play a primary role in the distribution, recommendation and prescription of any pharmaceutical product for which we obtain marketing approval. Our arrangements with third-party payors and customers expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements through which we market, sell and distribute any products for which we have obtained or may obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:

51

[Table of Contents](#TOC)

|  |  |  |
| --- | --- | --- |
|  | • | The US federal healthcare Anti-Kickback Statute prohibits any person from, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchasing, leasing, ordering or arranging for or recommending of any good or service for which payment may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid. The term “remuneration” has been broadly interpreted to include anything of value. The Anti-Kickback Statute is subject to evolving interpretation and has been applied by government enforcement officials to a number of common business arrangements in the pharmaceutical industry. The government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of the statute or specific intent to violate it. There are a number of statutory exemptions and regulatory safe harbors protecting some common activities from prosecution; however, those exceptions and safe harbors are drawn narrowly. Failure to meet all of the requirements of a particular statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute, but the legality of the arrangement will be evaluated on a case-by-case basis based on the totality of the facts and circumstances. We seek to comply with the available statutory exemptions and safe harbors whenever possible, but our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants or patient or product assistance programs. |

|  |  |  |
| --- | --- | --- |
|  | • | The federal civil False Claims Act prohibits, among other things, knowingly presenting, or causing to be presented, claims for payment of government funds that are false or fraudulent, or knowingly making, or using or causing to be made or used, a false record or statement material to a false or fraudulent claim to avoid, decrease, or conceal an obligation to pay money to the federal government. Private individuals, commonly known as “whistleblowers,” can bring civil False Claims Act *qui tam* actions, on behalf of the government and such individuals and may share in amounts paid by the entity to the government in recovery or settlement. In recent years, several pharmaceutical and other healthcare companies have faced enforcement actions under the federal False Claims Act for, among other things, allegedly submitting false or misleading pricing information to government health care programs and providing free product to customers with the expectation that the customers would bill federal programs for the product. Federal enforcement agencies also have showed increased interest in pharmaceutical companies’ product and patient assistance programs, including reimbursement and co-pay support services, and a number of investigations into these programs have resulted in significant civil and criminal settlements. Other companies have faced enforcement actions for causing false claims to be submitted because of the companies’ marketing the product for unapproved, and thus non-reimbursable, uses. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false claim or statement for violations. Because of the potential for large monetary exposure, healthcare and pharmaceutical companies often resolve allegations without admissions of liability for significant and material amounts to avoid the uncertainty of treble damages and per claim penalties that may be awarded in litigation proceedings. Companies may be required, however, to enter into corporate integrity agreements with the government, which may impose substantial costs on companies to ensure compliance. Criminal penalties, including imprisonment and criminal fines, are also possible for making or presenting a false, fictitious or fraudulent claim to the federal government. |

|  |  |  |
| --- | --- | --- |
|  | • | HIPAA, among other things, imposes criminal and civil liability for knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors, and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. HIPAA also prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal healthcare Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. |

52

[Table of Contents](#TOC)

|  |  |  |
| --- | --- | --- |
|  | • | The federal Physician Payment Sunshine Act, being implemented as the Open Payments Program, requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to the US Department of Health and Human Services, Centers for Medicare and Medicaid Services, information related to payments and other transfers of value, directly or indirectly, to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives. A manufacturer’s failure to submit timely, accurately and completely the required information for all payments, transfers of value or ownership or investment interests may result in civil monetary penalties. |

|  |  |  |
| --- | --- | --- |
|  | • | Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payors, including private insurers or patients. Several states also require pharmaceutical companies to report expenses relating to the marketing and promotion of pharmaceutical products in those states and to report gifts and payments to individual health care providers in those states. Some of these states also prohibit certain marketing-related activities, including the provision of gifts, meals, or other items to certain health care providers, and restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs. Some states require the posting of information relating to clinical studies and their outcomes. Some states and cities require identification or licensing of sales representatives. In addition, several states require pharmaceutical companies to implement compliance programs or marketing codes. |

|  |  |  |
| --- | --- | --- |
|  | • | Similar restrictions are imposed on the promotion and marketing of medicinal products in the EU Member States and other countries, including restrictions prohibiting the promotion of a compound prior to its approval. Laws (including those governing promotion, marketing and anti-kickback provisions), industry regulations and professional codes of conduct often are strictly enforced. Even in those countries where we may decide not to directly promote or market our products, inappropriate activity by our international distribution partners could have implications for us. |

The shifting commercial compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance or reporting requirements in multiple jurisdictions increase the possibility that we or our partners may fail to comply fully with one or more of these requirements. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with applicable fraud and abuse or other healthcare laws and regulations or guidance. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid in the US and similar programs outside the US, contractual damages, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. If any of the physicians or other providers or entities with whom we do or expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our financial condition and divert resources and the attention of our management from operating our business.

***Our business and operations, including the use of hazardous and biological materials may result in liabilities with respect to environmental, health and safety matters.***

Our research and development activities involve the controlled use of potentially hazardous substances, including chemical, biological and radioactive materials. In addition, our operations produce hazardous waste products, including hazardous waste. Federal, state and local laws and regulations govern the use, manufacture, management, storage, handling and disposal of hazardous materials and wastes. We may incur significant additional costs or liabilities

53

[Table of Contents](#TOC)

to comply with, or for violations of, these and other applicable laws in the future. Also, even if we are in compliance with applicable laws, we cannot completely eliminate the risk of contamination or injury resulting from hazardous materials and we may incur liability as a result of any such contamination or injury. Further, in the event of a release of or exposure to hazardous materials, including at the sites we currently or formerly operate or at sites such as landfills where we send wastes for disposal, we could be held liable for cleanup costs or damages or subject to other costs or penalties and such liability could exceed our resources. We do not have any insurance for liabilities arising from hazardous materials or under environmental laws. Compliance with or liability under applicable environmental laws and regulations or with respect to hazardous materials may be expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, which could cause the price of our securities to fall.

**RISKS RELATING TO OUR ORDINARY SHARES**

***The market price for our shares has and may continue to fluctuate widely and may result in substantial losses for purchasers of our ordinary shares.***

The market price for our shares has and may continue to fluctuate widely and may result in substantial losses for purchasers of our ordinary shares. To the extent that low trading volumes for our ordinary shares continues, our stock price may fluctuate significantly more than the stock market as a whole or the stock prices of similar companies. Without a larger public float of actively traded shares, our ordinary shares are likely to be more sensitive to changes in sales volumes, market fluctuations and events or perceived events with respect to our business, than the shares of common stock of companies with broader public ownership, and as a result, the trading prices for our ordinary shares may be more volatile. Among other things, trading of a relatively small volume of ordinary shares may have a greater effect on the trading price than would be the case if our public float of actively traded shares were larger. In addition, as further described below under the risk factor entitled “—*Concentration of ownership will limit your ability to influence corporate matters,”* a number of shareholders hold large concentrations of our shares which, if sold within a relatively short timeframe, could cause the price of our shares to drop significantly. In addition, as a result of the exchangeable note offering by GSK, up to 9,644,792 ordinary shares held by GSK could become freely tradeable after September 1, 2020, if holders of the GSK Notes were to exchange their notes for our ordinary shares.

Market prices for securities of biotechnology and biopharmaceutical companies have been highly volatile, and we expect such volatility to continue for the foreseeable future, so that investment in our ordinary shares involves substantial risk. Additionally, the stock market from time to time has experienced significant price and volume fluctuations unrelated to the operating performance of particular companies.

The following are some of the factors that may have a significant effect on the market price of our ordinary shares:

|  |  |  |
| --- | --- | --- |
|  | • | any adverse developments or results or perceived adverse developments or results with respect to YUPELRI, including without limitation, lower than expected sales of YUPELRI, difficulties or delays encountered with regard to the FDA or other regulatory authorities in this program or any indication from clinical or non-clinical studies that YUPELRI is not safe or efficacious; |

|  |  |  |
| --- | --- | --- |
|  | • | any adverse developments or results or perceived adverse developments or results with respect to the GSK Partnered Respiratory Programs including, without limitation, lower than expected sales of TRELEGY, difficulties or delays encountered with regard to the FDA or other regulatory authorities in these programs or any indication from clinical or non-clinical studies that the compounds in such programs are not safe or efficacious; |

|  |  |  |
| --- | --- | --- |
|  | • | any adverse developments or results or perceived adverse developments or results with respect to our key clinical development programs, for example our JAK inhibitor program or ampreloxetine, including, without limitation, any delays in development in these programs, any halting of development in these programs, any difficulties or delays encountered with regard to the FDA or other regulatory authorities in these programs (including any class-based risks that emerge as a FDA or other regulatory agency focus), or any indication from clinical or non-clinical studies that the compounds in such programs are not safe or efficacious; |

54

[Table of Contents](#TOC)

|  |  |  |
| --- | --- | --- |
|  | • | any announcements of developments with, or comments by, the FDA or other regulatory authorities with respect to products we or our partners have under development, are manufacturing or have commercialized; |

|  |  |  |
| --- | --- | --- |
|  | • | any adverse developments or disagreements or perceived adverse developments or disagreements with respect to our relationship with Innoviva, such as our 2019 arbitration proceeding with them or our current arbitration proceeding with them concerning their proposed use of TRC funds to make investments in private companies, or the relationship of Innoviva or TRC on the one hand and GSK on the other hand, including any such developments or disagreements resulting from or relating to the TRC LLC Agreement or to the Spin-Off; |

|  |  |  |
| --- | --- | --- |
|  | • | any adverse developments or perceived adverse developments with respect to our relationship with any of our research, development or commercialization partners, including, without limitation, disagreements that may arise between us and any of those partners; |

|  |  |  |
| --- | --- | --- |
|  | • | any adverse developments or perceived adverse developments in our programs with respect to partnering efforts or otherwise; |

|  |  |  |
| --- | --- | --- |
|  | • | announcements of patent issuances or denials, technological innovations or new commercial products by us or our competitors; |

|  |  |  |
| --- | --- | --- |
|  | • | publicity regarding actual or potential study results or the outcome of regulatory review relating to products under development by us, our partners or our competitors; |

|  |  |  |
| --- | --- | --- |
|  | • | regulatory developments in the US and foreign countries; |

|  |  |  |
| --- | --- | --- |
|  | • | announcements with respect to governmental or private insurer reimbursement policies; |

|  |  |  |
| --- | --- | --- |
|  | • | announcements of equity or debt financings; |

|  |  |  |
| --- | --- | --- |
|  | • | possible impairment charges on non-marketable equity securities; |

|  |  |  |
| --- | --- | --- |
|  | • | economic and other external factors beyond our control, such as the COVID-19 pandemic and fluctuations in interest rates; |

|  |  |  |
| --- | --- | --- |
|  | • | loss of key personnel; |

|  |  |  |
| --- | --- | --- |
|  | • | likelihood of our ordinary shares to be more sensitive to changes in sales volume, market fluctuations and events or perceived events with respect to our business due to our small public float; |

|  |  |  |
| --- | --- | --- |
|  | • | low public market trading volumes for our ordinary shares related in part to the concentration of ownership of our shares; |

|  |  |  |
| --- | --- | --- |
|  | • | the sale of large concentrations of our shares, which may be more likely to occur due to the concentration of ownership of our shares, such as what we experienced when our largest shareholder, Woodford Investment Management Limited, divested its holdings in 2019 or which may occur as a result of the exchangeable note offering by GSK if holders of the GSK Notes were to exchange their notes for our ordinary shares; |

|  |  |  |
| --- | --- | --- |
|  | • | developments or disputes as to patent or other proprietary rights; |

|  |  |  |
| --- | --- | --- |
|  | • | approval or introduction of competing products and technologies; |

|  |  |  |
| --- | --- | --- |
|  | • | results of clinical trials; |

|  |  |  |
| --- | --- | --- |
|  | • | failures or unexpected delays in timelines for our potential products in development, including the obtaining of regulatory approvals; |

55

[Table of Contents](#TOC)

|  |  |  |
| --- | --- | --- |
|  | • | delays in manufacturing adversely affecting clinical or commercial operations; |

|  |  |  |
| --- | --- | --- |
|  | • | fluctuations in our operating results; |

|  |  |  |
| --- | --- | --- |
|  | • | market reaction to announcements by other biotechnology or pharmaceutical companies; |

|  |  |  |
| --- | --- | --- |
|  | • | initiation, termination or modification of agreements with our collaborators or disputes or disagreements with collaborators; |

|  |  |  |
| --- | --- | --- |
|  | • | litigation or the threat of litigation; |

|  |  |  |
| --- | --- | --- |
|  | • | public concern as to the safety of product candidates or medicines developed by us; and |

|  |  |  |
| --- | --- | --- |
|  | • | comments and expectations of results made by securities analysts or investors. |

If any of these factors causes us to fail to meet the expectations of securities analysts or investors, or if adverse conditions prevail or are perceived to prevail with respect to our business, the price of the ordinary shares would likely drop significantly. A significant drop in the price of a company’s securities often leads to the filing of securities class action litigation against the company. This type of litigation against us could result in substantial costs and a diversion of management’s attention and resources.

***Concentration of ownership will limit your ability to influence corporate matters.***

Based on our review of publicly available filings, as of December 31, 2020, our three largest shareholders collectively owned 43.5% of our outstanding ordinary shares. These shareholders could control the outcome of actions taken by us that require shareholder approval, including a transaction in which shareholders might receive a premium over the prevailing market price for their shares.

***Certain provisions in our constitutional and other documents may discourage our acquisition by a third-party, which could limit your opportunity to sell shares at a premium.***

Our constitutional documents include provisions that could limit the ability of others to acquire control of us, modify our structure or cause us to engage in change-of-control transactions, including, among other things, provisions that:

|  |  |  |
| --- | --- | --- |
|  | • | require supermajority shareholder voting to effect certain amendments to our amended and restated memorandum and articles of association; |

|  |  |  |
| --- | --- | --- |
|  | • | establish a classified board of directors; |

|  |  |  |
| --- | --- | --- |
|  | • | restrict our shareholders from calling meetings or acting by written consent in lieu of a meeting; |

|  |  |  |
| --- | --- | --- |
|  | • | limit the ability of our shareholders to propose actions at duly convened meetings; and |

|  |  |  |
| --- | --- | --- |
|  | • | authorize our board of directors, without action by our shareholders, to issue preferred shares and additional ordinary shares. |

In addition, in May 2018, our shareholders approved a resolution authorizing our board of directors to adopt a shareholder rights plan in the future intended to deter any person from acquiring more than 19.9% of our outstanding ordinary shares without the approval of our board of directors.

These provisions could have the effect of depriving you of an opportunity to sell your ordinary shares at a premium over prevailing market prices by discouraging third parties from seeking to acquire control of us in a tender offer or similar transaction.

56

[Table of Contents](#TOC)

***Our shareholders may face difficulties in protecting their interests because we are incorporated under Cayman Islands law.***

Our corporate affairs are governed by our amended and restated memorandum and articles of association, by the Companies Law (2020 Revision) of the Cayman Islands and by the common law of the Cayman Islands. The rights of our shareholders and the fiduciary responsibilities of our directors under the laws of the Cayman Islands are different from those under statutes or judicial precedent in existence in jurisdictions in the US. Therefore, you may have more difficulty in protecting your interests than would shareholders of a corporation incorporated in a jurisdiction in the US, due to the different nature of Cayman Islands law in this area.

Shareholders of Cayman Islands exempted companies such as our company have no general rights under Cayman Islands law to inspect corporate records and accounts or to obtain copies of lists of shareholders. Our directors have discretion under our amended and restated memorandum and articles of association to determine whether or not, and under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts necessary for a shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest.

Our Cayman Islands counsel, Maples and Calder, is not aware of any reported class action having been brought in a Cayman Islands court. Derivative actions have been brought in the Cayman Islands courts, and the Cayman Islands courts have confirmed the availability for such actions. In most cases, the company will be the proper plaintiff in any claim based on a breach of duty owed to it, and a claim against (for example) our officers or directors usually may not be brought by a shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority and be applied by a court in the Cayman Islands, exceptions to the foregoing principle apply in circumstances in which:

|  |  |  |
| --- | --- | --- |
|  | • | a company is acting, or proposing to act, illegally or beyond the scope of its authority; |

|  |  |  |
| --- | --- | --- |
|  | • | the act complained of, although not beyond the scope of the authority, could be effected if duly authorized by more than the number of votes which have actually been obtained; or |

|  |  |  |
| --- | --- | --- |
|  | • | those who control the company are perpetrating a “fraud on the minority.” |

A shareholder may have a direct right of action against the company where the individual rights of that shareholder have been infringed or are about to be infringed.

***There is uncertainty as to shareholders’ ability to enforce certain foreign civil liabilities in the Cayman Islands.***

We are incorporated as an exempted company limited by shares with limited liability under the laws of the Cayman Islands. A material portion of our assets are located outside of the US. As a result, it may be difficult for our shareholders to enforce judgments against us or judgments obtained in US courts predicated upon the civil liability provisions of the federal securities laws of the US or any state of the US.

We understand that the courts of the Cayman Islands are unlikely (i) to recognize or enforce against Theravance Biopharma judgments of courts of the US predicated upon the civil liability provisions of the securities laws of the US or any State; and (ii) in original actions brought in the Cayman Islands, to impose liabilities against Theravance Biopharma predicated upon the civil liability provisions of the securities laws of the US or any State, on the grounds that such provisions are penal in nature. However, in the case of laws that are not penal in nature, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the US, the courts of the Cayman Islands will recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands’ judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, and or be of a kind the enforcement of which is, contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to

57

[Table of Contents](#TOC)

public policy). A Cayman Islands court, including the Grand Court of the Cayman Islands, may stay proceedings if concurrent proceedings are being brought elsewhere, which would delay proceedings and make it more difficult for our shareholders to bring action against us.

***If securities or industry analysts cease coverage of us or do not publish research, or publish inaccurate or unfavorable research, about our business, the price of our ordinary shares and trading volume could decline.***

The trading market for our ordinary shares depends in part on the research and reports that securities or industry analysts publish about us or our business. If few securities analysts commence coverage of us, or if industry analysts cease coverage of us, the trading price for our ordinary shares could be negatively affected. If one or more of the analysts who cover us downgrade our ordinary shares or publish inaccurate or unfavorable research about our business or if our results fail to meet the expectations of these analysts, the price of our ordinary shares would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our ordinary shares could decrease, which might cause our share price and trading volume to decline.

***We do not anticipate paying any cash dividends on our capital shares in the foreseeable future; as a result, capital appreciation, if any, of our ordinary shares will be your sole source of gain for the foreseeable future.***

We have never declared or paid cash dividends on our capital shares. We do not anticipate paying any cash dividends on our capital shares in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. In addition, the terms of any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our ordinary shares. As a result, capital appreciation, if any, of our ordinary shares will be your sole source of gain for the foreseeable future.

​

​

**ITEM 1B. UNRESOLVED STAFF COMMENTS**

Not applicable.

​

**ITEM 2. PROPERTIES**

Our principal physical properties in the US consist of approximately 170,000 square feet of office and laboratory space leased in two buildings in South San Francisco, California. The South San Francisco lease expires in May 2030. Our Irish subsidiary operates from approximately 6,100 square feet of leased office space in Dublin, Ireland, and the lease expires in April 2027. We believe our current space is sufficient for our needs.

**ITEM 3. LEGAL PROCEEDINGS**

On June 10, 2020, we disclosed in a Form 8-K that we had formally objected to TRC and Innoviva, as the manager of TRC, regarding their proposed plan to use TRELEGY royalties to invest in certain privately-held companies, funds that would otherwise be available for distribution to us under the terms of the TRC LLC Agreement. We intend to continue to seek to protect our interests in this matter consistent with the dispute resolution procedures of the TRC LLC Agreement. In this regard, we initiated an arbitration proceeding against Innoviva and TRC in October 2020 challenging the authority of Innoviva and TRC to pursue such a business plan rather than distribute such funds to us in a manner consistent with the TRC LLC Agreement and our 85% economic interest in TRC. The arbitration hearing was held during the week of February 16, 2021, with post-hearing briefing and arguments to take place over the next few weeks. We currently anticipate a decision in those proceedings near the end of the first quarter or early in the second quarter of 2021.

​

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

**​**

58

[Table of Contents](#TOC)

**PART II**

**ITEM 5. MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES**

Our ordinary shares have traded on The Nasdaq Global Market under the symbol “TBPH” since June 3, 2014. As of February 19, 2021, there were 68 shareholders of record of our ordinary shares. As many of our ordinary shares are held by brokers and other institutions on behalf of shareholders, we are unable to estimate the total number of shareholders represented by these record holders.

​

*Dividend Policy*

We currently intend to retain any future earnings to finance our research and development efforts. We have never declared or paid cash dividends on our ordinary shares and do not intend to declare or pay cash dividends on our ordinary shares in the foreseeable future.

*Equity Compensation Plans*

The following table provides certain information with respect to all of our equity compensation plans in effect as of December 31, 2020:

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** |  | **​** |  | **​** | **​** |  | **Number of Securities** |
| **​** | **​** | **​** | **​** | **​** | **​** | **​** | **Remaining Available** |
| **​** | **​** | **Number of Securities** | **​** | **​** | **​** | **​** | **for Future Issuance** |
| **​** | **​** | **to be Issued Upon** | **​** | **Weighted-Average** | | **​** | **Under Equity** |
| **​** | **​** | **Exercise of** | **​** | **Exercise Price of** | | **​** | **Compensation Plans** |
| **​** | **​** | **Outstanding Options,** | **​** | **Outstanding Options,** | | **​** | **(excluding securities** |
| **Plan Category** |  | **Warrants and Rights (a)** |  | **Warrants and Rights** | |  | **reflected in column (a))** |
| Options |  | 3,082,419 | ​ | $ | 25.09 |  | 4,345,599 |
| Restricted shares |  | 4,993,918 | ​ |  | n/a |  | n/a |
| Employee share purchase plan |  | n/a | ​ |  | n/a |  | 2,361,457 |
| Equity compensation plans approved by security holders |  | 8,076,337 | ​ | $ | 25.09 |  | 6,707,056 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Options |  | 216,760 | ​ | $ | 17.27 |  | 203,261 |
| Equity compensation plans not approved by security holders |  | 216,760 | ​ | $ | 17.27 |  | 203,261 |
| Total |  | 8,293,097 | ​ | $ | 24.58 |  | 6,910,317 |

​

We have three equity compensation plans — our 2013 Equity Incentive Plan (the “2013 EIP”), our 2013 Employee Share Purchase Plan (the “2013 ESPP”), and our 2014 New Employee Equity Incentive Plan (the “2014 NEEIP”). At inception of the plans, we were authorized to issue 5,428,571 ordinary shares under the 2013 EIP and 857,142 ordinary shares under the 2013 ESPP, and 750,000 ordinary shares under the 2014 NEEIP.

​

The 2013 EIP provides for the issuance of share-based awards, including restricted shares, restricted share units, options, share appreciation rights (“SARs”) and other equity-based awards, to our employees, officers, directors and consultants. As of January 1 of each year, commencing on January 1, 2015 and ending on (and including) January 1, 2023, the aggregate number of ordinary shares that may be issued under the 2013 EIP shall automatically increase by a number equal to the least of (i) 5% of the total number of ordinary shares outstanding on December 31 of the prior year; (ii) 3,428,571 ordinary shares; or (iii) a number of ordinary shares determined by our board of directors. Options may be granted with an exercise price not less than the fair market value of the ordinary shares on the grant date. Under the terms of our 2013 EIP, options granted to employees generally have a maximum term of 10 years and vest over a four-year period from the date of grant; 25% vest at the end of one year, and 75% vest monthly over the remaining three years. We may grant options with different vesting terms from time to time. Unless an employee’s termination of service is due to disability or death, upon termination of service, any unexercised vested options will generally be forfeited at the end of three months or the expiration of the option, whichever is earlier.

​

59

[Table of Contents](#TOC)

Under the 2013 ESPP, our officers and employees may purchase ordinary shares through payroll deductions at a price equal to 85% of the lower of the fair market value of the ordinary share at the beginning of the offering period or at the end of each applicable purchase period. As of January 1 of each year, commencing on January 1, 2015 and ending on (and including) January 1, 2033, the aggregate number of ordinary shares that may be issued under the 2013 ESPP shall automatically increase by a number equal to the least of (i) 1% of the total number of ordinary shares outstanding on December 31 of the prior year; (ii) 857,142 ordinary shares; or (iii) a number of ordinary shares determined by our board of directors. The ESPP generally provides for consecutive and overlapping offering periods of 24 months in duration, with each offering period generally composed of four consecutive six-month purchase periods. The purchase periods end on either May 15 or November 15. ESPP contributions are limited to a maximum of 15% of an employee’s eligible compensation.

​

Our 2013 ESPP also includes a feature that provides for the existing offering period to terminate and for participants in that offering period to automatically be enrolled in a new offering period when the fair market value of an ordinary share at the beginning of a subsequent offering period falls below the fair market value of an ordinary share on the first day of such offering period.

​

The 2014 NEEIP provides for the issuance of share-based awards, including restricted shares, restricted share units, non-qualified options and SARs, to our employees. Options may be granted with an exercise price not less than the fair market value of the ordinary shares on the grant date. Under the terms of our 2014 NEEIP, options granted to employees generally have a maximum term of 10 years and vest over a four-year period from the date of grant; 25% vest at the end of one year, and 75% vest monthly over the remaining three years. We may grant options with different vesting terms from time to time. Unless an employee’s termination of service is due to disability or death, upon termination of service, any unexercised vested options will generally be forfeited at the end of three months or the expiration of the option, whichever is earlier.

​

Additional information regarding share-based compensation is included in *“Item 8, Note 1. Organization and Summary of Significant Accounting Policies,”* and *“Item 8, Note 11.* *Share-Based Compensation,”* to the consolidated financial statements appearing in this Annual Report on Form 10-K.

*Share Performance Graph*

The graph set forth below compares the cumulative total shareholder return on our ordinary shares from December 31, 2015 through December 31, 2020, with the cumulative total return of (i) the Nasdaq Composite Index, (ii) the NYSE Arca Pharmaceutical Index (previously labeled as the Nasdaq Pharmaceutical Index) and (iii) the Nasdaq Biotechnology Index over the same period. This graph assumes the investment of $100 on December 31, 2015 in each of (1) our ordinary shares, (2) the Nasdaq Composite Index, (3) the NYSE Arca Pharmaceutical Index and (4) the Nasdaq Biotechnology Index, and assumes the reinvestment of dividends, if any, although dividends have never been declared on our ordinary shares.

​

The comparisons shown in the graph below are based upon historical data. We caution that the price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our ordinary shares.

​

Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act or the Exchange Act that might incorporate this Annual Report on Form 10-K or future filings made by us under those statutes, this Performance Graph section shall not be deemed filed with the SEC and shall not be deemed incorporated by reference into any of those prior filings or into any future filings made by us under those statutes.

​

60

[Table of Contents](#TOC)

​

​

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **$100 Investment in TBPH Shares or Index** |  | **TBPH** | |  | **Nasdaq Composite Index** | |  | **NYSE Arca Pharmaceutical Index** | | ​ | **Nasdaq Biotechnology Index** | |
| December 31, 2015 | ​ | $ | 100.00 | ​ | $ | 100.00 | ​ | $ | 100.00 | ​ | $ | 100.00 |
| December 31, 2016 | ​ |  | 194.51 | ​ | ​ | 108.97 | ​ | ​ | 91.66 | ​ | ​ | 78.65 |
| December 31, 2017 | ​ | ​ | 170.16 | ​ | ​ | 141.36 | ​ | ​ | 106.86 | ​ | ​ | 95.67 |
| December 31, 2018 | ​ |  | 156.13 | ​ | ​ | 137.39 | ​ | ​ | 114.86 | ​ | ​ | 87.19 |
| December 31, 2019 | ​ | ​ | 157.96 | ​ | ​ | 187.87 | ​ | ​ | 135.98 | ​ | ​ | 109.08 |
| December 31, 2020 | ​ | ​ | 108.42 | ​ | ​ | 272.51 | ​ | ​ | 147.86 | ​ | ​ | 137.90 |

​

​

**ITEM 6. SELECTED FINANCIAL DATA**

Omitted as permitted under SEC Regulation S-K, Item 301.

​

**ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

Management’s Discussion and Analysis (“MD&A”) is intended to facilitate an understanding of our business and results of operations. This discussion and analysis should be read in conjunction with our consolidated financial statements and notes included in this Annual Report on Form 10-K. The information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, our operating expenses, and future payments under our collaboration agreements, includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). Such statements are based upon current

61

[Table of Contents](#TOC)

expectations that involve risks and uncertainties. You should review the section entitled *“Risk Factors”* in Item 1A of Part I above for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. See the section entitled *“Special Note regarding Forward-Looking Statements”* above for more information.

​

**Management Overview**

Theravance Biopharma is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Our research is focused in the areas of inflammation and immunology.

​

In pursuit of our purpose, we apply insights and innovation at each stage of our business and utilize our internal capabilities and those of partners around the world. We apply organ-selective expertise to biologically compelling targets to discover and develop medicines designed to treat underserved localized diseases and to limit systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including the US FDA approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with COPD. Our pipeline of internally discovered programs is targeted to address significant patient needs.

​

We have an economic interest in potential future payments from GSK pursuant to its agreements with Innoviva relating to certain programs, including TRELEGY.

​

**Critical Accounting Policies and Estimates**

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with US Generally Accepted Accounting Principles (“GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including these estimates, will depend on future developments that are highly uncertain and may be impacted by the emergence of new information concerning the COVID-19 pandemic and the actions taken to contain or treat the disease, including vaccine availability, distribution, acceptance and effectiveness. For more information, see Part I—Item 1—Business—*Impact of COVID-19 Pandemic***.** Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.

***Revenue Recognition***

We recognize revenue under Accounting Standards Codification (“ASC”), Topic 606, *Revenue from Contracts with Customers* (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, an entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.

​

At contract inception, once the contract is determined to be within the scope of ASC 606, we identify the performance obligations in the contract by assessing whether the goods or services promised within each contract are distinct. We then recognize revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

62

[Table of Contents](#TOC)

​

*Collaborative Arrangements under ASC 606*

We enter into collaborative arrangements with partners that fall under the scope of Accounting Standards Codification, Topic 808, *Collaborative Arrangements* (“ASC 808”). While these arrangements are in the scope of ASC 808, we may analogize to ASC 606 for some aspects of these arrangements. We analogize to ASC 606 for certain activities within collaborative arrangements for the delivery of a good or service (i.e., a unit of account) that is part of our ongoing major or central operations. Revenue recognized by analogizing to ASC 606 is recorded as “collaboration revenue” or “licensing revenue” whereas, revenue recognized in accordance with ASC 808 is recorded on a separate collaboration revenue line on the consolidated statements of operations.

​

The terms of our collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; (iii) royalties on net sales of licensed products; (iv) reimbursements or cost-sharing of research and development expenses; and (v) profit/loss sharing arising from co-promotion arrangements. Each of these payments results in collaboration revenues or an offset against research and development expense. Where a portion of non-refundable up-front fees or other payments received is allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as collaboration revenue when (or as) the underlying performance obligation is satisfied.

​

As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price may include such estimates as, forecasted revenues or costs, development timelines, discount rates and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if they can be satisfied at a point in time or over time, and we measure the services delivered to our collaborative partner which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.

​

*Up-front Fees:* If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize collaboration revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing collaboration revenue from the allocated transaction price. For example, when we receive up-front fees for the performance of research and development services, or when research and development services are not considered to be distinct from a license, we recognize collaboration revenue for those units of account over time using a measure of progress. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue or expense recognition as a change in estimate.

​

*Milestone Payments:* At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the collaborative partner’s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, we re-evaluate the probability of achievement of milestones that are within our or the collaborative partner’s control, such as operational developmental milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to our estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.

​

63

[Table of Contents](#TOC)

*Royalties:* For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

​

Following the sale of VIBATIV to Cumberland in November 2018, VIBATIV royalties earned from Cumberland are included within “interest and other income, net” on the consolidated statements of operations. In addition, our income earned related to TRELEGY sales is included within “income from our investment in TRC, LLC” on the consolidated statements of operations.

​

*Reimbursement, cost-sharing and profit-sharing payments:* Under certain collaborative arrangements, we have been reimbursed for a portion of our research and development expenses or participate in the cost-sharing of such research and development expenses. Such reimbursements and cost-sharing arrangements have been reflected as a reduction of research and development expense in our consolidated statements of operations, as we do not consider performing research and development services for reimbursement to be a part of our ongoing major or central operations.

​

***Research and Development Expenses***

Research and development (“R&D”) expenses are recorded in the period that services are rendered or goods are received. R&D expenses consist of salaries and benefits, laboratory supplies and facility costs, as well as fees paid to third parties that conduct certain R&D activities on our behalf, net of certain external R&D expenses reimbursed under our collaborative arrangements.

​

As part of the process of preparing our consolidated financial statements, we are required to estimate and accrue certain R&D expenses. This process involves the following:

​

|  |  |  |
| --- | --- | --- |
|  | • | identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost; |

|  |  |  |
| --- | --- | --- |
|  | • | estimating and accruing expenses in our consolidated financial statements as of each balance sheet date based on facts and circumstances known to us at the time; and |

|  |  |  |
| --- | --- | --- |
|  | • | periodically confirming the accuracy of our estimates with selected service providers and making adjustments, if necessary. |

​

Examples of estimated research and development expenses that we accrue include:

​

|  |  |  |
| --- | --- | --- |
|  | • | fees paid to clinical research organizations (“CROs”) in connection with preclinical and toxicology studies and clinical studies; |

|  |  |  |
| --- | --- | --- |
|  | • | fees paid to investigative sites in connection with clinical studies; |

|  |  |  |
| --- | --- | --- |
|  | • | fees paid to contract manufacturing organizations (“CMOs”) in connection with the production of product and clinical study materials; and |

|  |  |  |
| --- | --- | --- |
|  | • | professional service fees for consulting and related services. |

​

We base our expense accruals related to clinical studies on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical studies on our behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors, such as the successful enrollment of patients and the completion of clinical study milestones. Our service providers typically invoice us monthly in arrears for services performed. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If we do not identify costs that we have begun to incur or if we underestimate or

64

[Table of Contents](#TOC)

overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates.

​

To date, we have not experienced significant changes in our estimates of accrued research and development expenses after a reporting period. However, due to the nature of estimates, there is no assurance that we will not make changes to our estimates in the future as we become aware of additional information about the status or conduct of our clinical studies and other research activities. Such changes in estimates will be recognized as research and development expenses in the period that the change in estimate occurs.

​

***Theravance Respiratory Company, LLC (“TRC”)***

Through our 85% equity interest in TRC, the Company is entitled to receive an 85% economic interest in any future payments made by GSK under the strategic alliance agreement and under the portion of the collaboration agreement assigned to TRC (net of TRC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters). The primary drug program assigned to TRC is TRELEGY.

​

We analyzed our ownership, contractual and other interests in TRC to determine if TRC is a variable-interest entity (“VIE”), whether we have a variable interest in TRC and the nature and extent of that interest. We determined that TRC is a VIE. The party with the controlling financial interest, the primary beneficiary, is required to consolidate the entity determined to be a VIE. Therefore, we also assessed whether we are the primary beneficiary of TRC based on the power to direct its activities that most significantly impact its economic performance and our obligation to absorb its losses or the right to receive benefits from it that could potentially be significant to TRC. Based on our assessment, we determined that we are not the primary beneficiary of TRC, and, as a result, we do not consolidate TRC in our consolidated financial statements. TRC is recognized in our consolidated financial statements under the equity method of accounting. Income related to our equity ownership of TRC is reflected within our consolidated statements of operations and is classified as non-operating income.

​

***Income Taxes***

We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are anticipated to be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

​

Our total unrecognized tax benefits of $63.4 million and $58.8 million, as of December 31, 2020 and December 31, 2019, respectively, may reduce the effective tax rate in the period of recognition. We currently have a full valuation allowance against our deferred tax assets, which would impact the timing of the effective tax rate benefit should any of our uncertain positions be favorably settled in the future.

​

We assess all material positions, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.

​

The recognition and measurement of tax benefits requires significant judgment. We have taken certain positions where we believe that our position is greater than 50% likely to be realized upon ultimate settlement and for which no reserve for uncertain tax positions has been recorded. If we do not ultimately realize the expected benefit of these positions, we will record additional income tax expenses in future periods. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.

​

65

[Table of Contents](#TOC)

Any tax levied or credited by a governmental taxing authority that is not based on our income is outside the scope of accounting for income taxes. Therefore, we record such items as a component in our loss before income taxes.

​

**Results of Operations**

The following tables set forth our results of operations for the periods presented. Management’s commentary for the 2020 results compared to 2019 results are presented in the paragraphs below, and management’s commentary for the 2019 results compared to the 2018 results are included in our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission (“SEC”) on February 27, 2020.

​

***Revenue***

Revenue, as compared to the prior years, was as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | **​** | **​** | **​** | **​** | **​** | **​** | **​** | **​** | **Change** | | | | | | | | | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | | **​** | **2020** | | | | **​** | **2019** | | | | **​** |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | |  | **$** | |  | **%** |  | **$** | |  | **%** |  |
| Product Sales | **​** | $ | — | **​** | $ | — | **​** | $ | 15,304 | **​** | $ | — | **​** | — | % | $ | (15,304) | **​** | NM | % |
| Collaboration revenue | ​ | ​ | 26,464 | ​ | ​ | 31,250 | ​ | ​ | 41,791 | ​ | ​ | (4,786) | ​ | (15) | ​ | ​ | (10,541) | ​ | (25) | ​ |
| Licensing revenue | ​ | ​ | 1,500 | ​ | ​ | 28,500 | ​ | ​ | — | ​ | ​ | (27,000) | ​ | (95) | ​ | ​ | 28,500 | ​ | NM | ​ |
| Viatris collaboration agreement | ​ |  | 43,893 | ​ |  | 13,664 | ​ | ​ | 3,275 | ​ | ​ | 30,229 | ​ | 221 | ​ | ​ | 10,389 | ​ | 317 | ​ |
| Total revenue | ​ | $ | 71,857 | ​ | $ | 73,414 | ​ | $ | 60,370 | ​ | $ | (1,557) | ​ | (2) | % | $ | 13,044 | ​ | 22 | % |

NM: Not Meaningful

As a result of the sale of our VIBATIV business to Cumberland in November 2018, no product sales were recognized in 2020 and 2019.

​

Collaboration revenue was $26.5 million in 2020, which represented a $4.8 million decrease from 2019. Collaboration revenue was primarily comprised of revenue recognized related to the $100.0 million upfront payment received in 2018 pursuant to the Janssen collaboration agreement that was entered into in February 2018. The $4.8 million decrease was primarily attributed to a smaller portion of recognized revenue from the Janssen collaboration agreement in 2020.

​

Licensing revenue was $1.5 million in 2020, which represented a $27.0 million decrease from 2019. In 2019, we recognized $28.5 million in licensing revenue related to an $18.5 million upfront payment (before a required tax withholding) from Viatris associated with a June 2019 amendment for the commercialization and development rights to nebulized revefenacin in China and adjacent territories (“Viatris China Amendment”) and a $10.0 million upfront payment from a Pfizer collaboration agreement for our preclinical skin-selective, locally-acting pan-JAK inhibitor program. Licensing revenue in 2020 was comprised of $1.5 million from the achievement of a milestone related to the acceptance of a clinical trial application associated with the Viatris China Amendment.

​

We are entitled to a share of US profits and losses (65% to Viatris; 35% to Theravance Biopharma) received in connection with commercialization of YUPELRI. In accordance with the applicable accounting guidance, amounts receivable from Viatris in connection with the commercialization of YUPELRI are recorded within the consolidated statements of operations as revenue from “Viatris collaboration agreement” irrespective of whether the overall collaboration is profitable. Amounts payable to Viatris in connection with the commercialization of YUPELRI, if any, are recorded within the consolidated statements of operations as a collaboration loss within selling, general and administrative expenses. Any reimbursement from Viatris attributed to the 65% cost-sharing of our research and development (“R&D”) expenses is characterized as a reduction of R&D expense, as we do not consider performing research and development services for reimbursement to be a part of our ordinary operations.

​

In 2020 and 2019, we recognized $43.9 million and $13.7 million, respectively, in revenue from the Viatris collaboration agreement which represented the receivables due from Viatris related to YUPELRI. Revenue from the

66

[Table of Contents](#TOC)

Viatris collaboration agreement was $3.3 million in 2018 and represented the receivables due from Viatris during the initial channel buildout for YUPELRI in late 2018.

​

***Cost of Goods Sold***

Cost of goods sold, as compared to the prior years, was as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | | | | | **​** | **​** | **​** | **​** | **Change** | | | | | | | | |  |
| **​** | **​** | **Year Ended December 31,** | | | | | | | | **​** | **2020** | | | | **​** | **2019** | | | |  |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | |  | **$** | |  | **%** |  | **$** | |  | **%** | **​** |
| Cost of goods sold | ​ | $ | — | ​ | $ | — | ​ | $ | 715 | ​ | $ | — | ​ | — | % | $ | (715) | ​ | NM | % |

NM: Not Meaningful

As a result of the sale of our VIBATIV business to Cumberland in November 2018, no cost of goods sold was recognized in 2020 and 2019.

​

***Reduction in Workforce***

**​**

In January 2019, we announced a reduction in workforce to align with our focus on continued execution of key strategic programs and advancement of selected late-stage research programs toward clinical development. We reduced our overall headcount by 51 individuals, with the affected employees primarily focused on early research or the infrastructure in support of VIBATIV which was sold by us to Cumberland in November 2018.

​

The workforce reduction was substantially completed in the first quarter of 2019. We recognized and paid severance related charges totaling $3.5 million in 2019, including compensation expense made to affected employees through any minimum statutory notice periods. The severance related charges are presented on the consolidated statements of operations within research and development expenses and selling, general and administrative expenses.

​

***Research and Development***

Our R&D expenses consist primarily of employee-related costs, external costs, and various allocable expenses. We budget total R&D expenses on an internal department level basis, and we manage and report our R&D activities across the following four cost categories:

​

|  |  |  |
| --- | --- | --- |
|  | 1) | Employee-related costs, which include salaries, wages and benefits; |

​

|  |  |  |
| --- | --- | --- |
|  | 2) | Share-based compensation, which includes expenses associated with our equity plans; |

​

|  |  |  |
| --- | --- | --- |
|  | 3) | External-related costs, which include clinical trial related expenses, other contract research fees, consulting fees, and contract manufacturing fees; and |

​

|  |  |  |
| --- | --- | --- |
|  | 4) | Facilities and other, which include laboratory and office supplies, depreciation and other allocated expenses, which include general and administrative support functions, insurance and general supplies. |

​

67

[Table of Contents](#TOC)

The following table summarizes our R&D expenses incurred, net of any reimbursements from collaboration partners, as compared to the prior years:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | | | | | **​** | **​** | **​** | **​** | **Change** | | | | | | | | | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | | **​** | **2020** | | | | **​** | **2019** | | | | **​** |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | |  | **$** | |  | **%** |  | **$** | |  | **%** |  |
| Employee-related | ​ | $ | 60,557 | ​ | $ | 64,531 | ​ | $ | 62,896 | ​ | $ | (3,974) | **​** | (6) | % | $ | 1,635 | **​** | 3 | % |
| Share-based compensation | ​ |  | 31,294 | ​ |  | 28,953 | ​ | ​ | 25,563 | ​ | ​ | 2,341 | ​ | 8 | ​ | ​ | 3,390 | ​ | 13 | ​ |
| External-related | ​ |  | 135,114 | ​ |  | 92,921 | ​ | ​ | 77,305 | ​ | ​ | 42,193 | ​ | 45 | ​ | ​ | 15,616 | ​ | 20 | ​ |
| Facilities, depreciation and other allocated expenses | ​ |  | 33,988 | ​ |  | 32,843 | ​ | ​ | 35,584 | ​ | ​ | 1,145 | ​ | 3 | ​ | ​ | (2,741) | ​ | (8) | ​ |
| Total research & development | ​ | $ | 260,953 | ​ | $ | 219,248 | ​ | $ | 201,348 | ​ | $ | 41,705 | ​ | 19 | % | $ | 17,900 | ​ | 9 | % |

​

R&D expenses increased by $41.7 million in 2020 compared to 2019. The increase was due to a $42.2 million increase in external-related expenses, a $2.3 million increase in share-based compensation expenses, a $1.2 million increase in facilities, depreciation and other allocated expenses, and partially offset by a $4.0 million decrease in employee-related expenses.

​

The $42.2 million increase in external-related expenses was primarily due to the advancement of our priority programs, notably the continued progression of izencitinib, ampreloxetine, and TD-8236, and the initiation of the TD-0903 program in 2020. The $2.3 million increase in share-based compensation expense was primarily due to an increase in annual grants of share-based awards to employees, and the $1.2 million increase in facilities, depreciation and other allocated expenses was primarily due to an increase in allocated overhead costs. The $4.0 million decrease in employee-related expenses was primarily due to lower compensation-related expenses and lower travel and entertainment-related expenses.

​

Under certain of our collaborative arrangements, we receive partial reimbursement of employee-related costs and external costs, which have been reflected as a reduction of R&D expenses of $10.1 million, $5.6 million and $9.1 million for 2020, 2019 and 2018, respectively. The increase in expense reimbursements in 2020 compared to 2019 was primarily due to an increase in certain study activities related to izencitinib and TD-5202 that were reimbursable by our collaboration partners.

​

We anticipate our future R&D expenses will decrease from the current levels over the next 12 months primarily due to the planned completion of certain priority programs.

​

***Selling, General and Administrative***

Selling, general and administrative expenses, as compared to the prior years, were as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | | | | | **​** | **​** | **​** | **​** | **Change** | | | | | | | | |  |
| **​** | **​** | **Year Ended December 31,** | | | | | | | | **​** | **2020** | | | | **​** | **2019** | | | |  |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | |  | **$** | |  | **%** |  | **$** | |  | **%** | **​** |
| Selling, general and administrative | ​ | $ | 108,661 | ​ | $ | 106,081 | ​ | $ | 97,058 | ​ | $ | 2,580 | ​ | 2 | % | $ | 9,023 | ​ | 9 | % |

​

Selling, general and administrative expenses increased by $2.6 million in 2020 compared to 2019. The increase was primarily due to a $1.6 million increase in employee-related expenses, a $1.2 million increase in external-related expenses, and a $1.1 million increase in facilities, depreciation and other allocated expenses and was partially offset by a $1.6 million decrease in YUPELRI collaboration loss.

​

The $1.6 million increase in employee-related expenses was primarily due to an increase in compensation-related expenses which was partially offset by lower travel and entertainment-related expenses. The $1.2 million increase in external-related expenses was primarily due to increases in costs associated with ampreloxetine and partially offset by decreases in expenses primarily related to legal and consulting services. The $1.1 million increase in facilities, depreciation and other allocated expenses was primarily due to an increase in overhead costs. The $1.6 million decrease in YUPELRI collaboration loss was due to costs incurred in early 2019 associated with the formal launch of YUPELRI.

68

[Table of Contents](#TOC)

​

Share-based compensation expense related to selling, general and administrative expenses was $31.7 million, $31.5 million, and $25.8 million in 2020, 2019 and 2018, respectively.

​

***Income from Investment in TRC, LLC (“TRC”)***

Income from investment in TRC, as compared to the prior years, was as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | ​ | **​** | | | | | **​** | **​** | **​** | **​** | **Change** | | | | | | | | |  |
| **​** | **​** | **Year Ended December 31,** | | | | | | | | **​** | **2020** | | | | **​** | **2019** | | | |  |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | |  | **$** | |  | **%** |  | **$** | |  | **%** | **​** |
| Income from investment in TRC, LLC | ​ | $ | 68,438 | ​ | $ | 33,705 | ​ | $ | 11,182 | ​ | $ | 34,733 | ​ | 103 | % | $ | 22,523 | ​ | 201 | % |

​

The income from investment in TRC, LLC represents our share of the royalty payments from GSK to TRC on the net sales of TRELEGY (net of our share of TRC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters).

​

Income from investment in TRC increased by $34.7 million in 2020 compared to 2019. The increase was attributed to the continued sales growth of TRELEGY and an $8.5 million payment representing our share of a $10.0 million fee that GSK agreed to pay TRC upon termination of the inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program in June 2020. Our share of TRC expenses was $2.2 million and $2.7 million in 2020 and 2019, respectively, which was primarily comprised of TRC’s legal and related fees associated with the arbitration cases between Innoviva and TRC and us in both years.

​

In connection with the issuance of our $380.0 million net principal amount Non-Recourse 2035 Notes in February 2020, 75% of the income from our investment in TRC is available only for payment of the Non-Recourse 2035 Notes and is not available to pay other creditor obligations or claims.

​

On June 10, 2020, we disclosed in a Form 8-K that we had formally objected to TRC and Innoviva, as the manager of TRC, regarding their proposed plan to use TRELEGY royalties to invest in certain privately-held companies, funds that would otherwise be available for distribution to us under the terms of the TRC LLC Agreement. We intend to continue to seek to protect our interests in this matter consistent with the dispute resolution procedures of the TRC LLC Agreement. In this regard, we initiated an arbitration proceeding against Innoviva and TRC in October 2020 challenging the authority of Innoviva and TRC to pursue such a business plan rather than distribute such funds to us in a manner consistent with the TRC LLC Agreement and our 85% economic interest in TRC. The arbitration hearing was held during the week of February 16, 2021, with post-hearing briefing and arguments to take place over the next few weeks. We currently anticipate a decision in those proceedings near the end of the first quarter or early in the second quarter of 2021. See *“Risk Factors – We do not control the commercialization of TRELEGY and we do not control TRC; accordingly the amount of royalties we receive will depend, among other factors, on GSK’s ability to further commercialize TRELEGY and TRC’s decisions concerning use of cash in accordance with the TRC LLC Agreement”* for additional information.

​

***Interest Expense***

Interest expense primarily consisted of interest payments due on the Convertible Senior 2023 Notes, the redeemed Non-Recourse 2033 Notes, and the Non-Recourse 2035 Notes, as well as, the amortization of the associated debt issuance costs. Interest expense, as compared to the comparable periods in the prior year, was as follows:

​

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | ​ | **​** | | | | | **​** | **​** | **​** | **​** | **Change** | | | | | | | | |  |
| **​** | **​** | **Year Ended December 31,** | | | | | | | | **​** | **2020** | | | | **​** | **2019** | | | |  |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | |  | **$** | |  | **%** |  | **$** | |  | **%** | **​** |
| Interest expense | ​ | $ | (44,585) | ​ | $ | (31,862) | ​ | $ | (10,482) | ​ | $ | (12,723) | ​ | 40 | % | $ | (21,380) | ​ | 204 | % |

​

Interest expense increased by $12.7 million in 2020 compared to 2019. The increase was attributed to additional interest expense related to the issuance of the Non-Recourse 2035 Notes in February 2020. As of December 31, 2020,

69

[Table of Contents](#TOC)

the net principal amount outstanding under the Non-Recourse 2035 Notes was $397.6 million at an interest rate of 9.5% compared to the retired Non-Recourse 2033 Notes which had an original net principal amount of $237.5 million and an interest rate of 9.0%.

​

***Loss on Extinguishment of Debt***

*​*

Loss on extinguishment of debt as compared to the comparable periods in the prior year, was as follows:

​

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | ​ | **​** | | | | | **​** | **​** | **​** | **​** | **Change** | | | | | | | | |  |
| **​** | **​** | **Year Ended December 31,** | | | | | | | | **​** | **2020** | | | | **​** | **2019** | | | |  |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | |  | **$** | |  | **%** |  | **$** | |  | **%** | **​** |
| Loss on extinguishment of debt | ​ | $ | (15,464) | ​ | $ | — | ​ | $ | — | ​ | $ | (15,464) | ​ | NM | % | $ | — | ​ | — | % |

NM: Not Meaningful

In 2020, we recognized a $15.5 million loss on the extinguishment of debt related to the issuance of the Non-Recourse 2035 Notes in February 2020. A portion of the proceeds from the Non-Recourse 2035 Notes were used to repay the outstanding balance of the Non-Recourse 2033 Notes that were issued in November 2018. The $15.5 million loss was comprised of a redemption premium related to the early repayment of the Non-Recourse 2033 Notes and the write-off of the previously deferred debt issuance costs related to the portion of the Non-Recourse 2033 Notes that was considered extinguished.

​

***Interest and Other Income***

Interest and other income, as compared to the prior years, was as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | ​ | **​** | | | | | **​** | **​** | **​** | **​** | **Change** | | | | | | | | |  |
| **​** | **​** | **Year Ended December 31,** | | | | | | | | **​** | **2020** | | | | **​** | **2019** | | | |  |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | |  | **$** | |  | **%** |  | **$** | |  | **%** | **​** |
| Interest and other income, net | ​ | $ | 4,441 | ​ | $ | 8,395 | ​ | $ | 11,966 | ​ | $ | (3,954) | ​ | (47) | % | $ | (3,571) | ​ | (30) | % |
| Costs related to GSK offering | ​ | ​ | (1,610) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (1,610) | ​ | NM | ​ | ​ | — | ​ | — | ​ |
| Total interest and other income, net | ​ | $ | 2,831 | ​ | $ | 8,395 | ​ | $ | 11,966 | ​ | $ | (5,564) | ​ | (66) | % | $ | (3,571) | ​ | (30) | % |

NM: Not Meaningful

Interest and other income, net, decreased by $4.0 million in 2020 compared 2019. The decrease was primarily attributed to lower interest income earned in 2020 resulting from lower investment yields on our portfolio of marketable securities compared to 2019.

​

In June 2020, GSK completed its offering of $300.0 million of exchangeable senior notes due 2023, $280.3 million of which are exchangeable into our ordinary shares that are held by a subsidiary of GSK. We will not be issuing any new ordinary shares in connection with the GSK offering, and we did not receive any proceeds from the GSK offering. We incurred $1.6 million in costs, primarily comprised of financial advisory, accounting and legal-related costs.

​

***Provision for Income Tax (Expense) Benefit***

The provision for income tax, as compared to the prior years, was as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | | | | | **​** | **​** | **​** | **​** | **Change** | | | | | | | | |  |
| **​** | **​** | **Year Ended December 31,** | | | | | | | | **​** | **2020** | | | | **​** | **2019** | | | |  |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | |  | **$** | |  | **%** |  | **$** | |  | **%** | **​** |
| Provision for income tax benefit | ​ | $ | 8,520 | ​ | $ | 5,222 | ​ | $ | 10,561 | ​ | $ | 3,298 | ​ | 63 | % | $ | (5,339) | ​ | (51) | % |

​

70

[Table of Contents](#TOC)

The 2020 and 2019 benefits for income taxes of $8.5 million and $5.2 million, respectively, were primarily due to the reversals of previously accrued contingent tax liabilities for uncertain tax positions due to a lapse of the statute of limitations.

​

**Liquidity and Capital Resources**

To date, we have financed our operations primarily through public offering of equity and debt securities, private placements of equity and debt, revenue from collaboration and licensing arrangements and, to a lesser extent, revenue from product sales. As of December 31, 2020, we had approximately $292.9 million in cash, cash equivalents, and investments in marketable securities (excluding restricted cash). Also, as of December 31, 2020, we had outstanding (i) $230.0 million in principal Convertible Senior 2023 Notes and (ii) $397.6 million in principal Non-Recourse 2035 Notes which are stated net of a 5.0% retention by us in compliance with Regulation RR — Credit Risk Retention (17 C.F.R. Part 246).

​

The Non-Recourse 2035 Notes were issued on February 28, 2020 and are secured by all of the Triple Royalty Sub II LLC’s (the “Issuer II”) rights, title and interest as a holder of the Issuer II Class C Units in TRC. The primary source of funds to make payments on the Non-Recourse 2035 Notes is the 63.75% economic interest of the Issuer (evidenced by the Issuer II Class C Units) in any future payments that may be made by GSK to TRC under the strategic alliance agreement and under the portion of the collaboration agreement assigned to TRC by Innoviva (net of TRC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters) relating to the GSK-Partnered Respiratory Programs, including the Trelegy program. As a result, the holders of the Non-Recourse 2035 Notes have no recourse against Theravance Biopharma even if the TRELEGY payments are insufficient to cover the principal and interest payments for the Non-Recourse 2035 Notes. Prior to and including the December 5, 2024 payment date, in the event that the distributions received by the Issuer II from TRC in a quarter is less than the interest accrued for that quarter, the principal amount of the Non-Recourse 2035 Notes will increase by the interest shortfall amount for that quarter. While the holders of the Non-Recourse 2035 Notes have no recourse against Theravance Biopharma, the terms of the Non-Recourse 2035 Notes also provide that Theravance Biopharma, at its option, may satisfy the quarterly interest payment obligations by making a capital contribution to the Issuer II.

​

A portion of the proceeds from the Non-Recourse 2035 Notes issuance were used to repay, in full, the remaining outstanding balance of the Non-Recourse 2033 Notes, as well as, a 5% premium on the early redemption of the Non-Recourse 2033 Notes. The Non-Recourse 2033 Notes were issued in November 2018 and were structured similarly to the Non-Recourse 2035 Notes.

​

On February 14, 2020, we sold 5,500,000 ordinary shares at a price to the public of $27.00 per share (the “Shares”). The gross proceeds from the offering were $148.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. The Shares were issued pursuant to our currently effective shelf registration statement on Form S-3, which became effective automatically on December 3, 2019, and a prospectus supplement filed with the SEC in connection with the offering.

​

We expect to continue to incur net losses over at least the next several years due to significant expenditures relating to our continuing drug discovery efforts, preclinical and clinical development of our current product candidates and commercialization costs relating to YUPELRI. In particular, to the extent we advance our product candidates into and through later-stage clinical studies without a partner, we will incur substantial expenses. We expect the clinical development of our key development programs will require significant investment in order to continue to advance in clinical development. In addition, we expect to invest strategically in our research efforts to continue to grow our development pipeline. In the past, we have received a number of significant payments from collaboration agreements and other significant transactions. In the future, we may continue to receive potential substantial payments from future collaboration transactions if the drug candidates in our pipeline achieve positive clinical or regulatory outcomes or if our product candidates are approved and meet certain milestones. Our current business plan is subject to significant uncertainties and risks as a result of, among other factors, the COVID-19 pandemic, clinical program outcomes, whether, when and on what terms we are able to enter into new collaboration arrangements, expenses being higher than anticipated, the sales levels of any approved products, unplanned expenses, cash receipts being lower than anticipated, and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations.

71

[Table of Contents](#TOC)

​

*Adequacy of cash resources to meet future needs*

We expect our cash and cash equivalents and marketable securities will be sufficient to fund our operations for at least the next 12 months from the issuance date of these consolidated financial statements based on current operating plans and financial forecasts.

​

We may seek to obtain additional financing in the form of public or private equity offerings, debt financing or additional collaborations and licensing arrangements. However, future financing may not be available in amounts or on terms acceptable to us.

​

Without adequate financial resources to fund our operations as presently conducted, we may be required to relinquish rights to our technologies, product candidates or territories, or grant licenses on terms that are not favorable to us, in order to raise additional funds through collaborations or licensing arrangements. We may also have to sequence preclinical and clinical studies as opposed to conducting them concomitantly in order to conserve resources, or delay, reduce or eliminate one or more of our research or development programs and reduce overall overhead expenses. In addition, we may have to make reductions in our workforce and may be prevented from continuing our discovery, development and commercialization efforts and exploiting other corporate opportunities.

​

***Cash Flows***

Cash flows, as compared to the prior years, were as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | | **​** | **Change** | | | | |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | |  | **2020** | | ​ | **2019** | |
| Net cash used in operating activities | ​ | $ | (250,403) | ​ | $ | (238,197) | ​ | $ | (112,867) | ​ | $ | (12,206) | ​ | $ | (125,330) |
| Net cash provided by (used in) investing activities | ​ |  | 10,721 | ​ |  | (83,051) | ​ | ​ | 176,708 | ​ |  | 93,772 | ​ | ​ | (259,759) |
| Net cash provided by financing activities | ​ |  | 263,085 | ​ |  | 1,291 | ​ | ​ | 225,200 | ​ |  | 261,794 | ​ | ​ | (223,909) |

​

*Net cash flows used in operating activities*

Net cash used in operating activities was $250.4 million in 2020, consisting primarily of a net loss of $278.0 million, a net increase in cash resulting from adjustments for total non-cash and other reconciling items of $67.1 million and a net decrease in cash resulting from changes in operating assets and liabilities of $39.5 million.

​

Net cash used in operating activities was $238.2 million in 2019, consisting primarily of a net loss of $236.5 million, a net increase in cash resulting from adjustments for total non-cash and other reconciling items of $43.7 million and a net decrease in cash resulting from changes in operating assets and liabilities of $45.4 million.

​

*Net cash flows provided by (used in) investing activities*

Net cash provided by investing activities was $10.7 million in 2020 and was primarily attributed the proceeds from the sales of marketable securities of $19.9 million which was partially offset by (i) $6.6 million related to the purchase of property and equipment and (ii) $2.7 million in cash outflows resulting from net purchases and maturities of marketable securities.

​

Net cash used in investing activities was $83.1 million in 2019 and was primarily attributed to cash outflows resulting from net purchases and maturities of marketable securities of $84.9 million.

​

*Net cash flows provided by financing activities*

Net cash provided by financing activities was $263.1 million in 2020, consisting primarily of the sale of 5,500,000 ordinary shares for total net proceeds of $139.9 million and the issuance of our Non-Recourse 2035 Notes for total net proceeds of $374.7 million. A portion of the of the Non-Recourse 2035 Notes proceeds were used to repay, in full, the remaining $235.3 million outstanding balance of our Non-Recourse 2033 Notes and an $11.5 million

72

[Table of Contents](#TOC)

redemption premium related to the payoff of the Non-Recourse 2033 Notes. In addition to the above, net cash provided by financing activities was partially offset by the repurchase of shares to satisfy tax withholding obligations in the amount of $9.7 million.

​

Net cash provided by financing activities was $1.3 million in 2019, consisting of $6.6 million of cash inflows from employee share plan purchase proceeds and share option exercises which was partially offset by $3.2 million of net cash outflows related to the repurchase of shares to satisfy tax withholding obligations and $2.1 million of net cash outflows related to the principal paydown of our Non-Recourse 2033 Notes.

​

***Contractual Obligations and Commercial Commitments***

In the table below, we set forth our significant obligations and future commitments, as well as obligations related to all contracts that we are likely to continue, regardless of the fact that they were cancelable as of December 31, 2020. Some of the figures that we include in this table are based on management’s estimate and assumptions about these obligations, including their duration. Because these estimates and assumptions are necessarily subjective, the amount of the obligations we will actually pay in future periods may vary from those reflected in the table.

​

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | ​ | **​** | **​** | **Years** | | | | | | | | | | |
| **(In thousands)** |  | **Total** | |  | **Within 1** | |  | **Over 1 to 3** | |  | **Over 3 to 5** | |  | **After 5** | |
| 3.25% Convertible senior notes due 2023 - principal | ​ | $ | 230,000 | ​ | $ | — | ​ | $ | 230,000 | ​ | $ | — | ​ | $ | — |
| 3.25% Convertible senior notes due 2023 - interest | ​ | ​ | 21,200 | ​ | ​ | 7,475 | ​ | ​ | 13,725 | ​ | ​ | — | ​ | ​ | — |
| 9.5% Non-recourse notes due 2035 - net principal \* | ​ | ​ | 397,643 | ​ |  | \* | ​ |  | \* | ​ |  | \* | ​ |  | \* |
| Facility operating leases (1) | ​ |  | 99,683 | ​ |  | 9,522 | ​ | ​ | 19,852 | ​ | ​ | 21,000 | ​ | ​ | 49,309 |
| Purchase obligations (2) | ​ |  | 311,181 | ​ |  | 152,881 | ​ | ​ | 84,611 | ​ | ​ | 64,876 | ​ | ​ | 8,813 |
| Total | ​ | $ | 1,059,707 | ​ | $ | 169,878 | ​ | $ | 348,188 | ​ | $ | 85,876 | ​ | $ | 58,122 |

​

|  |  |
| --- | --- |
| \* | The Non-Recourse 2035 Notes are secured by the Issuer II’s right, title, and interest in TRC. The primary source of funds to make payments on the Non-Recourse 2035 Notes is the 63.75% economic interest of the Issuer II in any future payments made by GSK under the collaboration agreement, dated as of November 14, 2002, by and between Innoviva and GSK relating to the Trelegy program. In addition, prior to December 5, 2024, in the event that the distributions received by the Issuer II from TRC in a quarter is less than the interest accrued for the quarter, the principal amount of the Non-Recourse 2035 Notes will increase by the interest shortfall amount for that period. Since the timing of the principal and interest payments on the Non-Recourse 2035 Notes are ultimately based on royalties from TRELEGY product sales, which will vary from quarter to quarter and are unknown to us, only the total net principal payment amount at issuance is included in the above table. See “*Item 8, Note 7. Debt"* of the accompanying consolidated financial statements for further information. |

|  |  |
| --- | --- |
| (1) | As security for performance of certain obligations under the operating leases for our principal physical properties, we issued a letter of credit in the amount of $0.8 million, collateralized by an equal amount of restricted cash. |

​

|  |  |
| --- | --- |
| (2) | Substantially all of this amount was subject to open purchase orders, as of December 31, 2020, that were issued under existing contracts. This amount does not represent any minimum contract termination liabilities for our existing contracts. |

​

***Commitments and Contingencies***

We indemnify our officers and directors for certain events or occurrences, subject to certain limits. We believe the fair value of these indemnification agreements is minimal. Accordingly, we have not recognized any liabilities relating to these agreements as of December 31, 2020.

73

[Table of Contents](#TOC)

***​***

*Performance-Contingent Awards*

In 2016, we granted long-term retention and incentive restricted share awards (“RSAs”) and restricted share units (“RSUs”) to members of senior management and long-term retention and incentive cash bonus awards to certain employees. The vesting and payout of such awards is dependent on meeting certain operating goals and objectives during the five-year period from 2016 to December 31, 2020. These goals are strategically important for us, and we believe the goals should increase shareholder value. The awards have dual triggers of vesting based upon the achievement of these goals and continued employment, and they are broken into three separate tranches. We recognize compensation expense relating to awards subject to performance conditions if it is considered probable that the performance goals will be achieved. The probability of achievement is reassessed at each quarter-end reporting period. Previously recognized expense is reversed in the period in which it becomes probable that the requisite service period will not be rendered.

​

We determined that achievement of the requisite performance conditions for the first tranche was completed in June 2018, and the expense associated with this first tranche was fully recognized in 2018. We determined that achievement of the requisite performance conditions for the second tranche were completed in February 2019, and the expense associated with this second tranche was fully recognized as of March 31, 2020. For the year ended December 31, 2020, we recognized $0.4 million and $0.5 million of share-based compensation expense and cash bonus expense, respectively, related to the second tranche of these awards.

​

In February 2020, we determined that the requisite performance conditions for the third tranche were completed. For the year ended December 31, 2020, we recognized $2.6 million and $2.8 million of share-based compensation expense and cash bonus expense, respectively, related to the third tranche of these awards. As of December 31, 2020, the maximum remaining share-based compensation expense and cash bonus expense associated with the third tranche was $0.4 million each.

​

Separate from the performance-contingent awards described above, we periodically grant performance-contingent RSUs to individual employees. For the year ended December 31, 2020, we recognized $1.0 million of share-based compensation expense related to such awards. As of December 31, 2020, there were 70,000 shares of these performance-contingent RSUs outstanding that have a maximum remaining share-based compensation expense of $0.5 million with performance expiration dates through June 2022.

​

***Off-Balance Sheet Arrangements***

Our equity interest in TRC constitutes an off-balance sheet arrangement. Under the agreement governing TRC, the manager of TRC may request quarterly capital contributions from us to fund the operating costs of TRC; however, we are not obligated to make such contributions. Our equity interest in TRC entitles us to an 85% economic interest in any future payments, which includes royalties and milestone payments, made by GSK under the strategic alliance agreement and under the portion of the collaboration agreement assigned to TRC by Innoviva (the “GSK Agreements”). We have determined TRC to be a variable interest entity that is not consolidated in our financial statements. The potential importance of TRC to our future financial condition and results of operations is dependent upon the progression of drug candidates covered by the GSK Agreements through development to commercialization and the rate of commercialization for approved drugs covered by the GSK Agreements.We rely on publicly available information about those drug candidates as we do not have access to confidential information regarding their progression or status.

​

***Recent Accounting Pronouncements***

The information required by this item is included in *“Item 8, Note 1. Organization and Summary of Significant Accounting Policies,”* in our consolidated financial statements included in this Annual Report on Form 10-K.

​

74

[Table of Contents](#TOC)

**ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

We are exposed to market risks in the ordinary course of our business. These risks primarily include risk related to interest rate sensitivities.

**Interest Rate Sensitivity**

We have invested primarily in money market funds, federal agency notes, corporate debt securities, commercial papers and US treasury notes. To reduce the volatility relating to these exposures, we have put investment and risk management policies and procedures in place. The securities in our investment portfolio are not leveraged and are classified as available-for-sale due to their short-term nature. We currently do not engage in hedging activities.

​

We performed a sensitivity analysis to determine the impact a change in interest rates would have on the value of our investment portfolio. As of December 31, 2020 and 2019, we have estimated that a hypothetical 100 basis point increase in interest rates would have resulted in a decrease in the fair market value of our investment portfolio of $0.5 million and $0.8 million, respectively. Such losses would only be realized if we sold the investments prior to maturity.

​

We are also subject to interest rate sensitivity on our outstanding Convertible Senior 2023 Notes that were issued in November 2016 and our Non-Recourse 2035 Notes that were issued in February 2020. Increases in interest rates would result in a decrease in the fair value of our outstanding debt and decreases in interest rates would result in an increase in the fair value of our outstanding debt. These decreases or increases in the fair value of our outstanding debt would be partially offset by corresponding decreases or increases in our fixed income investment portfolio. The Convertible Senior 2023 Notes pay interest semi-annually, and the $230.0 million of principal is scheduled to be repaid in 2023. The Non-Recourse 2035 Notes pay interest and principal quarterly, and the remaining net principal of $397.6million is due by 2035.

**​**

**​**

75

[Table of Contents](#TOC)

**ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA**

|  |  |
| --- | --- |
| [Report of Independent Registered Public Accounting Firm](#ReportofIndependentRegisteredPublicAcco) | 77 |
| [Consolidated Balance Sheets as of December 31, 2020 and 2019](#BALANCESHEETS_51823) | 79 |
| [Consolidated Statements of Operations for each of the three years in the period ended December 31, 2020](#STATEMENTSOFOPERATIONS_145667) | 80 |
| [Consolidated Statements of Comprehensive Loss for each of the three years in the period ended December 31, 2020](#COMPREHENSIVELOSS_235302) | 81 |
| [Consolidated Statements of Shareholders’ Deficit for each of the three years in the period ended December 31, 2020](#SHAREHOLDERSEQUITYDEFICIT_563819) | 82 |
| [Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2020](#CASHFLOWS_106664) | 83 |
| [Notes to Consolidated Financial Statements](#NOTESTOCONSOLIDATED_244803) | 84 |
| [Supplementary Financial Data (unaudited)](#SUPPLEMENTARYFINANCIALDATA_850975) | 117 |

​

​

76

[Table of Contents](#TOC)

**Report of Independent Registered Public Accounting Firm**

**To the Shareholders and the Board of Directors of Theravance Biopharma, Inc.**

​

**Opinion on the Financial Statements**

We have audited the accompanying consolidated balance sheets of Theravance Biopharma, Inc. (the “Company”) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, shareholders’ deficit, and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.

​

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated February 26, 2021 expressed an unqualified opinion thereon.

​

**Basis for Opinion**

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

​

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

​

**Critical Audit Matter**

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

|  |  |
| --- | --- |
|  | ​  ​ |
| ***Revenue from collaborative and licensing arrangements*** | |
| *Description of the Matter* | The Company recognized revenue from collaboration and licensing agreements of $71.9 million for the year ended December 31, 2020. As described in Note 1, collaboration payment structures may include many elements such as up-front fees, milestones, royalties, expense reimbursement, and/or profit sharing. Furthermore, collaborations may include the delivery of various goods or services to the collaborative partner such as licenses to intellectual property or research and development services. In some circumstances, management is required to use judgment to determine whether analogies to the revenue accounting literature are appropriate for elements of collaboration |

77

[Table of Contents](#TOC)

|  |  |
| --- | --- |
|  | arrangements. Of the $71.9 million recognized as collaboration revenue, $26.4 million was recognized for research and development services under the agreement with Janssen Biotech, Inc. (the “Janssen Agreement”) based on a measure of the Company’s efforts toward satisfying performance obligations relative to the total expected efforts or inputs to satisfy such performance obligations (e.g., costs incurred compared to total budget).  Auditing the Company’s accounting for revenues from collaboration arrangements was especially challenging due to the complex and highly judgmental nature of evaluating the terms of the related agreements, identifying performance obligations, evaluating whether analogies to the revenue accounting guidance are appropriate, determining and allocating the transaction price to the performance obligations, evaluating estimates of the expected efforts to complete performance obligations and measuring efforts toward satisfying those performance obligations, especially as such measuring of efforts relates to the Janssen Agreement. |
| *How We Addressed the Matter in Our Audit* | We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company’s processes for assessing the accounting treatment of any new collaboration agreements or modifications to existing collaboration agreements, establishing an estimated budget of costs, assessing the effort to satisfy performance obligations, and recording actual costs incurred including controls over the completeness and accuracy of data used in the underlying analysis.  To test the accounting for revenue from collaboration arrangements we tested and evaluated, among other things, the performance obligations identified, the estimates and assumptions used to determine transaction price, and the allocation of transaction price to performance obligations. We assessed whether management’s analogies to the revenue literature were a consistent and rational application of accounting policy. To test the measurement of efforts toward satisfying performance obligations, our audit procedures included, among others, reviewing management’s analysis for accuracy and completeness by agreeing data to underlying agreements and inspecting communications with collaboration partners. Our audit procedures specific to the recognition of revenue under the Janssen Agreement focused on evaluating the measure of progress based on costs incurred including performing corroborative inquiries with those outside of the finance department, performing sensitivity analyses of key inputs, evaluating the historical accuracy of management’s budgeted cost estimates, and inspecting evidence of actual costs incurred.  ​ |

​

/s/ Ernst & Young LLP

​

We have served as the Company’s auditor since 2013.

Redwood City, California

February 26, 2021

​

​

78

[Table of Contents](#TOC)

**THERAVANCE BIOPHARMA, INC.**

**CONSOLIDATED BALANCE SHEETS**

**(In thousands, except per share data)**

​

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **December 31,** | | **​** | **December 31,** | |
| **​** |  | **2020** | |  | **2019** | |
| **Assets** | ​ | ​ | ​ | ​ | ​ | ​ |
| Current assets: | ​ | ​ | ​ | ​ | ​ | ​ |
| Cash and cash equivalents | ​ | $ | 81,467 | ​ | $ | 58,064 |
| Short-term marketable securities | ​ |  | 211,474 | ​ |  | 222,767 |
| Receivables from collaborative arrangements | ​ |  | 15,868 | ​ |  | 11,996 |
| Receivables from licensing arrangements | ​ | ​ | — | ​ | ​ | 10,000 |
| Amounts due from TRC, LLC | ​ | ​ | 53,799 | ​ | ​ | 28,574 |
| Prepaid clinical and development services | ​ | ​ | 20,374 | ​ | ​ | 2,736 |
| Other prepaid and current assets | ​ | ​ | 10,359 | ​ | ​ | 4,351 |
| Total current assets | ​ |  | 393,341 | ​ |  | 338,488 |
| Property and equipment, net | ​ |  | 16,422 | ​ |  | 12,644 |
| Long-term marketable securities | ​ |  | — | ​ |  | 4,985 |
| Operating lease assets | ​ | ​ | 43,260 | ​ | ​ | 46,604 |
| Equity in net assets of TRC, LLC | ​ | ​ | 12,750 | ​ | ​ | — |
| Tax receivable | ​ | ​ | — | ​ | ​ | 3,682 |
| Restricted cash | ​ |  | 833 | ​ |  | 833 |
| Other assets | ​ | ​ | 2,451 | ​ | ​ | 1,590 |
| Total assets | ​ | $ | 469,057 | ​ | $ | 408,826 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **Liabilities and Shareholders' Deficit** | ​ | ​ | ​ | ​ | ​ | ​ |
| Current liabilities: | ​ | ​ | ​ | ​ | ​ | ​ |
| Accounts payable | ​ | $ | 6,775 | ​ | $ | 4,758 |
| Accrued personnel-related expenses | ​ |  | 35,238 | ​ |  | 28,180 |
| Accrued clinical and development expenses | ​ |  | 28,799 | ​ |  | 17,587 |
| Accrued general and administrative expenses | ​ | ​ | 6,048 | ​ | ​ | 4,394 |
| Accrued interest payable | ​ | ​ | 3,974 | ​ | ​ | 5,659 |
| Current portion of non-recourse notes due 2035, net | ​ | ​ | 19,334 | ​ | ​ | — |
| Current portion of non-recourse notes due 2033, net | ​ | ​ | — | ​ | ​ | 9,851 |
| Operating lease liabilities | ​ | ​ | 9,867 | ​ | ​ | 7,762 |
| Deferred revenue | ​ |  | 11,523 | ​ |  | 31,575 |
| Other accrued liabilities | ​ |  | 2,013 | ​ |  | 1,937 |
| Total current liabilities | ​ |  | 123,571 | ​ |  | 111,703 |
| Convertible senior notes due 2023, net | ​ | ​ | 226,963 | ​ | ​ | 225,890 |
| Non-recourse notes due 2035, net | ​ | ​ | 372,873 | ​ | ​ | — |
| Non-recourse notes due 2033, net | ​ | ​ | — | ​ | ​ | 219,300 |
| Long-term operating lease liabilities | ​ | ​ | 47,220 | ​ | ​ | 47,725 |
| Long-term deferred revenue | ​ | ​ | 348 | ​ | ​ | 6,761 |
| Other long-term liabilities | ​ | ​ | 1,833 | ​ | ​ | 21,287 |
| Commitments and contingencies | ​ | ​ | ​ | ​ | ​ | ​ |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **Shareholders’ Deficit** | ​ | ​ | ​ | ​ | ​ | ​ |
| Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding | ​ |  | — | ​ | ​ | — |
| Ordinary shares, $0.00001 par value: 200,000 shares authorized; 64,328 and 57,015 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively | ​ |  | 1 | ​ | ​ | 1 |
| Additional paid-in capital | ​ |  | 1,222,818 | ​ | ​ | 1,024,614 |
| Accumulated other comprehensive income | ​ |  | 47 | ​ |  | 145 |
| Accumulated deficit | ​ |  | (1,526,617) | ​ |  | (1,248,600) |
| Total shareholders’ deficit | ​ |  | (303,751) | ​ |  | (223,840) |
| Total liabilities and shareholders’ deficit | ​ | $ | 469,057 | ​ | $ | 408,826 |

​

*See accompanying notes to consolidated financial statements*

**​**

79

[Table of Contents](#TOC)

**THERAVANCE BIOPHARMA, INC.**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**(In thousands, except per share data)**

**​**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | |
| **​** |  | **2020** | |  | **2019** | | ​ | **2018** | |
| ​ | **​** | **​** | **​** | **​** | **​** | | ​ | ​ | ​ |
| Revenue: | **​** | **​** | **​** | **​** | **​** | **​** | ​ | ​ | ​ |
| Product sales | **​** | $ | — | **​** | $ | — | ​ | $ | 15,304 |
| Collaboration revenue | ​ | ​ | 26,464 | ​ | ​ | 31,250 | ​ | ​ | 41,791 |
| Licensing revenue | ​ | ​ | 1,500 | ​ | ​ | 28,500 | ​ | ​ | — |
| Viatris collaboration agreement | ​ |  | 43,893 | ​ |  | 13,664 | ​ |  | 3,275 |
| Total revenue | ​ |  | 71,857 | ​ |  | 73,414 | ​ |  | 60,370 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Costs and expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Cost of goods sold | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 715 |
| Research and development (1) | ​ | ​ | 260,953 | ​ | ​ | 219,248 | ​ | ​ | 201,348 |
| Selling, general and administrative (1) | ​ | ​ | 108,661 | ​ | ​ | 106,081 | ​ | ​ | 97,058 |
| Total costs and expenses | ​ |  | 369,614 | ​ |  | 325,329 | ​ |  | 299,121 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Loss from operations | ​ |  | (297,757) | ​ |  | (251,915) | ​ |  | (238,751) |
| Income from investment in TRC, LLC | ​ | ​ | 68,438 | ​ | ​ | 33,705 | ​ | ​ | 11,182 |
| Interest expense | ​ | ​ | (44,585) | ​ | ​ | (31,862) | ​ | ​ | (10,482) |
| Loss on extinguishment of debt | ​ | ​ | (15,464) | ​ | ​ | — | ​ | ​ | — |
| Interest and other income, net | ​ | ​ | 2,831 | ​ | ​ | 8,395 | ​ | ​ | 11,966 |
| Loss before income taxes | ​ |  | (286,537) | ​ |  | (241,677) | ​ |  | (226,085) |
| Provision for income tax benefit | ​ | ​ | 8,520 | ​ | ​ | 5,222 | ​ | ​ | 10,561 |
| Net loss | ​ | $ | (278,017) | ​ | $ | (236,455) | ​ | $ | (215,524) |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Net loss per share: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Basic and diluted net loss per share | ​ | $ | (4.46) | ​ | $ | (4.25) | ​ | $ | (3.99) |
| Shares used to compute basic and diluted net loss per share | ​ |  | 62,345 | ​ |  | 55,610 | ​ |  | 53,969 |

|  |  |
| --- | --- |
| (1) | Amounts include share-based compensation expense as follows: |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | | | | | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | |
| **(In thousands)** |  | **2020** | |  | **2019** | | ​ | **2018** | |
| Research and development | ​ | $ | 31,294 | ​ | $ | 28,953 | ​ | $ | 25,563 |
| Selling, general and administrative | ​ |  | 31,682 | ​ |  | 31,497 | ​ |  | 25,750 |
| Total share-based compensation expense | ​ | $ | 62,976 | ​ | $ | 60,450 | ​ | $ | 51,313 |

​

*See accompanying notes to consolidated financial statements.*

**​**

80

[Table of Contents](#TOC)

**THERAVANCE BIOPHARMA, INC.**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**

**(In thousands)**

**​**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | |
| **​** |  | **2020** | |  | **2019** | |  | **2018** | |
| Net loss | ​ | $ | (278,017) | ​ | $ | (236,455) | ​ | $ | (215,524) |
| Other comprehensive income (loss): | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Net unrealized gain (loss) on available-for-sale investments, net of tax | ​ |  | (98) | ​ |  | 311 | ​ |  | 567 |
| Comprehensive loss | ​ | $ | (278,115) | ​ | $ | (236,144) | ​ | $ | (214,957) |

​

*​*

*See accompanying notes to consolidated financial statements.*

**​**

81

[Table of Contents](#TOC)

**THERAVANCE BIOPHARMA, INC.**

**CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ DEFICIT**

**(In thousands)**

**​**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | **Accumulated** | | **​** | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | **​** | **​** | **​** | **​** | **Additional** | | **​** | **Other** | | **​** | **​** | **​** | **​** | **Total** | |
| **​** | **​** | **Ordinary Shares** | | | | **​** | **Paid-In** | | **​** | **Comprehensive** | | **​** | **Accumulated** | | **​** | **Shareholders'** | |
| **​** |  | **Shares** |  | **Amount** | |  | **Capital** | |  | **Income (Loss)** | |  | **Deficit** | |  | **Deficit** | |
| Balances at December 31, 2017 | ​ | 54,381 | ​ | $ | 1 | ​ | $ | 913,650 | ​ | $ | (733) | ​ | $ | (797,740) | ​ | $ | 115,178 |
| Proceeds from ESPP purchases | ​ | 204 | ​ | ​ | — | ​ | ​ | 4,173 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,173 |
| Employee share-based compensation expense | ​ | — | ​ | ​ | — | ​ | ​ | 51,313 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 51,313 |
| Issuance of restricted shares | ​ | 1,168 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — |
| Option exercises | ​ | 75 | ​ | ​ | — | ​ | ​ | 1,393 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,393 |
| Cumulative effect upon the adoption of ASC 606 | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,119 | ​ | ​ | 1,119 |
| Repurchase of shares to satisfy tax withholding | ​ | (147) | ​ | ​ | — | ​ | ​ | (9,808) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (9,808) |
| Net unrealized gain on marketable securities | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 567 | ​ | ​ | — | ​ | ​ | 567 |
| Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (215,524) | ​ | ​ | (215,524) |
| Balances at December 31, 2018 | ​ | 55,681 | ​ | $ | 1 | ​ | $ | 960,721 | ​ | $ | (166) | ​ | $ | (1,012,145) | ​ | $ | (51,589) |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | **Accumulated** | | **​** | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | **​** | **​** | **​** | **​** | **Additional** | | **​** | **Other** | | **​** | **​** | **​** | **​** | **Total** | |
| **​** | **​** | **Ordinary Shares** | | | | **​** | **Paid-In** | | **​** | **Comprehensive** | | **​** | **Accumulated** | | **​** | **Shareholders'** | |
| **​** |  | **Shares** |  | **Amount** | |  | **Capital** | |  | **Income (Loss)** | |  | **Deficit** | |  | **Deficit** | |
| Balances at December 31, 2018 | ​ | 55,681 | ​ | $ | 1 | ​ | $ | 960,721 | ​ | $ | (166) | ​ | $ | (1,012,145) | ​ | $ | (51,589) |
| Proceeds from ESPP purchases | ​ | 203 | ​ | ​ | — | ​ | ​ | 3,474 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,474 |
| Employee share-based compensation expense | ​ | — | ​ | ​ | — | ​ | ​ | 60,450 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 60,450 |
| Issuance of restricted shares | ​ | 1,105 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — |
| Option exercises | ​ | 164 | ​ | ​ | — | ​ | ​ | 3,142 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,142 |
| Repurchase of shares to satisfy tax withholding | ​ | (138) | ​ | ​ | — | ​ | ​ | (3,173) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (3,173) |
| Net unrealized gain on marketable securities | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 311 | ​ | ​ | — | ​ | ​ | 311 |
| Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (236,455) | ​ | ​ | (236,455) |
| Balances at December 31, 2019 | ​ | 57,015 | ​ | $ | 1 | ​ | $ | 1,024,614 | ​ | $ | 145 | ​ | $ | (1,248,600) | ​ | $ | (223,840) |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | **Accumulated** | | **​** | ​ | ​ | ​ | ​ | ​ |
| ​ | ​ | **​** | **​** | **​** | **​** | **​** | **Additional** | | **​** | **Other** | | **​** | **​** | **​** | **​** | **Total** | |
| ​ | ​ | **Ordinary Shares** | | | | **​** | **Paid-In** | | **​** | **Comprehensive** | | **​** | **Accumulated** | | **​** | **Shareholders'** | |
| ​ | ​ | **Shares** |  | **Amount** | |  | **Capital** | |  | **Income (Loss)** | |  | **Deficit** | |  | **Deficit** | |
| Balances at December 31, 2019 | ​ | 57,015 | ​ | $ | 1 | ​ | $ | 1,024,614 | ​ | $ | 145 | ​ | $ | (1,248,600) | ​ | $ | (223,840) |
| Net proceeds from sale of ordinary shares | ​ | 5,500 | ​ | ​ | — | ​ | ​ | 139,915 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 139,915 |
| Proceeds from ESPP purchases | ​ | 245 | ​ | ​ | — | ​ | ​ | 3,701 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,701 |
| Employee share-based compensation expense | ​ | — | ​ | ​ | — | ​ | ​ | 62,976 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 62,976 |
| Issuance of restricted shares | ​ | 1,907 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — |
| Option exercises | ​ | 68 | ​ | ​ | — | ​ | ​ | 1,361 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,361 |
| Repurchase of shares to satisfy tax withholding | ​ | (407) | ​ | ​ | — | ​ | ​ | (9,749) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (9,749) |
| Net unrealized loss on marketable securities | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (98) | ​ | ​ | — | ​ | ​ | (98) |
| Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (278,017) | ​ | ​ | (278,017) |
| Balances at December 31, 2020 | ​ | 64,328 | ​ | $ | 1 | ​ | $ | 1,222,818 | ​ | $ | 47 | ​ | $ | (1,526,617) | ​ | $ | (303,751) |

​

​

*See accompanying notes to consolidated financial statements.*

**​**

82

[Table of Contents](#TOC)

**THERAVANCE BIOPHARMA, INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(In thousands)**

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | |
| **​** |  | **2020** | |  | **2019** | |  | **2018** | |
| **Operating activities** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Net loss | ​ | $ | (278,017) | ​ | $ | (236,455) | ​ | $ | (215,524) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Depreciation and amortization | ​ |  | 6,798 | ​ |  | 6,441 | ​ | ​ | 4,481 |
| Amortization and accretion income, net | ​ | ​ | (1,079) | ​ | ​ | (3,451) | ​ | ​ | (1,315) |
| Share-based compensation | ​ |  | 62,976 | ​ |  | 60,450 | ​ | ​ | 51,313 |
| Net gain from the sale of VIBATIV business | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (6,056) |
| Amortization of right-of-use assets | ​ | ​ | 3,344 | ​ | ​ | 3,224 | ​ | ​ | — |
| Undistributed earnings from TRC, LLC | ​ | ​ | (37,975) | ​ | ​ | (23,152) | ​ | ​ | (5,152) |
| Interest shortfall on 2035 notes, net | ​ | ​ | 17,643 | ​ | ​ | — | ​ | ​ | — |
| Loss on extinguishment of debt | ​ | ​ | 15,464 | ​ | ​ | — | ​ | ​ | — |
| Other | ​ | ​ | (95) | ​ | ​ | 146 | ​ | ​ | (43) |
| Changes in operating assets and liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Accounts receivable | ​ |  | — | ​ |  | 620 | ​ | ​ | 1,633 |
| Receivables from collaborative and licensing arrangements | ​ |  | 6,128 | ​ |  | (11,943) | ​ | ​ | (2,944) |
| Prepaid clinical and development services | ​ | ​ | (17,638) | ​ | ​ | (561) | ​ | ​ | (2,175) |
| Other prepaid and current assets | ​ | ​ | (2,327) | ​ | ​ | (73) | ​ | ​ | (225) |
| Inventory | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (1,629) |
| Tax receivable | ​ | ​ | (258) | ​ | ​ | (3,700) | ​ | ​ | 8,191 |
| Other assets | ​ | ​ | (852) | ​ | ​ | (358) | ​ | ​ | 45 |
| Accounts payable | ​ |  | 3,658 | ​ |  | (4,274) | ​ | ​ | 3,575 |
| Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities | ​ |  | 5,983 | ​ |  | 10,626 | ​ | ​ | (12,357) |
| Accrued interest payable | ​ | ​ | (1,685) | ​ | ​ | 2,573 | ​ | ​ | 1,841 |
| Deferred rent | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,308 |
| Deferred revenue | ​ | ​ | (26,465) | ​ | ​ | (31,245) | ​ | ​ | 69,224 |
| Operating lease liabilities | ​ | ​ | 1,600 | ​ | ​ | (2,317) | ​ | ​ | — |
| Other long-term liabilities | ​ |  | (7,606) | ​ |  | (4,748) | ​ | ​ | (10,058) |
| Net cash used in operating activities | ​ |  | (250,403) | ​ |  | (238,197) | ​ | ​ | (112,867) |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **Investing activities** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Purchases of property and equipment | ​ |  | (6,616) | ​ |  | (3,176) | ​ | ​ | (7,240) |
| Purchases of marketable securities | ​ |  | (401,987) | ​ |  | (423,898) | ​ | ​ | (183,261) |
| Maturities of marketable securities | ​ |  | 399,318 | ​ |  | 339,018 | ​ | ​ | 347,192 |
| Proceeds from the sale of marketable securities | ​ | ​ | 19,942 | ​ | ​ | — | ​ | ​ | — |
| Proceeds from the sale of property and equipment | ​ | ​ | 64 | ​ | ​ | 5 | ​ | ​ | 17 |
| Proceeds from the sale of VIBATIV business, net | ​ |  | — | ​ |  | 5,000 | ​ | ​ | 20,000 |
| Net cash provided by (used in) investing activities | ​ |  | 10,721 | ​ |  | (83,051) | ​ |  | 176,708 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **Financing activities** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Proceeds from the sale of ordinary shares, net | ​ | ​ | 139,915 | ​ | ​ | — | ​ | ​ | — |
| Proceeds from issuance of 2035 notes, net | ​ | ​ | 380,000 | ​ | ​ | — | ​ | ​ | — |
| Payment of issuance costs on 2035 notes | ​ | ​ | (5,326) | ​ | ​ | — | ​ | ​ | — |
| Proceeds from issuance of 2033 notes, net | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 229,441 |
| Payment of redemption premium on 2033 notes | ​ | ​ | (11,470) | ​ | ​ | — | ​ | ​ | — |
| Principal payment on 2033 notes | ​ | ​ | (235,347) | ​ | ​ | (2,152) | ​ | ​ | — |
| Proceeds from ESPP purchases | ​ | ​ | 3,701 | ​ | ​ | 3,474 | ​ | ​ | 4,173 |
| Proceeds from option exercises | ​ | ​ | 1,361 | ​ | ​ | 3,142 | ​ | ​ | 1,393 |
| Repurchase of shares to satisfy tax withholding | ​ | ​ | (9,749) | ​ | ​ | (3,173) | ​ | ​ | (9,807) |
| Net cash provided by financing activities | ​ |  | 263,085 | ​ |  | 1,291 | ​ |  | 225,200 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **Net increase (decrease) in cash, cash equivalents, and restricted cash** | ​ |  | 23,403 | ​ |  | (319,957) | ​ | ​ | 289,041 |
| **Cash, cash equivalents, and restricted cash at beginning of period** | ​ |  | 58,897 | ​ |  | 378,854 | ​ | ​ | 89,813 |
| **Cash, cash equivalents, and restricted cash at end of period** | ​ | $ | 82,300 | ​ | $ | 58,897 | ​ | $ | 378,854 |
| **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **Supplemental disclosure of cash flow information** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Cash paid for interest | ​ | $ | 24,024 | ​ | $ | 26,178 | ​ | $ | 7,475 |
| Cash paid (received) for income taxes, net | ​ | $ | 14 | ​ | $ | 22 | ​ | $ | (7,316) |
| Right-of-use assets obtained in exchange for lease obligations (1) | ​ | $ | — | ​ | $ | 49,847 | ​ | $ | — |

(1)Amounts for the year ended December 31, 2019 include the transition adjustment for the adoption of ASC 842, *Leases*.

*See accompanying notes to consolidated financial statements*.

**​**

83

[Table of Contents](#TOC)

**THERAVANCE BIOPHARMA, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

​

​

**1. Organization and Summary of Significant Accounting Policies**

Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. The Company’s purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. The Company’s research is focused in the areas of inflammation and immunology.

​

***Basis of Presentation***

The Company’s consolidated financial statements as of December 31, 2020 and 2019, and for the year ended December 31, 2020, 2019, and 2018 have been prepared in conformity with United States (“US”) Generally Accepted Accounting Principles ("GAAP"), and the US Securities and Exchange (“SEC”) regulations for annual reporting.

​

***Principles of Consolidation***

The consolidated financial statements include the accounts of Theravance Biopharma and its wholly-owned subsidiaries, all of which are denominated in US dollars. All intercompany balances and transactions have been eliminated in consolidation.

***Use of Estimates***

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

​

***Segment Reporting***

The Company operates in a single segment, which is the discovery (research), development and commercialization of human therapeutics. The Company’s business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. The Company is comprehensively managed as one business segment by the Company’s Chief Executive Officer and the management team. Product sales, if any, are attributed to regions based on ship-to location and revenue from collaborative arrangements, including royalty revenue, are attributed to regions based on the location of the collaboration partner. Revenue from profit sharing-type arrangements is attributed to the geographic market in which the products are sold. Capitalized property and equipment is predominantly located in the US.

***​***

***Cash and Cash Equivalents***

The Company considers all highly-liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at fair value.

***​***

***Restricted Cash***

The Company maintains restricted cash for certain lease agreements and letters of credit by which the Company has pledged cash and cash equivalents as collateral. The Company may also maintain restricted cash for debt servicing of its non-recourse notes. See *“Note 5. Cash, Cash Equivalents, and Restricted Cash”* for more information.

***​***

***Investments in Marketable Securities***

The Company invests in marketable securities, primarily corporate notes, government bonds and government agency bonds. The Company classifies its marketable securities as available-for-sale securities and reports them at fair value in cash and cash equivalents or marketable securities on the consolidated balance sheets with related unrealized

84

[Table of Contents](#TOC)

gains and losses included as a component of shareholders’ deficit. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest and other income (loss) on the consolidated statements of operations. The cost of securities sold is based on the specific identification method. Realized gains and losses and interest and dividends on securities are included in interest and other income (loss).

​

The Company accounts for credit losses on available-for-sale debt securities in accordance with Accounting Standards Codification (“ASC”), Topic 326, *Financial Instruments – Credit Losses* (“ASC 326”). Under ASC 326, the Company regularly reviews its investments for declines in estimated fair value below amortized cost. The factors considered in determining whether a credit loss exists include the creditworthiness of the security issuers, the number of securities in unrealized loss positions, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that the Company will be required to sell the securities before the recovery of the security’s amortized cost basis.

​

In circumstances where the Company intends to sell, or is more likely than not required to sell, the security before it recovers its amortized cost basis, the difference between fair value and amortized cost is recognized as a loss in the consolidated statements of operations, with a corresponding write-down of the security's amortized cost. In circumstances where neither condition exists, the Company then evaluates whether a decline is due to credit-related factors. To determine the portion of a decline in fair value that is credit-related, the Company compares the present value of the expected cash flows of the security discounted at the security's effective interest rate to the amortized cost basis of the security. A credit-related impairment is limited to the difference between fair value and amortized cost and recognized as an allowance for credit loss on the consolidated balance sheets with a corresponding adjustment to net income (loss). Any remaining decline in fair value that is non-credit related is recognized in other comprehensive loss, net of tax. Improvements in expected cash flows due to improvements in credit are recognized through reversal of the credit loss and corresponding reduction in the allowance for credit loss.

***​***

***Fair Value of Financial Instruments***

The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

​

The Company’s valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect the Company’s market assumptions. The Company classifies these inputs into the following hierarchy:

*​*

*Level 1* — Quoted prices for identical instruments in active markets.

*​*

*Level 2* — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

*​*

*Level 3* — Unobservable inputs and little, if any, market activity for the assets.

​

Financial instruments include cash equivalents, marketable securities, accounts receivable, accounts payable, accrued liabilities and debt. The Company’s cash equivalents and marketable securities are carried at estimated fair value and remeasured on a recurring basis. The carrying value of accounts receivable, receivables from collaborative arrangements, accounts payable and accrued liabilities approximate their estimated fair value due to the relatively short-term nature of these instruments. The fair value of the Company's debt is classified as a level 2 financial instrument and is disclosed in *“Note 7. Debt”*.

***​***

***Accounts Receivable***

For the periods presented, the Company’s accounts receivable primarily relate to amounts due arising from its collaboration and licensing agreements. When appropriate, the Company provides for an allowance for specifically

85

[Table of Contents](#TOC)

identified doubtful accounts. The Company performs periodic credit evaluations of its customers and generally does not require collateral. For the periods presented, the Company did not have any material write-offs of accounts receivable

***​***

***Concentration of Credit Risks***

The Company invests in a variety of financial instruments and, based on its policy, limits the amount of credit exposure with any one issuer, industry or geographic area for investments other than instruments backed by the US federal government.

​

The Company’s receivables primarily relate to amounts due under its collaboration and licensing agreements. Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical companies or specific to its collaboration agreements. The Company performs periodic evaluations of its customers and generally does not require collateral. For the year ended December 31, 2020, 2019, and 2018, the Company did not experience any material losses related to its receivables.

***​***

***Property and Equipment***

Property, equipment and leasehold improvements are stated at cost, net of accumulated depreciation, and amortized using the straight-line method as follows:

​

|  |  |  |
| --- | --- | --- |
| ​ | ​ | ​ |
| Leasehold improvements |  | Shorter of remaining lease terms or useful life |
| Equipment, furniture and fixtures | ​ | 5 - 7 years |
| Software and computer equipment | ​ | 3 - 5 years |

​

***Leases***

The Company determines whether a contract is or contains a lease at inception of the arrangement. In evaluating whether a contract is indicative of a lease, the Company considers all relevant facts and circumstances to assess whether the arrangement has extended to the Company the right to both (i) obtain substantially all the economic benefits from use of an identified asset and (ii) direct the use of the identified asset. To the extent that the Company determines a contract represents a lease, the arrangement is classified as either an operating lease or a finance lease, with the classification affecting the presentation and pattern of expense recognition in the consolidated statements of operations. The Company did not have any finance leases at either December 31, 2020 or 2019.

​

Operating lease assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the leasing arrangement. The Company records operating leases on the consolidated balance sheets through an operating lease asset and a corresponding short-term and long-term operating lease liability, as applicable. Lease liabilities are measured based on the present value of lease payments over the lease term discounted at the implicit interest rate, when readily available or using the Company’s incremental borrowing rate, if the implicit rate is not determinable. The incremental borrowing rate is considered the rate of interest that the Company would have to pay to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. The Company measures its operating lease assets based on the corresponding operating lease liabilities adjusted for (i) prepayments made to the lessor at or before the commencement date, (ii) any initial direct costs incurred, and (iii) tenant incentives granted under the lease contract.

​

In calculating operating lease assets and liabilities, the Company may elect to combine lease and non-lease components based on the asset type. The Company’s lease terms may include options to extend the lease only when it is reasonably certain that such options will be exercised, and the Company recognizes lease expense on a straight-line basis over the lease term. Operating lease assets are evaluated for possible impairment in accordance with the Company’s long-lived assets policy.

​

The Company does not recognize operating lease assets or liabilities for leases that have a lease term of 12 months or less at commencement date, and the lease expense related to these short-term lease arrangements is recognized on a straight-line basis over the term of the lease.

​

86

[Table of Contents](#TOC)

***Capitalized Software***

The Company capitalizes certain costs related to direct material and service costs for software obtained for internal use. Upon being placed in service, these costs and other future capitalizable costs related to the internal use software system integration are depreciated over five years. There were no material capitalized software costs recorded for the year ended December 31, 2020 or 2019.

​

***Impairment of Long-Lived Assets***

The Company’s long-lived assets consists of property and equipment, operating lease assets and other assets. The carrying value of long-lived assets is reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. There were no impairments of long-lived assets recorded for the year ended December 31, 2020, 2019 or 2018.

***​***

***Revenue Recognition***

The Company recognizes revenue under ASC Topic 606, *Revenue from Contracts with Customers* (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, an entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.

​

At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the performance obligations in the contract by assessing whether the goods or services promised within each contract are distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

​

*Collaborative Arrangements under ASC 606*

The Company enters into collaborative arrangements with partners that fall under the scope of ASC Topic 808, *Collaborative Arrangements* (“ASC 808”). While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects of these arrangements. The Company analogizes to ASC 606 for certain activities within collaborative arrangements for the delivery of a good or service (i.e., a unit of account) that is part of its ongoing major or central operations. Revenue recognized by analogizing to ASC 606 is recorded as “collaboration revenue” or “licensing revenue” whereas, revenue recognized in accordance with ASC 808 is recorded on a separate collaboration revenue line on the consolidated statements of operations.

​

The terms of the Company’s collaborative arrangements typically include one or more of the following: (i) up-front fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; (iii) royalties on net sales of licensed products; (iv) reimbursements or cost-sharing of research and development expenses; and (v) profit/loss sharing arising from co-promotion arrangements. Each of these payments results in collaboration revenues or an offset against research and development expense. Where a portion of non-refundable up-front fees or other payments received is allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as collaboration revenue when (or as) the underlying performance obligation is satisfied.

​

As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price may include such estimates as, forecasted revenues or costs, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. The effect of any change made to an

87

[Table of Contents](#TOC)

estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.

​

*Up-front Fees:* If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes collaboration revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing collaboration revenue from the allocated transaction price. For example, when the Company receives up-front fees for the performance of research and development services, or when research and development services are not considered to be distinct from a license, the Company recognizes collaboration revenue for those units of account over time using a measure of progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.

​

*Milestone Payments:* At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s or the collaborative partner’s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the collaborative partner’s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company’s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.

​

*Royalties:* For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

​

Following the sale of VIBATIV to Cumberland Pharmaceuticals Inc. (“Cumberland”) in November 2018, VIBATIV royalties earned from Cumberland are included within “interest and other income, net” on the consolidated statements of operations. In addition, the Company’s income earned related to TRELEGY sales is included within “income from investment in TRC, LLC” on the consolidated statements of operations.

​

*Reimbursement, cost-sharing and profit-sharing payments:* Under certain collaborative arrangements, the Company has been reimbursed for a portion of its research and development expenses or participates in the cost-sharing of such research and development expenses. Such reimbursements and cost-sharing arrangements have been reflected as a reduction of research and development expense in the Company’s consolidated statements of operations, as the Company does not consider performing research and development services for reimbursement to be a part of its ongoing major or central operations.

​

*Product Sales*

In November 2018, the Company completed the sale of its assets related to the manufacture, marketing and sale of the VIBATIV product to Cumberland. Up until that date, the Company sold VIBATIV in the US market by making the drug product available through a limited number of distributors, who sold VIBATIV to healthcare providers. Title and risk of loss transferred upon receipt by these distributors. The Company recognized VIBATIV product sales and related cost of product sales when the distributors obtained control of the drug product, which was at the time title transferred to the distributors.

​

88

[Table of Contents](#TOC)

The Company recorded sales on a net sales basis which included estimates of variable consideration. The variable consideration resulted from sales discounts, government-mandated rebates and chargebacks, distribution fees, estimated product returns and other deductions for sales made by the Company prior to the November 2018 sale to Cumberland. The Company reflected such reductions in revenue as either an allowance to the related account receivable from the distributor, or as an accrued liability, depending on the nature of the sales deduction. Sales deductions were based on management’s estimates that considered payor mix in target markets, industry benchmarks and historical experience. In general, these estimates took into consideration a range of possible outcomes which were probability-weighted in accordance with the expected value method in ASC 606. The Company monitored inventory levels in the distribution channel, as well as sales by distributors to healthcare providers, using product-specific data provided by the distributors. Product return allowances were based on amounts owed or to be claimed on related sales. These estimates took into consideration the terms of the Company’s agreements with customers, historical product returns, rebates or discounts taken, estimated levels of inventory in the distribution channel, the shelf life of the product and specific known market events, such as competitive pricing and new product introductions. The Company updated its estimates and assumptions each quarter and if actual future results varied from its estimates, the Company adjusted these estimates, which could have had an effect on product sales and earnings in the period of adjustment.

​

***Research and Development Expenses***

Research and development (“R&D”) expenses are recorded in the period that services are rendered or goods are received. R&D expenses consist of salaries and benefits, laboratory supplies and facility costs, as well as fees paid to third parties that conduct certain R&D activities on behalf of the Company, net of certain external R&D expenses reimbursed under the Company’s collaborative arrangements.

​

As part of the process of preparing its consolidated financial statements, the Company is required to estimate and accrue certain R&D expenses. This process involves the following:

​

|  |  |  |
| --- | --- | --- |
|  | • | identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost; |

​

|  |  |  |
| --- | --- | --- |
|  | • | estimating and accruing expenses in the Company’s consolidated financial statements as of each balance sheet date based on facts and circumstances known to it at the time; and |

​

|  |  |  |
| --- | --- | --- |
|  | • | periodically confirming the accuracy of the Company’s estimates with selected service providers and making adjustments, if necessary. |

​

Examples of estimated research and development expenses that the Company accrues include:

​

|  |  |  |
| --- | --- | --- |
|  | • | fees paid to clinical research organizations (“CROs”) in connection with preclinical and toxicology studies and clinical studies; |

​

|  |  |  |
| --- | --- | --- |
|  | • | fees paid to investigative sites in connection with clinical studies; |

​

|  |  |  |
| --- | --- | --- |
|  | • | fees paid to contract manufacturing organizations (“CMOs”) in connection with the production of product and clinical study materials; and |

​

|  |  |  |
| --- | --- | --- |
|  | • | professional service fees for consulting and related services. |

​

The Company bases its expense accruals related to clinical studies on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical studies on the Company’s behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors, such as the successful enrollment of patients and the completion of clinical study milestones. The Company’s service providers typically invoice it

89

[Table of Contents](#TOC)

monthly in arrears for services performed. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the Company does not identify costs that it has begun to incur or if it underestimates or overestimates the level of services performed or the costs of these services, the Company’s actual expenses could differ from its estimates.

​

To date, the Company has not experienced significant changes in its estimates of accrued research and development expenses after a reporting period. However, due to the nature of estimates, there is no assurance that the Company will not make changes to its estimates in the future as it becomes aware of additional information about the status or conduct of its clinical studies and other research activities. Such changes in estimates will be recognized as research and development expenses in the period that the change in estimate occurs.

​

***Advertising Expenses***

The Company expenses the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $6.3 million, $2.4 million and $1.9 million for the year ended December 31, 2020, 2019 and 2018, respectively.

​

***Fair Value of Share-Based Compensation Awards***

The Company uses the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under its equity incentive plans and rights to acquire shares granted under its employee share purchase plan (“ESPP”). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected share price volatility. The Company uses the “simplified” method as described in Staff Accounting Bulletin No. 107, *Share-Based Payment*, to estimate the expected option term.

​

Share-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for actual forfeitures as they occur. Compensation expense for purchases under the ESPP is recognized based on the fair value of the award on the date of offering.

​

***Debt Instruments***

Coupon interest on the Company’s debt instruments is accrued using the effective interest rate method over the estimated period the debt will be repaid. Debt issuance costs are capitalized as deferred financing costs and presented as a reduction of the carrying value of the financial liability on the Company’s consolidated balance sheets. Debt issuance costs subsequently are amortized to interest expense over the estimated life of the related debt based on the effective interest method. The Company considers whether there are any embedded features in its debt instruments that require bifurcation and separate accounting as derivative financial instruments pursuant to ASC Topic 815, *Derivatives and Hedging*. As of December 31, 2020 and 2019, the Company’s debt instruments did not include any features that require bifurcation and separate derivative accounting.

​

***Theravance Respiratory Company, LLC (“TRC”)***

Through the Company’s 85% equity interest in TRC, the Company is entitled to receive an 85% economic interest in any future payments made by Glaxo Group or one of its affiliates (“GSK”) under the strategic alliance agreement and under the portion of the collaboration agreement assigned to TRC (net of TRC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters). The primary drug program assigned to TRC is Trelegy.

​

The Company analyzed its ownership, contractual and other interests in TRC to determine if TRC is a variable-interest entity (“VIE”), whether the Company has a variable interest in TRC and the nature and extent of that interest. The Company determined that TRC is a VIE. The party with the controlling financial interest, the primary beneficiary, is required to consolidate the entity determined to be a VIE. Therefore, the Company also assessed whether the Company is the primary beneficiary of TRC based on the power to direct its activities that most significantly impact its economic performance and the Company’s obligation to absorb its losses or the right to receive benefits from it that could potentially be significant to TRC. Based on the Company’s assessment, it determined that it is not the primary beneficiary of TRC, and, as a result, the Company does not consolidate TRC in its consolidated financial statements.

90

[Table of Contents](#TOC)

TRC is recognized in the Company’s consolidated financial statements under the equity method of accounting. Income related to the Company’s equity ownership of TRC is reflected within its consolidated statements of operations and is classified as non-operating income.

***​***

***Income Taxes***

The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are anticipated to be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

​

The Company’s total unrecognized tax benefits of $63.4 million and $58.8 million, as of December 31, 2020 and December 31, 2019, respectively, may reduce the effective tax rate in the period of recognition. The Company currently has a full valuation allowance against its deferred tax assets, which would impact the timing of the effective tax rate benefit should any of the Company’s uncertain positions be favorably settled in the future.

​

The Company assesses all material positions, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.

​

The recognition and measurement of tax benefits requires significant judgment. The Company has taken certain positions where it believes that its position is greater than 50% likely to be realized upon ultimate settlement and for which no reserve for uncertain tax positions has been recorded. If the Company does not ultimately realize the expected benefit of these positions, it will record additional income tax expenses in future periods. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.

​

Any tax levied or credited by a governmental taxing authority that is not based on the Company’s income is outside the scope of accounting for income taxes. Therefore, the Company records such items as a component of its loss before income taxes.

​

***Net Loss per Share***

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares outstanding, less ordinary shares subject to forfeiture. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares outstanding, less ordinary shares subject to forfeiture, plus all additional ordinary shares that would have been outstanding, assuming dilutive potential ordinary shares had been issued for other dilutive securities.

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | | | | | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | |
| **(In thousands, except per share data)** |  | **2020** | |  | **2019** | | ​ | **2018** | |
| **Numerator:** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Net loss | ​ | $ | (278,017) | ​ | $ | (236,455) | ​ | $ | (215,524) |
| **Denominator:** | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Weighted-average ordinary shares outstanding | ​ | ​ | 62,808 | ​ | ​ | 56,452 | ​ | ​ | 55,076 |
| Less: weighted-average ordinary shares subject to forfeiture | ​ | ​ | (463) | ​ | ​ | (842) | ​ | ​ | (1,107) |
| Weighted-average ordinary shares used to compute basic and diluted net loss per share | ​ | ​ | 62,345 | ​ | ​ | 55,610 | ​ | ​ | 53,969 |
| Basic and diluted net loss per share | ​ | $ | (4.46) | ​ | $ | (4.25) | ​ | $ | (3.99) |

​

For the year ended December 31, 2020, 2019 and 2018, diluted and basic net loss per share were identical since potential ordinary shares were excluded from the calculation, as their effect was anti-dilutive.

91

[Table of Contents](#TOC)

*​*

*Anti-dilutive Securities*

The following ordinary equivalent shares were not included in the computation of diluted net loss per share because their effect was anti-dilutive:

​

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | | | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | |
| **(In thousands)** |  | **2020** |  | **2019** | ​ | **2018** |
| Share issuances under equity incentive plans and ESPP | **​** | 6,553 | ​ | 6,577 | ​ | 3,492 |
| Restricted shares | **​** | — | ​ | — | ​ | 2 |
| Share issuances upon the conversion of convertible senior notes | **​** | 6,676 | ​ | 6,676 | ​ | 6,676 |
| Total |  | 13,229 | ​ | 13,253 | ​ | 10,170 |

​

In addition, there were 414,000 and 978,750 shares subject to performance-based vesting criteria which have been excluded from the ordinary equivalent shares table above for the year ended December 31, 2019 and 2018, respectively. There were no such shares excluded as of December 31, 2020.

​

***Comprehensive Loss***

Comprehensive loss is comprised of net loss and changes in unrealized gains and losses on the Company’s available-for-sale investments.

​

***Related Parties***

GSK owned 15.0% of the Company’s ordinary shares outstanding as of December 31, 2020. On June 22, 2020, GSK Finance (No.3) plc (“GSK Finance”), a wholly-owned subsidiary of GSK, issued $280,336,000 of exchangeable senior notes due 2023 (the “GSK Notes”), initially exchangeable into 9,644,792 ordinary shares of Theravance Biopharma held by GSK and its affiliates. The GSK Notes are guaranteed by GSK and are exchangeable at the option of noteholders on any business day on or after September 1, 2020. The GSK Notes will mature on June 22, 2023 and do not bear interest. The GSK Notes were offered at an issue price 108.5% of their principal amount. The initial exchange rate is 34.4044 shares of Theravance Biopharma ordinary shares per $1,000 principal amount of GSK Notes, which is equivalent to an initial exchange price of approximately $29.066 per share, representing a premium of 35% over the volume weighted-average price of Theravance Biopharma’s ordinary shares on June 17, 2020.

​

Upon exchange of the GSK Notes, GSK Finance is expected to deliver its ordinary shares of Theravance Biopharma, but may at its option under certain circumstances, deliver cash or a combination of Theravance Biopharma ordinary shares and cash to noteholders. The GSK offering involves the expected exchange of substantially all of the 9,644,807 ordinary shares of Theravance Biopharma held by GSK and its affiliates. Theravance Biopharma will not be issuing any new ordinary shares in connection with the GSK offering, and Theravance Biopharma did not receive any proceeds from the GSK offering.

​

Robert V. Gunderson, Jr. is a member of the Company’s board of directors. The Company has engaged Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, of which Mr. Gunderson is a partner, as its primary legal counsel. Fees incurred for services provided by Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP were $0.5 million, $0.4 million and $0.5 million for the year ended December 31, 2020, 2019 and 2018, respectively.

​

***Recently Adopted Accounting Pronouncements***

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, *Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments* (“ASU 2016-13"). This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. ASU 2016-13 also eliminates the concept of “other-than-temporary” impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on

92

[Table of Contents](#TOC)

available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. ASU 2016-13 became effective on January 1, 2020, and the adoption did not have a material impact on the Company’s consolidated financial statements and related disclosures primarily due to the high credit quality and short-term maturities of the Company’s marketable securities.

​

In August 2018, the FASB issued ASU 2018-15, *Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract* (“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. Accordingly, ASU 2018-15 requires a customer in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 became effective on January 1, 2020, and the adoption did not have a material impact on the Company’s consolidated financial statements and related disclosures. However, the adoption of ASU 2018-15 may result in an increase in capitalized assets related to qualifying cloud computing arrangement implementation costs in the future.

​

In November 2018, the FASB issued ASU 2018-18, *Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606* (“ASU 2018-18”). The issuance of Topic 606 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaboration arrangement participant is a customer; (ii) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer; and (iii) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. ASU 2018-18 became effective on January 1, 2020, and the Company elected to adopt ASU 2018-18 retrospectively, only for contracts that were not completed as of January 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company’s consolidated financial statements and related disclosures.

​

***Recently Issued Accounting Pronouncements Not Yet Adopted***

In December 2019, the FASB issued ASU 2019-12, *Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes* (“ASU 2019-12”) as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards. ASU 2019-12 removes certain exceptions from Topic 740, *Income Taxes*, including (i) the exception to the incremental approach for intra period tax allocation when there is a loss from continuing operations and income or a gain from other items such as discontinued operations or other comprehensive income; (ii) the exception to accounting for outside basis differences of equity method investments and foreign subsidiaries; and (iii) the exception to limit tax benefit recognized in interim periods in cases when the year-to-date losses exceed anticipated losses. ASU 2019-12 also simplifies GAAP in several other areas of Topic 740 such as (i) franchise taxes and other taxes partially based on income; (ii) step-up in tax basis goodwill considered part of a business combination in which the book goodwill was originally recognized or should be considered a separate transaction; (iii) separate financial statements of entities not subject to tax; and (iv) interim recognition of enactment of tax laws or rate changes. ASU 2019-12 is effective for annual reporting periods and interim periods within those years beginning after December 15, 2020. The adoption of ASU 2019-12 is not expected to have a material impact on the Company’s consolidated financial statements and related disclosures.

​

In August 2020, the FASB issued ASU 2020-06, *Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging: Contracts in Entity’s Own Equity (Subtopic 815-10)* (“ASU 2020-06”). ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of liabilities and equity by removing certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. The standard also enhances the consistency of earnings-per-share calculations by requiring that an entity use the if-converted method and that the effect of potential share settlement be included in diluted earnings-per-share calculations. ASU 2020-06 is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2021, and early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2020-06 on its consolidated financial statements and related disclosures.

​

93

[Table of Contents](#TOC)

The Company has evaluated other recently issued accounting pronouncements and does not currently believe that any of these pronouncements will have a material impact on its consolidated financial statements and related disclosures.

​

**2. Revenue**

***Revenues from Collaborative Arrangements***

The Company recognized revenues from its collaborative arrangements as follows:

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | | | | | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | |
| **(In thousands)** |  | **2020** | |  | **2019** | | ​ | **2018** | |
| Janssen | ​ | $ | 26,426 | ​ | $ | 31,096 | ​ | $ | 31,053 |
| Alfasigma | ​ | ​ | 14 | ​ | ​ | 125 | ​ | ​ | 10,678 |
| Other | ​ | ​ | 24 | ​ | ​ | 29 | ​ | ​ | 60 |
| Total collaboration revenue | ​ | $ | 26,464 | ​ | $ | 31,250 | ​ | $ | 41,791 |

​

***Changes in Deferred Revenue Balances***

Changes in deferred revenue balances arose as a result of the Company recognizing the following revenue from collaborative arrangements during the periods below:

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | | | | | ​ | ​ | ​ |
| **​** | ​ | **Year Ended December 31,** | | | | | | | |
| **(In thousands)** | ​ | **2020** | | **​** | **2019** | | ​ | **2018** | |
| **Collaboration revenue recognized in the period from:** | ​ | **​** | ​ | ​ | ​ | **​** | ​ | ​ | ​ |
| Amounts included in deferred revenue at the beginning of the period | ​ | $ | 26,464 | ​ | $ | 31,245 | ​ | $ | 130 |
| Performance obligations satisfied in previous period | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — |

​

***Janssen Biotech***

In February 2018, the Company entered into a global co-development and commercialization agreement with Janssen Biotech, Inc. (“Janssen”) for izencitinib (formerly known as TD-1473) and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn’s disease (the “Janssen Agreement”). Under the terms of the Janssen Agreement, the Company received an upfront payment of $100.0 million. The Company is conducting a Phase 2 (DIONE) study of izencitinib in Crohn’s disease and a Phase 2b/3 (RHEA) induction and maintenance study of izencitinib in ulcerative colitis.Following the initial Phase 2 development period, including the completion of the Phase 2 Crohn’s study and the Phase 2b induction portion of the ulcerative colitis study, Janssen can elect to obtain an exclusive license to develop and commercialize izencitinib and certain related back-up compounds by paying the Company a fee of $200.0 million. Upon any such election, the Company and Janssen will jointly develop and commercialize izencitinib in inflammatory intestinal diseases and share profits in the US and expenses related to Phase 3 development and registration activities (67% to Janssen; 33% to Theravance Biopharma). The Company would receive royalties on ex-US sales at double-digit tiered percentage royalty rates, and the Company would be eligible to receive up to an additional $700.0 million in development and commercialization milestone payments from Janssen.

​

The Janssen Agreement is considered to be within the scope of Accounting Standards Codification, Topic 808, *Collaborative Arrangements* (“ASC 808”), as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the Janssen Agreement and determined it is partially within the scope of Accounting Standards Codification, Topic 606, *Revenue from Contracts with Customers* (“ASC 606”) as the research and development activities to be performed through the initial Phase 2 development period of the collaborative arrangement are considered to be part of the Company’s ordinary activities. The Company has identified research and development activities as its only performance obligation. The Company further determined that the transaction price under the arrangement was the $100.0 million upfront payment which was allocated to the single performance obligation.

​

The $900.0 million in future potential payments, inclusive of the $200.0 million opt-in fee and $700.0 million future development and commercialization milestones, is considered variable consideration if Janssen elects to remain in the collaboration arrangement following completion of the initial Phase 2 development period, as described above and,

94

[Table of Contents](#TOC)

as such, was not included in the transaction price, as the potential payments were all determined to be fully constrained under ASC 606. As part of the Company’s evaluation of this variable consideration constraint, it determined that the potential payments are contingent upon developmental and regulatory milestones that are uncertain and are highly susceptible to factors outside of its control. The Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.

​

For the year ended December 31, 2020, 2019 and 2018, the Company recognized $26.4 million, $31.1 million, and $31.1 million as revenue from collaboration arrangements related to the Janssen Agreement. The remaining transaction price of $11.4 million, related to the $100.0 million upfront payment, was recorded in deferred revenue on the consolidated balance sheets and is expected to be recognized as collaboration revenue as the research and development services are delivered over the initial Phase 2 development period. Collaboration revenue is recognized for the research and development services based on a measure of the Company’s efforts toward satisfying the performance obligation relative to the total expected efforts or inputs to satisfy the performance obligation (e.g., costs incurred compared to total budget). Consequently, delays in trial activity and/or changes to the total budget will impact the timing and amount of revenue recognized in any given reporting period. For the year ended December 31, 2020, 2019 and 2018, the Company incurred $38.5 million, $39.9 million and $38.6 million, respectively, in research and development costs related to the Janssen Agreement. In future reporting periods, the Company will reevaluate the estimates related to its efforts towards satisfying the performance obligation and may record a change in estimate if deemed necessary.

​

***Viatris***

***​***

In January 2015, the Company and Viatris Inc. (formerly, Mylan Ireland Limited) (“Viatris”) established a strategic collaboration (the “Viatris Agreement”) for the development and commercialization of revefenacin, including YUPELRI® (revefenacin) inhalation solution. The Company entered into the collaboration to expand the breadth of its revefenacin development program and extend its commercial reach beyond the hospital setting.

​

Under the Viatris Agreement, Viatris paid the Company an upfront fee of $15.0 million for the delivery of the revefenacin license in 2015 and, in 2016, Viatris paid the Company a milestone payment of $15.0 million for the achievement of 50% enrollment in the related Phase 3 twelve-month safety study.

​

As of December 31, 2020, excluding the aggregate $30.0 million payment noted above, the Company is eligible to receive from Viatris potential global (ex-China and adjacent territories) development, regulatory and sales milestone payments totaling up to $205.0 million in the aggregate, with $160.0 million associated with YUPELRI monotherapy, and $45.0 million associated with future potential combination products. Of the $160.0 million associated with monotherapy, $150.0 million relates to sales milestones based on achieving certain levels of net sales and $10.0 million relates to regulatory actions in the European Union (“EU”). The $45.0 million associated with future potential combination products relates solely to development and regulatory actions.

​

The Viatris Agreement is considered to be within the scope of ASC 808 and partially within the scope of ASC 606, as the parties are active participants and exposed to the risks and rewards of the collaborative activity with a unit of account provided to Viatris as a customer. Under the terms of the Viatris Agreement, Viatris was responsible for reimbursement of the Company’s costs related to the registrational program up until the approval of the first new drug application in November 2018, thereafter, R&D expenses are shared. Performing R&D services for reimbursement is considered to be a collaborative activity under the scope of ASC 808. Reimbursable program costs are recognized proportionately with the performance of the underlying services and accounted for as reductions to R&D expense. For this unit of account, the Company did not recognize revenue or analogize to ASC 606 and, as such, the reimbursable program costs are excluded from the transaction price.

​

The Company determined the license to develop and commercialize revefenacin to be a unit of account and a separate performance obligation for which Viatris is a customer. The joint steering committee participation was also determined to be a performance obligation for which the Company analogized to ASC 606 to recognize revenue. Using the concepts from ASC 606, the Company further determined that the transaction price under the arrangement was comprised of the following: (1) $15.0 million upfront license fee received in 2015; (2) $4.2 million premium received in 2015 related to an ordinary share purchase agreement with Viatris; and (3) $15.0 million milestone for 50% enrollment in the Phase 3 twelve-month safety study received in 2016. The total transaction price of $34.2 million was allocated to

95

[Table of Contents](#TOC)

the two performance obligations based on the Company’s best estimate of the relative stand-alone selling prices. For the delivery of the license, the Company based the stand-alone selling price on a discounted cash flow approach and considered several factors including, but not limited to: discount rate, development timeline, regulatory risks, estimated market demand and future revenue potential. For the committee participation, the Company based the stand-alone selling price on the average compensation of its committee members estimated to be incurred over the performance period. The Company expects to recognize collaboration revenue from the committee participation ratably over the performance period of approximately seventeen years.

​

The future potential milestone amounts for the Viatris Agreement were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606. As part of the Company’s evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals which are not within its control and uncertain at this stage. The Company expects that the sales-based milestone payments and royalty arrangements will be recognized when the sales occur or the milestone is achieved. The Company will re-evaluate the transaction price each quarter and as uncertain events are resolved or other changes in circumstances occur.

​

As of December 31, 2020, $0.3 million was recorded in deferred revenue on the consolidated balance sheets related to the Viatris Agreement. This amount reflects revenue allocated to joint steering committee participation which will be recognized as collaboration revenue over the course of the remaining performance period of approximately eleven years.

​

The Company is also entitled to a share of US profits and losses (65% to Viatris; 35% to Theravance Biopharma) received in connection with commercialization of YUPELRI, and the Company is entitled to low double-digit tiered royalties on ex-US net sales. Viatris is the principal in the sales transactions, and as a result, the Company does not reflect the product sales in its consolidated financial statements.

​

Following the US Food and Drug Administration (“FDA”) approval of YUPELRI in November 2018, net amounts payable to or receivable from Viatris each quarter under the profit-sharing structure are disaggregated according to their individual components. In accordance with the applicable accounting guidance, amounts receivable from Viatris in connection with the commercialization of YUPELRI are recorded within the consolidated statements of operations as revenue from “Viatris collaboration agreement” irrespective of whether the overall collaboration is profitable. Amounts payable to Viatris in connection with the commercialization of YUPELRI are recorded within the consolidated statements of operations as a collaboration loss within selling, general and administrative expenses. Any reimbursement from Viatris attributed to the 65% cost-sharing of the Company’s R&D expenses is characterized as a reduction of R&D expense, as the Company does not consider performing research and development services for reimbursement to be a part of its ordinary activities.

​

The following YUPELRI-related amounts were recognized within revenue and selling, general and administrative expense in the Company’s consolidated statements of operations:

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | | | | | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | |
| **(In thousands)** | ​ | **2020** | | ​ | **2019** | | ​ | **2018** | |
| Viatris collaboration agreement - *Amounts receivable from Viatris* | **​** | $ | 43,893 | ​ | $ | 13,664 | ​ | $ | 3,275 |
| Collaboration loss - *Amounts payable to Viatris* | ​ | $ | — | ​ | $ | 1,582 | ​ | $ | 2,997 |

​

Prior to the FDA approval of YUPELRI in late 2018, the Company recognized its 35% share of expenses within R&D expense and selling, general and administrative expense on its consolidated statements of operations.

​

While Viatris records the total net sales of YUPELRI within its consolidated financial statements, Viatris collaboration agreement revenue includes the Company’s implied 35% share of net sales of YUPELRI for the year ended December 31, 2020, 2019, and 2018 of $50.0 million, $19.3 million, $3.7 million, respectively.

**​**

96

[Table of Contents](#TOC)

***Alfasigma***

Under an October 2012 development and collaboration agreement for velusetrag, the Company and Alfasigma S.p.A (“Alfasigma”) agreed to collaborate in the execution of a two-part Phase 2 program to test the efficacy, safety and tolerability of velusetrag in the treatment of patients with gastroparesis (a medical condition consisting of a paresis (partial paralysis) of the stomach, resulting in food remaining in the stomach for a longer time than normal) (the “Alfasigma Agreement”). As part of the Alfasigma Agreement, Alfasigma funded the majority of the costs associated with the Phase 2 gastroparesis program, which consisted of a Phase 2 study focused on gastric emptying and a Phase 2 study focused on symptoms. Alfasigma had an exclusive option to develop and commercialize velusetrag in the EU, Russia, China, Mexico and certain other countries, while the Company retained full rights to velusetrag in the US, Canada, Japan and certain other countries.

​

In April 2018, Alfasigma exercised its exclusive option to develop and commercialize velusetrag, and the Company elected not to pursue further development of velusetrag. As a result, the Companyis transferring global rights for velusetrag to Alfasigma under the terms of the existing collaboration agreement. The Company received a $10.0 million option exercise fee and a $1.0 million non-refundable reimbursement from Alfasigma, and the Company is eligible to receive future potential development, regulatory and sales milestone payments of up to $26.8 million and tiered royalties on global net sales ranging from high single digits to the mid-teens.

​

The Alfasigma Agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company has historically received reimbursements related to R&D services performed under the Alfasigma Agreement. Performing R&D services for reimbursement is considered to be a collaborative activity under the scope of ASC 808. Reimbursable program costs are accounted for as reductions to R&D expense. For this unit of account, the Company does not recognize revenue or analogize to ASC 606 and, as such, the reimbursable program costs are excluded from the transaction price.

​

As a result of Alfasigma’s election to exercise its exclusive option to develop and commercialize velusetrag in April 2018, Alfasigma paid the Company a total of $11.0 million, comprised of the $10.0 million option exercise fee and the $1.0 million non-refundable reimbursement. The Company analogized to ASC 606 for the delivery of the following identified performance obligations: (i) delivery of the velusetrag license; (ii) transfer of technical know-how; (iii) delivery of clinical study reports (“CSRs”); (iv) delivery of registration batches, including drug substances; and (v) joint steering committee participation. The Company determined that all of the five performance obligations were distinct, and it allocated the transaction price based on the estimated stand-alone selling prices of each of the performance obligations. The stand-alone selling price of the license was based on a discounted cash flow approach and considered several factors including, but not limited to: discount rate, development timeline, regulatory risks, estimated market demand and future revenue potential.

​

The Company determined that any potential development or regulatory milestones were to be fully constrained as prescribed under ASC 606. As part of its evaluation of this variable consideration constraint, the Company determined that the potential payments are contingent upon developmental and regulatory milestones that are uncertain and are highly susceptible to factors outside of the Company’s control. In addition, the Company expects that any consideration related to sales-based milestones would be recognized when the subsequent sales occur.

​

For the year ended December 31, 2019, and 2018, the Company recognized $0.1 million and $10.7 million, respectively, as revenue from collaboration arrangements related to the Alfasigma Agreement. There was a minimal amount of collaboration revenue recognized related to the Alfasigma Agreement for the year ended December 31, 2020, and as of December 31, 2020, $0.2 million remains in deferred revenue on the consolidated balance sheets and is expected to be recognized as collaboration revenue over approximately the next six years.

​

***Reimbursement of R&D Expenses***

As noted above, under certain collaborative arrangements the Company is entitled to reimbursement of certain R&D expenses. Activities under collaborative arrangements for which the Company is entitled to reimbursement are considered to be collaborative activities under the scope of ASC 808. For these units of account, the Company does not

97

[Table of Contents](#TOC)

analogize to ASC 606 or recognize revenue. The Company records reimbursement payments received from its collaboration partners as reductions to R&D expense.

​

The following table summarizes the reductions to R&D expenses related to reimbursement payments:

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | | | | | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | |
| **(In thousands)** |  | **2020** | |  | **2019** | | ​ | **2018** | |
| Janssen | **​** | $ | 8,554 | **​** | $ | 5,129 | ​ | $ | 1,597 |
| Viatris | **​** | ​ | 1,524 | **​** | ​ | 460 | ​ | ​ | 7,515 |
| Total reduction to R&D expense, net | ​ | $ | 10,078 | ​ | $ | 5,589 | ​ | $ | 9,112 |

​

***Revenue from Licensing Arrangements***

***​***

***Viatris***

In June 2019, the Company announced the expansion of the Viatris Agreement (the “Viatris Amendment”) to grant Viatris exclusive development and commercialization rights to nebulized revefenacin in China and adjacent territories. In exchange, the Company received an upfront payment of $18.5 million (before a required tax withholding) and will be eligible to receive potential development and sales milestones totaling $54.0 million and low double-digit tiered royalties on net sales of nebulized revefenacin, if approved. Of the $54.0 million in potential milestones, $9.0 million is associated with the development of YUPELRI monotherapy, $7.5 million associated with the development of future potential combination products, and $37.5 million is associated with sales milestones. Viatris is responsible for all aspects of development and commercialization in the partnered regions, including pre- and post-launch activities and product registration and all associated costs.

​

The Viatris Amendment is accounted for under ASC 606 as a separate contract from the original Viatris Agreement that was entered into in January 2015. The Company identified a single performance obligation comprising of the delivery of the license to develop and commercialize revefenacin in China and adjacent territories. The transaction price was determined to be the upfront payment of $18.5 million which the Company recognized as licensing revenue following the completion of the performance obligation in June 2019.

​

The future potential milestone amounts for the Viatris Amendment were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606. As part of the Company’s evaluation of the development milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals which are not within its control and uncertain at this stage. The Company expects that the sales-based milestone payments and royalty arrangements will be recognized when the sales occur or the milestone is achieved. The Company will re-evaluate the transaction price each quarter and as uncertain events are resolved or other changes in circumstances occur.

​

In March 2020, the Company earned a $1.5 million development milestone payment for the acceptance of a clinical trial application associated with the use of YUPELRI monotherapy in China and adjacent territories.

​

***Pfizer***

In December 2019, the Company entered into a global license agreement with Pfizer Inc. for its preclinical skin-selective, locally-acting pan-JAK inhibitor program (the “Pfizer Agreement”). The compounds in this program are designed to target validated pro-inflammatory pathways and are specifically designed to possess skin-selective activity with minimal systemic exposure.

​

Under the Pfizer Agreement, Pfizer has an exclusive license to develop, manufacture and commercialize certain compounds for all uses other than gastrointestinal, ophthalmic and respiratory applications. Under the terms of the Pfizer Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive up to an additional $240.0 million in development and sales milestone payments from Pfizer. In addition, the Company will be eligible to receive a tiered royalty on worldwide net sales of any potential products under the license at percentage royalty rates ranging from middle single-digits to low double-digits.

**​**

98

[Table of Contents](#TOC)

The Pfizer Agreement is accounted for under ASC 606. The Company identified two performance obligations primarily comprised of the delivery of the license and samples of tangible materials which was completed in December 2019. The transaction price was determined to be the upfront payment of $10.0 million which the Company recognized as licensing revenue in December 2019.

​

The future potential milestones payable under the Pfizer Amendment were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606. As part of the Company’s evaluation of the development milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals which are not within its control and uncertain at this stage. The Company expects that the sales-based milestone payments will be recognized when the sales occur or the milestone is achieved. The Company will re-evaluate the transaction price each quarter and as uncertain events are resolved or other changes in circumstances occur.

​

​

**3. Sale of VIBATIV**

On November 12, 2018, the Company completed the sale of its assets related to the manufacture, marketing and sale of VIBATIV to Cumberland pursuant to the Asset Purchase Agreement dated November 1, 2018 (the “APA”). Under the APA, Cumberland paid the Company $20.0 million at the closing of the transaction and $5.0 million in April 2019. In addition, Cumberland pays the Company tiered royalties of up to 20% of US net sales of VIBATIV until such time as royalties cumulatively total $100.0 million.

​

In connection with the closing of the transaction, Cumberland acquired, among other things, (i) intellectual property rights relating to VIBATIV; (ii) active pharmaceutical ingredient for VIBATIV, work-in-process and finished drug product; (iii) the US marketing authorization for VIBATIV; (iv) certain assigned contracts relating to the manufacture and commercialization of VIBATIV; and (v) books and records related to VIBATIV. Cumberland also assumed certain clinical study obligations related to VIBATIV and certain post-closing liabilities and obligations as described in the APA.

The Company retained financial responsibility for any liabilities relating to products sold prior to the closing of the transaction, and Cumberland assumed financial responsibility for any liabilities relating to products sold on or after the closing of the transaction. The Company agreed to provide transition services to Cumberland for limited periods of time following the closing of the transaction. The Company has also agreed for a limited period not to engage in specified activities that would compete with the manufacture, marketing and sale of VIBATIV.

​

The Company recognized a net gain of $6.1 million upon the sale of VIBATIV within “Interest and other income, net” in the consolidated statements of operations for the year ended December 31, 2018. Transition-related costs of $1.1 million were recognized concurrently and included as a reduction to the net gain on the sale. The Company records the royalties receivable from US net sales by Cumberland within the same “Interest and other income, net”.

**​**

**4. Segment Information**

The Company operates in a single segment, which is the discovery (research), development and commercialization of human therapeutics. The following table summarizes total revenue by geographic region:

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| ​ | ​ | **Year Ended December 31,** | | | | | | | |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | |
| US | ​ | $ | 70,319 | ​ | $ | 54,760 | ​ | $ | 49,239 |
| Europe | ​ |  | 1,538 | ​ | ​ | 18,654 | ​ |  | 11,117 |
| Asia | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 14 |
| Total revenue | ​ | $ | 71,857 | ​ | $ | 73,414 | ​ | $ | 60,370 |

​

99

[Table of Contents](#TOC)

The following table summarizes total revenue from each of the Company’s customers or collaboration partners who individually accounted for 10% or more of total revenue (as a percentage of total revenues) during the most recent three years:

​

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| ​ | ​ | **Year Ended December 31,** | | | | | ​ |
| **(% of total revenue)** |  | **2020** |  | **2019** |  | **2018** | ​ |
| Viatris | ​ | 63 | % | 44 | % | — | ​ |
| Janssen | ​ | 37 | % | 42 | % | 51 | % |
| Pfizer | ​ | — | ​ | 14 | % | — | ​ |
| Alfasigma | ​ | — | ​ | — | ​ | 18 | % |

​

​

**5. Cash, Cash Equivalents, and Restricted Cash**

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the current period and comparable prior year period consolidated balance sheets that sum to the total of the same such amounts shown on the consolidated statements of cash flows.

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **December 31,** | | | | | | | |
| **(In thousands)** | **​** | **2020** | | **​** | **2019** | | ​ | **2018** | |
| Cash and cash equivalents | ​ | $ | 81,467 | ​ | $ | 58,064 | ​ | $ | 378,021 |
| Restricted cash | ​ | ​ | 833 | ​ | ​ | 833 | ​ | ​ | 833 |
| Total cash, cash equivalents, and restricted cash shown on the  consolidated statements of cash flows | ​ | $ | 82,300 | ​ | $ | 58,897 | ​ | $ | 378,854 |

​

The Company maintains restricted cash for certain lease agreements and letters of credit by which the Company has pledged cash and cash equivalents as collateral. As of December 31, 2020, the Company also maintained restricted cash for debt servicing of its 9.5% non-recourse 2035 notes. See *“Note 7. Debt”* for further information regarding the 9.5% non-recourse 2035 notes. The cash-related amounts reported in the table above exclude the Company’s investments in short and long-term marketable securities that are reported separately on the consolidated balance sheets.

**​**

**​**

**6. Investments and Fair Value Measurements**

***Available-for-Sale Securities***

The estimated fair value of marketable securities is based on quoted market prices for these or similar investments obtained from a commercial pricing service. The fair market value of marketable securities classified within Level 1 is based on quoted prices for identical instruments in active markets. The fair value of marketable securities classified within Level 2 is based on quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-driven valuations whose inputs are observable or whose significant value drivers are observable. Observable inputs may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications.

​

100

[Table of Contents](#TOC)

Available-for-sale securities are summarized below:

​

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | **​** | **December 31, 2020** | | | | | | | | | | |
| **​** |  | **​** |  | **​** | **​** |  | **Gross** | |  | **Gross** | |  | **​** | **​** |
| **​** | **​** | **​** | **​** | **Amortized** | | **​** | **Unrealized** | | **​** | **Unrealized** | | **​** | **Estimated** | |
| **(In thousands)** | **​** | **​** | **​** | **Cost** | | **​** | **Gains** | | **​** | **Losses** | | **​** | **Fair Value** | |
| US government securities | ​ | Level 1 | ​ | $ | 75,036 | ​ | $ | 34 | ​ | $ | — | ​ | $ | 75,070 |
| US government agency securities | ​ | Level 2 | ​ |  | 74,971 | ​ | ​ | 18 | ​ | ​ | — | ​ |  | 74,989 |
| Corporate notes | ​ | Level 2 | ​ |  | 5,046 | ​ | ​ | — | ​ | ​ | (1) | ​ |  | 5,045 |
| Commercial paper | ​ | Level 2 | ​ | ​ | 56,374 | ​ | ​ | 1 | ​ | ​ | (5) | ​ | ​ | 56,370 |
| Marketable securities | ​ | ​ | ​ | ​ | 211,427 | ​ | ​ | 53 | ​ | ​ | (6) | ​ | ​ | 211,474 |
| Money market funds | ​ | Level 1 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — |
| Total | ​ | ​ | ​ | $ | 211,427 | ​ | $ | 53 | ​ | $ | (6) | ​ | $ | 211,474 |

​

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | **​** | **December 31, 2019** | | | | | | | | | | |
| **​** |  | **​** |  | **​** | **​** |  | **Gross** | |  | **Gross** | |  | **​** | **​** |
| **​** | **​** | **​** | **​** | **Amortized** | | **​** | **Unrealized** | | **​** | **Unrealized** | | **​** | **Estimated** | |
| **(In thousands)** | **​** | **​** | **​** | **Cost** | | **​** | **Gains** | | **​** | **Losses** | | **​** | **Fair Value** | |
| US government securities | ​ | Level 1 | ​ | $ | 100,746 | ​ | $ | 108 | ​ | $ | — | ​ | $ | 100,854 |
| Corporate notes | ​ | Level 2 | ​ |  | 25,466 | ​ |  | 9 | ​ |  | (1) | ​ |  | 25,474 |
| Commercial paper | ​ | Level 2 | ​ | ​ | 112,066 | ​ | ​ | 31 | ​ | ​ | (2) | ​ | ​ | 112,095 |
| Marketable securities | ​ | ​ | ​ | ​ | 238,278 | ​ | ​ | 148 | ​ | ​ | (3) | ​ | ​ | 238,423 |
| Money market funds | ​ | Level 1 | ​ | ​ | 35,736 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 35,736 |
| Total | ​ | ​ | ​ | $ | 274,014 | ​ | $ | 148 | ​ | $ | (3) | ​ | $ | 274,159 |

​

As of December 31, 2020, all of the Company’s available-for-sale securities had contractual maturities within 8 months and the weighted-average maturity of marketable securities was approximately 3 months. There were no transfers between Level 1 and Level 2 during the periods presented, and there have been no material changes to the Company’s valuation techniques during the year ended December 31, 2020 or 2019.

​

Available-for-sale debt securities with unrealized losses are summarized below:

​

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | ​ | **December 31, 2020** | | | | | | | | | | | | | | | | |
| **​** | **​** | **Less than 12 Months** | | | | | **​** | **Greater than 12 Months** | | | | | **​** | **Total** | | | | |
| **​** |  | **​** | **​** |  | **Gross** | | **​** | **​** |  | **​** | **Gross** | |  | **​** | **​** | **​** | **Gross** | |
| ​ | **​** | **Estimated** | | **​** | **Unrealized** | | **​** | **Estimated** | | **​** | **Unrealized** | | **​** | **Estimated** | | **​** | **Unrealized** | |
| **(In thousands)** | **​** | **Fair Value** | | **​** | **Losses** | | **​** | **Fair Value** | | **​** | **Losses** | | **​** | **Fair Value** | | **​** | **Losses** | |
| Corporate notes | ​ | $ | 5,045 | ​ | $ | (1) | ​ | $ | — | ​ | $ | — | ​ | $ | 5,045 | ​ | $ | (1) |
| Commercial paper | ​ | ​ | 39,375 | ​ | ​ | (5) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 39,375 | ​ | ​ | (5) |
| Total | ​ | $ | 44,420 | ​ | $ | (6) | ​ | $ | — | ​ | $ | — | ​ | $ | 44,420 | ​ | $ | (6) |

​

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| ​ | ​ | **December 31, 2019** | | | | | | | | | | | | | | | | |
| ​ | **​** | **Less than 12 Months** | | | | | **​** | **Greater than 12 Months** | | | | | **​** | **Total** | | | | |
| **​** |  | **​** | **​** |  | **Gross** | | **​** | **​** |  | **​** | **Gross** | |  | **​** | **​** | **​** | **Gross** | |
| ​ | **​** | **Estimated** | | **​** | **Unrealized** | | **​** | **Estimated** | | **​** | **Unrealized** | | **​** | **Estimated** | | **​** | **Unrealized** | |
| **(In thousands)** | **​** | **Fair Value** | | **​** | **Losses** | | **​** | **Fair Value** | | **​** | **Losses** | | **​** | **Fair Value** | | **​** | **Losses** | |
| Corporate notes | ​ | $ | 5,507 | ​ | $ | (1) | ​ | $ | — | ​ | $ | — | ​ | $ | 5,507 | ​ | $ | (1) |
| Commercial paper | ​ | ​ | 28,137 | ​ | ​ | (2) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 28,137 | ​ | ​ | (2) |
| Total | ​ | $ | 33,644 | ​ | $ | (3) | ​ | $ | — | ​ | $ | — | **​** | $ | 33,644 | ​ | $ | (3) |

​

The Company invests primarily in high credit quality and short-term maturity debt securities with the intent to hold such securities until maturity at par value. The Company does not intend to sell the investments that are currently in an unrealized loss position, and it is unlikely that it will be required to sell the investments before recovery of their amortized cost basis, which may be maturity. The Company reviewed its available-for-sale debt securities and determined that there were no credit-related losses to be recognized as of December 31, 2020.

101

[Table of Contents](#TOC)

As of December 31, 2020, the Company’s accumulated other comprehensive income on its consolidated balance sheets consisted of net unrealized gains or losses on available-for-sale investments. For the year ended December 31, 2020, the Company sold marketable securities for total proceeds of $19.9 million and recognized minimal net realized gains from the sales based on the specific identification method. For the year ended December 31, 2019 and 2018, the Company did not sell any of its marketable securities.

​

**7. Debt**

Debt consisted of the following liability components:

​

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **December 31,** | | | | |
| **(In thousands)** |  | **2020** | |  | **2019** | |
| 9.5% Non-Recourse 2035 Notes: | ​ | ​ | ​ | **​** | **​** | **​** |
| Principal amount | ​ | $ | 418,572 | **​** | $ | — |
| Less: 5% retained by the Company | ​ | ​ | (20,929) | **​** | **​** | — |
| Unamortized debt issuance costs - 9.5% Non-Recourse 2035 Notes | ​ |  | (3,847) | **​** | **​** | — |
| Unamortized debt issuance costs - Modified 9.0% Non-Recourse 2033 Notes | ​ | ​ | (1,589) | **​** | **​** | — |
| 3.25% Convertible 2023 Notes: | ​ | ​ | ​ | ​ | ​ | ​ |
| Principal amount | ​ | ​ | 230,000 | ​ | ​ | 230,000 |
| Unamortized debt issuance costs | ​ | ​ | (3,037) | ​ | ​ | (4,110) |
| 9.0% Non-Recourse 2033 Notes: | ​ |  | ​ | ​ |  | ​ |
| Principal amount | ​ | ​ | — | ​ | ​ | 247,734 |
| Less: 5% retained by the Company | ​ | ​ | — | ​ | ​ | (12,387) |
| Unamortized debt issuance costs | ​ | ​ | — | ​ | ​ | (6,196) |
| Total debt | ​ | $ | 619,170 | ​ | $ | 455,041 |

***​***

Debt interest expense consists of the following components:

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | |
| **(In thousands)** |  | **2020** | |  | **2019** | | **​** | **2018** | |
| Stated coupon interest | ​ | $ | 42,625 | ​ | $ | 28,811 | ​ | $ | 9,316 |
| Amortization of debt issuance costs | ​ | ​ | 1,960 | ​ | ​ | 3,051 | ​ | ​ | 1,166 |
| Total debt interest expense | ​ | $ | 44,585 | ​ | $ | 31,862 | ​ | $ | 10,482 |

​

***9.5% Non-Recourse Notes Due 2035***

​

On February 21, 2020, Theravance Biopharma R&D, Inc. (“Theravance R&D”), a wholly-owned subsidiary of the Company, and Triple Royalty Sub II LLC (the “Issuer II” or “Triple II”), a wholly-owned subsidiary of Theravance Biopharma R&D, entered into certain note purchase agreements (“Note Purchase Agreements”) with certain note purchasers (“Note Purchasers”), relating to the private placement by Issuer II of $400.0 million 9.5% Fixed Rate Term Notes due on or before 2035 (the “Non-Recourse 2035 Notes”). Ninety-five percent of the Non-Recourse 2035 Notes were sold to the Note Purchasers pursuant to the Note Purchase Agreements. The remaining 5% of the Non-Recourse 2035 Notes (the “Retained Notes”) were retained by the Company to comply with Regulation RR — Credit Risk Retention (17 C.F.R. Part 246). The Retained Notes are eliminated in the Company’s consolidated financial statements. The transaction closed on February 28, 2020.

​

The Non-Recourse 2035 Notes are secured by all of Issuer II’s right, title and interest as a holder of certain membership interests (the “Issuer II Class C Units”) in Theravance Respiratory Company, LLC (“TRC”). TRC holds the right to receive upward-tiering royalties ranging from 6.5% to 10% on worldwide net sales of TRELEGY, and the Company holds an 85% economic interest in TRC. The Issuer II Class C Units represent 75% of the Company's 85% economic interest, which equates to 63.75% of the economic interests in TRC.

​

The source of principal and interest payments for the Non-Recourse 2035 Notes are the future royalty payments generated from the TRELEGY program, and as a result, the holders of the Non-Recourse 2035 Notes have no recourse against the Company even if the TRELEGY payments are insufficient to cover the principal and interest payments for

102

[Table of Contents](#TOC)

the Non-Recourse 2035 Notes. Prior to and including the December 5, 2024 payment date, in the event that the distributions received by the Issuer II from TRC in a quarter is less than the interest accrued for that quarter, the principal amount of the Non-Recourse 2035 Notes will increase by the interest shortfall amount for that quarter. The net principal amount of the Non-Recourse 2035 Notes increased by $17.6 million which represented the shortfall between the distributions received from TRC and the total interest payments due during the year ended December 31, 2020. While the holders of the Non-Recourse 2035 Notes have no recourse against the Company, the terms of the Non-Recourse 2035 Notes also provide that the Company, at its option, may satisfy the quarterly interest payment obligations by making a capital contribution to the Issuer II.

*​*

The Non-Recourse 2035 Notes are not convertible into Company equity and have no security interest in nor rights under any agreement with Glaxo Group Limited or one of its affiliates (“GSK”). See *“Note 9. Theravance Respiratory Company, LLC”* for further information regarding GSK. The Non-Recourse 2035 Notes may be redeemed by Issuer II on and after February 28, 2022, in whole or in part, at specified redemption premiums. The Non-Recourse 2035 Notes bear an annual interest rate of 9.5%, with interest and principal paid quarterly beginning June 5, 2020. Since the principal and interest payments on the Non-Recourse 2035 Notes are ultimately based on royalties from TRELEGY product sales, which will vary from quarter to quarter, the Non-Recourse 2035 Notes may be repaid prior to the final maturity date in 2035. Following the redemption or repayment of the Non-Recourse 2035 Notes, all TRELEGY-related pledged cash flows will revert back to the Company.

​

The portion of the Non-Recourse 2035 Notes classified as a current liability, if any, is based on the amount of royalties received, or receivable, as of December 31, 2020, that are expected to be used to make a principal repayment on the Non-Recourse 2035 Notes within the next 12 months.

​

As of December 31, 2020, the net principal and estimated fair value of the Non-Recourse 2035 Notes were $397.6 million and $399.6 million, respectively. The inputs to determine fair value of the Non-Recourse 2035 Notes are categorized as Level 2 inputs. Level 2 inputs include quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

​

***9.0% Non-Recourse Notes Due 2033***

In November 2018, the Company entered into note purchase agreements relating to the private placement of $250.0 million aggregate principal amount of 9.0% non-recourse notes, due on or before 2033 (the “Non-Recourse 2033 Notes”) issued by the Company’s wholly-owned subsidiary, Triple Royalty Sub LLC (the “Issuer”). On February 28, 2020, the Company refinanced the Non-Recourse 2033 Notes by issuing the Non-Recourse 2035 Notes and a portion of those proceeds were used to repay, in full, the remaining outstanding balance of the Company’s Non-Recourse 2033 Notes. Pursuant to the terms of the Non-Recourse 2033 Notes, the Company paid a debt redemption premium of 5% of the outstanding principal as of the refinancing date.

​

The refinancing of the Non-Recourse 2033 Notes involved multiple lenders who were considered members of a loan syndicate. To determine whether the refinancing was to be accounted for as a debt extinguishment or modification, the Company considered whether the lenders involved in the Non-Recourse 2033 Notes and the Non-Recourse 2035 Notes remained the same or changed and whether the change in debt terms was substantial. The debt terms are considered substantially different if the present value of the cash inflows and outflows of the Non-Recourse 2035 Notes, including all principal increases and lender fees on the refinancing date, was at least 10% different from the present value of the remaining cash inflows and outflows of the Non-Recourse 2033 Notes (the “10% Test”). The Company performed the 10% Test for each individual lender participating in the loan syndication by assuming the exercise and non-exercise of the prepayment option. The cash flow assumption generating the smaller change was used as the basis for determining whether the 10% threshold was met. For existing lenders who participated in the Non-Recourse 2035 Notes as part of the new loan syndicate, the refinancing was accounted for as an extinguishment or a modification depending upon whether the change in the cash flows was more or less than 10%, respectively. Amounts due to lenders of the Non-Recourse 2033 Note offering who did not participate in the Non-Recourse 2035 Notes were accounted for as a debt extinguishment.

​

103

[Table of Contents](#TOC)

For debt determined to be extinguished, the total unamortized deferred financing costs and the associated redemption premium of $15.5 million were expensed as “Loss on extinguishment of debt” within the consolidated statements of operations for the year ended December 31, 2020. In addition, $0.3 million of new third-party costs were expensed, and $4.4 million of new creditor fees were capitalized as debt discount. For debt determined to be modified, $0.5 million of new creditor fees were expensed, and the related unamortized deferred financing costs of $1.8 million, as of February 28, 2020, will continue to be amortized through the remaining term of the Non-Recourse 2035 Notes.

​

***3.25% Convertible Senior Notes Due 2023***

In November 2016, the Company completed an underwritten public offering of $230.0 million of 3.25% convertible senior notes, due 2023 (the "Convertible Senior 2023 Notes") for net proceeds of $222.5 million. The Company incurred $7.5 million in debt issuance costs, which are being amortized to interest expense over the estimated life of the Convertible Senior 2023 Notes. The Convertible Senior 2023 Notes bear an annual interest rate of 3.25%, payable semi-annually in arrears, on November 1 and May 1 of each year.

The Convertible Senior 2023 Notes are senior unsecured obligations and rank senior in right of payment to any of the Company’s indebtedness that is expressly subordinated in right of payment to the Convertible Senior 2023 Notes; equal in right of payment to any of the Company’s indebtedness that is not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of the Company’s subsidiaries.

The Convertible Senior 2023 Notes will mature on November 1, 2023, unless earlier redeemed or repurchased by the Company or converted. Holders may convert their Convertible Senior 2023 Notes into ordinary shares at an initial conversion rate of 29.0276 shares for each $1,000 principal amount of Convertible Senior 2023 Notes, which is equivalent to an initial conversion price of approximately $34.45 per share, subject to adjustment, in certain circumstances (including upon the occurrence of a fundamental change), at any time prior to the close of business on the second business day immediately preceding the maturity date. Upon the occurrence of a fundamental change involving the Company, holders of the Convertible Senior 2023 Notes may require the Company to repurchase all or a portion of their Convertible Senior 2023 Notes for cash at a redemption price equal to 100% of the principal amount of the Convertible Senior 2023 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, in some circumstances, the conversion rate of the Convertible Senior 2023 Notes will increase with a make whole premium for conversions in connection with certain fundamental changes.

The debt issuance costs related to the Convertible Senior 2023 Notes offering were capitalized as deferred financing costs and presented as a reduction of the carrying value of the financial liability on the Company’s consolidated balance sheets at December 31, 2020 and 2019.

The estimated fair value of the Convertible Senior 2023 Notes was $217.9 million and $236.0 million at December 31, 2020 and 2019, respectively. The estimated fair value was primarily based upon the underlying price of Theravance Biopharma’s publicly traded shares and other observable inputs as of December 31, 2020 and 2019. The inputs to determine fair value of the Convertible Senior 2023 Notes are categorized as Level 2 inputs. Level 2 inputs include quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

​

**8. Leases**

The Company leases approximately 170,000 square feet of office and laboratory space in two buildings in South San Francisco, California, under a non-cancelable operating lease that ends in May 2030 (“SSF Lease”). This lease includes a tenant improvement allowance that expires in May 2022 and had a remaining balance of $12.1 million and $15.6 million, as of December 31, 2020 and 2019, respectively. The Company’s Irish subsidiary leases approximately 6,100 square feet of office space in Dublin, Ireland under a lease that expires in April 2027 (“Dublin

104

[Table of Contents](#TOC)

Lease”). In addition, the Company leases equipment for clinical research studies with an estimated lease term ending in August 2022.

​

The SSF Lease contains two options to extend the term of the lease for successive periods of five years each, and the Dublin Lease contains a lease termination option in April 2024 at the Company’s discretion. The equipment lease has undergone extensions to the initial lease term due to delays in patient enrollment in the clinical trial, which the Company has characterized as lease modifications. The equipment lease contains options to terminate the agreements at the Company’s discretion. The two options to extend the SSF Lease and the options to terminate the Dublin Lease and equipment lease were not recognized in the determination of the Company’s right-of-use assets and lease liabilities below.

​

The Company has evaluated its leases and determined that they were all operating leases. The present values of the remaining lease payments and corresponding right-of-use assets were as follows, and the difference between the right-of-use assets and lease liabilities was due to office-related deferred rent payments that are payable in future periods.

​

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **(In thousands)** | **Classification** |  | **December 31, 2020** | |  | **December 31, 2019** | |
| Assets | **​** | **​** | **​** | **​** | **​** | **​** | **​** |
| Operating lease assets | Operating lease assets | ​ | $ | 43,260 | ​ | $ | 46,604 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Liabilities | **​** | **​** | **​** | **​** | **​** | **​** | **​** |
| *Current:* | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Operating lease liabilities | Operating lease liabilities | ​ | $ | 9,867 | ​ | $ | 7,762 |
| *Non-current:* | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Operating lease liabilities | Long-term operating lease liabilities | ​ |  | 47,220 | ​ |  | 47,725 |
| Total operating lease liabilities | ​ | ​ | $ | 57,087 | ​ | $ | 55,487 |

​

Lease expense was included within operating expenses in the consolidated statements of operations as follows:

​

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | **Year Ended** | | **​** | **Year Ended** | | ​ | **Year Ended** | |
| **(In thousands)** | **Classification** |  | **December 31, 2020** | |  | **December 31, 2019** | |  | **December 31, 2018** | |
| Operating lease expense | Selling, general and administrative expense | ​ | $ | 7,974 | ​ | $ | 7,959 | ​ | $ | 7,985 |
| Operating lease expense | Research and development expense | ​ | ​ | 758 | ​ | ​ | 164 | ​ | ​ | — |
| Total operating lease expense (1) | ​ | ​ | $ | 8,732 | ​ | $ | 8,123 | ​ | $ | 7,985 |

|  |  |
| --- | --- |
| (1) | Excludes short-term leases which were immaterial and office lease service-related charges. |

​

Cash paid for amounts included in the measurement of lease liabilities was as follows:

​

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | **Year Ended** | | ​ | **Year Ended** | |
| **(In thousands)** | **​** |  | **December 31, 2020** | |  | **December 31, 2019** | |
| Cash paid for amounts included in the measurement of lease liabilities | **​** | **​** | **​** | **​** | ​ | **​** | **​** |
| Operating cash flows from operating leases | **​** | **​** | $ | 3,804 | ​ | $ | 7,210 |

​

105

[Table of Contents](#TOC)

As of December 31, 2020, the maturities of the Company’s lease liabilities were as follows:

​

​

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ |
| **(In thousands)** | ​ | ​ | ​ | ​ |
| Year ending December 31: | ​ |  | ​ | ​ |
| 2021 | ​ | ​ | $ | 10,330 |
| 2022 | ​ | ​ | ​ | 10,345 |
| 2023 | ​ | ​ | ​ | 10,134 |
| 2024 | ​ | ​ | ​ | 10,351 |
| 2025 | ​ | ​ | ​ | 10,649 |
| Thereafter | ​ | ​ | ​ | 49,309 |
| Total operating lease payments | ​ | ​ | $ | 101,118 |
| Less: Estimated tenant improvement allowance | ​ | ​ | ​ | (12,053) |
| Less: Imputed interest | ​ | ​ | ​ | (31,978) |
| Present value of operating lease liabilities | ​ | ​ | $ | 57,087 |

​

As of December 31, 2020, the weighted-average remaining lease term was 9.1 years, and the weighted-average discount rate used to determine the lease liabilities was 8.64%. The Company’s discount rate was primarily derived from the 9.0% interest rate on its previously issued Non-Recourse 2033 Notes in November 2018 and did not involve any significant assumptions.

​

**9. Theravance Respiratory Company, LLC**

Through the Company’s 85% equity interest in TRC, the Company is entitled to receive an 85% economic interest in any future payments made by GSK under the strategic alliance agreement and under the portion of the collaboration agreement assigned to TRC (net of TRC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters). The primary drug program assigned to TRC is Trelegy.

​

In May 2014, the Company entered into the TRC LLC Agreement with Innoviva, Inc. (“Innoviva”) that governs the operation of TRC. Under the TRC LLC Agreement, Innoviva is the manager of TRC, and the business and affairs of TRC are managed exclusively by the manager, including (i) day to day management of the drug programs in accordance with the existing GSK agreements; (ii) preparing an annual operating plan for TRC; and (iii) taking all actions necessary to ensure that the formation, structure and operation of TRC complies with applicable law and partner agreements. The Company is responsible for its proportionate share of TRC’s administrative expenses incurred, and communicated to the Company, by Innoviva.

​

The Company analyzed its ownership, contractual and other interests in TRC to determine if it is a variable-interest entity (“VIE”), whether the Company has a variable interest in TRC and the nature and extent of that interest. The Company determined that TRC is a VIE. The party with the controlling financial interest, the primary beneficiary, is required to consolidate the entity determined to be a VIE. Therefore, the Company also assessed whether it is the primary beneficiary of TRC based on the power to direct TRC’s activities that most significantly impact TRC’s economic performance and its obligation to absorb TRC’s losses or the right to receive benefits from TRC that could potentially be significant to TRC. Based on the Company’s assessment, the Company determined that it is not the primary beneficiary of TRC, and, as a result, the Company does not consolidate TRC in its consolidated financial statements. TRC is recognized in the Company’s consolidated financial statements under the equity method of accounting.

​

For the year ended December 31, 2020, 2019, and 2018, the Company recognized net royalty income of $68.4 million, $33.7 million, and $11.2 million, respectively, within the consolidated statements of operations within “Income from investment in TRC, LLC”. These amounts were recorded net of the Company’s share of TRC’s expenses of $2.2 million, $2.7 million for the year ended December 31, 2020 and 2019, respectively. There were minimal TRC expenses for the year ended December 31, 2018. The Company’s share of TRC expenses for 2020 and 2019 was primarily comprised of TRC legal and related fees associated with the arbitration between Innoviva, TRC and the Company.

​

106

[Table of Contents](#TOC)

As of December 31, 2020, the amounts due from TRC were $53.8 million which were primarily comprised of (i) net royalty income payments for the period from the first quarter of 2020 through the fourth quarter of 2020 and (ii) $8.5 million representing the Company’s share of the one-time fee that GSK paid to TRC upon termination of the inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist (“MABA”) program in June 2020. The total amounts due, as of December 31, 2020, were net of a $2.5 million payment received from Innoviva in the fourth quarter of 2020 and have been recorded as a current asset in the consolidated balance sheets within “Amounts due from TRC, LLC”. In January 2021, the Company received an additional $21.3 million payment from Innoviva related to the receivable balance as of December 31, 2020.

​

TRC’s summary financial information was as follows as of or for the year ended December 31:

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **(In thousands)** |  | **2020** | |  | **2019** | | ​ | **2018** | |
| Current assets | ​ | $ | 63,027 | ​ | $ | 36,737 | ​ | ​ | ​ |
| Non-current assets | ​ | ​ | 16,959 | ​ | ​ | — | ​ | ​ | ​ |
| Current liabilities | ​ | ​ | 508 | ​ | ​ | 3,069 | ​ | ​ | ​ |
| Royalty revenue for the year ended | ​ | ​ | 73,089 | ​ | ​ | 42,790 | ​ | $ | 13,379 |
| Revenue from collaborative arrangements for the year ended | ​ | ​ | 10,000 | ​ | ​ | — | ​ | ​ | — |
| Income from continuing operations and net income for the year ended | ​ | $ | 81,662 | ​ | $ | 39,653 | ​ | $ | 13,261 |

​

On June 10, 2020, the Company disclosed in a Form 8-K that it had formally objected to TRC and Innoviva, as the manager of TRC, regarding their proposed plan to use TRELEGY royalties to invest in certain privately-held companies, funds that would otherwise be available for distribution to the Company under the terms of the TRC LLC Agreement. In October 2020, Innoviva announced that TRC had invested $15.0 million of TRELEGY royalties in the equity securities of a privately held biopharmaceutical company. Consequently, the Company’s share of this investment of $12.8 million has been recorded as a long-term asset in the consolidated balance sheets under “Equity in net assets of TRC, LLC”. However, in October 2020, the Company initiated an arbitration proceeding against Innoviva and TRC challenging the authority of Innoviva and TRC to pursue such a business plan rather than distribute such funds to the Company in a manner consistent with the TRC LLC Agreement and the Company’s 85% economic interest in TRC. The arbitration hearing was held during the week of February 16, 2021, with post-hearing briefing and arguments to take place over the next few weeks. The Company currently anticipates a decision in those proceedings near the end of the first quarter or early in the second quarter of 2021.

​

**​**

**10.** **Property and Equipment**

Property and equipment are held predominantly in the US and consisted of the following:

​

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **December 31,** | | | | |
| **(In thousands)** |  | **2020** | |  | **2019** | |
| Computer equipment | ​ | $ | 2,314 | ​ | $ | 2,119 |
| Software | ​ | ​ | 2,076 | ​ | ​ | 1,718 |
| Furniture and fixtures | ​ | ​ | 3,812 | ​ | ​ | 3,665 |
| Laboratory equipment | ​ | ​ | 29,753 | ​ | ​ | 30,546 |
| Leasehold improvements | ​ | ​ | 24,275 | ​ | ​ | 22,164 |
| Subtotal | ​ | ​ | 62,230 | ​ | ​ | 60,212 |
| Less: accumulated depreciation | ​ | ​ | (45,808) | ​ | ​ | (47,568) |
| Property and equipment, net | ​ | $ | 16,422 | ​ | $ | 12,644 |

​

For the year ended December 31, 2020, 2019 and 2018, depreciation expense for property and equipment was $3.3 million, $3.3 million and $3.0 million, respectively.

​

​

107

[Table of Contents](#TOC)

**11. Share-Based Compensation**

***Theravance Biopharma Equity Plans***

The Company has three equity compensation plans — its 2013 Equity Incentive Plan (the “2013 EIP”), its 2013 Employee Share Purchase Plan (the “2013 ESPP”) and its 2014 New Employee Equity Incentive Plan (the “2014 NEEIP”). At inception, the Company was authorized to issue 5,428,571 ordinary shares under the 2013 EIP, 857,142 ordinary shares under the 2013 ESPP, and 750,000 ordinary shares under the 2014 NEEIP.

​

The 2013 EIP provides for the issuance of share-based awards, including restricted shares, restricted share units, options, share appreciation rights (“SARs”) and other equity-based awards, to Company employees, officers, directors and consultants. As of January 1 of each year, commencing on January 1, 2015 and ending on (and including) January 1, 2023, the aggregate number of ordinary shares that may be issued under the 2013 EIP shall automatically increase by a number equal to the least of 5% of the total number of ordinary shares outstanding on December 31 of the prior year, 3,428,571 ordinary shares, or a number of ordinary shares determined by the Company’s board of directors. Options may be granted with an exercise price not less than the fair market value of the ordinary shares on the grant date. Under the terms of the Company’s 2013 EIP, options granted to employees generally have a maximum term of 10 years and vest over a four-year period from the date of grant; 25% vest at the end of one year, and 75% vest monthly over the remaining three years. The Company may grant options with different vesting terms from time to time. Unless an employee’s termination of service is due to disability or death, upon termination of service, any unexercised vested options will generally be forfeited at the end of three months or the expiration of the option, whichever is earlier.

​

Under the 2013 ESPP, the Company’s officers and employees may purchase ordinary shares through payroll deductions at a price equal to 85% of the lower of the fair market value of the ordinary share at the beginning of the offering period or at the end of each applicable purchase period. As of January 1 of each year, commencing on January 1, 2015 and ending on (and including) January 1, 2033, the aggregate number of ordinary shares that may be issued under the 2013 ESPP shall automatically increase by a number equal to the least of 1% of the total number of ordinary shares outstanding on December 31 of the prior year, 571,428 ordinary shares or a number of ordinary shares determined by the Company’s board of directors. The ESPP generally provides for consecutive and overlapping offering periods of 24 months in duration, with each offering period generally composed of four consecutive six-month purchase periods. The purchase periods end on either May 15 or November 15. ESPP contributions are limited to a maximum of 15% of an employee’s eligible compensation. The 2013 ESPP also includes a feature that provides for the existing offering period to terminate and for participants in that offering period to automatically be enrolled in a new offering period when the fair market value of an ordinary share at the beginning of a subsequent offering period falls below the fair market value of an ordinary share on the first day of such offering period.

​

The 2014 NEEIP provides for the issuance of share-based awards, including restricted shares, restricted share units, non-qualified options and SARs, to the Company’s employees. Options may be granted with an exercise price not less than the fair market value of the ordinary shares on the grant date. Under the terms of the 2014 NEEIP, options granted to employees generally have a maximum term of 10 years and vest over a four-year period from the date of grant; 25% vest at the end of one year, and 75% vest monthly over the remaining three years. The Company may grant options with different vesting terms from time to time. Unless an employee’s termination of service is due to disability or death, upon termination of service, any unexercised vested options will generally be forfeited at the end of three months or the expiration of the option, whichever is earlier.

​

***Innoviva’s Equity Plans***

Prior to the spin-off from its former parent company, Innoviva, in 2014 (“Spin-Off”), the Company’s employees may have received Innoviva stock-based compensation awards, and, therefore, the following disclosures include information regarding stock-based compensation expense allocated to Theravance Biopharma that relates to Innoviva stock-based equity awards.

​

At the time of the Spin-Off, Innoviva had one active stock-based incentive plan under which it granted stock-based awards to employees, officers and consultants, the 2012 Equity Incentive Plan. All outstanding stock options and restricted stock units (“RSUs”) held by (i) Innoviva employees who became the Company’s employees; and (ii) members of the board of directors of Innoviva who became members of the Company’s board of directors, in

108

[Table of Contents](#TOC)

connection with the Spin-Off were adjusted for the Spin-Off. Such awards, along with outstanding restricted stock awards (“RSAs”) held by Innoviva employees who became the Company’s employees in connection with the Spin-Off, will continue to vest and remain outstanding based on continuing employment or service with the Company.

​

The 2012 Equity Incentive Plan provided for the grant of incentive stock options, non-statutory stock options, restricted stock awards, stock unit awards and SARs to employees, non-employee directors and consultants. Stock options were granted with an exercise price not less than the fair market value of the common stock on the grant date. Stock options granted to employees generally have a maximum term of 10 years and vest over a four-year period from the date of grant; 25% vest at the end of one year, and 75% vest monthly over the remaining three years. However, Innoviva granted options with different vesting terms from time to time. Unless an employee’s termination of service is due to disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of three months or the expiration of the option, whichever is earlier.

​

***Performance-Contingent Awards***

In 2016, the Compensation Committee of the Company’s board of directors (“Compensation Committee”) approved the grant of 1,575,000 performance-contingent restricted share awards (“RSAs”) and 135,000 performance-contingent restricted share units (“RSUs”) to senior management. The vesting of such awards is dependent on the Company meeting its critical operating goals and objectives during the five-year period from 2016 to December 31, 2020, as well as, continued employment. The goals that must be met in order for the performance-contingent RSAs and RSUs to vest are strategically important for the Company, and the Compensation Committee believes the goals should increase shareholder value. The awards have dual triggers of vesting based upon the achievement of these goals and continued employment.

​

Expense associated with these awards may be recognized during the years 2016 to 2020 depending on the probability of meeting certain performance conditions. Compensation expense relating to awards subject to performance conditions is recognized if it is considered probable that the performance goals will be achieved. The probability of achievement is reassessed at each quarter-end reporting period. Previously recognized expense is reversed in the period in which it becomes probable that the requisite service period will not be rendered. The awards are broken into three separate tranches and comprised of a share-based award component and a cash bonus award component. See *“Note 13. Commitments and Contingencies”* for information related to the cash bonus award component.

​

As of December 31, 2020, there were 414,000 of these performance-contingent RSAs and 54,000 of these performance-contingent RSUs outstanding, and as of December 31, 2019, there were 776,250 of these performance-contingent RSAs and 101,250 of these performance-contingent RSUs outstanding. The performance conditions associated with the first tranche of these awards were completed in the second quarter of 2018, and the Company recognized $1.7 million of share-based compensation expense for the year ended December 31, 2018 associated with the first tranche of these awards.

​

The performance conditions associated with the second tranche of these awards were completed in the first quarter of 2019, and the expense associated with this second tranche was fully recognized in the first quarter of 2020. For the year ended December 31, 2020, 2019 and 2018, the Company recognized $0.4 million, $1.9 million and $2.6 million, respectively, of share-based compensation expense related to the second tranche of these awards.

​

In the first quarter of 2020, the performance conditions associated with the remaining third tranche were completed and, as a result, the Company recognized $2.6 million in share-based compensation expense related to these awards for the year ended December 31, 2020. As of December 31, 2020, the maximum remaining expense associated with the third tranche was $0.4 million (allocated as $0.1 million for research and development expense and $0.3 million for selling, general and administrative expense) and will be amortized through the first quarter of 2021.

​

Separate from the performance-contingent awards described above, the Company periodically grants performance-contingent RSUs to individual employees. For the year ended December 31, 2020 and 2019, the Company recognized $1.0 million of share-based compensation expense related to such awards in each year. As of December 31, 2020, there were 70,000 shares of these performance-contingent RSUs outstanding that have a maximum remaining share-based compensation expense of $0.5 million with performance expiration dates through June 2022.

109

[Table of Contents](#TOC)

***​***

***Share-Based Compensation Expense***

Share-based compensation expense included in the consolidated statements of operations was recognized as follows:

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **​** | | | | | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | |
| **(In thousands)** |  | **2020** | |  | **2019** | | ​ | **2018** | |
| Research and development | ​ | $ | 31,294 | ​ | $ | 28,953 | ​ | $ | 25,563 |
| Selling, general and administrative | ​ |  | 31,682 | ​ |  | 31,497 | ​ |  | 25,750 |
| Total share-based compensation expense | ​ | $ | 62,976 | ​ | $ | 60,450 | ​ | $ | 51,313 |

​

Share-based compensation expense included in the consolidated statements of operations by award type was as follows:

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | |
| *Innoviva equity:* | ​ | **​** | ​ | ​ | **​** | ​ | ​ | **​** | ​ |
| Options | ​ | $ | — | ​ | $ | — | ​ | $ | 280 |
| RSUs | ​ |  | — | ​ | ​ | — | ​ | ​ | — |
| RSAs | ​ |  | — | ​ | ​ | 64 | ​ | ​ | 457 |
| Performance RSAs | ​ |  | — | ​ | ​ | — | ​ | ​ | — |
| *Theravance Biopharma equity:* | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Options | ​ |  | 6,536 | ​ | ​ | 6,381 | ​ | ​ | 8,441 |
| RSUs | ​ | ​ | 49,803 | ​ | ​ | 39,520 | ​ | ​ | 34,077 |
| Performance RSAs and RSUs | ​ | ​ | 3,943 | ​ | ​ | 12,717 | ​ | ​ | 4,707 |
| ESPP | ​ |  | 2,694 | ​ | ​ | 1,768 | ​ | ​ | 3,351 |
| Total share-based compensation expense | ​ | $ | 62,976 | ​ | $ | 60,450 | ​ | $ | 51,313 |

​

Total share-based compensation expense capitalized to inventory, in the period from January 1, 2018 to the disposition of the Company’s VIBATIV business in late 2018, was not material for the year ended December 31, 2018.

​

As of December 31, 2020, the unrecognized share-based compensation cost, net of actual forfeitures, and the estimated weighted-average amortization period, using the straight-line attribution method, was as follows:

​

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ |
| ​ |  | **Unrecognized** | | **​** | **Weighted‑Average** |
| **​** |  | **Compensation** | | **​** | **Amortization Period** |
| **(In thousands, except amortization period)** |  | **Cost** | |  | **(Years)** |
| *Theravance Biopharma equity:* | ​ | ​ | ​ | ​ | ​ |
| Options | ​ | $ | 11,513 | ​ | 2.62 |
| RSUs | ​ | ​ | 101,588 | ​ | 2.53 |
| Performance RSAs and RSUs (1) | ​ | ​ | 502 | ​ | 0.21 |
| ESPP | ​ | ​ | 1,122 | ​ | 0.62 |
| Total | ​ | $ | 114,725 | ​ | ​ |

|  |  |
| --- | --- |
| (1) | Represents unrecognized share-based compensation cost associated with the Company’s performance-contingent awards described above that are probable of vesting. |

110

[Table of Contents](#TOC)

***Compensation Awards***

The following table summarizes option activity under the 2013 EIP and 2014 NEEIP for the year ended December 31, 2020:

​

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ |
| **​** |  | **Number of Shares** |  | **Weighted-Average** | |
| **​** | ​ | **Subject** | ​ | **Exercise Price** | |
| **​** | ​ | **to Outstanding Options** | ​ | **of Outstanding Options** | |
| Outstanding at December 31, 2019 | ​ | 2,950,472 | ​ | $ | 24.75 |
| Granted | ​ | 600,300 | ​ | ​ | 22.58 |
| Exercised | ​ | (68,171) | ​ | ​ | 19.96 |
| Forfeited | ​ | (183,422) | ​ | ​ | 22.49 |
| Outstanding at December 31, 2020 | ​ | 3,299,179 | ​ | $ | 24.58 |

​

As of December 31, 2020, the aggregate intrinsic value of the options outstanding was $1.2 million. As of December 31, 2020, the aggregate intrinsic value of the options exercisable was $0.8 million. The total estimated fair value of options vested (excluding vested options that have expired) was $6.4 million in 2020.

​

The following table summarizes total RSU and RSA activity (including performance RSUs and RSAs) for the year ended December 31, 2020:

​

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ |
| **​** |  | **Number of Shares** |  | **Number of Shares** |
| **​** | **​** | **Subject to** | **​** | **Outstanding Subject to** |
| **​** | **​** | **Outstanding RSUs** | **​** | **Performance Conditions (RSAs)** |
| Outstanding at December 31, 2019 | ​ | 4,939,774 |  | 776,250 |
| Granted | ​ | 2,576,326 |  | — |
| Released | ​ | (1,907,307) | ​ | (362,250) |
| Forfeited | ​ | (614,875) |  | — |
| Outstanding at December 31, 2020 | ​ | 4,993,918 |  | 414,000 |

​

As of December 31, 2020, the aggregate intrinsic value of the RSUs and RSAs outstanding was $88.7 million and $7.4 million, respectively. The total estimated fair value of RSUs vested was $46.8 million and $32.4 million in 2020 and 2019, respectively.

​

***Valuation Assumptions***

The range of assumptions used to estimate the fair value of options granted and rights granted under the 2013 ESPP was as follows:

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | | | |
| **​** |  | **2020** | |  | **2019** | |  | **2018** | |
| ***Options*** | ***​*** | ***​*** | ***​*** | ***​*** | ***​*** | ***​*** | ***​*** | ***​*** | ***​*** |
| Risk-free interest rate |  | ​ | 0.3% - 1.7% | ​ | ​ | 1.6% - 2.5% | ​ | ​ | 2.3% - 3.0% |
| Expected term (in years) |  | ​ | 5.2 - 6.1 | ​ | ​ | 6.0 | ​ | ​ | 6.0 |
| Volatility |  | ​ | 50% - 53% | ​ | ​ | 51% - 53% | ​ | ​ | 53% - 54% |
| Dividend yield |  | ​ | — | ​ | ​ | — | ​ | ​ | — |
| Weighted-average estimated fair value | ​ | $ | 11.03 | ​ | $ | 10.20 | ​ | $ | 14.32 |
| ***2013 ESPP*** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Risk-free interest rate | ​ | ​ | 0.1% - 0.2% | ​ | ​ | 1.5% - 2.4% | ​ | ​ | 2.1% - 2.8% |
| Expected term (in years) | ​ | ​ | 0.5 - 2.0 | ​ | ​ | 0.5 - 2.0 | ​ | ​ | 0.5 - 2.0 |
| Volatility | ​ | ​ | 53% - 76% | ​ | ​ | 40% - 48% | ​ | ​ | 42% - 53% |
| Dividend yield | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — |
| Weighted-average estimated fair value | ​ | $ | 8.04 | ​ | $ | 6.17 | ​ | $ | 9.13 |

​

​

111

[Table of Contents](#TOC)

**12. Income Taxes**

Theravance Biopharma was incorporated in the Cayman Islands in July 2013 under the name Theravance Biopharma, Inc. as a wholly-owned subsidiary of Innoviva and began operations subsequent to the Spin-Off with wholly-owned subsidiaries in the Cayman Islands, US, United Kingdom, and Ireland. Effective July 1, 2015, Theravance Biopharma became an Irish tax resident, therefore, the loss before income taxes of Theravance Biopharma, the parent company, are included in Ireland in the tables below.

The components of the loss before income taxes were as follows:

​

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| ​ | ​ | **Year Ended December 31,** | | | | | | | |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | |
| Income (loss) before provision for income taxes: |  | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ |
| Cayman Islands | ​ | $ | 37,567 | ​ | $ | 11,779 | ​ | $ | 14,838 |
| United States | ​ | ​ | (46,500) | ​ | ​ | (99,225) | ​ | ​ | (69,695) |
| Ireland | ​ | ​ | (277,105) | ​ | ​ | (154,217) | ​ | ​ | (171,134) |
| United Kingdom | ​ | ​ | (499) | ​ | ​ | (14) | ​ | ​ | (94) |
| Total | ​ | $ | (286,537) | ​ | $ | (241,677) | ​ | $ | (226,085) |

​

The components of provision for income tax benefit (expense) were as follows:

​

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| ​ | ​ | **Year Ended December 31,** | | | | | | | | ​ |
| **(In thousands)** |  | **2020** | |  | **2019** | |  | **2018** | | ​ |
| Provision for income tax benefit (expense): | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Current: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Cayman Islands | ​ | $ | — | ​ | $ | — | ​ | $ | — | ​ |
| United States | ​ | ​ | 8,545 | ​ | ​ | 5,210 | ​ | ​ | 10,563 | ​ |
| Ireland | ​ | ​ | (13) | ​ | ​ | — | ​ | ​ | — | ​ |
| United Kingdom | ​ | ​ | (12) | ​ | ​ | 12 | ​ | ​ | (2) | ​ |
| Subtotal | ​ | ​ | 8,520 | ​ | ​ | 5,222 | ​ | ​ | 10,561 | ​ |
| Deferred | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ |
| Total | ​ | $ | 8,520 | ​ | $ | 5,222 | ​ | $ | 10,561 | ​ |
| Effective tax rate | ​ | ​ | 2.97 | % | ​ | 2.16 | % | ​ | 4.67 | % |

​

The provision for income tax benefit (expense) was $8.5 million, $5.2 million and $10.6 million for the year ended December 31, 2020, 2019 and 2018 respectively.

The 2020 net income tax benefit was primarily attributed to a reversal of previously accrued contingent tax liabilities for uncertain tax positions due to a lapse of the statute of limitations and their related interest accruals. The 2019 net income tax benefit was primarily due to the reversal of previously accrued contingent tax liabilities for uncertain tax positions due to a lapse of the statute of limitations and current year US research and development credits.

​

No provision for income taxes has been recognized on undistributed earnings of the Company’s foreign subsidiaries because it considers such earnings to be indefinitely reinvested. In the event of a distribution of these earnings in the form of dividends or otherwise, the Company may be liable for income taxes, subject to an adjustment, if any, for foreign tax credits and foreign withholdings taxes payable to certain foreign tax authorities. As of December 31, 2020, there were no undistributed earnings.

​

​

​

​

112

[Table of Contents](#TOC)

As a result of the Company becoming an Irish tax resident effective July 1, 2015, the tax rates reflect the Irish statutory rate of 25%. The differences between the Irish statutory income tax rate and the Company’s effective tax rates were as follows:

​

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **Year Ended December 31,** | | | | | **​** |
| **​** |  | **2020** |  | **2019** |  | **2018** | **​** |
| Provision at statutory income tax rate | ​ | 25.00 | % | 25.00 | % | 25.00 | % |
| Foreign rate differential | ​ | (11.49) |  | (6.96) |  | (7.51) | ​ |
| Share-based compensation | ​ | 0.75 | ​ | (1.17) | ​ | 0.28 | ​ |
| Non-deductible executive compensation | ​ | (0.63) | ​ | (0.51) | ​ | (0.72) | ​ |
| Uncertain tax positions | ​ | (1.26) | ​ | (0.63) | ​ | (4.00) | ​ |
| Research and development tax credit carryforwards | ​ | 1.83 | ​ | 2.50 | ​ | 1.79 | ​ |
| Foreign exchange loss | ​ | — | ​ | — | ​ | 8.52 | ​ |
| Intangible asset | ​ | 10.01 | ​ | — | ​ | — | ​ |
| Change in valuation allowance | ​ | (20.56) |  | (14.90) |  | (18.82) | ​ |
| Other | ​ | (0.68) |  | (1.17) |  | 0.13 | ​ |
| Effective tax rate | ​ | 2.97 | % | 2.16 | % | 4.67 | % |

​

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities were as follows:

​

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **December 31,** | | | | |
| **(In thousands)** |  | **2020** | |  | **​** | **2019** |
| Deferred tax assets: | ​ | ​ | ​ | ​ | ​ | ​ |
| Net operating loss carryforwards |  | $ | 82,821 | ​ | $ | 58,161 |
| Capital loss carryforwards | ​ |  | 19,409 | ​ |  | 19,409 |
| Research and development tax credit carryforwards | ​ |  | 24,075 | ​ |  | 15,723 |
| Fixed assets and intangibles | ​ | ​ | 310,187 | ​ | ​ | 285,341 |
| Share-based compensation | ​ | ​ | 15,087 | ​ | ​ | 15,480 |
| Accruals | ​ | ​ | 8,145 | ​ | ​ | 8,245 |
| Operating lease liabilities | ​ | ​ | 11,662 | ​ | ​ | 11,358 |
| Other | ​ |  | 346 | ​ |  | 7 |
| Subtotal | ​ | ​ | 471,732 | ​ | ​ | 413,724 |
| Valuation allowance | ​ |  | (462,711) | ​ |  | (403,836) |
| Total deferred tax assets | ​ | ​ | 9,021 | ​ | ​ | 9,888 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Deferred tax liabilities: | ​ | ​ | ​ | ​ | ​ | ​ |
| Operating lease assets | ​ | ​ | (8,680) | ​ | ​ | (9,429) |
| Prepaid assets | ​ | ​ | (341) | ​ | ​ | (459) |
| Total deferred tax liabilities | ​ | ​ | (9,021) | ​ | ​ | (9,888) |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Net deferred tax assets (liabilities) | ​ | $ | — | ​ | $ | — |

​

The Company follows the accounting guidance related to accounting for income taxes which requires that a company reduce its deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of its deferred tax assets will not be realized. As of December 31, 2020, the Company’s deferred tax assets were offset in full by a valuation allowance.

​

The valuation allowance as of December 31, 2020 increased from $403.8 million (the valuation allowance as of December 31, 2019) to $462.7 million, primarily as a result of additional tax loss generated in various jurisdictions during the current year and the intercompany transfer of intangible assets eligible for tax amortization. Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that the deferred tax assets are recoverable. As required, the Company prepares its assessment of the realizability of deferred tax assets on a jurisdiction-by-jurisdiction basis.

113

[Table of Contents](#TOC)

​

As of December 31, 2020, the Company had $209.8 million of US federal net operating loss carryforwards and $21.1 million of federal research and development tax credit carryforwards which expire beginning in 2035. After the enactment of the Tax Cut and Jobs Act (the “Tax Act”) in December 2017, the operating losses generated had an indefinite carryforward life, but was limited to 80% of taxable income when utilized. As of December 31, 2020, this amount was $164.9 million. The Company had state net operating loss carryforwards of $70.9 million which generally begin to expire in 2034 and state research and development credit carryforwards of $21.2 million to be carried forward indefinitely.

​

The Company also had Irish net operating loss carryforwards of $565.8 million with no expiration date and capital loss carryforwards of $58.8 million to be carried forward indefinitely.

​

Utilization of net operating loss and tax credit carryforwards may be subject to an annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The amount of tax expense related to interest or penalties was immaterial for the year ended December 31, 2020 and 2019.

***Uncertain Tax Positions***

A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits were as follows:

​

|  |  |  |  |
| --- | --- | --- | --- |
| ​ | ​ | ​ | ​ |
| **(In thousands)** |  | ​ | ​ |
| Unrecognized tax benefits as of December 31, 2018 | ​ | $ | 52,404 |
| Gross decrease in tax positions for prior years | ​ | ​ | (2,010) |
| Gross increase in tax positions for current year | ​ | ​ | 8,369 |
| Unrecognized tax benefits as of December 31, 2019 | ​ | ​ | 58,763 |
| Gross decrease in tax positions for prior years | ​ | ​ | (8,059) |
| Gross increase in tax positions for current year | ​ | ​ | 12,743 |
| Unrecognized tax benefits as of December 31, 2020 | ​ | $ | 63,447 |

​

The Company records liabilities related to uncertain tax positions in accordance with the income tax guidance which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. The Company includes any applicable interest and penalties within the provision for income taxes in the consolidated statements of operations.

​

The total unrecognized tax benefits of $63.4 million and $58.8 million, as of December 31, 2020 and December 31, 2019, respectively, may reduce the effective tax rate in the period of recognition. However, carryforward tax attributes that were generated in years beginning on or before January 1, 2018 may still be adjusted upon examination by tax authorities since the attributes are not yet utilized. The Company does not expect to record any other material reductions in the measurement of its unrecognized tax benefits within the next twelve months. The Company currently has a full valuation allowance against its deferred tax assets, which would impact the timing of the effective tax rate benefit should any of these uncertain positions be favorably settled in the future.

​

The Company is subject to taxation in Ireland, the US, and various other jurisdictions. The tax years 2017 and forward remain open to examination in Ireland, tax years 2018 and forward remain open to examination in the US, and the tax years 2015 and forward remain open to examination in other jurisdictions.

114

[Table of Contents](#TOC)

​

The Company is currently under Internal Revenue Service (“IRS”) examination for the tax year ended December 31, 2018. The Company believes that an adequate provision has been made for any material adjustments that may result from the tax examination. The Company concluded its IRS examination for the tax year ended December 31, 2017 in December 2020 with no adjustments required.

​

On March 27, 2020, the *Coronavirus Aid, Relief, and Economic Security Act* (the “CARES Act”), that features significant tax provision and other measures to assist individuals and businesses impacted by the economic effects of the COVID-19 pandemic, was signed into law. Tax relief measures for businesses include a five-year net operating loss carryback (including a related technical correction to the 2017 Tax Reform Act), a change in Section 163(j) interest deduction limitations, accelerated alternative minimum tax refunds, payroll tax relief, a temporary suspension of certain aviation excise taxes, a tax credit for employers who retain employees, and a ‘qualified improvement property’ technical correction to the 2017 Tax Reform Act. The Company has considered the corporate income tax provisions of the CARES Act and related initial guidance as part of its income tax expense and concluded that these provisions did not have a material impact on the Company’s 2020 income tax expense.

​

The Company’s future income tax expense may be affected by such factors as changes in tax laws, its business, regulations, tax rates, interpretation of existing laws or regulations, the impact of accounting for share-based compensation, the impact of accounting for business combinations, its international organization, shifts in the amount of income before tax earned in the US as compared with other regions in the world, and changes in overall levels of income before tax.

​

**13. Commitments and Contingencies**

***Performance-Contingent Awards***

In 2016, the Compensation Committee granted long-term retention RSAs and RSUs to members of senior management and incentive cash bonus awards to certain employees. The vesting and payout of such awards is dependent on the Company meeting its critical operating goals and objectives during a five-year period from 2016 to December 31, 2020. These goals are strategically important for the Company, and it believes the goals, if achieved, should increase shareholder value. The awards have dual triggers of vesting based upon the achievement of these goals and continued employment.

​

Expense associated with these awards may be recognized during the years 2016 to 2020 depending on the probability of meeting certain performance conditions. Compensation expense relating to awards subject to performance conditions is recognized if it is considered probable that the performance goals will be achieved. The probability of achievement is reassessed at each quarter-end reporting period. Previously recognized expense is reversed in the period in which it becomes probable that the requisite service period will not be rendered. The awards are broken into three separate tranches and comprised of a share-based award component and a cash bonus award component. See *“Note 11. Share-Based Compensation”* for information related to the share-based award component.

​

The performance conditions associated with the first tranche of the cash bonus awards were completed in the second quarter of 2018, and the Company recognized $3.5 million of cash bonus expense for the year ended December 31, 2018 associated with the first tranche of these awards.

​

The performance conditions associated with the second tranche of these awards were completed in the first quarter of 2019 and the expense associated with this second tranche was fully recognized in the first quarter of 2020. For year ended December 31, 2020, 2019 and 2018, the Company recognized $0.5 million, $2.4 million and $1.9 million, respectively, of cash bonus expense related to the second tranche of these awards.

​

In the fourth quarter of 2019, the Company determined that the remaining third tranche was probable of vesting, and in the first quarter of 2020, the performance conditions associated with the third tranche were completed. As a result, the Company recognized $2.8 million and $11.8 million in cash bonus expense related to these awards for the year ended December 31, 2020 and 2019, respectively. As of December 31, 2020, the maximum remaining cash bonus expense

115

[Table of Contents](#TOC)

associated with the third tranche was $0.4 million (allocated as $0.3 million for research and development expense and $0.1 million for selling, general and administrative expense) and will be amortized through the first quarter of 2021.

​

***Guarantees and Indemnifications***

The Company indemnifies its officers and directors for certain events or occurrences, subject to certain limits. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recognized any liabilities relating to these agreements as of December 31, 2020 and 2019.

**14. Public Offering of Ordinary Shares**

On February 14, 2020, the Company sold 5,500,000 ordinary shares at a price to the public of $27.00 per share (the “Shares”). The gross proceeds to the Company from the offering were $148.5 million, before deducting underwriting discounts and commissions and offering expenses. The Shares were issued pursuant to the Company’s currently effective shelf registration statement on Form S-3 and an accompanying prospectus (File No. 333-235339) filed with the SEC, which became effective automatically on December 3, 2019, and a prospectus supplement filed with the SEC in connection with the offering.

​

**15. Reduction in Workforce**

In January 2019, the Company announced a reduction in workforce to align with its focus on continued execution of key strategic programs and advancement of selected late-stage research programs toward clinical development. The Company reduced its overall headcount by 51 individuals, with the affected employees primarily focused on early research or the infrastructure in support of VIBATIV, which was sold by the Company to Cumberland in November 2018.

​

As a result of the reduction in workforce, the Company recognized and paid severance related charges totaling $3.5 million for the year ended December 31, 2019, including compensation expense made to affected employees through any minimum statutory notice periods. The severance related charges are presented on the consolidated statements of operations within research and development expenses and selling, general and administrative expenses.

​

​

​

**​**

116

[Table of Contents](#TOC)

**SUPPLEMENTARY FINANCIAL DATA**

**(UNAUDITED)**

**(In thousands, except per share data)**

The following table presents certain unaudited consolidated quarterly financial information for the eight quarters in the periods ended December 31, 2020 and 2019. This information has been prepared on the same basis as the audited consolidated financial statements and includes all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the unaudited quarterly results of operations set forth herein.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| **​** | **​** | **For the Quarter Ended** | | | | | | | | | | |
| **​** |  | **March 31,** | |  | **June 30,** | |  | **September 30,** | |  | **December 31,** | |
| **2020** | **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Total revenue | ​ | $ | 19,862 | ​ | $ | 15,008 | ​ | $ | 18,257 | ​ | $ | 18,730 |
| Costs and expenses | ​ |  | 92,338 | ​ |  | 87,184 | ​ |  | 94,872 | ​ |  | 95,220 |
| Loss from operations | ​ |  | (72,476) | ​ |  | (72,176) | ​ |  | (76,615) | ​ |  | (76,490) |
| Net loss | ​ |  | (83,053) | ​ |  | (62,887) | ​ |  | (73,643) | ​ |  | (58,434) |
| Basic and diluted net loss per share | ​ | $ | (1.40) | ​ | $ | (1.00) | ​ | $ | (1.16) | ​ | $ | (0.92) |
| **2019** | **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Total revenue | ​ | $ | 5,338 | ​ | $ | 26,150 | ​ | $ | 12,427 | ​ | $ | 29,499 |
| Costs and expenses | ​ |  | 79,004 | ​ |  | 68,626 | ​ |  | 77,628 | ​ |  | 100,071 |
| Loss from operations | ​ |  | (73,666) | ​ |  | (42,476) | ​ |  | (65,201) | ​ |  | (70,572) |
| Net loss | ​ |  | (72,580) | ​ |  | (39,838) | ​ |  | (58,431) | ​ |  | (65,606) |
| Basic and diluted net loss per share | ​ | $ | (1.32) | ​ | $ | (0.72) | ​ | $ | (1.05) | ​ | $ | (1.17) |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| ***Share of Total YUPELRI Net Sales (1)*** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| ​ | ​ | **For the Quarter Ended** | | | | | | | | | | |
| ***​*** | ​ | **March 31,** | |  | **June 30,** | |  | **September 30,** | |  | **December 31,** | |
| **2020** | **​** | $ | 12,880 | ​ | $ | 10,589 | ​ | $ | 12,960 | ​ | $ | 13,550 |
| **2019** | ​ | $ | 1 | ​ | $ | 3,184 | ​ | $ | 5,763 | ​ | $ | 10,352 |

​

|  |  |  |
| --- | --- | --- |
|  | (1) | The Company co-promotes YUPELRI in the US under a profit and loss sharing arrangement with Viatris (65% to Viatris; 35% to Theravance Biopharma). The amounts represent the Company’s implied 35% share of the total net sales of YUPELRI that were recognized within Viatris’ financial statements for the periods presented. |

**​**

​

117

[Table of Contents](#TOC)

|  |  |
| --- | --- |
| **ITEM 9.** | **CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE** |

Not applicable.

​

**ITEM 9A. CONTROLS AND PROCEDURES**

*Evaluation of Disclosure Controls and Procedures.*

We conducted an evaluation required by paragraph (d) of Rule 13a-15 of the Exchange Act as of December 31, 2020, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined under Rule 13a-15(e) of the Exchange Act), which are controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized and reported within required time periods. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

*Management’s Report on Internal Control over Financial Reporting*

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) of the Exchange Act. In connection with the preparation of this Annual Report, our management, including our Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2020 based on criteria established in *Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission* (2013 framework) (the “COSO criteria”). Based on its assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2020.

The effectiveness of our internal control over financial reporting as of December 31, 2020 has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their report which is included herein.

*Limitations on the Effectiveness of Controls*

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within Theravance Biopharma have been detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

*Changes in Internal Control over Financial Reporting*

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 of the Exchange Act, which occurred during the fourth quarter of the year ended December 31, 2020 which has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal control over financial reporting despite the fact that many of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the potential impact of COVID-19 on our internal controls to minimize the impact on their design and operating effectiveness.

**​**

118

[Table of Contents](#TOC)

**Report of Independent Registered Public Accounting Firm**

**To the Shareholders and the Board of Directors of Theravance Biopharma, Inc.**

**Opinion on Internal Control over Financial Reporting**

We have audited Theravance Biopharma, Inc.’s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Theravance Biopharma, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2020 consolidated financial statements of the Company and our report dated February 26, 2021 expressed an unqualified opinion thereon.

​

**Basis for Opinion**

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

​

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

​

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

​

**Definition and Limitations of Internal Control Over Financial Reporting**

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

​

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

​

/s/ Ernst & Young LLP

​

Redwood City, California

February 26, 2021

119

[Table of Contents](#TOC)

​

**ITEM 9B. OTHER INFORMATION**

None.

​

**PART III**

**ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE**

For the information required by this Item, see “Questions and Answers About Procedural Matters”, “Election of Directors”, “Nominees”, “Audit Committee”, “Meetings of the Board of Directors”, “Code of Conduct”, “Executive Officers” and “Section 16(a) Beneficial Ownership Reporting Compliance” in the Proxy Statement to be filed with the SEC, which sections are incorporated herein by reference.

**ITEM 11. EXECUTIVE COMPENSATION**

For the information required by this Item, see “Director Compensation”, “Executive Compensation” and “Compensation Committee Interlocks and Insider Participation” in the Proxy Statement to be filed with the SEC, which sections are incorporated herein by reference.

|  |  |
| --- | --- |
| **ITEM 12.** | **SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS** |

For the information required by this Item, see “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information” in the Proxy Statement to be filed with the SEC, which sections are incorporated herein by reference.

|  |  |
| --- | --- |
| **ITEM 13.** | **CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE** |

For the information required by this Item, see “Director Independence” and “Policies and Procedures for Related Party Transactions” in the Proxy Statement to be filed with the SEC, which sections are incorporated herein by reference.

**ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES**

For the information required by this Item, see “Ratification of the Appointment of Independent Registered Public Accounting Firm” and “Pre-Approval of Audit and Non-Audit Services” in the Proxy Statement to be filed with the SEC, which sections are incorporated herein by reference.

​

120

[Table of Contents](#TOC)

**PART IV**

**ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES**

|  |  |
| --- | --- |
| (a) | The following documents are filed as part of this Annual Report on Form 10-K: |

|  |  |  |
| --- | --- | --- |
|  | 1. | Financial Statements: |

The following financial statements and schedules of the Registrant are contained in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K:

|  |  |  |
| --- | --- | --- |
| [Report of Independent Registered Public Accounting Firm](#ReportofIndependentRegisteredPublicAcco) |  | 77 |
| [Consolidated Balance Sheets as of December 31, 2020 and 2019](#BALANCESHEETS_51823) | ​ | 79 |
| [Consolidated Statements of Operations for each of the three years in the period ended December 31, 2020](#STATEMENTSOFOPERATIONS_145667) | ​ | 80 |
| [Consolidated Statements of Comprehensive Loss for each of the three years in the period ended December 31, 2020](#COMPREHENSIVELOSS_235302) | ​ | 81 |
| [Consolidated Statements of Shareholders’ Deficit for each of the three years in the period ended December 31, 2020](#SHAREHOLDERSEQUITYDEFICIT_563819) | ​ | 82 |
| [Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2020](#CASHFLOWS_106664) | ​ | 83 |
| [Notes to Consolidated Financial Statements](#NOTESTOCONSOLIDATED_244803) | ​ | 84 |
| [Supplementary Financial Data (unaudited)](#SUPPLEMENTARYFINANCIALDATA_850975) | ​ | 117 |

​

|  |  |  |
| --- | --- | --- |
|  | 2. | Financial Statement Schedules: |

All schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements, financial notes or supplementary financial information.

|  |  |
| --- | --- |
| (b) | Exhibits required by Item 601 of Regulation S-K |

The information required by this Item is set forth on the exhibit index that precedes the signature page of this report.

**​**

121

[Table of Contents](#TOC)

**Exhibit Index**

|  |  |  |  |
| --- | --- | --- | --- |
| **​** | **​** | **Incorporated by Reference** | |
| **Exhibit Number** | **Description** | **Form** | **Filing Date/Period End Date** |
| 2.1 | [Separation and Distribution Agreement by and between Theravance Biopharma, Inc. and Innoviva, Inc., dated June 1, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000110465914043506/a14-14496_1ex10d1.htm) | 8-K | June 3, 2014 |
| 2.2\* | [Asset Purchase Agreement, dated as of November 1, 2018, by and among Cumberland Pharmaceuticals Inc. on the one hand, and Theravance Biopharma Ireland Limited and Theravance Biopharma US, Inc. on the other hand.](http://www.sec.gov/Archives/edgar/data/1583107/000110465918068998/a18-40284_1ex2d1.htm) | 8-K | November 16, 2018 |
| 3.1 | [Amended and Restated Memorandum and Articles of Association](http://www.sec.gov/Archives/edgar/data/1583107/000104746914004381/a2219942zex-3_1.htm) | 10-12B | April 30, 2014 |
| 4.1 | [Specimen Share Certificate](http://www.sec.gov/Archives/edgar/data/1583107/000104746914004381/a2219942zex-4_1.htm) | 10-12B | April 30, 2014 |
| 4.2 | [Registration Rights Agreement, dated March 3, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000104746914003560/a2218724zex-4_2.htm) | 10-12B | April 8, 2014 |
| 4.3 | [First Amendment of Registration Rights Agreement, dated February 10, 2020 by and between Theravance Biopharma, Inc. and Glaxo Group Limited](https://www.sec.gov/Archives/edgar/data/1583107/000155837020006021/tbph-20200331xex10d3.htm) | 10-Q | March 31, 2020 |
| 4.4 | [Shelf Rights Plan Resolution](http://www.sec.gov/Archives/edgar/data/1583107/000104746918001961/a2234945zdef14a.htm) | DEF 14A | March 21, 2018 |
| 4.5 | [Sales Agreement between Theravance Biopharma, Inc. and Cowen and Company, LLC dated December 3, 2019](http://www.sec.gov/Archives/edgar/data/1583107/000104746919006605/a2240115zex-1_2.htm) | S-3 | December 3, 2019 |
| 4.6 | [Indenture, dated as of November 2, 2016, between Theravance Biopharma, Inc. and Wells Fargo Bank, National Association, as trustee](http://www.sec.gov/Archives/edgar/data/1583107/000110465916154218/a16-20893_1ex4d1.htm) | 8-K | November 2, 2016 |
| 4.7 | [First Supplemental Indenture, dated as of November 2, 2016, between Theravance Biopharma, Inc. and Wells Fargo Bank, National Association, as trustee](http://www.sec.gov/Archives/edgar/data/1583107/000110465916154218/a16-20893_1ex4d2.htm) | 8-K | November 2, 2016 |
| 4.8 | [Form of 3.25% Convertible Senior Note due 2023 (included in Exhibit 4.6)](http://www.sec.gov/Archives/edgar/data/1583107/000110465916154218/a16-20893_1ex4d2.htm) | 8-K | November 2, 2016 |
| 4.9 | [Indenture, dated as of February 28, 2020, by and among Triple Royalty Sub II LLC, as issuer, U.S. Bank National Association, as initial trustee, transfer agent, paying agent, registrar and calculation agent and, solely with respect to Section 2.11(o) and Section 2.11(p) Theravance Biopharma, Inc.](https://www.sec.gov/Archives/edgar/data/1583107/000110465920029209/tm2011370d1_ex4-1.htm) | 8-K | March 04, 2020 |
| 4.10 | [Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934](https://www.sec.gov/Archives/edgar/data/1583107/000155837020001644/ex-4d10.htm) | 10-K | December 31, 2019 |
| 4.11 | [Registration Rights Agreement among Theravance Biopharma, Inc., GSK Finance (No.3) plc and GlaxoSmithKline plc dated June 22, 2020.](https://www.sec.gov/Archives/edgar/data/1583107/000110465920076844/tm2023294d1_ex10-1.htm) | 8-K | June 25, 2020 |
| 4.12 | [Waiver and Assignment of Registration Rights and Voting Agreement among GSK Finance (No.3) plc, Glaxo Group Limited and Theravance Biopharma, Inc. dated as of June 22, 2020.](https://www.sec.gov/Archives/edgar/data/1583107/000110465920076844/tm2023294d1_ex10-2.htm) | 8-K | June 25, 2020 |
| 10.1 | [Transition Services Agreement by and between Theravance Biopharma, Inc. and Innoviva, Inc., dated June 2, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000110465914043506/a14-14496_1ex10d2.htm) | 8-K | June 3, 2014 |
| 10.2 | [Tax Matters Agreement by and between Theravance Biopharma, Inc. and Innoviva, Inc., dated June 2, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000110465914043506/a14-14496_1ex10d3.htm) | 8-K | June 3, 2014 |
| 10.3 | [Employee Matters Agreement by and between Theravance Biopharma, Inc. and Innoviva, Inc., dated June 1, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000110465914043506/a14-14496_1ex10d4.htm) | 8-K | June 3, 2014 |
| 10.4+ | [2013 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1583107/000110465914061602/a14-19178_1ex99d1.htm) | S-8 | August 18, 2014 |
| 10.5+ | [UK Addendum to the 2013 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1583107/000110465914060469/a14-18091_1ex10d1.htm) | 10-Q | August 14, 2014 |
| 10.6+ | [2014 New Employee Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1583107/000110465914081030/a14-24393_1ex99d1.htm) | S-8 | November 14, 2014 |
| 10.7+ | [2013 Employee Share Purchase Plan, as amended](http://www.sec.gov/Archives/edgar/data/1583107/000110465914061602/a14-19178_1ex99d2.htm) | S-8 | Aug. 18, 2014 |
| 10.8+ | [Forms of award agreements under the 2013 Equity Incentive Plan and 2014 New Employee Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1583107/000110465916119714/a16-6543_1ex10d2.htm) | 10-Q | May 10, 2016 |
| 10.9+ | [Forms of Equity Award Amendment](http://www.sec.gov/Archives/edgar/data/1583107/000104746914004658/a2220057zex-10_31.htm) | 10-12B | May 7, 2014 |
| 10.10+ | [Form of TFIO Cash Award Amendment](http://www.sec.gov/Archives/edgar/data/1583107/000104746914004658/a2220057zex-10_32.htm) | 10-12B | May 7, 2014 |
| 10.11+ | [Form of Acknowledgment for Irish Non-Employee Directors](http://www.sec.gov/Archives/edgar/data/1583107/000104746916011039/a2227703zex-10_46.htm) | 10-K | March 11, 2016 |

122

[Table of Contents](#TOC)

|  |  |  |  |
| --- | --- | --- | --- |
| **​** | **​** | **Incorporated by Reference** | |
| **Exhibit Number** | **Description** | **Form** | **Filing Date/Period End Date** |
| 10.12+ | [Irish Addendum to the 2013 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1583107/000104746916011039/a2227703zex-10_47.htm) | 10-K | March 11, 2016 |
| 10.13+ | [Irish Addendum to the 2014 New Employee Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1583107/000104746916011039/a2227703zex-10_48.htm) | 10-K | March 11, 2016 |
| 10.14+ | [UK and Irish Addendums to the 2013 Employee Share Purchase Plan](http://www.sec.gov/Archives/edgar/data/1583107/000104746916011039/a2227703zex-10_49.htm) | 10-K | March 11, 2016 |
| 10.15+ | [Theravance Biopharma, Inc. Performance Incentive Plan](http://www.sec.gov/Archives/edgar/data/1583107/000110465916118447/a16-10580_1ex10d1.htm) | 8-K | May 6, 2016 |
| 10.16+ | [Form of Notice of Option Grant and Option Agreement under the Company’s Performance Incentive Plan](http://www.sec.gov/Archives/edgar/data/1583107/000110465917066731/a17-20642_1ex10d2.htm) | 10-Q | November 8, 2017 |
| 10.17+ | [Form of Notice of Performance Restricted Share Unit Award and Restricted Share Unit Agreement under the Company’s Performance Incentive Plan](http://www.sec.gov/Archives/edgar/data/1583107/000110465917066731/a17-20642_1ex10d3.htm) | 10-Q | November 8, 2017 |
| 10.18+ | [Change in Control Severance Plan](http://www.sec.gov/Archives/edgar/data/1583107/000104746914003560/a2218724zex-10_7.htm) | 10-12B | April 8, 2014 |
| 10.19+ | [Cash Bonus Program](http://www.sec.gov/Archives/edgar/data/1583107/000104746913010796/a2217474zex-10_9.htm) | 10-12B | November 22, 2013 |
| 10.20+ | [Form of Indemnity Agreement](http://www.sec.gov/Archives/edgar/data/1583107/000104746914004381/a2219942zex-10_10.htm) | 10-12B | April 30, 2014 |
| 10.21 | [Amended and Restated Lease Agreement, 951 Gateway Boulevard, between Innoviva, Inc. and HMS Gateway Office L.P., dated January 1, 2001](http://www.sec.gov/Archives/edgar/data/1583107/000104746913007989/a2216160zex-10_11.htm) | 10-12B | August 1, 2013 |
| 10.22 | [First Amendment to Lease for 951 Gateway Boulevard effective as of June 1, 2010 between Innoviva, Inc. and ARE-901/951 Gateway Boulevard, LLC](http://www.sec.gov/Archives/edgar/data/1583107/000104746913007989/a2216160zex-10_12.htm) | 10-12B | August 1, 2013 |
| 10.23 | [Lease Agreement, 901 Gateway Boulevard, between Innoviva, Inc. and HMS Gateway Office L.P., dated January 1, 2001](http://www.sec.gov/Archives/edgar/data/1583107/000104746913007989/a2216160zex-10_13.htm) | 10-12B | August 1, 2013 |
| 10.24 | [First Amendment to Lease for 901 Gateway Boulevard effective as of June 1, 2010 between Innoviva, Inc. and ARE-901/951 Gateway Boulevard, LLC](http://www.sec.gov/Archives/edgar/data/1583107/000104746913007989/a2216160zex-10_14.htm) | 10-12B | August 1, 2013 |
| 10.25 | [Consent to Assignment by and among ARE-901/951 Gateway Boulevard, LLC, Innoviva, Inc. and Theravance Biopharma, Inc. and Assignment and Assumption of Lease for 901 Gateway Blvd.](http://www.sec.gov/Archives/edgar/data/1583107/000110465914060469/a14-18091_1ex10d14.htm) | 10-Q | August 14, 2014 |
| 10.26 | [Consent to Assignment by and among ARE-901/951 Gateway Boulevard, LLC, Innoviva, Inc. and Theravance Biopharma, Inc. and Assignment and Assumption of Lease for 951 Gateway Blvd.](http://www.sec.gov/Archives/edgar/data/1583107/000110465914060469/a14-18091_1ex10d15.htm) | 10-Q | August 14, 2014 |
| 10.27 | [Theravance Respiratory Company, LLC Limited Liability Company Agreement, dated May 31, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000110465914043506/a14-14496_1ex10d5.htm) | 8-K | June 3, 2014 |
| 10.28\* | [Technology Transfer and Supply Agreement, dated as of May 22, 2012 between Innoviva, Inc. and Hospira Worldwide, Inc.](http://www.sec.gov/Archives/edgar/data/1583107/000104746914004658/a2220057zex-10_16.htm) | 10-12B | May 7, 2014 |
| 10.29\* | [First Amendment to the Technology Transfer and Supply Agreement by and between Innoviva, Inc. and Hospira Worldwide, Inc., dated May 16, 2013](http://www.sec.gov/Archives/edgar/data/1583107/000110465916155621/a16-17232_1ex10d1.htm) | 10-Q | November 9, 2016 |
| 10.30\* | [Second Amendment to the Technology Transfer and Supply Agreement by and between Theravance Biopharma Antibiotics, Inc. and Hospira Worldwide, Inc., dated October 17, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000110465916155621/a16-17232_1ex10d3.htm) | 10-Q | November 9, 2016 |
| 10.31\* | [Third Amendment to the Technology Transfer and Supply Agreement by and between Theravance Biopharma Ireland Limited and Hospira Worldwide, Inc., dated April 14, 2016](http://www.sec.gov/Archives/edgar/data/1583107/000110465916155621/a16-17232_1ex10d2.htm) | 10-Q | November 9, 2016 |
| 10.32\* | [Fourth Amendment to the Technology Transfer and Supply Agreement by and between Theravance Biopharma Ireland Limited and Pfizer CentreOne group of Pfizer, Inc., dated September 29, 2016](http://www.sec.gov/Archives/edgar/data/1583107/000110465916155621/a16-17232_1ex10d4.htm) | 10-Q | November 9, 2016 |
| 10.33 | [Amendment No. 1 to the License, Development, and Commercialization Agreement by and between Theravance Biopharma Ireland Limited and Clinigen Group PLC dated August 4, 2016](http://www.sec.gov/Archives/edgar/data/1583107/000110465916138040/a16-11641_1ex10d2.htm) | 10-Q | August 9, 2016 |
| 10.34 | [License Agreement with Janssen Pharmaceutica, dated as of May 14, 2002](http://www.sec.gov/Archives/edgar/data/1583107/000110465914060469/a14-18091_1ex10d12.htm) | 10-Q | August 14, 2014 |
| 10.35 | [Collaboration Agreement between Innoviva, Inc. and Glaxo Group Limited, dated November 14, 2002 (1)](http://www.sec.gov/Archives/edgar/data/1080014/000110465914058343/a14-13984_1ex10d1.htm) | ​ | ​ |
| 10.36 | [Strategic Alliance Agreement by and between Innoviva, Inc. and Glaxo Group Limited, dated March 30, 2004 (2)](http://www.sec.gov/Archives/edgar/data/1080014/000104746914001691/a2218387zex-10_13.htm) | ​ | ​ |
| 10.37 | [Amendment to Strategic Alliance Agreement by and between Innoviva, Inc. and Glaxo Group Limited, dated October 3, 2011 (3)](http://www.sec.gov/Archives/edgar/data/1080014/000104746912001614/a2207068zex-10_34.htm) | ​ | ​ |

123

[Table of Contents](#TOC)

|  |  |  |  |
| --- | --- | --- | --- |
| **​** | **​** | **Incorporated by Reference** | |
| **Exhibit Number** | **Description** | **Form** | **Filing Date/Period End Date** |
| 10.38 | [Collaboration Agreement Amendment by and between Innoviva, Inc. and Glaxo Group Limited dated, March 3, 2014 (4)](http://www.sec.gov/Archives/edgar/data/1080014/000110465914017128/a14-7412_1ex10d2.htm) | ​ | ​ |
| 10.39 | [Strategic Alliance Agreement Amendment by and between Innoviva, Inc. and Glaxo Group Limited dated, March 3, 2014 (4)](http://www.sec.gov/Archives/edgar/data/1080014/000110465914017128/a14-7412_1ex10d3.htm) | ​ | ​ |
| 10.40 | [Master Agreement by and between Innoviva, Inc., Theravance Biopharma, Inc. and Glaxo Group Limited, dated March 3, 2014 (4)](http://www.sec.gov/Archives/edgar/data/1080014/000110465914017128/a14-7412_1ex10d1.htm) | ​ | ​ |
| 10.41 | [Extension Agreement by and between the Company and Glaxo Group Limited, dated March 3, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000104746914003560/a2218724zex-10_25.htm) | 10-12B | April 8, 2014 |
| 10.42+ | [Amended Offer Letter with Rick E Winningham dated August 5, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000110465914079772/a14-19949_1ex10d2.htm) | 10-Q | November 12, 2014 |
| 10.43+ | [Offer Letter with Frank Pasqualone May 12, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000110465914060469/a14-18091_1ex10d6.htm) | 10-Q | August 14, 2014 |
| 10.44+ | [Offer Letter with Brett K. Haumann dated May 12, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000110465914060469/a14-18091_1ex10d3.htm) | 10-Q | August 14, 2014 |
| 10.46+ | [Offer Letter with Brad Shafer dated August 20, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000110465914079772/a14-19949_1ex10d4.htm) | 10-Q | November 12, 2014 |
| 10.48+ | [Offer Letter with Ken Pitzer September 15, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000110465916119714/a16-6543_1ex10d4.htm) | 10-Q | May 10, 2016 |
| 10.49+ | [Offer Letter with Phil Worboys September 9, 2014](http://www.sec.gov/Archives/edgar/data/1583107/000110465916119714/a16-6543_1ex10d5.htm) | 10-Q | May 10, 2016 |
| 10.50+ | [Offer Letter with Richard Graham, Ph.D. dated August 12, 2015](http://www.sec.gov/Archives/edgar/data/1583107/000110465917066731/a17-20642_1ex10d1.htm) | 10-Q | September 30, 2020 |
| 10.51\*\* | [Development and Commercialization Agreement by and between Theravance Biopharma R&D, Inc. and Mylan Ireland Limited, dated January 30, 2015](tbph-20201231xex10d51.htm) | ​ | ​ |
| 10.52\* | [License and Collaboration Agreement by and between Theravance Biopharma Ireland Limited and Millennium Pharmaceuticals, Inc. dated June 8, 2016](http://www.sec.gov/Archives/edgar/data/1583107/000110465916138040/a16-11641_1ex10d1.htm) | 10-Q | August 9, 2016 |
| 10.53 | [Form of Note Purchase Agreement, dated February 21, 2020 by and among Theravance Biopharma R&D, Inc., Triple Royalty Sub II LLC, and the Purchasers](https://www.sec.gov/Archives/edgar/data/1583107/000155837020001644/ex-10d68.htm) | 10-K | December 31, 2019 |
| 10.54 | [Sale and Contribution Agreement, dated as of February 28, 2020, among Theravance Biopharma R&D, Inc., as the transferor, Triple Royalty Sub II LLC, as the transferee, and Theravance Biopharma, Inc.](http://www.sec.gov/Archives/edgar/data/1583107/000110465918070942/a18-40916_1ex10d1.htm) | 8-K | March 04, 2020 |
| 10.55 | [Pledge and Security Agreement, dated as of February 28, 2020, between Theravance Biopharma R&D, Inc., as the equity holder, and U.S. Bank National Association, as the trustee](http://www.sec.gov/Archives/edgar/data/1583107/000110465918070942/a18-40916_1ex10d2.htm) | 8-K | March 04, 2020 |
| 10.56 | [Servicing Agreement, dated as of February 28, 2020, between Triple Royalty Sub II LLC and Theravance Biopharma US, Inc.](http://www.sec.gov/Archives/edgar/data/1583107/000110465918070942/a18-40916_1ex10d3.htm) | 8-K | March 04, 2020 |
| 10.57 | [Account Control Agreement, dated as of February 28, 2020, among Triple Royalty Sub II LLC, as the grantor, Theravance Biopharma US, Inc., as the servicer, U.S. Bank National Association, as the secured party, and U.S. Bank National Association, as the financial institution](http://www.sec.gov/Archives/edgar/data/1583107/000110465918070942/a18-40916_1ex10d4.htm) | 8-K | March 04, 2020 |
| 10.58 | [Amended and Restated Limited Liability Company Agreement of Triple Royalty Sub II LLC, dated February 28, 2020, by Theravance Biopharma R&D, Inc., as the initial sole equity member](http://www.sec.gov/Archives/edgar/data/1583107/000110465918070942/a18-40916_1ex10d5.htm) | 8-K | March 04, 2020 |
| 10.59 | [Annex A - Rules of Construction and Defined Terms of the Amended and Restated Limited Liability Company Agreement of Triple Royalty Sub II LLC, dated February 28, 2020](https://www.sec.gov/Archives/edgar/data/1583107/000110465920076844/tm2023294d1_ex10-2.htm) | 8-K | March 04, 2020 |
| 10.60\*\* | [License and Collaboration Agreement by and between Theravance Biopharma Ireland Limited and Janssen Biotech, Inc. dated as of February 5, 2018](tbph-20201231xex10d60.htm) | ​ | ​ |
| 10.61+ | [Memorandum to Brett K. Haumann regarding Transfer to Transfer to Theravance Biopharma UK Limited, executed April 1, 2020](http://www.sec.gov/Archives/edgar/data/1583107/000155837018006147/tbph-20180630ex101ec4270.htm) | 10-Q | March 31, 2020 |
| 10.62 | [Amendments to Lease for 901 Gateway Boulevard between Theravance Biopharma US, Inc. and ARE-901/951 Gateway Boulevard, LLC](http://www.sec.gov/Archives/edgar/data/1583107/000155837018006147/tbph-20180630ex10293d232.htm) | 10-Q | August 2, 2018 |
| 10.63 | [Amendments to Lease for 951 Gateway Boulevard between Theravance Biopharma US, Inc. and ARE-901/951 Gateway Boulevard, LLC](http://www.sec.gov/Archives/edgar/data/1583107/000155837018006147/tbph-20180630ex1036aa376.htm) | 10-Q | August 2, 2018 |
| 10.64 | [Agreement and General Release between Theravance Biopharma US, Inc. and Shehnaaz Suliman, dated March 1, 2019](http://www.sec.gov/Archives/edgar/data/1583107/000155837019004767/tbph-20190331ex102ce7b68.htm) | 10-Q | May 10, 2019 |
| 10.65 | [Offer Letter with Andrew Hindman dated May 30, 2019](http://www.sec.gov/Archives/edgar/data/1583107/000155837019007084/tbph-20190630ex1017d2103.htm) | 10-Q | August 5, 2019 |

124

[Table of Contents](#TOC)

|  |  |  |  |
| --- | --- | --- | --- |
| **​** | **​** | **Incorporated by Reference** | |
| **Exhibit Number** | **Description** | **Form** | **Filing Date/Period End Date** |
| 10.66\* | [Amendment No. 1 to the Development and Commercialization Agreement by and between Theravance Biopharma Ireland Limited and Mylan Ireland Limited, dated June 12, 2019](http://www.sec.gov/Archives/edgar/data/1583107/000155837019007084/tbph-20190630ex102a8169b.htm) | 10-Q | August 5, 2019 |
| 10.67\*\* | [License Agreement by and between Theravance Biopharma Ireland Limited and Pfizer Inc. dated December 21, 2019](https://www.sec.gov/Archives/edgar/data/1583107/000155837020001644/ex-10d67.htm) | 10-K | December 31, 2019 |
| 10.68+ | [Service Agreement by and between Brett K. Haumann and Theravance Biopharma UK Limited, dated April 1, 2020](https://www.sec.gov/Archives/edgar/data/1583107/000155837020006021/tbph-20200331xex10d2.htm) | 10-Q | March 31, 2020 |
| 10.69 | [Cooperation Agreement among Theravance Biopharma, Inc., GSK Finance (No.3) plc and GlaxoSmithKline plc dated June 22, 2020](https://www.sec.gov/Archives/edgar/data/1583107/000110465920076844/tm2023294d1_ex10-3.htm) | 8-K | June 25, 2020 |
| 21.1 | [Subsidiaries of Theravance Biopharma, Inc.](tbph-20201231xex21d1.htm) | ​ | ​ |
| 23.1 | [Consent of Independent Registered Public Accounting Firm](tbph-20201231xex23d1.htm) | ​ | ​ |
| 24.1 | [Power of Attorney (see signature page to this Annual Report on Form 10-K)](#SIGNATURES_556629) | ​ | ​ |
| 31.1 | [Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934](tbph-20201231xex31d1.htm) | ​ | ​ |
| 31.2 | [Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934](tbph-20201231xex31d2.htm) | ​ | ​ |
| 32 | [Certifications Pursuant to 18 U.S.C. Section 1350](tbph-20201231xex32.htm) | ​ | ​ |
| 101 | The following materials from Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020, formatted in Inline Extensible Business Reporting Language (iXBRL) includes: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Shareholders’ Deficit, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements. | ​ | ​ |
| 104 | Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101). | ​ | ​ |

|  |  |
| --- | --- |
| + | Management contract or compensatory plan or arrangement required to be filed pursuant to Item 15(b) of Form 10-K. |

|  |  |
| --- | --- |
| \* | Portions of this exhibit have been omitted and the omitted information has been filed separately with the Securities and Exchange Commission pursuant to an order granting confidential treatment. |

|  |  |
| --- | --- |
| \*\* | Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. |

|  |  |
| --- | --- |
| (1) | Incorporated by reference to an exhibit filed with the quarterly report on Form 10-Q of Innoviva, Inc., filed with the Securities and Exchange Commission on August 7, 2014. |

|  |  |
| --- | --- |
| (2) | Incorporated by reference to an exhibit filed with the annual report on Form 10-K of Innoviva, Inc., filed with the Commission on March 3, 2014. |

|  |  |
| --- | --- |
| (3) | Incorporated by reference to an exhibit filed with the annual report on Form 10-K of Innoviva, Inc., filed with the Commission on February 27, 2012. |

(4) Incorporated by reference to an exhibit filed with the current report on Form 8-K/A of Innoviva, Inc., filed with the Commission on March 6, 2014.

**​**

​

125

[Table of Contents](#TOC)

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

|  |  |  |
| --- | --- | --- |
| ​ | THERAVANCE BIOPHARMA, INC.  ​ | |
| Date: February 26, 2021 | By: | /s/ Rick E Winningham |
| ​ | ​ | Rick E Winningham |
| ​ | ​ | *Chief Executive Officer* |

​

​

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Rick E Winningham as their true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to the annual report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

​

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ |
| **​** | **Signature** | **​** | **​** | **​** | **​** | **Title** | **​** | **​** | **​** | **​** | **Date** | **​** |
| ​ | | | ​ | | | | | | | ​ | | |
| /s/ Rick E Winningham  Rick E Winningham | | | Chairman of the Board and Chief Executive Officer (Principal Executive Officer) | | | | | | | February 26, 2021 | | |
| ​ | | | ​ | | | | | | | ​ | | |
| /s/ Andrew Hindman  Andrew Hindman | | | Senior Vice President and Chief Financial Officer (Principal Financial Officer) | | | | | | | February 26, 2021 | | |
| ​  /s/ Laurie Smaldone Alsup, M.D.  Laurie Smaldone Alsup, M.D. | | | Director | | | | | | | February 26, 2021 | | |
| ​ | | | ​ | | | | | | | ​ | | |
| /s/ Eran Broshy  Eran Broshy | | | Director | | | | | | | February 26, 2021 | | |
| ​ | | | ​ | | | | | | | ​ | | |
| /s/ Robert V. Gunderson, Jr.  Robert V. Gunderson, Jr. | | | Director | | | | | | | February 26, 2021 | | |
| ​ | | | ​ | | | | | | | ​ | | |
| /s/ Donal O’Connor  Donal O’Connor | | | Director | | | | | | | February 26, 2021 | | |
| ​ | | | ​ | | | | | | | ​ | | |
| /s/ Burton G. Malkiel, Ph.D.  Burton G. Malkiel, Ph.D. | | | Director | | | | | | | February 26, 2021 | | |
| ​ | | | ​ | | | | | | | ​ | | |

126

[Table of Contents](#TOC)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ​ |  | ​ | | | ​ | ​ | ​ |  | ​ | ​ | ​ | | ​ | |  | ​ |
| **​** | **Signature** | **​** | | | **​** | **​** | **​** | **Title** | **​** | **​** | **​** | | **​** | | **Date** | **​** |
| ​  /s/ Dean J. Mitchell  Dean J. Mitchell | | | | | Director | | | | | | | | February 26, 2021 | | | |
| ​ | | | | | ​ | | | | | | | | ​ | | | |
| /s/ Susan M. Molineaux, Ph.D.  Susan M. Molineaux, Ph.D. | | | | | Director | | | | | | | | February 26, 2021 | | | |
| ​ | | | | | ​ | | | | | | | | ​ | | | |
| /s/ Deepika R. Pakianathan, Ph.D.  Deepika R. Pakianathan, Ph.D. | | | | | Director | | | | | | | | February 26, 2021 | | | |
| ​ | | | | | ​ | | | | | | | | ​ | | | |
| /s/ George M. Whitesides, Ph.D.  George M. Whitesides, Ph.D. | | | | | Director | | | | | | | | February 26, 2021 | | | |
| ​ | | | | | ​ | | | | | | | | ​ | | | |
| /s/ William D. Young  William D. Young | | | | | Director | | | | | | | | February 26, 2021 | | | |
|  | | |  |  | | | | | | | |  | |  | | | |
|  | | |  |  | | | | | | | |  | |  | | | |

​

​

**​**

**​**

127